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This thesis looks at risk factors for multiple sclerosis (MS), a chronic, 
degenerative autoimmune disease which is usually diagnosed between the ages of 20 
and 50 years. It is estimated to affect over 100,000 people in the UK. The research 
setting was Orkney and Shetland, two archipelagos situated north of mainland 
Scotland, and both of which have very high MS prevalence as do other countries at high 
latitudes. I examine genetic and environmental risk factors in Orkney and Shetland 
using multiple methods over four studies. I also review the vitamin D and UV exposure 
literatures as these are risk factors pertinent to MS in Orkney and Shetland. 
After devoting three chapters to introducing the purpose of the thesis, MS, and 
Orkney and Shetland, in the fourth chapter, I aim to establish whether the birthplace of 
cases show any spatial, temporal, or spatiotemporal clustering. Evidence of these kinds 
of clustering may indicate that there are environmental risk factors present in some 
areas or that were present over particular periods, which raise risk of developing MS. 
Although I find statistically significant temporal, spatial, and spatiotemporal clustering 
in Orkney, and a spatial cluster in Shetland, for multiple reasons these results need to 
be interpreted with caution. I conclude that the clusters are very likely to be artefacts. 
Furthermore, there are multiple possible alternative explanations for such clusters that 
could not be explored by the available data. 
Chapter 5 examines the heritability of MS in Orkney and Shetland to estimate 
the proportion of phenotypic variance attributable to additive genetic effects. I also 
look at the birthplaces of ancestors of cases and controls to see if any locations 
contribute a greater amount of ancestral DNA to the gene pool of modern MS cases, 
which I term ‘genetic clustering’. In Orkney I obtained a heritability estimate of 0.36 
(95% CI -0.26, 0.98); in Shetland this estimate was 0.20 (95% CI -1.88, 2.28). These 
modest estimates are consistent with the heritability literature. The genetic clustering 
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analyses highlight two Orkney registration districts, Kirkwall and Westray, which 
earlier studies identified as areas of MS clustering. I also identify three Shetland 
registration districts, however these locations had not shown any evidence of 
clustering in earlier studies. Again, I advise caution in interpreting results, particularly 
as all the error bars across registration districts overlap. 
Chapter 6 presents a scoping review to map the literature and identify evidence 
of an association between vitamin D and UV exposure with MS. In methodically 
searching the literature, I identify a large and heterogeneous evidence base comprising 
multiple observational, intervention, and genetic studies. Overall, many studies support 
an association between vitamin D deficiency and MS. There is also evidence for an 
association between UV exposure and MS, although UV exposure is considerably less 
explored than vitamin D. I finally identify gaps in the literature and make suggestions 
for future research. 
In Chapter 7 I aim to compare vitamin D levels in Orkney and mainland 
Scotland, and establish the determinants of vitamin D status in Orkney. I firstly 
compare mean vitamin D and prevalence of deficiency in cross-sectional data from 
studies in Orkney and mainland Scotland. I secondly use multivariable regression to 
identify factors associated with vitamin D levels in Orkney. I find that mean (standard 
deviation) vitamin D is significantly higher in Orkney compared to mainland Scotland 
(35.3 (18.0) and 31.7 (21.2), respectively), and prevalence of severe deficiency is lower 
in Orkney (6.6% to 16.2% p = 1.1 x 10-15). Factors associated with higher vitamin D in 
Orkney include older age, farming occupations and foreign holidays. I conclude that 
although mean vitamin D levels are higher in Orkney compared to mainland Scotland, 




Chapter 8 examines the correlates and determinants of UVB exposure in 
Shetland. I firstly construct correlation matrices to visualise how 1) personal 
characteristics such as sex, occupation, and skin type, 2) physical activity, and 3) body 
weight and fat, correlate with UVB exposure. I then use multivariable regression to 
identify factors associated with UVB exposure in Shetland. I run two multivariable 
models. The first includes the full sample size where activity data were measured by 
questionnaires. The second includes both questionnaire physical activity data and step-
count data from pedometers, however as only a subset of participants had been 
supplied with pedometers, this analysis comprises a smaller sample size. I find that the 
amount of skin exposed was most strongly correlated with UVB exposure. Step count 
and activity minutes were also moderately positively correlated, and indoor 
occupations moderately negatively correlated, with UVB exposure. The regression 
analysis using the full sample with questionnaire activity data found that factors 
associated with greater UVB exposure were age and ambient UVB, while working 
indoors was significantly associated with lower UVB exposure. The model including the 
pedometer data found that found that age, total steps, and the amount of ambient UVB 
were significantly associated with greater UVB exposure. I conclude that atmospheric 
conditions, working outdoors and older age are important factors in UVB exposure in 
Shetland. It remains to be seen how UVB exposure translates to vitamin D levels in 
Shetland. 
I found evidence for environmental and genetic risk factors for MS in Orkney 
and Shetland. The two environmental risk factors, vitamin D deficiency and reduced UV 
exposure, are more likely to affect the younger population who are still within their 








Multiple sclerosis (MS) is a condition that results in progressive disability, is 
usually diagnosed between the ages of 20 and 50 years, and is thought to affect over 
100,000 people in the UK. The islands of Orkney and Shetland are the worst affected. 
The reasons why so many people in Orkney and Shetland have MS is not clear, and so I 
set out to understand why people in these islands are at increased risk. To do so I first 
examined whether people who were born in particular places or times were more 
likely to develop MS later in life. This can help to identify features in the environment 
that may be related to an increased risk of MS. I found that people born in some places, 
and during some periods of time, appeared to be at greater risk. However, there are 
many reasons for this pattern, including problems with the data which may have 
incorrectly led to these results, and therefore I am cautious about drawing any 
conclusions from it. I then looked at possible genetic risk factors. I found that in Orkney, 
a little over one-third of differences in MS susceptibility could be attributed to genetic 
differences among individuals. In Shetland, genetic differences were responsible for 
one-fifth of differences in MS susceptibility. These results are similar to those found in 
studies of MS carried out elsewhere. The results mean that although genes are involved 
in MS, there must also be other elements that lead to the development of MS. I then 
looked at whether the ancestors of people with MS were more often born in the same 
place than ancestors of people without MS. I found three Shetland and two Orkney 
birthplaces where the ancestors of people with MS appeared to be more frequently 
born. However, again, multiple alternative explanations for this pattern need to be 
ruled out before we can conclude that genes are responsible for these findings. 
In Chapter 6 I identified studies that examined whether low levels of vitamin D 
in the blood or too little sunshine are associated with a greater risk of MS or worse 
disease progression. Many studies that we found showed that low levels of vitamin D 
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and reduced sunshine exposure were present in people with MS, and were sometimes 
present when disease progression was worse.  
Finally, I conducted two studies, one that examined vitamin D levels in Orkney, 
and the other that explored UV exposure in Shetland. The first study found that vitamin 
D levels in Orkney were higher than in mainland Scotland. I also found that older 
people, farmers, and people who take foreign holidays had higher vitamin D levels in 
Orkney. In the second study we found that older people, physical exercise, working 
outdoors, and the weather contributed to more exposure to sunshine in Shetland. 
Younger people – who are still within the ages at risk of being diagnosed with MS – are 
therefore more likely to have low vitamin D and low sunshine exposure than older 
people. These studies showed that genes contribute to the risk of MS. Younger people 
often have lower levels of vitamin D and sunshine exposure. Both of these factors may 
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CHAPTER 1. INTRODUCTION 
Research over the past sixty years has consistently identified a high prevalence 
of multiple sclerosis (MS) in Orkney and Shetland. The most recent study, conducted in 
2012, found that Orkney had the highest MS prevalence in the world, and Shetland was 
close behind (Visser et al., 2012). Despite advances in our understanding of the 
pathology of MS and its global epidemiology, the reasons for the high prevalence in 
Orkney and Shetland remain unclear. This ambiguity is troubling, because the 
identification of risk factors may help to explain why the residents of these islands are 
more frequently affected by MS, and may also identify ways in which behaviours could 
be modified to reduce risk. To address this problem, this thesis explores two avenues of 
research. The first concentrates on the genetic involvement in MS in Orkney and 
Shetland. The second focusses on two environmental risk factors: vitamin D deficiency 
and reduced ultraviolet (UV) exposure from sunlight.  
Two background chapters follow this introduction. Chapter 2 provides a 
detailed overview of MS, including the history of the disease, the development of 
diagnostic criteria, an overview of environmental and genetic risks, and the global and 
UK epidemiology of MS. Chapter 3 introduces the research setting of Orkney and 
Shetland. I discuss two qualities of the research setting in detail. Firstly, I give an 
overview of the high-latitude geographical location of Orkney and Shetland, and their 
characteristic inclement weather, both of which can impact on UV exposure and 
vitamin D levels in the population. Secondly, I describe the population histories from 
the time of their first settlement to today, covering archaeological evidence as well as 
historical and recent emigration and immigration. Despite the fluctuations in 
population, I explain that Orkney and Shetland are genetic isolates, shown through 
distinct genetic structures that are different from the rest of the UK, and different from 
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each other. Both genetic isolation, and the geographical location, are qualities that may 
increase MS risk in these islands.  
The high-latitude geographical location of Orkney and Shetland, alongside their 
often-inclement weather, means that sunshine is in short supply. Judicious exposure to 
UVB radiation from sunshine appears to be vital to human health, partly because it 
enables us to synthesise vitamin D from cutaneous cholesterol, and partly because it 
affects our immune systems independent of vitamin D. Inadequate UVB exposure and 
vitamin D deficiency have long been associated with MS. Additionally, there is a 
considerable literature that has sought to identify apparent clusters of MS to discover 
and attribute possible environmental causes for disease. Such endeavours have proved 
largely unsuccessful in identifying any causal agents, however it is possible that 
unidentified risks may be present in Orkney and Shetland which contribute to the high 
prevalence. Furthermore, genetic isolation can have adverse consequences for health. 
For example, it is possible that an as-yet unidentified genetic risk for MS could be found 
within Orkney and Shetland, or that common genetic variants which may collectively 
act to increase MS risk may present more frequently in this population. Potential 
genetic and environmental risks needed investigating in Orkney and Shetland, and 
were the aims addressed throughout this thesis. The questions that I sought to answer 
are as follows: 
1) Are the people born within some parishes or isles more frequently affected by MS 
than would be expected by chance?  
2) Do genes contribute a greater amount to the risk of MS in Orkney and Shetland than 
is observed elsewhere? 
3) Is vitamin D deficiency a potential risk factor for MS in Orkney that could help 
explain the high prevalence?  
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4) Is inadequate UVB exposure a potential risk factor for MS in Shetland that could 
help explain the high prevalence? 
 
Chapter 4 is devoted to addressing the first question. I explore the pattern of MS 
in Orkney and Shetland using temporal, spatial, and spatiotemporal clustering analyses. 
For these, I used participants’ birthdates and birthplaces. It has previously been 
hypothesised that MS risk can be increased by factors from or before birth, or in early 
childhood. Therefore, clustering by birthplace may identify the presence of early-life 
risk factors. However, the limitations of our data were such that, although statistically 
speaking it appeared that clusters were present, there was no way to meaningfully 
interpret them. Furthermore, the quality of the data was such that it remains 
questionable whether the statistically significant presence of clusters actually denotes 
the presence of true clusters. Despite all efforts to be as rigorous as possible regarding 
definitions of cases and controls, significant problems beyond our control remain, and 
there are multiple other reasons to explain apparent aggregations of disease. 
In Chapter 5 I explore the genetic contribution to MS in the Northern Isles, and 
how estimates of heritability in Orkney and Shetland compare with what is expected in 
the literature. As MS is a dichotomous trait (one either has it or does not), we calculated 
the heritability of liability to disease. This type of heritability estimate is based on the 
assumption that each individual has an underlying disease risk which is normally-
distributed, called the liability, and is thought to determine an individual’s probability 
of developing disease. I obtained modest estimates of the heritability to liability of MS 
from both Shetland and Orkney, suggesting that 20% (95% CI -188.0 to 228.0) 
(Shetland) and 36% (95% CI -26.0 to 98.0) (Orkney) of the variation in liability to MS 
between individuals is owing to additive genetic effects. However, the confidence 
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intervals are large and cross zero, probably resulting from overall small sample sizes 
and few related cases. I also explore possible genetic clustering of MS, using the strong 
genetic structuring in Orkney and Shetland by parish or isle as a proxy for genetic 
relatedness. To do so, I used the places of birth of ancestors of cases who had been born 
circa 1890, and weighted them by relatedness (for example, grandparents would 
contribute 0.25, great grandparents 0.125 etc.). This gave a genetic score for each 
district which denoted how much of a contribution each district made to the modern 
MS gene pool. I repeated the process with controls, and plotted all scores. The 
distribution across all registration districts were similar, and therefore no district 
appears to contribute more to the modern gene pool of MS than any other. 
The second half of the thesis is devoted to exploring the environmental risk 
factors of vitamin D deficiency and reduced exposure to UV from sunlight. To begin, 
Chapter 6 presents a scoping review of the literature concerning MS, vitamin D 
deficiency, and UV exposure. The scoping review methodology enables a way to 
aggregate all relevant literature and present findings in a broad, narrative account. I 
divided the identified literature into three main areas: observational studies, 
intervention studies, and genetic studies, and discuss patterns in findings, possible 
reasons for discrepancies, and gaps in the literature. 
In Chapter 7 I explore vitamin D levels in a cohort of Orcadians, and compare 
them to a cohort from the mainland of Scotland. Conversely to what we had anticipated, 
I found that Orcadians had higher mean vitamin D levels than people in mainland 
Scotland; furthermore, older people in Orkney had higher mean vitamin D levels than 
younger people. Further explorations of the data revealed that older people were more 
likely to work in traditional, outdoors occupation. Additionally, older people were more 
likely to take holidays abroad. Both these factors enable maximisation of sunshine 
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within Orkney and abroad, compared to indoor workers who largely remain within 
Orkney.  
Chapter 8 is concerned with identifying the determinants of individual UV 
exposure in Shetland. I began by identifying correlations between individual UV 
exposure and a range of lifestyle variables. I followed this with two multivariable 
analyses, both with individual UV exposure as the outcome, however Model 1 included 
questionnaire physical activity data, and Model 2 included pedometer activity data as 
well as the questionnaire physical activity. Both models yielded slightly different 
results. However, both models were in agreement that older age and greater ambient 
UV were associated with higher individual UV exposure. 
Finally, Chapter 9 contains a summary of the main findings of this thesis, how 
they fit into the existing literature, and their limitations. I conclude by addressing the 
implications of these findings. Particularly prominent is the need to firmly establish 
whether there is a causal connection between vitamin D deficiency and UV exposure 










CHAPTER 2. MULTIPLE SCLEROSIS: HISTORY, CLASSIFICATION, 
PATHOLOGY, AND EPIDEMIOLOGY 
In this chapter I give a broad introduction to multiple sclerosis (MS) and the 
evolution of our understanding of the disease. Beginning with a brief history of MS, I 
draw on early examples from mythology and historical literature, leading to how MS 
was originally recognised and framed as a disease. I then give a simplified overview of 
our current understanding of the molecular processes that underlie the pathology, and 
describe how these processes translate into symptomatic disease. This leads me to 
outline the development of the main sets of criteria that have been, and are now, used 
to diagnose this complex disease. In so doing, I also present the challenges involved in 
comparing older studies which use early criteria, with newer studies which use 
updated and current criteria, and how comparisons of studies in different geographical 
regions can present difficulties. Finally, I describe the epidemiology of MS, giving an 
overview of the main environmental and genetic risk factors, and the global and UK 
prevalence of MS. 
2.1 History of MS   
Before MS had been framed as a disease, details of mysterious illnesses with 
multiple transient neurological symptoms had been recorded for centuries in 
mythologies, genealogies, diaries, personal correspondence, and medical notes. Looking 
at such cases through the prism of modern medicine, it is possible to hypothesise that 
at least some of these unexplained illnesses may be attributable to MS; at the very least, 
MS would likely be highlighted as a possibility on a list of differential diagnoses. 
2.1.1 Icelandic Sagas 
 One of the earliest recorded ‘possible MS’ cases is that of Halldora, in the Saga of 
Thorlak, one of the Icelandic Biskopa Sögur or Bishops’ Sagas. Halldora was a young 
woman on the Vestmann Islands, who suffered from intermittent paresis (weakness or 
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partial paralysis) between 1193 and 1198. After three years confined to bed, the 
miraculous power of Bishop Thorlak, who had died in 1193, was called upon to cure 
Halldora. The Bishop appeared to a woman in a dream with instructions that Halldora 
must go to Skálholt if she wished to be cured. She was carried to Skálholt and arrived in 
time for the church festival where Bishop Paul requested that the congregation pray for 
her. She grew a little better each day that she was in Skálholt; the day following the 
festival’s end she went to the Althing and offered up a gold ring and shortly after was 
completely cured (Holmøy, 2006).  
 A further tale appears in the same saga of Bishop Thorlak, concerning a young 
woman named Halla who lived more than 100 years after Halldora, with her illness 
occurring between 1293 and 1323. Halla was said to have fallen ill on a Saturday, 
suddenly losing sight in both her eyes and developing bilateral ptosis (drooping 
eyelids). The following day she lost her speech. She is said to have made a vow to 
“almighty God for cure and Bishop Thorlak for intercession” that she would walk to 
Skálholt, fasting on bread and water, and praying before Thorlak’s mass. On the third 
day, it is said that a “candle wick was put around her head”, following which she 
regained the sight in one eye and was able to open both eyes. Within a week of the 
original illness she regained her speech, and within two weeks the sight in her second 
eye was restored (Poser, 1994).  
 The paucity of detail within both stories makes it difficult to accept a diagnosis 
of MS without some scepticism, particularly as these stories originate from an era in 
which illness and disease were little understood and powerful emotions were 
associated with fervent belief (Poser, 1994). The symptoms described in both stories 
are not incompatible with MS, however Halldora’s three year paresis is unusually long 
(Holmøy, 2006). Additionally, while some of Halla’s symptoms, such as bilateral loss of 
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vision, bilateral ptosis, and loss of speech are rare events in MS they are not unheard of. 
Hysteria has been considered the most likely explanation of their symptoms by readers 
of the untranslated sagas (Compston et al., 2006a), however others argue that the slow 
improvements recorded for both women make hysteria a questionable explanation, as 
any such symptoms would be likely to resolve swiftly (Poser, 1994). The cure of 
Halldora was one of the miracles for which Thorlak was canonised, and it is possible 
that the symptoms described were exaggerated to deepen the miraculous nature of the 
cure (Holmøy, 2006). Regardless of diagnoses, what these stories do show is that 
temporary paralysis was recognised in medieval Iceland (Holmøy 2006). 
2.1.2 Lidwina of Schiedam   
 Lidwina the Virgin, born in Schiedam, Holland, in 1380, is another early 
speculative example of “possible” MS. Following an illness in the winter of 1395-96 
from which she was slow to recover, she went ice-skating where she fell, and broke ribs 
on her right side. As the injury was healing she had difficulty walking and is described 
as having an intense pain in her teeth. Over the next years she lost sight in one eye, was 
sensitive to light, had paralysis in her right arm and pain in her right shoulder. She lost 
sensation and developed sores, and eventually had difficulty swallowing, became so 
weak she was unable to walk, and developed contractures of her limbs (Murray, 2004; 
Huysmans and Hastings, 1923).  
 However, like Halla and Halldora, Lidwina was fervently religious. She accepted 
her pain with an apparently pious joy and latterly took steps to increase her discomfort 
by swapping her bed for wooden planks and hay, and wearing a belt of horsehair to rub 
her remaining healthy skin raw (Huysmans and Hastings, 1923). A mythology grew up 
around her in her own lifetime; her sores and ulcers were said to emit a perfumed 
scent; she cried tears of blood; she turned a pitcher of beer into an aromatic potion. 
Further, her darkened room was said to glow – like fire – from visitations of angels and 
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saints. During the final three decades of her illness she was said to have experienced 
several such apparitions, and had visions of participating in the Passion of Christ 
following which her stigmata appeared. Through the later stages of her illness she was 
reportedly unable to tolerate any food other than consecrated Holy Communion wafers. 
Lidwina died in 1433 at the age of 53, her corpse apparently resembling her 17-year 
old self and bearing no signs of her illness (Huysmans and Hastings, 1923). She was 
canonised in 1890, and is the patron saint of the chronically ill and (rather bizarrely) of 
ice-skating.  
 Although many of her reported symptoms are compatible with an MS-like 
illness, like Halla and Halldora religious fervency and hysteria cannot be disregarded as 
reasonable explanations. Murray further notes that elements of histrionic behaviour 
and self-mutilation need to be considered (Murray, 2004). Although contemporary 
documents are in existence charting the life of this unfortunate woman, the mythology 
that had already built up around her must undermine their accuracy. 
2.1.3 Augustus d’Esté 
 Augustus d’Esté, born in 1794, was the son of Prince Augustus Frederick, Duke 
of Sussex and Lady Augusta Murray. Through his father he was also the grandson of 
King George III. However, the marriage of Prince Augustus and Lady Augusta was 
declared invalid by the King shortly after taking place, as he had never given the union 
his royal consent. Augustus d’Esté was thereby rendered illegitimate (Este, 1832).  
Harrow-educated, and rising to the rank of Lieutenant Colonel in the VIIth 
Royal Fusiliers in 1812, Augustus d’Esté had an unremarkable childhood and, it 
appears, a dissolute and rather boorish young adulthood (Firth, 1948). His greatest 
legacy, however, is his diary and gentleman’s almanac in which he recorded his descent 
11 
 
into an unexplained illness that lasted from 1822 until his death in 1848, and the 
treatments that he underwent in the hope of a cure (Firth, 1941).  
His symptoms first presented with bilateral optic neuritis (ON), which he 
attributed to exerting extreme effort not to cry at the funeral of a close friend. Over the 
next twenty years, further symptoms developed including diplopia (double vision), 
paraparesis (partial or mild paralysis of the lower limbs), anal incontinence and 
impotence, lack of coordination, weakness, sensory changes and cognitive impairment 
(Landtblom et al., 2010; Compston et al., 2006a). A relapsing-remitting course is 
described in the first years of disease, with complete recovery following the first two 
episodes and only partial recovery following the third (Compston et al., 2006a). He 
consulted the top physicians of the day, and underwent numerous treatments in the UK 
and Europe including bloodletting, leeches, emetics, a diet of beef steak and sweet wine, 
having his legs and back rubbed with brushes, spa therapies, tincture of Spanish fly, 
application of heat as hot as he could bear, herb and flower preparations, and daily 
showers. He was also prescribed and tried mercury, electricity, horse-riding, and taking 
the sea air in Brighton (Murray, 2004). Following periods of improvement, secondary 
progressive disease began between 1829 and 1839. In 1847 he began timing his daily 
walks around his apartment to within a fraction of a minute and recording them in his 
almanac, charting his decline and occasional achievements (January 17th 1848: “Not 
bad! I walk, this day in my room for 45¾” (Compston et al., 2006a)). He died in 1848 
having been confined to a wheelchair for his last years (Landtblom et al., 2010). It is 
widely accepted that the diary of Augustus d’Esté provides the first comprehensive 
account of definite MS (Murray, 2004; Compston et al., 2006a).  
2.1.4 W N P Barbellion 
 Before the discovery of Augustus d’Esté’s diary in 1942, the most complete 
account of MS was published in the Journal of a Disappointed Man by W N P Barbellion, 
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the pseudonym of Bruce Frederick Cummings, who was born in 1889 in Barnstaple, 
Devon (Compston et al., 2006a).  In April 1913 Barbellion noted with anxiety that he 
had some paralysis down his right side. His speech was affected, and he was placed on 
two months’ sick leave. Ocular disturbances, giddiness, fatigue, and nerve pains 
affected him over the coming months and years, and although he consulted a number of 
physicians, he only discovered his diagnosis after attempting to enlist in the army. 
Opening a sealed letter from his physician to the recruiting army Medical Officer, he 
saw his condition named: disseminated sclerosis (Barbellion, 1919).  
 Cummings married after symptom onset but before he knew his diagnosis. His 
fiancée had been told and ‘had married him for love, nevertheless, against every 
friendly counsel, the Doctor’s included’ (Barbellion, 1919). They had two daughters, 
and Cummings followed a successful career as an entomologist at the Natural History 
Museum in London. He died in 1919 at the age of 30, having announced the death of 
Barbellion some two years previously on publication of the diary (Barbellion, 1919).   
 Transient neurological illness that worsens over time has therefore been 
described for many years, with an interesting history of how those affected lived with 
and managed their symptoms. However, whilst the disparate collection of symptoms 
that may indicate MS had been noted and described before official recognition of the 
disease, it was not until the mid- to late-nineteenth century that the condition was 
encapsulated, described, and named. The next section describes how MS was first 
identified, moving on to give an overview of some of the key molecular changes that 
occur in the immune system, how these changes can lead to symptomatic disease, and 
how such different symptoms may be classified. 
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2.2 Classification of MS 
In 1868, the Parisian neurologist, Jean Martin Charcot, identified a triad of 
features which often presented together: intention tremor (involuntary movement of 
the hands associated with deliberate movements), nystagmus (involuntary movement 
of the eyes) and scanning speech (disruption of normal speech pattern characterised by 
long pauses). Following the dissection of the brain of a deceased patient exhibiting 
these three symptoms, Charcot identified the plaques associated with MS, calling it ‘la 
sclérose en plaques’ (Murray, 2004). Since that original recognition of the characteristic 
plaques, our understanding of MS, and the molecular changes that lead to symptomatic 
disease, has increased.  
2.2.1 Molecular involvement 
MS is a chronic, autoimmune, degenerative disease, where the body’s immune 
system attacks myelin, the fatty insulation of neurons which facilitates transmission of 
nerve impulses. These attacks lead to damage and destruction of the myelin, resulting 
in the formation of sclerotic plaques (abnormal hardening of the tissue), and the onset 
of symptomatic disease (Compston and Coles, 2008). However, these plaques are the 
culmination of a process involving inflammation, demyelination, remyelination, 
depletion of myelin-producing oligodendrocytes and scar-forming astrocytes, and 
degeneration of neurons and axons (Compston and Coles, 2008). Although such 
complex processes are beyond the scope of this chapter to discuss in detail, it is clear 
that multiple cells are involved in each stage of disease.  
It is thought that the disease is initiated when autoreactive lymphocytes, 
namely T and B cells, migrate across the blood-brain barrier. In people with MS, 
defective regulatory cells, such as Treg cells, do not suppress effector T cells, and 
therefore fail to shut down immune responses. Cells including T and B cells, plasma 
cells, and macrophages, accrue, and pro-inflammatory cytokines boost the immune 
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response by recruiting microglial cells (Compston and Coles, 2008). The microglia are 
innate immune cells, which activate when they detect pro-inflammatory factors. They 
then release cytotoxic elements, such as tumour necrosis factor, which aims to protect 
the body by destroying harmful invading pathogens. In MS, this microglial process may 
be critical in inflicting oligodendrocyte injury and degenerating axons (Correale and 
Farez, 2015; Lull and Block, 2010), which leads to increased grey and white matter 
atrophy (Dendrou et al., 2015). Astrocytes respond to chronic injury causing gliosis, a 
scar composed primarily of astrocytes although it can contain other glial cells including 
oligodendrocytes and fibromeningeal cells. The gliosis can effectively prevent repair 
and lead ultimately to permanent sclerotic plaques (Compston and Coles, 2008; 
Correale and Farez, 2015). These areas of damage in the central nervous system (CNS) 
are visible on MRI scans, and are one of the signs that MS is probably present.  
Clinical tests can detect other molecular changes. Cerebrospinal fluid (CSF) 
examination from people with MS tends to contain elevated immunoglobulin G (IgG) 
levels, which can be visualised as oligoclonal bands. Where oligoclonal bands are 
observed in CSF but not in serum, or where additional bands are observed in CSF that 
are not observed in serum, then there is clear evidence that the IgG is being produced 
within the CNS. As IgG is produced by sclerotic plaques, the presence of IgG in the CSF 
implies that there are active immunological processes in the CNS (Miller et al., 2006). 
Such increased understanding of these molecular processes has aided in the diagnosis 
of MS, and has also led to the identification of molecules that can be therapeutically 
targeted (Noseworthy et al., 2006). 
2.2.2 Physical symptoms 
The physical symptoms that result from these molecular processes are usually 
the first sign to the patient that something is amiss. The plaques that form following the 
demyelination process disrupt nerve signals resulting in a poor connection between the 
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brain and muscles, and ultimately leads to symptomatic disease (Confavreux and 
Compston, 2006).  
MS can manifest with a wide variety of different symptoms depending upon the 
location of the scleroses. In the cerebrum, cognitive impairments and depression can 
ensue; in the optic nerve, unilateral loss of vision; in the cerebellum and cerebellar 
pathways, tremor, and clumsiness including poor balance; in the brainstem, vertigo, 
difficulty swallowing, diplopia, oscillopsia (where objects in the field of vision appear to 
oscillate), and impaired speech; in the spinal cord, weakness, spasticity, bladder 
dysfunction; and in other areas, pain, fatigue, and sensitivity to temperature can result 
(Compston and Coles, 2008). Alongside these manifold symptoms, several different 
presentations of MS can occur. However, the current classification guidelines split MS 
into two core phenotypes: relapsing-remitting, and progressive disease. Each 
phenotype includes a spectrum of characteristics which are further sub-divided into 
active or inactive disease (Lublin, 2014). 
2.2.3 Relapsing-remitting disease 
Relapsing-remitting MS (RRMS) is the most common type of MS; symptoms 
develop over the course of a few days and then resolve either partially or fully over a 
few weeks or months. As RRMS progresses recovery from relapses becomes less 
complete and the condition gradually worsens; this is termed secondary progressive 
MS (SPMS). Most people with RRMS will develop SPMS within twenty years of disease 
onset (MS, 2015). 
Clinically isolated syndromes (CIS), such as optic neuritis (where a lesion 
appears on the optic nerve leading to disturbed vision) or transverse myelitis (where a 
section of the spinal cord becomes inflamed), can be early symptoms of MS. According 
to the most current criteria for defining MS subtype, such CIS can be classified as 
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inactive if there is no evidence of disease exacerbation following an episode, and 
classified as active CIS if there is evidence of disease exacerbation following an episode. 
Active CIS may then fulfil criteria to be labelled RRMS (Polman et al., 2011). RRMS is 
also characterised as active or inactive, although yearly medical assessment for disease 
activity is recommended (Lublin, 2014).  
2.2.4 Progressive disease 
Primary progressive MS (PPMS) is defined as MS that presents with symptoms 
that worsen over time: there are no periods of remission and likewise, there are no 
sudden periods of deterioration. It is instead a slow and steady decline, although there 
may be periods of slight improvement (MS, 2015). 
By the most current definition, progressive disease encompasses both primary 
and secondary progression, and further relates disease progress to the amount of 
disability. There are four sub-divisions: active disease with progression, where the 
individual has had an attack and is worsening; active disease without progression, 
where an individual has previously had an attack within a particular time frame; not 
active with progression, defined by yearly clinical evaluation of abilities, and not active 
and without progression, which summarises stable disease (Lublin, 2014). 
 There are therefore many physical symptoms associated with MS, and there is 
an increasing knowledge of the molecular processes involved in the pathology since 
Charcot’s original recognition of MS to today. However, despite such breakthroughs, 
diagnosing MS is a highly complex process. One key ongoing debate is whether MS has a 
range of different presentations and phenotypes which stem from a single cause, or 
whether many causes leading to different disease mechanisms result in a set of clinical 
signs and symptoms which fall within the spectrum of a single disorder (Lassmann et 
al., 2006). Difficulties arise as no clinical tests can definitively diagnose MS. A positive 
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result simply indicates that there is immune activity: other diseases of the CNS can 
produce the same clinical signs. Additionally, the myriad symptoms that can appear do 
not, on their own, definitively indicate MS. However, as our knowledge base has 
increased, a number of sets of criteria to aid in the diagnosis of MS have been 
developed, refined, and revised to try to narrow down those characteristics that make 
anything other than MS unlikely. I present here a brief overview of the development of 
the main sets of criteria to those that are used today, and outline the challenges 
involved in comparing studies that use different diagnostic criteria. 
2.2.5 Allison and Millar criteria 
The Allison and Millar criteria were probably the most successful of the early 
attempts to create a clear diagnostic scheme against which to define MS. It divided 
cases into ‘early’, ‘probable’, and ‘possible’ disseminated sclerosis (Allison and Millar, 
1954). Early disseminated sclerosis comprised people with a history of relapsing-
remitting symptoms, but with no or few clinical signs. This category is however not 
acceptable by the standards of modern diagnostic criteria (Poser and Brinar, 2004). 
Probable disseminated sclerosis included people with physical signs of MS, usually with 
some disability, and presenting with a history equating to a modern diagnosis of RRMS 
or SPMS (Poser and Brinar, 2004). Possible disseminated sclerosis comprised people 
with either unchanging or chronically progressive symptoms for which no other 
explanation had been found, equating most often to a modern diagnosis of PPMS 
(Allison and Millar, 1954; Price, 2009). The vagueness of such criteria has however 
been highlighted as being of little diagnostic value (Poser and Brinar, 2004). Moreover, 
despite the authors’ warning that the “criteria should be used only by experienced 
neurologists, certainly not by surrogates carrying on epidemiological surveys” (Allison 
and Millar, 1954), up until the 1980s many MS surveys used some adaptation of the 
Allison and Millar criteria (Compston et al., 2006a).  
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2.2.6 Schumacher criteria 
The Schumacher criteria were developed in 1961 and published in 1965 to 
meet a growing need for clearly defined diagnostic guidelines to which MS researchers, 
investigators, writers, and editors of scientific journals could adhere. Such 
comprehensive guidelines were anticipated to provide consistency in research and to 
aid collaboration between different institutions (Schumacher et al., 1965; Poser and 
Brinar, 2004). These criteria required objective signs of CNS dysfunction, a history of 
the involvement of two or more areas of the CNS with two or more episodes each 
lasting at least 24 hours and occurring at least one month apart, and progression of the 
disease over at least six months. Predominantly white matter involvement and onset 
age between 10 and 50 years were also listed. Like the Allison and Millar criteria, there 
should be no other better explanation for symptoms, based upon the examining 
clinician’s experience and expertise (Schumacher et al., 1965). An update of the 
Schumacher criteria in 1980 were the first to include testing for oligoclonal bands in 
CSF (Poser and Brinar, 2004).  
Whilst it was clearly noted that the Schumacher criteria may be subject to some 
false positive and false negative findings, it was nevertheless advised that those who 
met all criteria should be categorised as having definite MS and accepted into studies. 
However, owing to a lack tests that indisputably indicate the presence of MS it was 
highlighted that this ‘definite’ category should be considered high probability of MS 
only, and not a definitive diagnosis. The proposed guidelines became the gold standard, 
widely used in clinical settings and epidemiological studies worldwide excepting East 
Asia, where the presentation of MS is often different. This point is discussed further 
below (see section 2.2.9) (Poser and Brinar, 2004). 
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2.2.7 Poser criteria 
In 1965 Charles Poser wrote “many clinicians… insist that there is,… in 
diagnosing MS, an… almost mystic diagnostic item frequently referred to as the “feel” or 
the “smell” of the patient, and which can be best characterized by the almost classical, 
pontifical  pronouncement: ‘Don’t ask me why I think this patient has MS, I just know!’” 
(Poser, 1965). Poser’s 1965 study, conducted across 33 countries and involving 108 
clinicians including MS experts and general neurologists, highlighted that the 
application of any set of criteria to autopsy-verified MS cases, patients without MS, and 
patients with MS and another CNS condition, led to a consistent diagnostic accuracy 
rate of two-thirds – although it was not always the same two thirds that were correctly 
identified.  
Soon after, a number of diagnostic recommendations and new criteria were 
proposed, including those by Broman (Broman et al., 1965) who was the first to 
incorporate CSF examination before the significance of oligoclonal bands was 
discovered, and to clearly state the importance of dissemination of lesions in time and 
dissemination of lesions in space, two criteria which are central to MS diagnosis today 
(Poser and Brinar, 2004). Dissemination in time requires that abnormal activity in the 
CNS must be observed on at least two occasions; dissemination in space means that 
abnormal activity must affect at least two areas of the CNS, Other criteria were 
proposed by Poser, which never gained widespread acceptance (Poser, 1979), and 
several other researchers who all divided patients into some form of probable or 
possible MS (Poser and Brinar, 2004). However, in 1982 a panel led by Poser, including 
distinguished researchers in many aspects of MS, met in Washington DC with the aim of 
constructing a new set of clearly defined criteria incorporating laboratory evidence and 
reducing reliance on subjective assessment.  
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The Poser criteria, proposed in 1983, became the gold standard in MS diagnosis 
and remained in use until the end of the millennium (Poser et al., 1983). Dividing 
patients into ‘clinically definite’, ‘laboratory-supported clinically definite’, ‘clinically 
probable’ and ‘laboratory-supported clinically probable’ MS depending upon their 
history and evidence of disease, the Poser criteria required at least two attacks with 
either laboratory-supported (oligoclonal bands or increased IgG production in the CSF), 
or paraclinical (evoked potentials – to measure electrical impulses in response to 
stimulation of specific sensory pathways), or tissue imaging (such as CT scanning) 
evidence of other lesions (Poser et al., 1983). The Poser criteria did not however make 
accommodations for ‘suspected’ MS, as these individuals would not be acceptable for 
inclusion in research studies or clinical trials (Poser and Brinar, 2004; Poser et al., 
1983). ‘Suspected’ MS was therefore assigned to all patients thought to have 
demyelinating disease but without clinical symptoms, signs or laboratory evidence for 
more than one lesion (Compston et al., 2006a).  
2.2.8 McDonald Criteria 
The Poser criteria developed into the McDonald criteria, which were first 
introduced in 2001 by a team led by Professor Ian McDonald, and reflected advances in 
technology and increased understanding of the disease (Fangerau et al., 2004). The 
McDonald criteria divide people into ‘MS’, ‘possible MS’ and ‘not MS’. They have since 
been updated twice, in 2005 and 2010.  
The McDonald criteria require evidence of CNS damage in space and in time, 
defined as damage to two parts of the CNS occurring at least 30 days apart, with attacks 
that last for at least 24 hours. The criteria also incorporates CSF analysis, visual evoked 
potentials (to test optic nerve transmission), and, possibly the biggest difference from 
the preceding criteria, MRI data (Polman et al., 2011). These MRI data enable an MS 
diagnosis to be given to patients who have experienced CIS suggestive of MS. As such, it 
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has been implied that the criteria are prognostic for future disease activity rather than 
diagnostic of MS, and will therefore identify individuals who would not have fulfilled 
earlier diagnostic criteria (Miller et al., 2008). Additionally, about 1% of people who 
fulfilled earlier criteria for MS are diagnosed as ‘Not MS’ under the McDonald criteria 
(Fox et al., 2004).  
Nevertheless, soon after their introduction, the sensitivity (the probability that 
a test will find the disease among those who have the disease), and specificity (the 
probability that a test will find no disease among those who do not have the disease), of 
the McDonald criteria were shown to be high in comparison with the then-gold 
standard Poser criteria (Dalton et al., 2002; Tintoré et al., 2003; Swanton et al., 2007). 
Furthermore, the positive predictive value (the percentage of people who have a 
positive test result who actually have the disease) and the negative predictive value 
(the percentage of people with a negative test result who do not have the disease), of 
the McDonald criteria were both found to be high when the criteria were applied to CIS 
patients and followed up at different time points over three years (Dalton et al., 2002). 
These results indicate that the McDonald criteria’s ability to diagnose MS from CIS leads 
to accurate early detection of disease.  
 Whilst diagnostic accuracy is increasing with improved diagnostic criteria, it is 
however important to note that there is still no test that indisputably indicates the 
presence of MS. Rather, diagnosis is made by neurologists through building a clinical 
picture of  each patient’s signs, symptoms, disease course and investigative test results, 
and by ensuring that differential diagnoses are excluded (Miller et al., 2006). Despite 




2.2.9 Comparisons of studies across time and geographical regions 
Diagnostic criteria have therefore developed to both meet changing needs and 
to reflect advances in technology and increased knowledge of MS. However, these 
changes complicate comparisons of older studies with new. The ways in which cases 
were defined differs between the Allison and Millar criteria and the Poser criteria, 
hindering direct comparisons. Such differences arise when surveys are restricted to 
categories of probable and early (Allison and Millar), and definite and probable (Poser) 
cases. Because the way in which possible and suspected cases are excluded differs 
between the two criteria, included cases meet different diagnostic standards and are 
not necessarily comparable (Compston et al., 2006a). Additionally, comparisons 
between McDonald and Poser studies are also complicated by the differing 
categorisation of cases. A study comparing diagnoses made by the Poser criteria and 
McDonald criteria found that whilst the McDonald criteria were able to diagnose MS 
more frequently than ‘clinically definite MS’ according to the Poser criteria, when the 
‘clinically definite’ and ‘laboratory-supported clinically definite’ Poser categories were 
combined then the Poser criteria diagnosed MS more frequently (Figure 2.1) (Fangerau 
et al., 2004).   
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Figure 2.1 Pie charts of Poser- and McDonald-defined clinically definite MS 
(CDMS) and probable/possible MS 
 
 
Criteria choice can also complicate comparisons of contemporaneous studies 
based in different geographical regions. There is an ongoing debate regarding possible 
heterogeneity of MS pathology, diagnostic criteria for which may be capturing diseases 
which should be considered distinct entities (Compston et al., 2006b; Lassmann et al., 
2006). For example, comparisons of European Americans and African Americans with 
MS found differing presentations of MS, with significantly more neuromyelitis optica 
(NMO) (an inflammatory disease of the CNS with optic nerve and spinal cord 
involvement), and transverse myelitis (an inflamed section of spinal cord), observed in 
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the African American cohort. African heritage MS patients were further found to need 
ambulatory assistance more often than their European heritage counterparts 
suggesting more aggressive disease (Cree et al., 2004). The Latin American 
presentation of MS appears to comprise greater frequency of opticospinal involvement 
than observed in a European heritage MS population; NMO also presents more 
frequently (Aguirre-Cruz et al., 2011).  
Likewise, the East Asian presentation of MS tends to include a greater 
frequency of NMO-like MS. Studies of Japanese MS patients have shown that the 
presentation tends to be opticospinal, and the lesions often destructive and necrotic 
(Tabira and Tateishi, 1981; Ikuta et al., 1981). Recent work in Japan has suggested that 
as between 50-60% of opticospinal MS patients have the specific immunoglobulin 
against NMO, NMO-IgG, then opticospinal MS may be the same entity as NMO rather 
than MS (Kira, 2008).  
These differing presentations of MS in populations of non-European heritage 
mean that the criteria for diagnosing MS, which were developed against the 
‘conventional’ type of MS observed in European populations and those of European 
heritage (Polman et al., 2011), do not necessarily capture phenotypes in other ethnic 
groups. This has led to the adaptation of criteria in some areas (Chong et al., 2009). 
Such adaptations do however mean that atypical forms of MS are less likely to be 
detected by unadapted criteria in countries where conventional MS predominates 
(Cogan et al., 2014). The most current McDonald criteria attempts to address these 
differing presentations and bring some uniformity to diagnoses worldwide, with 
recommendations made specifically for Latin American and East Asian populations, as 
well as paediatric patients (Polman et al., 2011).   
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These criteria are therefore clearly beneficial in assisting and guiding diagnosis 
and promoting diagnostic consistency, however the complexity of MS is still being 
understood and no one test can diagnose MS with certainty. The lack of direct 
comparability between different sets of criteria, and the different presentations of MS 
in different populations and ethnicities which some criteria may be less able to 
accurately detect, complicate the interpretation of studies across time and across 
geographical regions. There is however no doubt that the evolution of our 
understanding of MS, which has led to an evolution in diagnostic criteria, and an 
evolution in the classification of MS into different subtypes, is work still ongoing. 
2.3 Epidemiology of MS 
 Our increasing understanding of MS biology, its molecular processes and 
symptomatic manifestations, has played a vital role in our ability to recognise, and 
treat, MS. However, the mechanism by which the inflammatory reaction is initially 
triggered is still unclear, and it is this uncertainty that this thesis sets out to explore in 
more detail by examining relevant risk factors in areas of extremely high prevalence. 
The field of epidemiology works at the population level, and seeks to understand the 
causes, and the distribution, of disease. 
 To round off this chapter about MS, it is important to introduce some of the 
epidemiological features of MS. These features include some of the more prominent MS 
risk factors, including genetic risk factors, and environmental risk factors, including 
smoking, Epstein-Barr virus (EBV) antibodies, vitamin D deficiency, and reduced UV 
radiation, alongside a simplified overview of the possible mechanisms by which these 
risk factors may work to increase MS risk. I then discuss how MS is measured at the 
population level, and illustrate the general global and UK distribution of disease with 
reference to some of the risk factors, before presenting concluding remarks. 
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2.3.1 Genetic risk factors 
Despite the earlier-mentioned controversies, MS is widely considered to be a 
disease of multifactorial origin, involving a complex interplay of genetic and 
environmental risk factors (Compston and Confavreux, 2006). Genetic epidemiology 
focusses on identifying the genetic causes of disease, and on the combined effects of 
genetic and environmental determinants (Smith et al., 2011).  
A genetic predisposition to MS has long been suspected, strongly supported by 
an increased frequency of MS which was noted in the families of affected individuals 
(Reynolds, 1904; Davenport, 1922; Mackay, 1950). Additionally, heritability studies, 
which allow a comparison of the relative importance of environmental and genetic risk 
factors, have clearly demonstrated a genetic component to disease and are discussed in 
more detail in Chapter 5.  
The Human Leukocyte Antigen (HLA) genes show the greatest genetic risk for 
MS. The HLA genes encode a group of proteins, together called the HLA complex, which 
work in the immune system to help distinguish between the body’s proteins and 
invading pathogens such as bacteria and viruses (NIH, 2017). The strongest genetic risk 
factor for MS is an HLA haplotype, HLA-DRB1*15:01. People who have two copies of this 
haplotype are at high risk, with an odds ratio (OR) exceeding 7; people with just one 
copy of the haplotype have an OR of between 3.5 and 5.0 (Oksenberg and McCauley, 
2016). A further high-risk DRB1 genotype has been identified, HLA-DRB1*15/08 which 
confers an OR of 7.7 (95% CI=4.1-14.4) (Barcellos et al., 2006).  
As technology progressed, the age of genome-wide association studies (GWAS), 
enabled the fast analysis of thousands of individuals and a large number of genome-
wide markers, which represent every gene in the genome. To date, this GWAS approach 
has identified 110 genetic variants in 103 separate loci, excluding those found within 
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the HLA (Oksenberg and McCauley, 2016). However, all these identified risk loci have 
fairly modest effect sizes, with ORs of between 1.09 and 1.34 (International Multiple 
Sclerosis Genetics Consortium and Wellcome Trust Case Control Consortium 2, 2011; 
International Multiple Sclerosis Genetics Consortium, 2013). Taken together, the 
proportion of genetic variance accounting for disease risk explained by these genetic 
variants is about 30%; additionally, the number of risk variants that each individual 
with MS carries varies considerably (Oksenberg and McCauley, 2016). Furthermore, 
these risk variants are also fairly common within the population (Oksenberg and 
McCauley, 2016), however not everyone who carries such genetic risks will develop 
MS. Therefore, other risk factors must be necessary for MS to be triggered. This 
prerequisite is further reinforced by an apparently increasing MS prevalence over the 
past fifty years (Orton et al., 2006), which may be partially explained by improvements 
in diagnostic criteria (see sections 2.2.6-2.2.8 and 2.3.3). However, as the frequency and 
distribution of genetic risks are unlikely to have changed over this time, it is argued 
that increased or decreased exposure to an environmental factor or factors must be 
crucial in triggering MS onset (Oksenberg and McCauley, 2016).    
2.3.2 Environmental risk factors 
 Although environmental risk factors appear to be necessary for MS to manifest, 
identifying any such triggers has proved difficult and has led to a wide variety of 
diverse theories, some of which will be touched upon in Chapter 4. However, those 
theories that have been most enduring include smoking, the presence of EBV antibodies 
and infectious mononucleosis (glandular fever), vitamin D deficiency, and inadequate 
UV exposure.  
 Smoking has shown strong dose-dependent associations with a substantial 
increase in MS risk (Riise et al., 2003; Hernán et al., 2001). Furthermore, smoking may 
also be a risk factor in the conversion of CIS to clinically-definite MS (Di Pauli et al., 
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2008), and from RRMS to SPMS (Hernán et al., 2005). There is also some evidence that 
smoking may interact with specific HLA genes to increase MS risk (Hedström et al., 
2011). In a large umbrella review of systematic reviews, smoking was found to be 
associated with MS risk, with an OR of 1.52 (95% CI 1.39-1.66) (Belbasis et al., 2015). 
Although it is not clear quite how smoking increases MS risk, a study from Sweden, 
where snuff is commonly used (Eriksen, 2015), showed that cigarette smoking, but not 
snuff use, was linked to increased MS risk. This finding suggests that the deleterious  
effects of tobacco come from inhaling the smoke (Hedström et al., 2009). 
 The same umbrella review also found significant associations between MS and 
IgG seropositivity to EBV, (OR 4.46, 95% CI 3.26-6.09) and infectious mononucleosis 
(IM) (OR 2.17, 95% CI 1.97-2.39) (Belbasis et al., 2015). EBV is a common herpes virus, 
and is the cause of IM. Most people carry the virus without being aware of it, and not 
everyone who has the virus becomes sick with IM. However, MS appears to be very rare 
in people who have not been infected with EBV (Ascherio and Munger, 2007). It is 
therefore unsurprising that the review found that both EBV and IM were associated 
with an increased risk of MS. Additionally, a history of IM further increases risk of MS 
(Ramagopalan et al., 2010b). People with high levels of these EBV antibodies are at an 
increased risk of MS compared to people with lower levels, and further, the relationship 
appears to be temporal, as EBV antibodies increase several years before the onset on 
MS symptoms (Ascherio et al., 2001; Levin et al., 2005; Sundström et al., 2004). It is 
interesting to note, too, that a high level of EBV nuclear antigens, a protein which 
results from EBV infection, appears to interact with smoking to increase MS risk (OR 
1.7, 95% CI 1.1-2.6) (Simon et al., 2010a). The mechanism by which EBV increases MS 
risk is unclear, however one theory involves molecular mimicry, defined as the cross-
recognition of foreign and self peptides (Wekerle and Hohlfeld, 2003). It has been 
shown that a T-cell receptor from an MS patient can recognise two different peptides. 
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The first is an HLA-DRB1*1501-restricted myelin basic protein, a constituent of myelin, 
and the second is an HLA-DRB5*0101-restricted EBV peptide (Lang et al., 2002). This 
mimicry between a peptide involved in MS, and an EBV peptide, may influence MS risk. 
Perhaps more controversial are the risk factors of reduced UV exposure and 
vitamin D deficiency with MS risk, explorations of which form three chapters of this 
thesis and will therefore not be discussed in detail here. There is however a long 
history of the link between reduced UV exposure, vitamin D deficiency and MS 
(Acheson et al., 1960; Goldberg, 1974; Kurtzke, 1975). Furthermore, there are 
compelling arguments for the ways in which UV exposure and vitamin D may act both 
synergistically and independently to increase MS risk (Lucas et al., 2015; Lucas et al., 
2011). Finally, some interesting interactions have been identified between genes that 
are associated with vitamin D and increased MS risk (Ramagopalan et al., 2009b; 
Ramagopalan et al., 2011), all of which strongly suggests a causal association. One of 
the first clues that vitamin D may have a role in MS was from the geographical 
distribution of MS, which is introduced in the next section. 
 Several enduring theories, with increasingly compelling evidence, therefore 
exist to explain how MS may be triggered by environmental risk factors. Although their 
mechanisms are still not fully understood, epidemiology has enabled the identification 
of such risk factors, and also the interaction of risk factors. In the next section I discuss 
the concept of prevalence, and give a brief outline of the global and UK epidemiology of 
MS, before concluding this chapter. 
2.3.3 MS prevalence 
MS is usually described in terms of prevalence: the number of existing cases at 
either a particular point in time (point prevalence) or within a certain period (period 
prevalence). Point prevalence is the more common measure of the two (Szklo and 
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Nieto, 2012). For relatively rare, chronic conditions like MS, prevalence is a better 
measure of disease frequency than incidence, which seeks only to determine new cases 
within a specified period.  
Prevalence is used as an indication of disease burden in different locations. 
However, comparisons of prevalence in different studies can be problematic for several 
reasons. Firstly, as touched upon above, diagnostic criteria may not be similarly 
applicable in all areas or countries, or different criteria may be used. Secondly, the 
reporting of MS may not be uniform in all countries, with some countries appearing to 
have a low prevalence as cases have not been recognised, access to clinical expertise 
has been limited, or it has simply not been reported consistently to researchers, while 
other countries appear to have a high prevalence owing to more advanced diagnostic 
techniques, more, and more experienced clinicians in the field, and thereby greater 
recognition. Those countries with improving diagnostic techniques may appear to have 
a rapidly increasing prevalence, as increased incidence will contribute to greater 
prevalence until all existing cases have been identified and only new cases are being 
diagnosed. Thirdly, MS prevalence may be disproportionately affected in different 
countries by survival: the longer the survival following diagnosis – and indeed 
therefore the earlier the diagnosis – the higher is the disease prevalence. Care therefore 
needs to be taken in interpreting prevalence from different regions.  
 In 2008 the Multiple Sclerosis International Federation (MSIF) produced a 
world atlas of MS epidemiology which was updated in 2013 (Multiple Sclerosis 
International Federation, 2013). This atlas collated worldwide information regarding 
MS and, although there are limitations regarding the data as outlined above, and that 
some countries, often lower income countries, did not respond, this is probably the 
most complete current picture of MS worldwide. Figures 2.2-2.6 show the prevalence of 
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MS recorded in each country. All graphs show countries grouped alphabetically in UN-
defined regions. European countries have been presented in Eastern and Western 
European groups as per the UN, however to highlight MS prevalence in the north and 
south, we drew an arbitrary line across Europe to further subdivide Eastern and 
Western Europe into countries situated in more northerly or southerly areas. Those 
















































































































































































































































Figure 2.6 MS prevalence in Oceania 
 
 
Overall, it is estimated that around 2,500,000 people worldwide live with MS 
(Compston and Coles, 2002). Despite such potential difficulties in comparing studies 
across different regions, a clear picture of MS distribution has been noted with more 
cases appearing in countries situated further from the equator. An argument against 
this latitudinal gradient of MS is that a number of prevalence studies have been 
inappropriately compared; small numbers of cases, ascertainment errors, selection bias 
in non-population-based studies, different methods for adjusting for age and sex 
alongside different diagnostic criteria can all introduce bias which complicate the 
comparison of such studies (Poser, 1992; Koch-Henriksen and Sørensen, 2010). 
Furthermore, the latitudinal gradient appears to be attenuated after 1980 when 
incidence is used as the measure rather than prevalence (Alonso and Hernán, 2008). 
However, a comprehensive review of 321 peer-reviewed studies and resultant meta-
analysis found a significant positive correlation between latitude and MS prevalence in 
both northern and southern hemispheres, with two exceptions (Simpson S. Jr. et al., 




Atlantic region, which both showed inverse latitudinal gradients. However, in the 
Italian region, adjustment for HLA-DRB1 haplotypes (a strong MS risk factor) resulted 
in a positive gradient, suggesting that the distribution of HLA-DRB1 haplotypes are 
responsible for the unusual latitudinal pattern. Although genetic data were not 
available for the North Atlantic and Scandinavia region, none of the prevalence studies 
that comprised the meta-analysis included large proportions of low-risk groups, such 
as the Sámi (indigenous people of northern Scandinavia). However, the low prevalence 
at these high latitudes may be partially attributable to Sámi genes. The authors also 
hypothesise that the dietary intake of vitamin D which exceeds other areas of Europe 
could be responsible for conferring a protective effect against MS, and thereby 
reversing the normal latitudinal pattern. The two differences that were noted could 
therefore be explained by specific genetic and/or behavioural-cultural factors within 
these regions (Simpson S. Jr. et al., 2011). The latitudinal gradient is discussed in 
further detail in Chapter 6. 
 MS affects more women than men; a number of studies originally identified a 
ratio of about 2:1 (Confavreux and Compston, 2006). However, several recent studies 
have found an increased incidence of MS in women over the past decades, leading to a 
greater prevalence of disease and increased female to male sex ratio, of between 2.3 
and 3.5:1 (Ahlgren et al., 2011; Alonso and Hernán, 2008; Ramagopalan et al., 2010a; 
Wallin et al., 2012). A disproportionate number of women with MS also appears to be 
apparent in Orkney and Shetland and has appeared to increase in recent decades, with 
a collective female:male ratio of 1.3:1 in the 1970s to 2.14:1 in the 2000s 
(unpublished). Reasons for this increase in women and not men are currently unclear, 
however it appears that the difference may be arising from an increase in female RRMS 
cases, the phenotype of which may be more dependent upon environmental factors, 




Furthermore, some studies have reported a latitudinal association with a temporal 
increase in female to male sex ratio to be greater in northern Europe than southern 
(Trojano et al., 2012), whilst others have found no such increase (Bostrom et al., 2013; 
Mackenzie et al., 2014). The sex ratio does appear to alter depending upon age at onset 
and disease course. A greater number of females are diagnosed with paediatric MS 
(Patel et al., 2009) and RRMS (Ramagopalan et al., 2010a), whilst the female 
preponderance tends to reduce in PPMS (Tremlett and Devonshire, 2006) with some 
studies reporting a higher frequency of PPMS in males (Polliack et al., 2001). Males also 
tend to have a faster progression of disability (Confavreux et al., 2003), which may only 
be present in relapsing MS (Ribbons et al., 2015).  
The UK has an estimated MS prevalence of 203/100,000, with a female to male 
ratio of 2.4:1 which showed no sign of temporal variation between 1990 and 2010 
(Mackenzie et al., 2014). Within the UK, Scotland has the highest prevalence 
(255/100,000) (Mackenzie et al., 2014). Orkney was identified in 2012 as having the 
highest MS prevalence within Scotland (402/100,000 – and indeed the world – with 
Shetland also very high (295/100,000) (Visser et al., 2012). The MS prevalence of 
Orkney and Shetland will be discussed in more detail in Chapter 4. 
2.4 Summary 
 In this chapter, I have discussed how MS was recognised as a disease after a 
long history of anecdotal reports of temporary paralysis with increasingly debilitating 
symptoms. From here, I have shown how our understanding of the biological 
mechanisms and physical changes that occur in MS has evolved with extensive 
research, however the precipitating factor that causes the initial inflammatory 
response is still unclear. Despite this enduring uncertainty, studies have identified 
numerous genetic risks of which HLA-DRB alleles are most prominent, two 




namely smoking and EBV, and two slightly more controversial and interconnected risk 
factors, vitamin D deficiency, and inadequate UV exposure, which will be explored in 
detail later in this thesis. What is clear from the many prevalence studies of MS and 
reviews is that MS is widespread globally but tends to appear more frequently with 









CHAPTER 3. THE RESEARCH SETTING: ORKNEY AND SHETLAND 
In this chapter, I introduce the islands of Orkney and Shetland, in which the 
primary research for this thesis was undertaken. Both the geographical location and 
relative isolation of the islands are important features to the studies of MS risk factors 
presented within this thesis. I begin this chapter by introducing the geographical 
location of Orkney and Shetland, and an overview of the general yearly climate. The 
geographical location and the local environment may have considerable implications 
for the population for two MS risk factors: vitamin D deficiency and reduced UV 
exposure, which I explore in detail in Chapters 7 and 8. I then go on to describe how the 
geographical location of the islands, alongside events over the centuries and in more 
recent years, have impacted the population structure and genetic makeup of the 
islanders today, resulting in distinct genetic isolates. Such genetic isolation may also 
have implications for MS. This is because in the absence of gene flow from the general 
population, rare and deleterious mutations can increase in frequency, and this can 
increase risk of disease in the population. I explore the possibility that the high 
prevalence of MS in Orkney and Shetland may result from an increased genetic risk in 
Chapter 5.  
3.1 The Archipelagos 
Collectively known as the Northern Isles, Orkney and Shetland are two distinct 
archipelagos forming the most northerly and remote areas of the British Isles (Figure 
3.1). Orkney lies ten to sixty miles from the north coast of Scotland, across the Pentland 
Firth; Shetland is situated 50 miles north of Orkney, 170 miles southeast of the Faroe 
Islands and 225 miles east of Norway. The archipelagos sit between latitudes 58.8o and 
60.7o north (similar to St Petersburg and Anchorage, Alaska), with the Atlantic Ocean to 
the west and the North Sea to the east. Orkney comprises about 70 islands, of which 17 




Figure 3.1 Map of Orkney and Shetland with 51st to 59th lines of latitude 
 
Orkney and Shetland are characterised by relatively high rainfall, few sunshine 
hours, and a temperate climate which is warmer than may be expected at such high 
latitudes, owing largely to the influence of the North Atlantic Current (Scottish 
Government, 2011) (Figures 3.2-3.4). To put the Orkney and Shetland climate into the 
context of the British Isles, Edinburgh and Glasgow, which are located further south in 
Scotland, and Hastings, located in the far south-east corner of England and which is 
noted for its warm and temperate climate, are included in the following figures. These 
other locations illustrate the diverse weather conditions within the UK and highlight 
that the climate in Orkney and Shetland is generally harsher and less temperate than 




















As well as high rainfall, scarce sunshine, and a relatively warm climate for their 
latitude, the islands are characterised by high wind speeds (Figure 3.5). Such inclement 
weather, coupled with the remote geographical location, has meant that historically 





Figure 3.5 Average wind speed, Orkney, Shetland, Edinburgh, Glasgow, Hastings 
 
(Windfinder, 2000) 
Population isolates result from cultural or geographical isolation of a 
subpopulation for which there are genetic consequences. In the next section, I give an 
overview of when Orkney and Shetland were settled, and how the population has 
evolved into the current population of the islands today. I also discuss how modern 
industry, emigration, and immigration have shaped the current population structure 
and contributed to the Northern Isles gene pool.  
3.2 Population history 
3.2.1 The Mesolithic, Neolithic, Bronze Age and Roman era 
 Evidence for human habitation of Orkney and Shetland dates back to the 
Mesolithic era some 10,000 years ago. At this time, sea levels were lower than they are 
today and the land mass was much larger; what would have been the high ground to 




2012; Flemming, 2004). The Mesolithic people were nomadic hunter-gatherers; their 
itinerant lifestyle, alongside the changing landscape means that a very limited 
archaeological record remains. However, pieces of charred hazelnut (Archaeonews, 
2007) and collections of worked flint (Towrie, 2007) provide evidence of their 
presence. The Neolithic period, beginning circa 4000 BC, is however well represented 
in Orkney and Shetland archaeology; the Heart of Neolithic Orkney, four monuments 
comprising two stone circles, a large settlement and a chambered tomb, is a UNESCO 
world heritage site paralleled in size and significance only by sites in Wessex (Unesco 
World Heritage Centre, 2016). 
 The Neolithic saw hunter-gatherers evolving into agricultural communities, 
which necessitated permanent settlement. The remains of houses, monuments, burial 
cairns, and the bones of domesticated animals give clues of their daily lives (Jones, 
1999; Reilly, 2003), whilst the discovery of the Ness of Brodgar, a vast Neolithic 
complex of domestic and ritual buildings, suggests a focal point for people across 
Orkney (Towrie, 2009). Additionally two types of Neolithic pottery found in Orkney 
may denote different tribes, or may instead suggest the emergence of an elite group 
forming a stratified society (Towrie, 2015b; Brophy and Sheridan, 2012). 
 A number of finds in Shetland, including knives made of locally-mined felsite, 
and extensive field systems at the Scourd of Brouster (Mercer, 1987) show increasing 
human habitation and a growing agricultural tradition in Shetland in the Neolithic 
(Edwards and Whittington, 1998; Childe, 1938). Contact between Orkney and Shetland 
had been made by the end of the era, evidenced by their shared use of ceremonial 
maceheads (Brophy and Sheridan, 2012). 
 The Bronze Age appeared to touch Orkney only lightly; it is thought that this 




increased, making living and farming in Orkney difficult and travel to the islands more 
hazardous (Towrie, 1996). Complex archaeological settlements are however evident in 
Shetland (Childe, 1938; Guttmann, 2005). From 600 BC the inhabitants of both island 
groups began building roundhouses, the design of which became increasingly 
sophisticated over the next centuries. By 100 BC these roundhouses had become 
Brochs, large round stone defensive dwellings of which the remains of up to and over 
100 are to be found in each of Orkney and Shetland. As it is estimated that each broch 
could house up to 50 people, the Iron Age population can be estimated to be up to 5000 
people in both island groups (Boyce et al., 1973). 
The Iron Age gave way to the Roman era; however, despite being fully aware of 
Orkney’s existence (although maybe not of Shetland), the Romans themselves probably 
never set foot on the islands (Berry and Firth, 1986). The Iron Age in Orkney and 
Shetland is therefore often considered to stretch from 700 BC to AD 800 (Armit and 
Ginn, 2007). During the late Iron Age, it is thought that Pictish culture emerged 
amongst the indigenous Iron Age populations of Orkney and Shetland, and continued 
from about 300 to 800 AD. The name ‘Pict’ likely derives from ‘Painted People’, so-
called by the Romans, however little else is known about this group of people. Their 
legacy on Orkney and Shetland largely comprises ornate stone carvings, sometimes 
with rune-like lettering (Berry and Firth, 1986).  
3.2.2 The Vikings, Earldoms, and annexation to the Scottish Crown 
What is evident, however, is that from the 8th century AD Norsemen began to 
colonise Orkney and Shetland. Whether the Vikings integrated peacefully or effectively 
obliterated the preceding culture is a matter of great debate. To the present day, the 
Vikings most noticeably left their mark on the place names of Orkney and Shetland; the 
scarcity of pre-Norse place names suggests that the incomers may have overwhelmed 




for peaceful integration also exist; a Norse house found on the site of a Pictish 
settlement was found to contain Pictish artefacts suggesting integration of the two 
cultures (Ritchie, 1976).  
As might be expected, genetic evidence in this North Atlantic region shows a 
large proportion of Scandinavian ancestry in Orkney and Shetland, although these data 
cannot tell us if invading Vikings took indigenous Pictish wives or if islanders of 
Scandinavian descent intermarried in later years with Pictish or Scottish immigrants. 
However, the invading forces of Orkney and Shetland appeared to settle as families. 
This is evidenced by roughly equal proportions of Scandinavian mitochondrial DNA, 
which is inherited from mothers, and Scandinavian Y-chromosomes, which are 
inherited from fathers, in Orkney and Shetland (Figure 3.6). Such equal proportions of 
maternal and paternal DNA strongly suggest that Scandinavian couples settled on the 
islands together. This finding is in contrast to those of Iceland and the Western 
Isles/Skye. Although it appears that whilst some couples settled in these locations 
together, the preponderance of Scandinavian Y chromosomes in comparison with 
Scandinavian mitochondrial DNA (particularly noticeable in Iceland) suggest that a 




Figure 3.6 Map showing the proportions of Scandinavian and British/Irish 
mitochondrial DNA and Y-chromosome for admixed populations in the North 
Atlantic region 
 
(Goodacre et al., 2005) 
 
Politically turbulent times followed the Norse colonisation of Orkney and 
Shetland. The Norse Jarls, or Earls, who were based in Orkney, began by ruling Orkney, 
Shetland, parts of Caithness, and Sutherland (so-named for being south of Orkney), 
however in 1195 Shetland was removed from the Jarl’s control as punishment for his 
involvement in a rebellion two years earlier (Imsen, 2010). Shetland became a Lordship 
and remained closely aligned with Scandinavia, however the Jarl’s remaining area of 
responsibility focussed much more on lands around the Pentland Firth. Perhaps 
unsurprisingly connections with Scotland strengthened in Orkney in this time (Imsen, 
2010).  
The last Jarl was murdered in 1231 with no heirs apparent. The Jarldom then 
passed into the family of Angus, a Scottish dynasty who were also Earls of Caithness, 
however Orkney officially remained subject to Norway. The Earls of Angus continued to 
rule throughout the thirteenth century, eventually losing Sutherland to a different 




respectively ruled Orkney, still under the Norwegian crown, and Caithness. However, in 
1375 the Earldom of Caithness passed back to the Scottish crown leaving Orkney the 
only remaining part of the Earldom.  
Norse rule remained until 1468 when Orkney was pledged as part of the dowry 
of Margaret, daughter of King Christian I of Demark, Norway and Sweden, who was 
betrothed to King James III of Scotland. The pledge was redeemable against a payment 
of 50,000 Rhenish Florins, however one year later, after no payment had been made, 
Shetland was pledged against a further 8,000 Rhenish Florins. Unable to redeem the 
islands, in 1472 Orkney and Shetland were annexed to the Scottish crown and absorbed 
into the Kingdom of Scotland (Miller, 1985).  
Over the next several hundred years the Scottish population of the islands 
increased, although the extent to which new settlers arrived and contributed to the 
island populations is unknown. A large number of Scots were given land by 
contemporary Earls, and families with surnames such as Spence, Sutherland, and 
Sinclair, prominent in today’s island populations, arrived during these centuries. A 
Shetland landowner noted in 1633 that the south parishes of Shetland “are, for the 
most part, Strangers from Scotland, and Orkney whose Language, Habite, Manners, and 
Dispositions, are almost the same with the Scottish…” (Monteith, 1845). The Court 
Book for Orkney and Shetland of 1614-1615 records the names Eriksone and 
Johnsdochter in Shetland; such local patronymics including Herculeson and Jarmson 
are still common in Shetland today. Orkney, conversely, had no patronymics recorded. 
Instead, the Orcadian names listed in the Court Book are typical Scots, such as Spence 
and Sinclair, or are instead derived from place-names, including Halcro, Clouston and 
Corrigall. Naming a farmer after his land is a Scottish tradition, suggesting that the 




name surnames, like the Shetlandic patronymic surnames, are highly enriched for 
Norse Y chromosomes, showing that whatever the origin of the tradition, Orcadian 
place-name surnames were overwhelmingly founded by Norsemen (Wilson et al., 
2001). Y-chromosome analysis of an Orkney-wide sample suggests an approximately 
53% Norse and 47% Scots split (Wilson, unpublished). Further evidence for the 
sizeable infiltration of Scottish people and culture comes from the loss of the Norn 
language, which was derived from Old Norse and had local dialects in each archipelago. 
By 1800, the language was no longer spoken with any proficiency (Barnes, 2010), 
suggesting that the Scots way of life had largely overtaken the old Norse ways. 
3.2.3 The impact of industry, modernity, emigration and immigration 
A well-documented history of Orkney’s involvement with the Hudson’s Bay 
Company (HBC) exists. Records kept by the HBC show that from 1702 the company 
started calling at Stromness in Orkney to recruit men for their labour force. Following 
the Act of Union between Scotland and England in 1707, these recruitment visits began 
on a yearly basis reaching a zenith between 1771 and 1799, when 80% of the 529 HBC 
employees were Orcadian. A large number of Orcadians settled in Canada and married 
Cree women, one of the First Nation peoples. They thereby bestowed local Orcadian 
names on the new lands, and surnames such as Flett, Foubister, and Linklater, on the 
native population (Troup, 2003; Moffat and Wilson, 2011). At least five instances are 
known of men returning to Orkney with Cree wives (Berry and Firth, 1986), thereby 
contributing Cree genes to the modern Orcadian genepool.  
A regular influx of Dutch traders is also well documented. The Dutch became 
familiar with Shetland from the herring fishing that brought them to the lucrative 
waters from the mid-1600s. In 1633 Montieth wrote that “All the natives can speak the 
Gothick or Norwegian tongue… by reason of their Commerce with the Hollander, they 




“those who commonly frequent this country and trade with the inhabitants are 
Hamburgers and sometimes Bremers and others… and in several places set up booths 
or shops where they sell liquors, as beer, brandy, etc., and wheaten bread… they also 
sell several sorts of creme-ware, as linen, muslin, etc” (Brand, 1701). The Dutch 
connection endured, despite the Anglo-Dutch wars that ran intermittently between 
1652 and 1784. Sir Walter Scott noted in his diary of his 1814 vacation: “At Lerwick the 
Dutch fishers had again appeared at their old haunts. A very interesting meeting took 
place between them and the Lerwegians, most of them being old acquaintances… In 
general they are extremely quiet, and employ themselves in bartering their little 
merchandise of gin and gingerbread for Zetland hose and nightcaps” (Grierson, 1932). 
Despite such a connection, it is considered that the Dutch left no enduring cultural 
mark on the islands (Grydehøj, 2013). 
Trade and industry were clearly bustling on the islands at this time with large 
numbers of people both coming and going. However, our knowledge of the Orkney and 
Shetland populations, and how they were affected by this movement, are limited, as few 
early attempts were made to systematically map the industry, economy, and population 
of Scotland. The first successful population census was produced in 1755, followed by 
the Old and New Statistical Accounts of Scotland, produced in 1799 and 1832 
respectively. The Third Statistical Account was published in 1951. Enumerators 
provided statistical returns from 1801 to 1831, which detailed the population sizes of 
Scottish districts, and in some cases noted the details of householders and their 
occupations. However, the quantity of information collected was dependent upon each 
individual enumerator; additionally, survival of the records is poor (personal 
communication, Martin, 8 April 2016). Full censuses, listing the name and occupation of 




these statistical returns provide a reasonable estimate of the population sizes of the 




























































































Between 1755 and 1801, the population in Shetland increased significantly, 
however Orkney’s population remained quite stable. This constant population size has 
been attributed to significant emigration from Orkney which prevented population 
growth (Thomson, 2008). Slow population growth continued in Orkney, with a slight 
decline in Shetland, between 1801 and 1811. A large number of Orcadian and 
Shetlandic men were pressganged into, or volunteered for, the navy at this time, to fight 
in the French Revolutionary Wars (Miller, 1985). In 1884 it was estimated that at the 
preceding war, 12,000 men from Orkney and Shetland had been in the navy (Fea, 
1884); a considerable number for the population size. 
Both groups of islands grew in population from 1811, peaking in 1861. 
Throughout these years, the herring fishing industry boomed and continued to increase 
through to the early 20th century. Scottish boats followed the herring from the West 
Coast to Shetland, Orkney, Wick and as far south as Lowestoft (Berry and Firth, 1986). 
It was estimated that an additional 4000 people arrived on these boats in Orkney each 
twelve-week herring season before moving on, whilst 21,201 people were involved in 
the industry at its peak in Shetland (Gordon, 1845; Simpson, 2009). It is from this 
period that the saying came into being, that a Shetlander is a fisherman with a croft and 
an Orcadian is a farmer with a boat (Thomson, 2008), an adage that continues to 
summarise the islands today.  
While Shetland’s craggy terrain and hilly moorlands resulted in meagre 
subsistence crofting, the fertile land in Orkney lent itself to generations of farming. 
Farming practices in Orkney began to change with the Agricultural Revolution, which 
began in the 18th century and led to a change from subsistence farming to a market 
economy. Lairds recruited people, likely from mainland Scotland, skilled in new 




Following the end of the First World War large taxes on big landowners led to a 
number of small farms being sold to their occupiers (Berry and Firth, 1986).  
Communication also became easier during the 19th century. The first 
commercial enterprise offering ease of access and departure was a steamboat service, 
run by the North of Scotland and Orkney and Shetland Steam Navigation Company, 
which was  founded in the 1830s to carry shipments of food and passengers (Special 
Collections Centre, 1810-2002). However, then and still today, sea travel is at the mercy 
of storm-force winds and rough conditions (Towrie, 2015a).  Although some 
construction of roads had begun in Orkney from the 1760s, a programme of substantial 
road building began in 1857. Shetland, whose roads until this time had been minimal, 
saw systematic construction of roads between 1849 and 1852 (Moodie Heddle and 
Mainland, 1920).  
These decades of population increase were followed by over a century of steady 
population decline. Despite periods of ample employment opportunity, many islanders 
were attracted by a new life in the colonies or America (Tudor, 1883). Enough people of 
Orcadian and Shetlandic descent had settled in America by the last quarter of the 19th 
century for the establishment of the Orkney and Shetland American newspaper. An 
1889 survey of emigrants collected 3000 Northern Isles names, and the editor 
estimated that the same number again had not replied (Thomson, 2008).  
During this period of emigration, more men were leaving Orkney and Shetland 
than women. This selective emigration led to greater numbers of women remaining in 
Orkney and Shetland. In 1861 Shetland had 143 females to every 100 males, while 
Orkney had 117 females to every 100 males (Census of Scotland, 1861). Although the 
home-knitting and herring industries, and other occupations, kept women gainfully 




By reason of this constant drain of the male part of our Inhabitants, we must necessarily 
have a much greater number of women than men among us, who being destitute of any 
kind of employment, must ly as an useless burden on the country; and, what is still 
worse, many of them must likewise be destitute of husbands, by which means they 
degenerate into that wretched species of beings called Old maids, so that to all our other 
evils, that of being pestered with the female Grimalkins is likewise added (Fea, 1884). 
 
The World Wars saw a large influx of military personnel, garrisoning the islands 
and manning the naval bases (Berry and Firth, 1986; Blackadder, 2007), while 
Orcadian and Shetlandic men were conscripted. In the Second World War Shetland 
upheld its Norwegian connections as civilians sailed to Nazi-occupied Norway in boats 
disguised as fishing vessels. There, they delivered weapons and supplies to the 
resistance, and rescued agents fearing capture by the occupying forces (Howarth, 
2008). Orkney’s wartime heritage lies in Scapa Flow – the naval base for the Grand 
Fleet in both wars – where shipwrecks of sunken vessels are still visible, and in the 
remains of gun batteries around the islands. The most significant change, however, is 
possibly the construction of the Churchill Barriers, a series of causeways linking the 
islands and further blocking off the eastern approaches. Constructed by Italian 
prisoners of war, these concrete barriers linked the previously separate isles of Lamb 
Holm, Glimps Holm, Burray and South Ronaldsay with the Mainland of Orkney. As well 
as permanently changing their topography, these barriers also provided easier 
movement throughout the south isles and to the mainland. 
Charting the population change by registration district in Orkney from 1891, 
near the beginning of the decline, to 1961 (Figure 3.8), clearly shows a greater loss 
from the island communities (coloured green), compared to mainland Orkney 
(coloured blue). The only parish to increase in population was the capital, Kirkwall. 
Slightly smaller losses were seen in places with small towns or large villages, for 




Although less clear because of the registration district boundaries in Shetland 
which group some island and mainland parishes together (coloured brown), it is still 
evident that the capital of Lerwick on the mainland (mainland districts coloured blue) 
was the only parish to increase in size (Figure 3.9). The island parishes, (in green), also 
incurred losses. Again, the parish with the next largest settlement shows the smallest 
































































































The 1970s and 1980s saw a substantial increase in the population sizes of 
Orkney and Shetland as it became increasingly easy to travel. Loganair started a 
chartered air service to Orkney in 1967, and to Shetland in 1970 (Loganair, 2010), 
which, until recently would be regularly grounded by thick sea mist (Towrie, 2015a). 
The discovery of North Sea oil and the concomitant industry that built up brought in a 
number of workers and their families. Additionally, urban refugees, seeking a change 
from town and city life, were also responsible for the increasing population (Forsythe, 
1980). Through this period, considerable immigration from English cities unfolded. The 
population of Shetland swelled by almost 10,000 between 1971 and 1981, an increase 
of 36.5%; Orkney’s population increased by the more modest but still considerable 
10% over the same period. In 1986, Egilsay had one native-born Orcadian among the 
remaining population of 24; further, an unnamed island with a population of 186 in 
1981 comprised 41% incomers (Berry and Firth, 1986).  
Since 1991, the population sizes in Orkney and Shetland have remained more 
stable, although they continue their upward trajectory possibly because of a longer-
lived and aging population. At the 2011 census, the Orkney population totalled 21,349, 
a near-11% increase on the previous census. Compared to mainland Scotland, Orkney 
has an older age profile, and an increasing elderly population. By gender, 49.5% of the 
population were male in 2011 (HIE, 2014a), compared with 48.5% on the Scottish 
mainland. The 2011 census also revealed that relative to Scotland, Orkney had a higher 
share of employment in agriculture, forestry or fishing (10% of the workforce 
compared to 2%), in construction (11% compared to 8%), and in transport and storage 
(9% compared to 7%). The workforce in Orkney and mainland Scotland were roughly 
equal in the mining, quarrying and utilities industry (~3%), accommodation and food 




were also more numerous in Orkney compared to Scotland (22.5% compared to 
12.5%) (HIE, 2014a).  
 Shetland, meanwhile, had a total population of 23,167 at the 2011 census, 
which was an increase of 5.4% on the previous decade. However, compared to the rest 
of Scotland Shetland has a younger age profile. Although there has been an increase in 
the older population in Shetland, proportionately it is a smaller increase than seen 
elsewhere. By gender, Shetland has a greater proportion of males than elsewhere in 
Scotland at 50.8% (HIE, 2014b). The 2011 census showed that relative to mainland 
Scotland, and like Orkney, Shetland has a higher proportion of the workforce employed 
in agriculture, forestry and fishing (~6%), construction (11%), and transport and 
storage (10%); and also education (~10% compared to ~8%) and health (16% 
compared to 15%). Similar to Orkney, skilled trades are more common (20% of the 






3.3 Population structure of Orkney and Shetland 
A number of events over the centuries and more recently have therefore shaped 
the origins of today’s Orcadians and Shetlanders. However, despite the fluctuating 
population size, emigration, and immigration over the years, Shetland and Orkney are 
genetic isolates.  
3.3.1 Orkney and Shetland’s DNA 
The genetic structure in Orkney has been more frequently studied than the 
genetic structure in Shetland, and is therefore understood in greater detail. A 2015 
study (which excluded Shetland) found that Orkney was the most genetically distinct 
compared to the other UK populations studied (Leslie et al., 2015). Furthermore, within 
Orkney, people of Westray, Stronsay and Sanday ancestry were found to be identifiable 
from DNA alone (O'Dushlaine et al., 2010; Leslie et al., 2015). This demonstrates that 
within Orkney, at least three islands have maintained considerable isolation 
(O'Dushlaine et al., 2010), and it is likely that other outlying districts would show a 
similar pattern. The picture within Shetland is considerably less explored and therefore 
more ambiguous. However, a 2005 study found that Shetland’s DNA is distinct from 
Orkney, and is possibly the most genetically differentiated of the ten Scottish 
populations studied (Vitart et al., 2005). This uniqueness of and within Orkney, and of 
Shetland, may have implications for genetic risks in this population. A recent study 
reported the identification of a highly prevalent BRCA1 mutation in a region in the 
Tyrol, in 238 apparently unrelated families, which correlates with an increased 
incidence of breast and ovarian cancers (Pölsler et al., 2016). There is a possibility that 
a similar, as-yet unidentified, genetic risk for MS could be found in our study region, or 
that small differences in the frequency of common genetic variants might act 





As well as information about the origins of the islanders, genetic differences 
and similarities among the various communities that make up Orkney and Shetland can 
be deduced from information about the inter-relationships of the island inhabitants 
(Roberts et al., 1973). Particularly where population sizes are small, recent increased 
movement between communities can have a large impact on genetic variation (Roberts 
et al., 1973). Demographic statistics available from the 1841 census onwards help to 
illuminate how the population structure may have changed over the last one to two 
hundred years (Harrison and Boyce, 1972).  
 One method of assessing the degree of isolation of a community is by examining 
the proportion of endogamous marriages (Figure 3.10), defined as a marriage in which 
both partners are from the same community. In 1861, there were already differences 
among the island parishes in the degree of isolation. Kirkwall and Stromness, the two 
most populous parishes of Orkney (containing small towns), showed the least 
endogamy while the North Isles, including Westray, North Ronaldsay and Sanday, had 
the highest degree of isolation by endogamous marriage (Roberts et al., 1973). Some of 
the South Isles and outlying Mainland parishes such as Birsay and Deerness also show 
























































































Analysis of marriage certificates between 1855 and 1965 on Sanday, which had 
a proportion of roughly two-thirds endogamous marriages in 1861, found that the 
distances between the residences of husbands and wives at the time of marrying in 
Sanday was largely negatively skewed (Figure 3.11). Few couples comprised one 
partner born outside of Sanday. Thirty percent of marriages were between spouses 
living 1 mile apart or less, with a further 28% between those living from 1 to 3 miles 
apart (Roberts et al., 1973). A similar pattern was noted on Westray, where the 
distance between the residences of future spouses was up to one mile for over 40% of 
couples marrying between 1855 and 1974 (Collacott, 1979).  
Figure 3.11 Distribution of distances between residences at time of marriage of 
husbands and wives marrying on Sanday between 1855 and 1965 
 
(Roberts et al., 1973) 
Whilst Figure 3.11 illustrates that spouses mainly lived close to each other at 




been living in the isle all their life, and who may be a newcomer. The end of the Sanday 
study preceded the large influx of people from the 1970s, and it may therefore be fair to 
assume that there were few newcomers. Meanwhile, the proportion of Westray 
residents marrying from within Westray had barely changed from 1855 to 1974 
(Collacott, 1979). However, from the 1970s onwards, it is more likely, due to the 
increased emigration, that more couples may comprise one partner who had been born 
outside the isles or even outside Scotland.  
A further method of illustrating the population genetic structuring present in 
the islands is by surname analysis. Data from the Orkney phone book from 1979 to 
1980, after the period of mass immigration to the islands, give an idea of how such 
immigration may have altered the population structure (Lamb, 1980). Figure 3.12 
highlights three surnames: Rendall, Sinclair, and Drever, each of which is particularly 
prominent in different parishes. Rendall shows an enrichment in Westray, but is also 
seen in Stronsay, Shapinsay, Stromness, and Kirkwall. Sinclair is a bit more widespread 
but nonetheless is concentrated in Sanday, Shapinsay, Stromness, Flotta, South Walls, 
and in the northern parish of South Ronaldsay. Drever likewise clusters in Westray 
with some scattering over the other North Isles and mainland. These examples 
demonstrate ongoing male lineages with little evidence of panmixia, meaning that there 














However, it is important to note that while this structuring remains within the 
isles, the modern movement of people into and out of each parish are different and may 
have disproportionately affected some parishes. Each parish and island community has 
its own unique history against which the remaining population today is shaped. The 
proportion of remaining indigenous populations are therefore quite different in each 




work the land; fishing communities more likely to lose their population as they either 
followed the fish, or, subsequent to the collapse of the fishing industry, sought 
employment elsewhere.  
3.4 Summary 
In this chapter, I have introduced Orkney and Shetland and have discussed their 
relative isolation caused by both their geographical location and by the characteristic 
inclement weather, which has historically discouraged travel to and from the islands. 
Further, I have discussed the population history of Orkney and Shetland, from the 
earliest settlers through to the present day, and illustrated how the populations have 
been shaped by industry, emigration, and immigration. Finally, I have discussed the 
present day population structure of the islands, and have shown that although 
increased movement of people has affected areas differently, analyses have shown that 











CHAPTER 4. DISTRIBUTION OF MULTIPLE SCLEROSIS IN THE 
NORTHERN ISLES 
4.1 Introduction 
Evidence from past and recent studies suggest that Orkney and Shetland have a 
very high prevalence of MS. In 2012 prevalence in Orkney was estimated to be the 
highest in the world, with the prevalence in Shetland being only slightly lower (Visser 
et al., 2012) and possibly the third highest worldwide after Atlantic Canada (Beck et al., 
2005). This finding followed a history of studies of the region, each observing a high MS 
prevalence in the Northern Isles compared to the rest of the UK and globally. Table 4.1 
presents an overview of some high prevalence regions within high prevalence 
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1 Studies included here resulted from a search of PubMed to identify high-risk areas of high-latitude 
countries. The search was not systematic or exhaustive; these studies are only to provide some context of 
how MS prevalence in such high-risk areas of high-latitude countries compare 
2 Not specified in the study but categories of MS described fit the Allison and Millar criteria 




For the studies of Orkney and Shetland in Table 4.1, prevalence was defined as 
the proportion of the population diagnosed with MS in the population at risk (Orkney 
or Shetland), at a particular point in time. It is clear from Table 4.1 that the prevalence 
of MS in Orkney and Shetland, despite the difficulties in comparing studies of different 
regions that were highlighted in Chapter 2, is very high on a global scale. However, it is 
also important to note limitations in interpreting and comparing the results from the 
four Orkney and Shetland studies. There are five reasons why the conclusions that can 
be drawn may be limited.  
Firstly, as previously discussed, prevalence is affected by survival. Thus, studies 
comparing multiple countries that have different health care systems may lead to 
disproportionate prevalence: countries with lower quality healthcare systems may 
have lower survival rates and therefore a lower prevalence than countries with higher 
quality healthcare systems. However, in comparing older with newer prevalence 
studies, advances in treatment over the years may mean that current prevalence 
estimates are also an artefact of survival effects rather than an increasing incidence of 
MS. 
Secondly, prevalence estimates depend upon diagnostic accuracy, the precision 
of which depends on the application of diagnostic criteria to assess whether presenting 
symptoms are caused by MS. Because the clinical phenotype is variable, application of 
such criteria will likely vary and have a considerable margin of error (Compston and 
Confavreux, 2006).  
Thirdly, updates to diagnostic criteria may lead to the inclusion or exclusion of 
individuals who would be differently categorised according to each set of criteria. This 
was seen in the studies of Fox et al. and Forbes et al. (Table 4.1), who both used two 




Forbes et al., 1999). The inclusion of MRI data in the McDonald criteria has enabled 
earlier detection of MS and therefore identifying CIS before conversion to clinically 
definite MS (Miller et al., 2008), and including CIS in prevalence estimates will be 
leading to increased prevalence.  
Fourth, initial studies of an area are likely to underestimate prevalence, while 
subsequent studies are likely to identify a greater number of cases as investigator 
vigilance increases and awareness among the population at risk is raised (Compston 
and Confavreux, 2006). Intensively studied areas, such as Orkney and Shetland, may 
therefore not be directly comparable to less studied areas.  
Finally, prevalence estimates rely on case ascertainment, which itself often 
inversely varies with the size and accessibility of the population at risk, particularly as 
people within smaller, cohesive communities are more likely to be aware of new and 
existing cases of disease compared to those in large, urban settings (Compston and 
Confavreux, 2006). The small community sizes of Orkney and Shetland could therefore 
result in greater identification of cases than in more populous regions.  
It should also be noted that the prevalence estimates from the most recent 
study of Orkney and Shetland are adjusted for age and sex (Visser et al., 2012). The 
crude, unadjusted estimate is slightly higher in Orkney (410 (95% CI 326 to 509), and 
slightly lower in Shetland (291 (95% CI 225 to 371)) in comparison with the adjusted 
estimates presented in Table 4.1. However, it is clear that these prevalence estimates 
are very high in comparison with other regions and other time periods within the same 
region. 
As described in Chapter 2, rising incidence can also lead to an increasing 




studies are difficult in small places because of the overall small number of cases and the 
time that would be needed for sufficient cases to occur. However, those that have 
studied incidence found that the incidence rate was either stable in both archipelagos 
(Poskanzer et al., 1980a) or, in Orkney, declining (Cook et al., 1985). However, I also 
described in Chapter 2 how a disproportionate increased incidence in women over the 
past decades has resulted in increased prevalence, as well as an increased female-to-
male sex ratio (Midgard et al., 1996; Kotzamani et al., 2012; Hirst et al., 2009; Barnett et 
al., 2003; Alonso and Hernán, 2008; Orton et al., 2006; Ramagopalan et al., 2010a; 
Wallin et al., 2012). The most recent prevalence study of Orkney and Shetland showed 
an increasing female-to-male ratio of prevalent cases by birth year (Visser et al., 2012). 
It is possible that the increasing sex ratio of prevalent cases in Orkney and Shetland 
reflects an increase in incidence, as it has elsewhere.  
Despite limitations, it is clear that Orkney and Shetland have a very high 
prevalence of MS which appears to have been increasing in recent years. Such high 
prevalence is of concern in these islands. In this chapter I seek to explore two questions 
regarding MS in the Northern Isles: 
1) Can clusters of MS be identified within Orkney and within Shetland, either in space, in 
time, or in space and time?  
2) Do any identified clusters illuminate potential environmental factors involved in the 
aetiology MS? 
I begin by exploring what is meant by ‘disease cluster’, and the challenges of 
establishing with any confidence whether disease clusters exist. I then discuss why 
disease clusters are interesting epidemiologically, and particularly in the context of the 





I then describe the methods for investigating potential MS clusters in the 
Northern Isles and present the results of analyses, and in conclusion I assess some of 
the challenges encountered in this investigation, and the limitations of the available 
data to address the research questions effectively. Finally, I make recommendations as 
to how this question could be more effectively investigated. 
4.2 Background 
4.2.1 What is a disease cluster? 
The term ‘disease cluster’ is inconsistently defined in epidemiology. However, 
when the purpose is to look for a shared environmental aetiology, the implication is 
that an excess of cases against some background rate should be evident. Clusters 
resulting from an environmental cause should be specified within boundaries of time, 
or of space, or of time and space. Temporal clusters refer to fluctuating incidence of 
disease that follows similar patterns in different places. Spatial clusters refer to an area 
in which a disease appears more highly prevalent (Rothman, 1990b). Spatiotemporal 
clusters, however, refer to an aggregation of disease in terms of both time and space 
and are considered the most revealing for an environmental aetiology, because 
explanations of the cluster are limited to factors that occur within the vicinity of, and 
with a temporal relationship to, the apparent disease excess (Rothman, 1990b). 
However, exactly how to define these boundaries is not clear.  
When several cases of disease are spotted together – such as a series of cancers 
along the same street – it is tempting to search for a common environmental exposure 
that could be aetiological. Such cluster identification focuses on the occurrence and 
identification of cases, and does not consider the timing of exposure. In this case, for 
example, any exposure which may have contributed to the cancer may have happened 
years prior to disease onset. This period of latency, as well as different periods of 




common exposures are merely coincidental, and will not be related to the same disease 
in other areas (Murray, 2004; Rothman, 1990b).  
Further, in small study regions, identifying a population denominator in terms 
of time and space is complicated by population fluctuations that are not recorded in the 
decades between censuses. These fluctuations, including emigration and immigration 
which lead to increasing or decreasing population sizes, can introduce errors that 
would be cancelled out in larger studies (Elliott and Wartenberg, 2004; Elliott and 
Wakefield, 2001).  
Three further issues also complicate clustering analyses. One of these problems 
in boundary shrinkage. This is a problem where the identified population from which 
the cases are supposed to have arisen is too small. As a consequence, this will inflate 
the numbers in the apparent cluster. To illustrate this point, Rothman (1990b) applied 
an analogy. He said that defining the cases first and the underlying population second is 
equivalent to firing a gun and then drawing a target around the bullet hole. 
 Secondly, the null hypothesis in cluster analyses is complete temporal, complete 
spatial, or complete spatiotemporal, randomness (Donnan et al., 2005). Statistical 
analyses to detect clusters invariably involve multiple comparisons of the rate of 
disease within geographical subregions and the area as a whole (Olsen et al., 1996). 
Therefore, if we set our family-wise nominal significance threshold at 0.05, and the null 
hypothesis is true, over the long run we can expect that 1 in 20 comparisons will yield a 
significant difference (Waller and Gotway, 2004). A more stringent significance 





 Thirdly, the available data can limit the types of exploration and hamper the 
conclusions that can be drawn from such analyses. Not only does case ascertainment 
need to be complete across the region and disease consistently defined, but details of 
each individual’s life are required to enable exploration of exposure histories for 
illnesses which have long latency periods (Elliott and Wartenberg, 2004). Additionally, 
further details about individuals’ pasts are necessary to control for possible 
confounding in analyses (Wartenberg, 2001). However, clusters of disease are usually 
well-publicised, at least within the community, and this renders the collection of 
unbiased data challenging or impossible as knowledge about the disease and rumours 
about its cause increase (Rothman, 1990b). Many clustering studies are also hindered 
by the ecological fallacy. What this means is that differences in healthy and unhealthy 
regions may not differentiate healthy and unhealthy individuals. Inferences at the 
group level cannot therefore be applied to the individuals comprising the group (Elliott 
and Wakefield, 2001).  
 Investigating reported clusters is therefore complex. Alongside the temptation 
to ‘fish’ for common environmental factors, the dangers of retrospectively analysing an 
area of clustering, chance findings from multiple testing, and difficulties in establishing 
an accurate dataset, limit confidence in establishing the existence of a cluster. However, 
despite these potential shortcomings, clustering studies can be epidemiologically 
interesting. 
4.2.2 Why investigate disease clusters? 
Disease clusters can provide aetiological insight and may be useful in 
generating aetiological hypotheses. However, they require confirmation by studies 
from another area or time period (Elliott and Wartenberg, 2004). Clusters are often 
initially reported by concerned residents who have spotted several cases in their 




Wartenberg, 2004; Olsen et al., 1996; Wartenberg, 2001). Such reports are often based 
on inconsistent and questionable criteria for diagnosis and case ascertainment 
(Rothman, 1990b). The background population is also likely to be poorly defined 
(Rothman, 1990b). There is currently no systematic, scientific method for determining 
when a possible cluster should be investigated, potentially leaving other unusual 
disease clusters undetected and unstudied. This random approach means that it is 
difficult to put results from clusters that have been investigated into context, as reports 
that are investigated could lead to a biased assessment (Wartenberg, 2001). That the 
investigation of clusters often results from interested and vociferous communities 
(Cutler et al., 1986; Richardson et al., 1999; Rothman, 1990b) may mean that some 
clusters are artefacts of close-knit locales. 
Cluster analysis is a form of spatial epidemiology and is divided into three main 
areas: disease mapping, geographic correlation studies, and disease clustering (Elliott 
and Wartenberg, 2004). One of the most famous examples of disease mapping is John 
Snow's 1855 work on cholera in London. Mapping the location of cholera cases enabled 
Snow to narrow down possible causes and eventually identify the aetiological 
involvement of the Broad Street water pump in the spread of disease (Snow, 1855). 
Cholera is a good example of how cluster investigations for a disease with a simple 
aetiology (infectious agent) and short period of latency between exposure and disease 
manifestation is less complicated than for a complex disease with multiple aetiologies 
and a long latency period. 
Geographical correlation studies have been often used in MS research to 
demonstrate that a greater number of cases occur in countries that are further from the 
equator. These studies generated the hypothesis that reduced UV exposure and the 




(Acheson et al., 1960; Goldberg, 1974). This theory that has been explored in numerous 
studies (Antico et al., 2012; Kriegel et al., 2011; Dobson et al., 2012; Kurtzke, 1975). 
Geographical correlation studies, do, however, require that the methods of identifying 
and diagnosing a disease are consistent across all regions and all study populations to 
ensure comparable results (Elliott and Wartenberg, 2004). Further, ecological studies 
are hindered by the ecological fallacy. Observations thus made therefore need 
confirming at the individual level, but are nonetheless useful for hypothesis generation.  
Putative disease clusters are explored to investigate potential environmental 
hazards that may be implicated in a disease aetiology (Elliott and Wartenberg, 2004; 
Olsen et al., 1996). Examples of such clusters would be the cholera epidemic noted 
earlier (Snow, 1855), the rate of respiratory disease in communities adjacent to a Thai 
industrial estate badly affected by air pollutants (Jadsri et al., 2006), and an apparent 
excess of childhood leukaemia cases around nuclear installations in the UK (Beral, 
1993).  
Clustering of disease within occupations have identified occupational hazards. 
Famous historical examples include phossy jaw which presented in the London match 
girls who worked with white phosphorous (Stockman, 1899). Another such example is 
squamous cell carcinomas of the skin of the scrotum in chimney sweeps who had been 
exposed to soot in early childhood (Butlin, 1892).  
Whilst some of these examples have yielded causal associations (cholera, 
respiratory disease and air pollutants, phossy jaw, and cancer relating to soot), the 
causal relationship in other examples has been more ambiguous (childhood leukaemia 
and nuclear sites). The reason for this ambiguity is that results across different 
geographical regions and time were inconsistent, arising from the earlier-discussed 




within each defined geographical area and movement of participants out of the study 
area additionally led to disparate results and increased controversy.  
Clusters can be investigated either post hoc or a priori. Post hoc investigations 
are designed to identify a common factor which may be causing an apparent cluster 
whereas a priori investigations are hypothesis-led (Elliott and Wakefield, 2001). 
Developing a hypothesis a priori reduces the risk of identifying apparent associations 
which may or may not be aetiologically involved in a disease. Additionally, 
understanding why clusters occur is of greater epidemiological and public health 
importance than the detection of clusters themselves (Rothman, 1990b). However, it 
can sometimes be difficult to distinguish between post hoc or a priori methodologies. 
This is because an apparent sudden rise in the incidence of a disease can be quickly 
associated with an apparent polluting source post hoc, which may then be investigated 
a priori (Elliott and Wakefield, 2001). It is important to note that, whatever the method, 
clustering studies rarely result in aetiological advances, and consequently some 
researchers (Rothman, 1990b) advocate the abandonment of cluster studies to reduce 
the number of false alarms and to direct resources more effectively. Whilst there are 
many complexities to consider in undertaking and interpreting such studies, exploring 
disease clusters has the potential to generate new knowledge (Olsen et al., 1996). 
However, possibly most importantly, clustering studies can help alleviate public 
concerns about living in an area where a disease has anecdotally been considered 
highly prevalent (Olsen et al., 1996; Elliott and Wartenberg, 2004; Wartenberg, 2001). 
4.2.3 Overview of MS clustering studies 
Apparent clusters of MS have been explored to attempt to elucidate 
environmental factors that may be implicated in disease. However, the conclusions that 
can be drawn from cluster studies are limited by the underlying difficulties of case 




MS prevalence in Duxbury, Massachusetts. Eight probable MS cases with disability were 
identified. Although the authors were keen to interpret their finding cautiously and did 
not attribute the cluster to any environmental pathogen, it later emerged that seven 
cases had developed MS elsewhere and had moved to Duxbury for retirement (Deacon 
et al., 1959; Kurland, 1994). The apparent cluster was therefore purely coincidental.  
Similarly, investigations into a rural Nova Scotia community where fourteen 
cases of MS had been reported in the population of 150 found two cases to be muscular 
dystrophy, one to be amyotrophic lateral sclerosis and another to be myasthenia gravis 
(Murray, 1976). Of the remaining ten cases several common factors were identified, but 
these were also common among the rest of the community. However, the author 
highlights two factors as being potentially aetiologically interesting. Firstly, he notes six 
of the cases were related in two families. Such familial clustering suggests possible 
genetic involvement in MS aetiology (Murray, 1976). Secondly, the only period in which 
the cases had been living within the same vicinity was between 1951 and 1952, and 
there had been a polio outbreak within this region in 1952. A 1963 paper had described 
some epidemiological similarities between polio and MS, and had suggested that MS 
could be a rare manifestation of a common childhood disease (Poskanzer et al., 1963). 
The possible role of childhood infections has been noted by other researchers in case-
control studies (Haile et al., 1982; Andersen et al., 1981; Poskanzer et al., 1980b; 
Compston et al., 1986) and a retrospective cohort study (Nielsen et al., 2000). However, 
other case control studies have found no evidence of polio (Poskanzer et al., 1980b) or 
other childhood infections (Bager et al., 2004) increasing MS risk. Two further cluster 
studies found disparate results regarding the possible role of infection. A 
spatiotemporal cluster study in Northern Ireland hypothesised that if childhood 
infections were aetiologically involved, clustering around the location and timing of 




in Northern Ireland failed to find any evidence of spatiotemporal clusters (Ashitey and 
MacKenzie, 1970).  
A more recent cluster study in Tayside, Scotland, used an MS registry containing 
Poser-defined probable and definite MS cases in the region. MS cases included in the 
registry were initially identified by a survey carried out in 1996, with each participant 
giving informed consent. The register was then maintained prospectively, giving a 
sample size of 772 cases which dated from between 1970 and 1997. Cluster analyses 
revealed that within these cases, there was a significant temporal cluster of 467 for the 
whole of Tayside between 1982 and 1995. During these years, the region demonstrated 
a significant increase in MS incidence compared to preceding years. A secondary 
spatiotemporal cluster of 42 cases was also identified between 1993-1995 in an area 
south-west of Perth (Donnan et al., 2005). The scan statistic used by the authors 
automatically adjusted for multiple testing within each cluster analysis, however, it 
should be noted that multiple analyses were run and no further adjustments were 
applied, leading to possible type 1 errors. Additionally, the location of cases used was 
their place of residence when they were entered into the register of MS cases in Tayside 
and therefore exposure to an environmental agent involved in aetiology may have 
happened years earlier in a different location. Although it appears that migration rates 
for Tayside are very low and so the probability of several cases moving to the region is 
small, it remains possible that, as in previous studies, the cluster developed by chance. 
Additionally, MRI was introduced in Tayside in 1990 and neurology services expanded 
in 1995. The service expansion occurs at around the same time that the peaks in 
incidence were highlighted by the spatiotemporal scan. It may be that the clusters 
result, at least in part, from improved case identification within the region in later 
years. Furthermore, the study endpoint was in 1997 and so the 1982-1995 cluster, and 




experienced symptom onset but had yet to be officially diagnosed before the study’s 
end. This therefore raises the possibility that the detection of a cluster was, instead, the 
detection of a rise in the incidence of MS. Although there is a possibility that the 
clusters could result from exposure to a pathogen during a specific time period, no 
infectious agent was identified (Donnan et al., 2005).  
Possibly the most famous MS clustering studies are those carried out in the 
Faroe Islands. Situated in the North Atlantic at a higher latitude than Shetland, the 
Faroe Islands have been comprehensively studied for MS cases since 1963. These 
observational studies identified fewer than expected cases compared to Orkney and 
Shetland (Allison, 1963; Fog and Hyllested, 1966). Multiple systematic searches failed 
to identify any cases of MS with a year of clinical onset dating prior to 1943 (Fog and 
Hyllested, 1966; Kurtzke, 1993; Kurtzke and Hyllested, 1979). However, 24 cases were 
identified between 1943 and 1960, which, the authors argue, clearly meets the 
definition of an epidemic: “disease occurrence ‘clearly in excess of normal expectancy’ 
and likely to derive ‘from a common or propagated source’”, taken from the American 
Public Health Association definition (Kurtzke and Hyllested, 1979). Further, these 24 
cases appeared to form two series. The first 14 cases had illness onset between 1943 
and 1949, and were at least 10 years of age in 1940 (range 11-45 years). The second 
series had 10 cases with illness onset between 1952 and 1960. Seven of the cases were 
below 10 years of age in 1940. The authors concluded that there was an epidemic of MS 
on the Faroe Islands. They further hypothesised that the 8000 British troops who 
occupied the islands for five years during the Second World War from 1940 introduced 
an infectious agent which may have had both a long and short period of incubation, 
following at least two years of exposure. This theory was supported by a spatial 




also supported by a temporal relationship between the timing of the first MS case and 
the arrival of the military. 
However, these spatial and temporal relationships rest on several assumptions, 
which have been much discussed and questioned (Poser et al., 1988; Poser and 
Hibberd, 1988; Compston and Confavreux, 2006). Such assumptions include the 
arbitrary two-year susceptibility period, which means that the study relies on date of 
illness onset as being relevant to date of illness acquisition (Poser et al., 1988). This 
association may be meaningless depending upon the period of latency in each case. 
Additionally, Kurtzke’s study accepted possible incomplete case ascertainment before 
1943 as evidence of MS absence in the Faroe Islands, rather than interpreting it more 
cautiously as absence of evidence (Poser et al., 1988). Poser’s reanalysis of the data in 
fact found additional cases with onset occurring before 1943 (Poser and Hibberd, 
1988). Moreover, this reanalysis found that the original study arbitrarily excluded 
cases and accepted questionable cases. When just one questionable case was changed 
from case to non-case, the statistical significance of the ‘epidemic’ disappears (Poser 
and Hibberd, 1988). 
Kurtzke’s findings were based on an intensively studied region which, as noted 
earlier, may lead to increasing case ascertainment as both researchers and residents 
become more vigilant. Additionally, the use of prevalent rather than incident cases 
favours survivors. Those who had died before they had been registered into the study 
are necessarily omitted. However, this omission can result in the appearance of a 
sudden cluster or an epidemic. Inclusion of people as they are diagnosed may instead 
show a steady incidence. Importantly, better access around the islands meant that 
travel to and from hospitals was easier following the Second World War (Poser and 




and expertise were now at hand to identify cases (Compston and Confavreux, 2006; 
Joensen, 2015).  
A post-war epidemic of MS was also observed in Iceland (Kurtzke et al., 1982). 
However, a point of contention is whether this epidemic reflected a genuine rise in 
incidence or coincided with the arrival of neurology services (Benedikz et al., 1994).  As 
the incidence stabilised several years after the arrival of the neurology services, the 
cluster may have resulted from increased case ascertainment until the excess of 
undiagnosed MS cases had been identified, leaving only new cases to be diagnosed 
(Compston and Confavreux, 2006). However, any stabilisation appears to have been 
only temporary as, reflecting the trend elsewhere, the MS incidence in Iceland appears 
to have continued to rise (Sveinbjornsdottir et al., 2014). 
The role of canine distemper virus as the transmissible agent for the Faroe 
Islands clusters was raised as a possible cause of the epidemiology of MS in Orkney, 
Shetland and Iceland (Cook et al., 1978). It is likely that dogs who arrived with British 
military officers introduced canine distemper into the Faroe Islands during the Second 
World War. However, there was no evidence that any identified individual with MS had 
been infected with the virus. There was also no association between outbreaks of 
canine distemper and the residential location of cases. Therefore, it was concluded that 
canine distemper virus was not associated with MS in the Faroe Islands (Kurtzke et al., 
1988). The initial identification of the Iceland cluster had also been noted as beginning 
shortly after an epidemic of canine distemper on the island (Kurtzke et al., 1982). 
However, there was also a high prevalence of MS in regions of Iceland where there had 
been no such epidemic (Nathanson et al., 1978). Further cluster studies are 





























































































































































































































































































































































































































































































































































































































































































































































































































Investigations into many clusters have therefore failed to definitively identify 
environmental conditions or pathogens that increase MS risk, although the infectious 
agent hypothesis has led to research which identified EBV as a significant risk factor 
(see Chapter 2). However, in at least one instance the theories raised by such studies 
have proven hazardous. Ingalls (1986b), who linked mercury to the Key West cluster, 
claimed that dental amalgam fillings were responsible for his MS symptoms (Ingalls, 
1986b). This claim resulted in many people having their fillings replaced, despite no 
evidence of any causal association (Murray, 2004). Although clustering studies aim to 
uncover potential causal mechanisms for disease, this example sets out the dangers of 
selection and confirmation bias to ‘prove’ theories that have little or no grounding in 
evidence. 
4.2.4 Clusters of MS in Orkney and Shetland 
 Orkney and Shetland have a high MS prevalence. However, it is less clear 
whether certain parishes or isles have a disproportionately high number of cases. A 
1981 study of MS explored whether cases of MS clustered in Orkney and Shetland 
based on particular points in patients’ life histories. These timepoints comprised birth, 
certain ages, disease onset, and specific years before onset. A table of all possible pairs 
of patients was assembled for each identified point in time. Each pair was classified by 
whether they lived in the same parish at each timepoint, and the length of time that 
separated the patients’ life history point. The null hypothesis was that the distribution 
of time intervals between pairs of cases in the same parish and pairs in different 
parishes would be the same. Clusters would be confirmed by a shorter time interval in 
pairs within the same parish to pairs within different parishes (Poskanzer et al., 1981). 
This type of analysis (‘ridit analysis’), does not utilise p-values but tests a group under 




of statistical significance. The ridit decreases as clustering increases with anything 
below 0.5 considered to demonstrate significant clustering. 
The results identified three clusters of MS within Orkney by place of residence 
21 to 23 years prior to onset and three clusters 2 years prior to onset of disease 
(Poskanzer et al., 1981). The clusters 21 to 23 years prior to onset were centred in 
Kirkwall, Westray and South Ronaldsay. The clusters just prior to disease onset were in 
Kirkwall, Westray and Shapinsay. It appears that patients who developed MS were 
more likely to live in these same parishes just prior to, or two decades prior to, onset. 
This finding is consistent with the theory that MS may have two periods of 
susceptibility, one with a long incubation period and the other with a short incubation 
period. It is, however, interesting that no clusters were identified in Shetland. It was 
considered that complete ascertainment had been achieved (Poskanzer et al., 1981), 
and therefore if an infectious agent or environmental exposure was responsible for the 
Orkney clusters, this study finds no answers for the high prevalence noted in Shetland.  
However, this study is likely underpowered because the number of cases was 
small. Moreover, designating a year of onset is fraught with difficulties in a disease that 
may not be recognised and diagnosed for years after symptoms begin (Poskanzer et al., 
1981). However, that Kirkwall and Westray appear as significant areas of clustering 
both two years and two decades prior to disease onset suggests that there may be a 
common risk factor. One possible alternative explanation is that there may have been a 
higher genetic predisposition in these districts which led to a greater number of MS 
cases. The analysis may then have detected clusters at these timepoints purely by 
chance. We investigate this idea of genetic clustering further in Chapter 5.  
Although the infectious agent hypothesis has yielded little in the way of 




trigger. In the relatively homogenous environments of Orkney and Shetland, there may 
be other explanations for the high prevalence. The high-latitude location of the islands 
means that reduced UV exposure and low vitamin D levels in the population could be 
more important as causal factors in genetically susceptible individuals. These 
possibilities are explored further later in the thesis.  
To further understand the pattern of MS in Orkney and Shetland, we explored 
the geographical distribution of disease to test whether the disease disproportionately 
affects people born in particular parishes or isles. As possible aetiological factors may 
increase risk from early childhood or even before birth (Gardener et al., 2009; Mirzaei 
et al., 2011), exploring clustering by place of birth may identify potential early life 
factors involved in disease (Ashitey and MacKenzie, 1970; Acheson and Bachrach, 
1960).  
4.3 Methods 
We first explored the distribution of MS within the isles and parishes that 
comprise the Northern Isles using two datasets. The first dataset was collected in the 
1970s (Poskanzer et al., 1980a), and the second in 2009 (Visser et al., 2012). The 2009 
dataset was called the Northern Isles Multiple Sclerosis study; taking the initials we 
refer to the earlier dataset as NIMS74 and the later dataset as NIMS09. The data from 
both datasets are limited to age at time of study, sex, and place of birth. NIMS74 
originally contained more detailed data, including place of residence between birth and 
onset of disease, however, these variables were not included in the dataset that we 
were given. 
4.3.1 Case definition 
The NIMS74 data were collected for a large epidemiological, virologic and 
genetic study of MS in Shetland and Orkney between 1974 and 1977. Cases were 




health professionals, as well as from previous MS surveys. Each case was reviewed and 
evaluated by Professor David Poskanzer, and classified as probable, possible, or not MS 
according to the Allison and Millar criteria (Poskanzer et al., 1980a). The authors were 
satisfied that complete case ascertainment was achieved (Poskanzer et al., 1981). 
The NIMS09 data were collected for a prevalence study of Orkney, Shetland, 
and Aberdeen, and for an associated genetic study which ran from 2008 onwards. The 
prevalence day was 24 September 2009. Cases were identified through GP databases, 
hospital discharge data from each region’s hospital, and a large rehabilitation facility. 
MS specialist nurse databases in Aberdeen and Shetland were also searched. Further 
cases were identified from Aberdeen Royal Infirmary lab results for positive CSF 
oligoclonal bands from 1999 and neurophysiology for abnormal visual evoked 
responses from 1973. All identified records were reviewed by a neurology research 
fellow (Dr Elizabeth Visser) and supervised medical student to confirm the diagnosis. 
Cases were accepted if they met the a) Poser criteria for clinically definite, laboratory-
supported clinically definite, clinically probable or laboratory-supported clinically 
probable MS, or b) McDonald 2001 or 2005 criteria. 
 For this present study, cases from NIMS74 were those that met Allison and 
Millar probable and possible criteria. There was insufficient information to classify 
cases further. Cases that comprised the 2009 prevalence study of MS in Orkney and 
Shetland who agreed to participate in the Northern Isles Multiple Sclerosis study were 
included in NIMS09. There was only one crossover case who had been in NIMS74 and 
was also in NIMS09. For the purposes of these analyses, this individual was included in 
NIMS09. 
Other potential cases were identified from two large, population-based studies, 




(VIKING). Permissions were obtained to contact their GPs to verify their MS status. 
Individuals were added when GPs confirmed that definite diagnoses of MS had been 
made by consultant neurologists according to McDonald criteria. Individuals that did 
not have a positive test result for MS were excluded. Additionally, a media appeal for 
anyone with MS to contact us led to the identification of 26 additional potential cases. 
However, with no reliable method of verifying their health status, they were not 
included in the final analyses.  
We also excluded cases where we only had death certificate information. In 
these cases, cause of death was described as ‘disseminated sclerosis’. Although this 
could indicate multiple sclerosis, it could also indicate various other conditions. These 
other conditions may have had more social stigma attached – such as tertiary syphilis – 
and were therefore not mentioned by name. However, some of these individuals had 
been seen and diagnosed by Allison in their lifetime, but were not included in the 1974 
study. They had however been included in a later study (Roberts, 1991), and were 
included in the NIMS74 dataset. 
Overall, we had 161 cases that met one of our study criteria. One hundred and 
five of these cases were born in Orkney and 56 were born in Shetland. Many cases had 
been entered into a specialist genealogical database, RootsMagic, however the paper 
files containing the NIMS74 data required computerisation. We entered each case with 
at least two generations of ancestors; the majority extended back for four or more 
generations. Where only one generation was recorded, individuals were missing, or 
there was a mismatch between NIMS74 data and data that we already had, we 
consulted the Old Parish Records for information before 1855, and the births, 
marriages and deaths (BMD) index for information after 1855, at General Register 




information in tracing families when spellings of names were not standardised and 
when many Shetlanders were still using the patronymic system, taking the father’s 
given name as their surname, often with the suffix of ‘son’. 
4.3.2 Birthplace definition 
 We recorded registration district of birth as the birthplace. The reasons for this 
were twofold. Firstly, the boundaries of the registration districts did not change as 
much as the parish boundaries. Therefore, when parish boundaries changed, the same 
registration district was likely to still encompass the same area. Where registration 
districts did change, we estimated population sizes by taking the percentage difference 
from earlier censuses and applying it to the registration districts that had conjoined or 
disjoined.  
Secondly, births from the 1970s onwards were more likely to take place in 
hospitals. In Orkney this meant that the birthplace was most often Kirkwall, and in 
Shetland, Lerwick. Additionally, high-risk pregnancies were, and are, normally 
delivered in Aberdeen. In these cases, using birthplace made little sense; taking the 
registration district of birth meant that it was more likely to capture the area in which 
the family was living at time of birth, and consequently the time of pregnancy and early 
childhood. We therefore checked all people with Lerwick, Kirkwall, and Aberdeen 
births in the BMD indexes to ensure that people noted as having these birthplaces were 
also registered in these areas. 
 This method of ascribing birthplace was not without its drawbacks. The use of 
registration districts made geographical sense in Orkney; the boundaries generally 
denote island and mainland parishes. However in Shetland, some island and mainland 
parishes are grouped in the same registration district, thereby losing the natural 




districts offered a relatively stable method of categorising the geography of the islands 
over many years. 
4.3.3 Analyses 
The spatial scan statistic (Kulldorff, 2015) has been used in several 
epidemiological studies to identify clusters of disease in a population (Donnan et al., 
2005; Sherman et al., 2014). The null hypothesis is that MS is randomly distributed 
spatially, temporally, and spatiotemporally. For the purposes of these analyses, as in 
similar studies (Donnan et al., 2005), we assumed a Poisson distribution for the 
number of cases in each district. Using the Poisson model, spatial clusters can be 
detected over a geographical area, temporal clusters over the whole area but within 
time, and spatiotemporal analyses which take into account both geographical area and 
time. 
The Poisson method uses a theoretically infinite number of circular windows of 
varying diameters that are centred on the registration districts to evaluate clusters in 
both spatial and spatiotemporal analyses. While spatial clusters use a 2D window, 
spatiotemporal clusters use a column which focusses over geographical areas and also 
extends in time. Temporal clusters likewise use a column that extends in time over the 
whole study region. The window diameter varies from zero, to a diameter that includes 
a pre-specified maximum proportion of the population at risk. In these analyses, the 
population at risk encompasses the whole population who do not have MS supplied 
from census information and averaged over time. The size of the population at risk in 
the years between censuses is estimated using linear interpolation. The maximum 
window diameter was set to include up to 50% of the population at risk with a 
maximum radius of 10 kilometres. Fifty percent is the recommended percentage as it 




Fixing the window size allows the programme to identify clusters within more defined 
geographical areas.  
For each window location and size, the software calculates the number of 
observed and expected observations, and then conducts a likelihood ratio test. 
Statistical significance of the likelihood ratio is tested using a Monte Carlo method. The 
test statistic was calculated for each replica.  
The window location and size with the highest likelihood is considered the most 
likely cluster, and is assigned a p-value. Statistical significance of a cluster occurs if the 
true test statistic value is among the 5% highest of the 1000 values generated by Monte 
Carlo procedure. In this way, it is possible to evaluate clusters of different sizes whilst 
adjusting for multiple testing (Kulldorff, 2015).  
To test for clustering in Orkney and Shetland we treated each island group 
separately and ran separate analyses using NIMS74 and NIMS09 to compare historical 
and current data. All analyses were carried out using SaTScan v.9.4 (Kulldorff, 2015). 
4.3.3.1 Clustering of MS by birth year and birthplace  
Clustering of MS by birthplace has been explored in military veterans in the 
United States, and assumes that place of birth is most likely to be the place of childhood 
and where MS risk is first introduced (Acheson and Bachrach, 1960). Birth dates for 
cases ranged from 1900 to 1990 (Table 4.3). For spatial analyses, the programme 
calculated an average overall population size from each census decade population 
count. The temporal analyses aimed to establish whether there was any significant 
clustering overall in each island group by birth year. The spatiotemporal analysis took a 
finer approach to looking within this period to see if clusters were observed in specific 




Table 4.3 Birth year ranges of MS cases by dataset and location 
Place and dataset Range of birth years 
Orkney NIMS09 1932 – 1990 
Orkney NIMS74 1900 – 1951 
Shetland NIMS09 1931 – 1981 
Shetland NIMS74 1901 – 1951 
 
4.4 Results 
Adjustment for multiple testing was automatic within each cluster analysis 
(Kulldorff, 2015). However, we ran twelve cluster analyses which meant that we 
needed to adjust for multiple testing over all analyses. Using the Bonferroni method, we 
corrected for 12 independent tests. We used 0.05/12 < 0.004 as the threshold for 
significance. Because the temporal and spatiotemporal clustering analyses, and the 
spatial and spatiotemporal clustering analyses, were not independent, the Bonferroni 
threshold is overly conservative. We therefore also calculated Benjamini-Hochberg 
adjusted p-values. The Benjamini-Hochberg method corrects for the false-discovery 
rate, and is thus less stringent than the Bonferroni adjustment, all the while still 
reducing the type 1 error rate (Benjamini and Hochberg, 1995). To correct p-values 
using the Benjamini-Hochberg method, p-values are first ranked from smallest to 
largest with the first receiving a rank of 1. The p-value for each significance test is then 
compared to a critical value equal to (i/m)Q where i is the rank of the p-value, m is the 
number of tests, and Q is the false discovery rate, usually .25, as it is in this instance. 
Calculations were carried out using p.adjust in R v 3.4.0. 
4.4.1 Temporal clustering by birth year 
 Firstly, we found evidence of temporal clustering in Orkney in NIMS09 and 




born between 1951 and 1960. This means that in our sample, more people with MS 
were born between 1951 and 1960 than would be expected by chance. A chance 
distribution would have expected that nine MS cases were born between 1951 and 
1960. There was a further cluster of 32 people with MS who had been born between 
1912 and 1931. Again, a more even distribution would have expected 20 cases to be 
born between these years. No significant temporal clusters by birth year were observed 
in Shetland in NIMS09 or NIMS74. 





Cluster years p-value 
Orkney MS cases 
NIMS09 
53 27 1951-1960 0.001** 
Orkney MS cases 
NIMS74 
52 32 1912-1931 0.005* 
Shetland MS cases 
NIMS09 
26 9 1942-1951 0.227 
Shetland MS cases 
NIMS74 
30 14 1922-1941 0.68 
* Survives Benjamini-Hochberg correction 
** Survives Bonferroni correction 
 
 
4.4.2 Spatial clustering by birth registration district  
 We found evidence of spatial clustering of MS by registration district of birth in 
Kirkwall, Orkney, and in Lerwick, Shetland, in the NIMS09 data. In our Orkney sample, 
32 cases were born in Kirkwall. The expected number of cases to be born in Kirkwall 
between these years is 15. In our Shetland sample, 18 cases were born in Lerwick. 
However, a chance distribution means that the number of expected cases would be 
eight. There was no evidence for clustering by birth registration district in NIMS74 




Table 4.5 Spatial clustering, Poisson model, MS cases, 10 km window radius 





53 Kirkwall & St Ola 32 0.000015** 
Westray 5 0.905 
Orkney MS 
cases NIMS74 
52 Birsay 6 0.417 
Eday & Pharay 3 0.842 
Shetland MS 
cases NIMS09 
26 Lerwick 18 0.00047** 
Shetland MS 
cases NIMS74 
30 Dunrossness, Sandwick 
& Cunningsburgh 
8 0.229 
Delting 3 0.830 
** Survives Bonferroni correction 
4.4.3 Spatiotemporal clustering by birth year and birth registration district  
To investigate further whether there is evidence of temporal clustering in 
specific areas, we did a spatiotemporal analysis (Table 4.6). We found a significant 
cluster of 22 cases in Kirkwall in the NIMS09 data between 1951 and 1970. This figure 
of 22 is significantly more than the number expected by chance, which is five. There 





Table 4.6 Spatial-temporal clustering, MS cases, 10km window radius 
Data Total 
cases 








53 Kirkwall & St Ola 
 
22 1951-1970 0.00000014* 
Westray 
 
4 1951-1970 0.560 
Sanday, Lady, Cross 
& Burness 
 
2 1951-1960 0.976 




52 Kirkwall & St Ola 
 
6 1922-1931 0.68 
Eday & Pharay 
 
3 1900-1921 0.78 
Shapinsay 
 




5 1912-1931 0.92 




















4 1912-1921 0.352 
Delting 2 1912-1931 0.993 
** Survives Bonferroni correction 
 
4.5 Discussion 
Earlier in the chapter, I defined clustering as ‘an excess of cases against some 
background rate’. However, as I shall explain, our results should be interpreted very 
cautiously as both the identification of cases (numerator), and the population at risk 




From the analyses we ran, we observed two temporal clusters in Orkney, the 
first in NIMS74 and the second in NIMS09, which suggested that people born between 
the years 1912-1931 and 1951-1960 were more likely to develop MS in later life. 
However, there are four main problems concerning the cases. Firstly, the two datasets 
use different diagnostic criteria. NIMS74 included people who may not be considered 
as having MS by the criteria used in NIMS09. It is therefore possible that the cluster 
observed in NIMS74 would not be significant if more specific and sensitive diagnostic 
criteria had been applied.  
Secondly, the cluster in NIMS09 includes people who would have been 
diagnosed sometime between 1985 and 1994. However, as the age of onset, taken as 
the date of diagnosis, for MS usually ranges from 20 to 50 (mean = 34) (Brønnum-
Hansen et al., 2004), there could still be people born within these years who were not 
diagnosed until 2010 or after, which is subsequent to the prevalence day. It is therefore 
possible that there are individuals who were born shortly after this apparent cluster 
who had not yet had MS diagnosed by the time this prevalence study was carried out. 
This means that the cluster may be an artefact of age at diagnosis. 
Thirdly, as we are taking year at birth as the basis for the cluster, it is likely that 
we are looking for an aetiological factor that occurs before birth or in early childhood 
across the whole of Orkney, but that only affects some individuals. Because we have no 
further knowledge about when these individuals were diagnosed or about their 
exposures between birth and diagnosis, we could not test whether many other factors 
contributed to the apparent increased risk in MS in this cluster. Additionally, the time at 
which the people in this cluster were likely diagnosed is after the introduction of the 




than the Allison and Millar criteria. We observed no significant temporal clustering in 
Shetland, however this may be attributable to the small number of cases. 
Finally, the numerator (cases) comprised people that had MS by the specified 
criteria, most of whom still lived within the Northern Isles. We were unable to trace 
people who had been born in Orkney or Shetland, and had later developed MS, but 
were no longer living in the islands. This means that our sample is inevitably biased, 
and that the apparent temporal clusters could be artefacts of emigration patterns. 
There are also two main problems with the denominator, or the population at 
risk. Firstly, despite our attempts to identify the population at risk from census 
information, there remain significant problems with this denominator. I demonstrated 
in Chapter 3 that the populations of Orkney and Shetland fluctuated over many years 
and are therefore not stable. However, as the census is only carried out once per 
decade, the population in the intervening years needs to be estimated. The unstable 
population indicates that this estimate is unlikely to be accurate. This means that the 
clusters that were identified in analyses may be artefacts of a poorly-defined 
population denominator rather than a true cluster.  
Secondly, census information includes all people resident in Orkney and 
Shetland when the census was being collected. This means that the population at risk 
includes people who were born outside the Northern Isles but moved there in the 
intervening years. As our numerator only included those born within the Northern 
Isles, and there was a large influx of people to the Northern Isles during the oil boom 
years, there are significant problems with this poorly-defined denominator. Such 
changes in population size and migration and resultant difficulties in defining the 
population at risk can introduce errors into the clustering analysis (Elliott and 




 We observed two significant spatial clusters in the NIMS09 dataset centred in 
Kirkwall and Lerwick respectively. This finding could suggest that MS cases aggregate 
more frequently in Kirkwall- and Lerwick-born individuals than would be expected if 
there was complete spatial randomness. However, alongside the same problems with 
the numerator and denominator raised as being problematic for the temporal 
clustering, this finding is questionable for two further reasons. Both reasons are central 
to the fact that Kirkwall and Lerwick are the capitals of Orkney and Shetland, and both 
contain the main hospitals.  
Firstly, most people in this period are born at the main hospitals, and although 
we attempted to overcome the difficulty of place of birth versus place of residence at 
birth by using registration districts, it is possible that this method was imperfect and 
that more people were registered in Kirkwall and Lerwick than were actually living 
there.  
Secondly, it is possible that, should the people who were born in Kirkwall and 
Lerwick have stayed in the vicinity, they would have had easier access to the main 
hospital where the neurology services are based. Therefore, they may have had more 
chance of being diagnosed. Again, there was no significant clustering in NIMS74. 
Finally, there was an apparent significant spatiotemporal cluster of MS in 
Kirkwall between the years of 1951 and 1970 in NIMS09. This could suggest that 
people born between these years in Kirkwall were more likely to develop MS. It seems 
likely that this spatiotemporal cluster is related to the spatial cluster in Kirkwall, and 
the temporal cluster in Orkney between 1951 and 1960, both of which were observed 




However, besides having the main hospital, Kirkwall was also the only parish in 
Orkney to increase in size between 1891 and 1961 (Figure 3.8). In common with other 
parts of the developed world at this time, and in Lerwick, Shetland, this increase was 
largely due to inward immigration from rural parts of Orkney. Therefore, it is possible 
that people who later developed MS were now living in Kirkwall rather than in their 
home parishes. In this case, the cluster would be an artefact of the population 
movement.  
As well as these difficulties involving definitions and ascertainment of cases and 
controls, it is important to note that, as mentioned earlier, diseases with long periods of 
latency between exposure and onset are more complicated to explore in clustering 
analyses than illness with short periods of latency. Multiple sclerosis is a complex 
disease with a period of latency which appears to stretch anywhere between about two 
and twenty years (Poskanzer et al., 1981). This long period between exposure to a 
potential causal agent and onset of disease means that multiple other possible 
exposures will also occur before disease manifests. This then complicates the process of 
identifying an exposure common to all (or many) cases, and in identifying whether any 
such common exposure may have causal consequences. Moreover, this lengthy period 
means that there is a greater chance that people may leave the area before disease 
onset, and therefore the pattern of the cluster is lost.  
It is interesting to note that, like our study, Kirkwall was found to be an area of 
significant clustering in Poskanzer et al.’s (1981) study, which used a more detailed 
version of this dataset. However, unlike our study, clustering did not occur by 
birthdate. Instead the cluster in Kirkwall was found 23 years prior to disease onset and 
just prior to disease onset (Poskanzer et al., 1981). Similarly significant clustering was 




potentially uses the location where exposure to an environmental agent first occurs 
(Bager et al., 2004; Libbey et al., 2014), many other potential risks may be encountered 
between birth and age at disease onset (Ebers, 2008; Handel et al., 2010; van der Mei et 
al., 2003). Therefore, the greater detail of cases’ lives would enable greater exploration 
of environmental risks at different times of life. 
Another source of differences in findings between the analyses in this present 
study and in Poskanzer et al.’s (1981) study may result from differences in inclusion 
criteria. Poskanzer et al. (1981) were able to separate cases and include only those who 
had probable MS by the Allison and Millar criteria. Our information was insufficient to 
separate probable and possible MS cases, and we therefore included both. This inability 
to separate cases will have led to our inclusion of questionable cases and possibly to the 
apparent temporal clusters that we observed in Orkney and Shetland. It is reassuring, 
however, that no other birthdate clusters were observed, in line with the previous 
study that used the data (Poskanzer et al., 1981). Cases in NIMS09 were classified using 
the Poser or McDonald criteria which, as previously mentioned, are more sensitive and 
specific than the Allison and Millar criteria. The difference in diagnostic criteria 
between NIMS74 and NIMS09 may affect who would be classified as a case, and thereby 
potentially the presence of clusters.  
It is also important to acknowledge, as previously noted, that all clustering 
studies are hindered by case ascertainment. Whilst it was estimated that case 
ascertainment was probably about 100% in the NIMS74 data (Poskanzer et al., 1981), 
several cases were missing from the NIMS09 data. These cases were people who had 
participated in the almost simultaneous genetic study, but who had chosen not to 
consent to their details being used for further studies, including the prevalence study. 




however, as there was no reliable method of verifying the health status of these 
individuals, they were not included in our analyses. This is further compounded by the 
problem raised earlier, that we were unable to trace people with MS who were born in 
the Northern Isles and had moved away. Incomplete case ascertainment may bias 
results by either strengthening or reducing any of the associations seen here. Moreover, 
there is likely to be an issue with power, as, despite the high prevalence of MS, numbers 
are overall small, particularly in Shetland. It is more important, however, to be 
absolutely certain of diagnosis, than to include questionable cases in an effort to 
increase power. 
Finally, the main purpose of cluster analyses is to generate testable hypotheses 
that may explain the presence of clusters (Rothman, 1990b). Kirkwall was the only area 
that consistently showed clustering, however no testable environmental hypothesis has 
been generated. This is because of the limitations of this study and the data, the 
imprecise knowledge regarding if or when an exposure may have taken place, and, 
importantly, the many alternative plausible explanation for the apparent clustering in 
Kirkwall.  
4.6 Conclusion 
Our results highlighted potential statistical spatial and spatiotemporal clusters 
in Kirkwall in NIMS09, and a spatial cluster in Lerwick in Shetland. However, because of 
the many problems with our data including biases from inaccurately estimated 
numerators and denominators, there is a strong possibility that our findings are 
artefactual. Additionally, we could not rule out many plausible alternative explanations.  
To understand more about whether MS clusters within the islands, further 
information, such as details regarding place of residence from birth to time of 




require all Northern Isles births to be traced and their MS status verified, whether or 
not they still inhabit the Northern Isles. Without these details, and with the multiple 
problems with our data, we are reluctant to conclude that the presence of significant p-
values resulting from our analyses actually denote the presence of true clusters and 
would advise that our results should be interpreted with extreme caution. The 






CHAPTER 5. HERITABILITY AND GENETIC CLUSTERING OF MS IN 
ORKNEY AND SHETLAND 
5.1 Introduction 
A further form of clustering briefly touched upon in Chapter 4 is genetic 
clustering. Such clustering studies, usually observed in related individuals in families, 
provide evidence of genetic susceptibility to disease. Estimating the heritability of 
complex traits from familiality has a long history and considerable literature has been 
produced (Polderman et al., 2015; Andreasen et al., 1977; Heston et al., 1966; Berman 
et al., 1979; Seaquist et al., 1989; Tollånes et al., 2014). Studies exploring familiality, 
such as the comparison of rates of diabetic nephropathy in diabetic siblings, found that 
clustering of diabetic nephropathy was evident within families. This finding is 
consistent with the involvement of heredity in susceptibility to diabetic nephropathy 
(Seaquist et al., 1989). Likewise, a population-based cohort study of cerebral palsy 
found that people born into families in which cerebral palsy is present are at an 
elevated risk. The degree of relatedness was found to be important: the highest relative 
risk recurrence was observed in twins, and reduced as relatedness decreased. However 
the study noted that the risk of cerebral palsy remains elevated for as much as third 
cousins (Tollånes et al., 2014). 
The aetiology of complex diseases is multifactorial, involving genetic and 
environmental factors. Therefore when several occurrences are observed in families, a 
key question to explore is to what extent genes and the family environment contribute 
to the trait.  
To begin this chapter, I explore definitions of heritability before briefly 
reviewing the literature on the familiality and heritability of MS. I then discuss an 




MS in the highly genetically-structured Northern Isles using family pedigrees and 
population data. Finally, I present the methods, results and discussion. 
5.1.1 Heritability 
Within populations, phenotypic variation occurs because of differences in 
genotypes and differences in exposure to environmental factors. Additionally, 
interactions between genes and environmental exposures may exert influence on the 
trait of interest (Wray and Visscher, 2008). One goal when exploring phenotypic 
variation is to determine the genetic effect size; the effect size is a measure of how 
much individual differences for the trait in the population can be attributed to genetic 
differences among individuals (Plomin et al., 2013).   
Estimates of heritability are calculated from the degree of resemblance between 
relatives (Fisher, 1919; Falconer and Mackay, 1996; Plomin et al., 2013). It is now 
common to estimate heritability genomically, which does not require prior knowledge 
of family pedigrees where markers can be used to estimate relatedness (Yang et al., 
2010; Yang et al., 2011). However, classically, heritability has been estimated from 
known relationships in pedigrees. Methods for estimating heritability include 
comparing the resemblance between monozygotic and dizygotic twins; resemblance 
expressed between siblings and cousins; and resemblance between parent-offspring 
pairs or trios (Falconer and Mackay, 1996; Tenesa and Haley, 2013).  
Mixed effects models can also be applied to families or pedigrees to estimate 
heritability (Visscher et al., 2008; Tenesa and Haley, 2013). Furthermore, parent-of-
origin effects can be investigated to see if one sex contributes significantly more to the 
observed variation than the other (Falconer and Mackay, 1996), and familial relative 




Heritability estimates can be further refined to identify the proportion of 
phenotypic variance owing to additive genetic effects, known as narrow-sense 
heritability (h2), and the proportion of phenotypic variance owing to total genetic 
effects, including the effects of dominance and epistasis, known as broad-sense 
heritability (H2) (Wray and Visscher, 2008). Because most genetic variance and familial 
resemblance is attributable to additive effects (Hill et al., 2008; Wray and Visscher, 
2008; Tenesa and Haley, 2013), narrow-sense heritability is commonly used for 
heritability estimates. Offspring receive only one copy of each gene from their parents, 
therefore most relatives share only one or no copies that are identical-by-descent (that 
is, from a common ancestor). Full siblings, however, are related in two ways – via their 
mothers and their fathers – and hence can share two copies of a gene identical-by-
descent. Dominance, or non-additive effects, based on sharing two copies, therefore 
contribute to phenotypic resemblance between siblings but not between parents and 
offspring (Visscher et al., 2008). 
 Heritability is an important area of study in the search for the aetiology of 
complex diseases. However, high heritability does not necessarily mean that a gene or 
genes with large effects are present (Bochud, 2012; Visscher et al., 2008), rather a 
number of genes, each conferring a very small effect, usually leads to high heritability 
estimates. Nevertheless, a study’s power for discovering genes associated with disease 
risk is itself associated with heritability. Therefore, when searching for such a genetic 
cause for the disease in question, it is advantageous to select a population that has a 
high heritability. Furthermore, awareness of a disease’s high heritability may support 
the requirement for a study into the genetic determinants of the disease of interest 




5.1.2 Heritability of MS 
The observation that MS clusters in families has been widely discussed since 
the beginnings of the search for risk factors, although historically the idea of a genetic 
predisposition for MS was not universally supported (Mackay, 1950). However, even 
from the end of the nineteenth century, the idea that genes may play a role in MS was 
beginning to take hold. In 1904 Reynolds reported on two families with multiple cases 
of MS, and suggested that familial cases may be identified more frequently as greater 
knowledge about MS and its varying forms is accrued (Reynolds, 1904). In 1922 
Davenport studied what were then described as ‘defects’ in draftees in the US Army. He 
found that the highest rates of MS in the US occurred in the northerly states of 
Michigan, Minnesota, and Wisconsin, and that people of Scandinavian and Finnish 
descent had higher rates of the disease. From this study, Davenport suggested that for 
MS to manifest, some form of endogenous cause, such as ‘racial constitution’, is 
essential. He posited that heredity should be considered one such possible endogenous 
cause, that leads to a raised or reduced risk of MS (Davenport, 1922). This reasoning 
still failed to garner unanimous support, and in 1930 Brain published a paper 
questioning the existence of any internal predisposition and instead laid the cause of 
familial MS – which he still considered to be rare – to the shared familial environment 
(Brain, 1930). However a 1950 review of all familial MS studies from 1896 to 1948 
clearly showed that familial MS was not as unusual as had been believed (Mackay, 
1950). 
Since then, multiple studies have been produced exploring the familial pattern 
of MS. A recent study of familial clustering of MS in a Dutch genetic isolate found that 
24 of the 48 MS cases could be traced to a single common ancestor in a pedigree of 14 
generations (Hoppenbrouwers et al., 2007). Familial studies have also yielded 




relatedness (Robertson et al., 1996; Sadovnick, 1993; Sadovnick et al., 1988; Carton et 
al., 1997; Montomoli et al., 2002; Nielsen et al., 2005; Dyment et al., 2004). Figure 5.1 
shows how these age-adjusted recurrence risks differ depending upon the degree of 
relatedness, and that even in more distant relatives the risk is greater compared to the 
general population (Dyment et al., 2004). Sadovnick et al. (1988) found that this 
increased risk extends as far as third-degree relatives. 
Figure 5. 1 Age-adjusted recurrence risks 
 
(Dyment et al., 2004) 
A 1970 review of twin studies found a concordance rate of 15.4% in 
monozygotic twins and 10.3% in dizygotic twins (Myrianthopoulos, 1970). A 
longitudinal, population-based study of Canadian twin pairs with MS found a 
concordance rate of 25.3% in monozygotic twins, 5.4% in dizygotic twins and 2.9% in 
non-twin siblings (Willer et al., 2003). The increasing MS risk with greater relatedness 
in these studies, in comparison with the risk in the general population, clearly 
demonstrates an additive genetic component to the disease; however, it is a fact that 




trigger to initiate disease in susceptible individuals. This requirement is further 
reinforced by the difference in MS rates between dizygotic twins and siblings. 
Further familial studies reinforced these findings. A study of spouses of MS 
patients showed that there was no increased risk caused by sharing an environment 
(Nielsen et al., 2005). Similarly, a study of 238 adoptees living with their adopted family 
by the age of one found that being raised with an MS patient, when there was no 
biological relationship, did not raise the risk of MS above that of the general population 
(Ebers et al., 1995). Studies of half-siblings likewise show that genetic relatedness, and 
not the familial microenvironment, is the important determinant of familial 
aggregation. As might be expected, the half-sibling recurrence risk was lower than the 
full sibling recurrence risk (1.32% and 3.46%, respectively in this study). Moreover, 
this recurrence risk remained stable regardless of whether the half-sibling had been 
raised with the MS patient (Sadovnick et al., 1996). Half-sibling studies have also 
afforded an opportunity to study parent-of-origin effects, with maternal transmission 
found to confer greater risk (maternal recurrence risk 2.35%, 95% CI 1.57-3.13%, 
paternal 1.31%, 95% CI 0.65-1.96%, p=0.048) (Ebers et al., 2004). This finding was 
reinforced by a recent study which found that there was a higher prevalence of 
maternally-transmitted compared to paternally-transmitted MS (Hoppenbrouwers et 
al., 2008). 
Together, these data provide strong evidence that MS is heritable, possibly 
more so when transmitted maternally compared to paternally, and suggest that familial 
aggregation is determined by shared genes and not the familial microenvironment. 
Such studies have clearly demonstrated the genetic basis to disease, however they do 
not demonstrate how much of the aetiology can be attributed to genes and to the 




Several estimates of the heritability of MS have been calculated (Table 5.1). 
These results range from very modest (15%) (Kuusisto et al., 2008) to high (64%) 
(Westerlind et al., 2014). A meta-analysis of MS heritability studies indicated that 
genetics and environmental factors each contribute 50%. The biometric modelling 
technique applied in this meta-analysis was further able to break down the 
environmental factors into the effects of the shared (0.21, 95% CI: 0.11, 0.30) and 
unshared environment (0.29, 95% CI: 0.26-0.33) (Fagnani et al., 2015), the former 
including factors such as the familial environment, the same school, teachers, 
community, or peer groups, and the latter different hobbies, schools, teachers, and 
events such as accidents or illnesses. This is consistent with familial aggregation 
studies, which suggest that it is not the familial environment, but more likely to be a 
population-level environmental risk that interacts with the necessary genetic factors to 
trigger MS. This reasoning is further reinforced by Kuusisto et al. (2008), who note that 
concordance of MS in dizygotic twins has increased in Finland over the past two 
decades, however heritability is low. Therefore, environmental factors are likely to be 
leading to the increasing incidence of MS which is more likely to be population-wide 
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Although a genetic component to disease had been long-recognised, it was not 
until the 1970s that the HLA locus was causally implicated in MS (Naito et al., 1972). As 
described in Chapter 2, the most strongly related variant to MS risk is the HLA-
DRB1*1501 allele (Oksenberg and McCauley, 2016). However, a study of a large cohort 
of Sardinian families with MS found that the risk of MS was associated with the HLA-
DRB1*03 and HLA-DRB1*04 alleles there, and not with HLA-DRB1*1501 as in Northern 
Europe (Marrosu et al., 1998). A recent study of familial clustering of MS in a Dutch 
genetic isolate similarly found that the HLA-DRB1*1501 allele was not found to be 
significantly more prevalent in cases compared to controls. These isolates may thus be 
valuable for explorations into novel genes that raise MS risk (Hoppenbrouwers et al., 




highlighted as arising only because the HLA haplotypes were present at greater 
frequency in the Orkney controls than in controls of other regions. In actuality, the 
frequency of the HLA variants in the Orkney cases was similar to that of other Northern 
European patients with MS (Compston, 1981).  
5.1.3 Genetic studies of MS in Orkney and Shetland 
 The island populations of Orkney and Shetland, like the Dutch genetic isolate, 
are genetically distinct from the larger population. These populations are suited to 
explorations of genetic susceptibility to disease. The large genetic study undertaken by 
Poskanzer and Roberts in the 1970s yielded several publications that explored the role 
of genes in the high prevalence of MS in the islands.  
Levels of inbreeding and kinship were assessed to explore the possibility that 
rare recessive variants and recently-introduced dominant or codominant variants may 
be leading to an increased risk of MS. Although levels of inbreeding were high in both 
Orkney and Shetland compared to the rest of the UK, the same levels of inbreeding 
were found in both cases and controls, and were not high enough to expect any severe 
effects to general health or mortality. That both cases and controls in both archipelagos 
are similar in terms of inbreeding suggests that there is no effect of rare recessive 
variants, however the authors conclude that more common recessive variants could be 
implicated (Roberts et al., 1979; Roberts et al., 1983).  
Similarly, levels of kinship did not differ between cases and controls in either 
Orkney or Shetland, suggesting that the ancestry of cases and controls is comparable 
(Roberts et al., 1979; Roberts et al., 1983). The authors therefore conclude that there is 
no involvement of recently-introduced dominant or codominant variants. However, 




introduced by an individual who made a significant contribution to the gene pool and 
thus created a founder effect.  
However, the polygenic hypothesis, raised within these papers as a way of 
understanding the genetic contribution to MS in Orkney and Shetland, provides the 
most likely explanation. This hypothesis fits the patterns of familial aggregation in 
families of cases compared to controls despite the overall paucity of families with 
multiple affected individuals, and the declining risk of MS as relationships with the 
proband, or index case, become more distant (Roberts et al., 1979; Roberts et al., 1983). 
A tentative heritability estimate was calculated for Orkney, which was 0.47 (95% CI 
0.28 – 0.66), however, the low number of cases (51) led to a note of caution in placing 
too much emphasis on the result (Roberts et al., 1979). No such calculation was 
attempted for the Shetland sample at it was considerably smaller (31) (Roberts et al., 
1983). 
It is worth noting that these two above-discussed Orkney and Shetland papers 
(Roberts et al., 1979; Roberts et al., 1983) obtained their results from analyses of MS 
cases and two sets of controls. The first set of controls were ‘contiguous controls’, 
chosen if they were born within the same parish as the case at around the same time, 
and lived there for the first 15 years of life. The second set of controls were 
‘discontiguous controls’, and were born around the same time as the matched case but 
lived for their first 15 years in a non-adjacent parish. However, a follow-up paper in 
1991 used the contiguous controls only. This study also included a further 28 patients 
who had died between 1958 and 1974. These additional patients were included if a) 
their MS status had been confirmed while they were alive; b) if they had been included 
in the 1954 series verified by Sutherland (Sutherland, 1956), or c) if they had been in 




previous study, Roberts found that cases in Orkney were more closely related to one 
another than were contiguous controls. He also found that the mean kinship of the 
parents of cases was twice that observed in the parents of contiguous controls 
(Roberts, 1991). This closer kinship between parents of cases compared to parents of 
controls would suggest that, at least in Orkney, genes shared by the parents of cases, 
and genes that are both maternally and paternally inherited, may influence risk of 
developing MS (Roberts, 1991). 
 Results therefore vary according to the choice of controls, however there are 
advantages to using the contiguous controls. As described, contiguous controls were 
randomly selected from the same parish as the matched case. This geographical 
matching suggests that, if anything, they were likely to be overmatched on genetic 
ancestry based upon small community sizes and limited historic population movement. 
However, the relatively small study sample size of cases and controls also needs to be 
considered.  
Further unpublished analyses from Orkney and Shetland data sought to 
investigate the relatedness of cases compared to age-matched controls, and to controls 
who were considerably older and beyond the lifetime risk of developing MS at the time 
of selection. Using the Northern Isles Multiple Sclerosis Study 2009 (NIMS09) data, the 
results showed that controls in both Orkney and Shetland were more closely related to 
each other than cases (personal communication, McQuillan 2016). However, the way in 
which cases and controls were selected differed on the following important aspects. As 
described in Chapter 4, cases in this study were identified as part of a genetic and 
prevalence study of MS in Orkney and Shetland. Considering that complete and 
accurate case ascertainment for such a study is vital, much effort was directed to these 




Northern Isles heritage and were more likely than cases to have all four grandparents 
from the islands. Families also often volunteered together, or family ‘matriarchs’ 
encouraged others in the wider family to join up. The greater Orcadian or Shetlandic 
ancestry of controls and the potential bias generated by the inclusion of some large 
families meant that controls were found to be more closely related to each other than 
the cases (personal communication, McQuillan, 2016). Therefore, no clear conclusions 
about the pattern of familial MS could be drawn from these data.  
5.1.4 Genetic clustering: a novel approach 
As discussed in Chapter 3, there is strong genetic structuring in Orkney, which 
is also likely to be present in Shetland. This structuring suggests that geographic 
regions are a proxy for genetic relatedness. Alongside our deep pedigrees of families 
with MS, this genetic structuring enabled us to explore whether, historically, the 
contribution to the modern gene pool of MS from some parishes or isles is excessive 
compared to other parishes or isles.  
For this present study we had one aim, which was to further explore the 
possible genetic inheritance of MS in Orkney and Shetland using pedigree data 
combined from our two datasets. We had two objectives to achieve this aim. These 
were -  
Objective 1 – Using NIMS74 and NIMS09 datasets, obtain an estimate of the heritability 
of MS in Orkney and Shetland  
Objective 2 – Using NIMS74 data only, compare the registration districts of Orkney and 
Shetland for their genetic contribution to MS, using ancestors of cases and controls to 




5.2 Methods  
5.2.1 Heritability 
5.2.1.1 Case definition 
 These analyses use the same data and case definitions as described in Chapter 
4. However, more individuals were included in the heritability analyses than were 
included in the clustering analysis. This was because an inclusion criterion for the 
heritability analysis required only that an individual has Northern Isles grandparents 
whereas the clustering study required individuals to be born in the Northern Isles. In 
total, we had 182 cases, which met a) Allison and Millar definitions for probable or 
possible MS, or b) Poser criteria for clinically definite, laboratory-supported clinically 
definite, clinically probable or laboratory-supported clinically probable MS, or c) 
McDonald 2001 or 2005 criteria. 
5.2.1.2 Birthplace definition 
 For the analyses, fine-grained birthplace definitions by parish or isle were not 
necessary. We did however categorise cases as Orcadian or Shetlandic according to the 
archipelagos of their grandparents’ births. Additionally, we found four individuals who 
fell into both archipelago categories with equal numbers of Orcadian and Shetlandic 
grandparents. One-hundred and eighteen cases were considered to be of Orcadian 
ancestry as they had two or more Orcadian grandparents, and 68 of which were of 
Shetlandic ancestry, with two or more Shetlandic grandparents.  
5.2.1.3 Analyses 
 The cases in our study came from an ascertained sample. However, despite our 
best efforts to create a full and accurate dataset, information regarding case status of 
some of the older, and deceased, relatives, was unknown and impossible to verify. A 
censored sample was therefore inevitable. Falconer’s method takes into account this 




As with other methods, Falconer’s method assumes a normally distributed 
liability for developing a dichotomous trait, such as MS. These models posit that each 
individual has an underlying risk to disease, which is normally distributed. This normal 
distribution is termed the liability, and is thought to determine an individual’s 
probability of developing disease (Smith et al., 2011; Visscher et al., 2008). Heritability 
can be estimated from the liability, and is referred to as the heritability of liability to 
disease (Tenesa and Haley, 2013). 
 Falconer’s method to estimate the narrow-sense heritability of liability to 
disease can be applied to groups of relatives of the same structure; we applied it to 
parent-offspring trios in Orkney and Shetland following the guidelines set out in Tenesa 
and Haley (2013). The liability of disease is determined from the prevalence of disease 
within the population; this prevalence determines the threshold of liability above 
which the disease is expressed, as shown in Figure 5.2.  
The population prevalence of MS is denoted by qg, and was taken from the most 
recent prevalence study of MS in Orkney and Shetland (Visser et al., 2012). The 
threshold of liability above which disease is expressed is xg. Ф is the standard normal 
cumulative distribution, and Ф-1 the inverse of the same. The liability variance, or Vp is 
assumed to be 1. Then, qg = 1- Ф-1(xg) and xg = Ф-1(qg). The density of the normal 
distribution at the liability threshold is denoted zg; the mean liability of index cases (ag) 
is calculated ag= zg/qg. Additionally, qr is the prevalence of disease among the relatives 
of the index cases (in these cases, affected parents), and xr is the normal deviate of qr. 
The unstandardized regression coefficient of a relative’s liability on the liability of an 
index case is  
𝑏𝑏 =






Figure 5.2 Falconer's method to estimate h2 of liability to disease 
 
(Tenesa and Haley, 2013) 
   
 We ran analyses using parent-offspring trios separately for Orkney and 
Shetland to obtain estimates of heritability for each archipelago. We also calculated 
95% confidence intervals for the estimates. Heritability analyses were run using R by 
David Clark following discussions about the analyses to be undertaken; I calculated the 
95% confidence intervals in Excel. 
5.2.2 Genetic clustering 
To explore possible genetic clustering by registration district, we arrived at a 
sample of ancestors of cases and controls who had been born as close to 1890 as 
possible, using the NIMS74 index cases and controls. We chose to define a specific time 
instead of simply looking at the grandparents of cases and controls, as the period in 
which the grandparents were born spanned over one hundred years beginning in 1801. 




genetic ancestry for any registration district over such an extended period was 
therefore impossible. Ancestors born closest to 1890 meant that we could use the 1891 
census for the population size. 
5.2.2.1 Case definition 
 The case definition was as described for the NIMS74 data in Chapter 4. We only 
used NIMS74 to maintain consistency with regards to controls. 
5.2.2.2 Control definition 
As mentioned above, two sets of controls were selected when the data were 
originally collected in 1974. Contiguous controls were randomly selected from a 
sampling frame of ten individuals whose dates of birth were closest to the date of birth 
of the case (either earlier or later), and had been born within the birth parish of the 
case. Contiguous controls further needed to be unrelated to the matched case, of the 
same sex as their matched case, had lived in the same area as the matched case for their 
first 15 years and did not have a known neurological disease (Poskanzer et al., 1980a). 
As these controls were selected at the time of the study to be temporally and 
geographically matched to the case, the authors feared that they may have 
overmatched on an aetiological factor (Poskanzer et al., 1980a). A set of discontiguous 
controls were therefore also selected. Firstly, all parishes in each archipelago were 
weighted according to population size taken from the census closest to the birth year of 
each case, and assigned a number. To assign discontiguous, or non-adjacent parishes to 
cases, a number was randomly drawn for each case and applied to this list. If a 
contiguous parish was selected, the process was repeated until a suitable discontiguous 
parish was found. Once a discontiguous parish had been selected, cases were matched 




5.2.2.3 Birthplace definition  
 The birthplace definition was the same as for Chapter 4: registration district of 
birth. However, instead of recording the registration district of the cases and controls 
as we did in Chapter 4, in this study we noted the birth registration districts for the 
ancestors of cases and controls, who had been born closest to 1890. 
5.2.2.4 Analyses 
Taking the ancestors born circa 1890 of all possible and probable MS cases 
identified in NIMS74, we noted the birthplace in terms of registration district within 
Orkney or Shetland and then assigned each ancestor a score based on how related they 
were to the case: parents = 0.5; grandparents = 0.25, great-grandparents = 0.125 and 
great-great grandparents = 0.0625. This score was each ancestor’s predicted 
contribution to their descendant’s DNA. We then summed these scores for each 
registration district of ancestors’ births, giving a figure that represented the total 
amount that the ancestors of cases contributed to the NIMS74 MS gene pool in each 
registration district.  
We then divided this figure by the population size of the registration district to 
correct for the different population sizes. The resultant number was the genetic 
proportion of the registration district in the 1890s who went on to have a descendent 
with MS in NIMS74 (hereafter called the genetic proportion). 
For comparison purposes, we repeated the procedure with the contiguous 
controls of the NIMS74 dataset. Case-control comparisons require that the two 
populations being studied are as similar as possible on all factors except that which is 
being investigated (CASP, 2016). However, because there is the possibility that the 
contiguous controls may be over-matched on ancestry, which is crucial to these 




We graphed the results for all registration districts to visualise how the genetic 
proportions of cases and controls within each registration district compare to each 
other and across districts. We also calculated 95% CI in each registration district, 
shown as error bars on Figures 5.3 and 5.5. The null hypothesis was that no 
registration district would contribute significantly more to the gene pool of modern MS 
cases than any other. We would therefore expect to see a fairly even distribution of 




 In Orkney, there were 118 cases; of these there were 4 cases who had a parent 
with MS. We also had 232 non-cases who did not have parents with MS. From these 
data, we obtained a heritability estimate of 0.36 (95% CI -0.26, 0.98). This means that 
36% of the variation in liability to MS between individuals in Orkney is owing to 
additive genetic effects. In Shetland, we had 68 cases of which there was 1 case who 
had a parent with MS. We had 135 non-cases who did not have parents with MS. From 
these data we obtained a heritability estimate of 0.20 (95% CI -1.88, 2.28), meaning 
that 20% of the variation in liability to MS between individuals in Shetland is owing to 
additive genetic effects.  
5.3.2 Genetic clustering 
 The genetic clustering results showing the genetic proportion of cases and 
controls in each registration district are shown in Figures 5.3-5.6. Overall, there were 
no significant differences between cases and controls across all registration districts, 
shown clearly by the overlapping error bars which provide a range of values in which 
the true population parameter may fall. This means that no registration district appears 






















































































































































































































































































































































































We obtained heritability estimates from parent-offspring trios of 0.36 in Orkney 
and 0.20 in Shetland with respective confidence intervals of -0.26 to 0.98 and -1.88 to 
2.28. These estimates are modest but are consistent with heritability estimates 
obtained from twin studies outlined in Table 5.1 (Kuusisto et al., 2008; French Research 
Group on Multiple Sclerosis, 1992; Islam et al., 2006). However, the confidence 
intervals are large and cross zero. Heritability estimates should fall within the 
theoretical limits of zero and one; negative confidence intervals for heritability 
estimates are therefore impossible to interpret meaningfully. In this study, the negative 
confidence intervals are attributable to the small sample sizes and few related cases in 
each archipelago, which led to large standard errors. A simulation study which 
compared heritability estimates from parent-offspring regression with frequentist and 
Bayesian animal models in wild populations found that small sample sizes in parent-
offspring regression had a considerable impact on the precision of the heritability 
estimates. Moreover, heritability estimates from parent-offspring regression could be 
negative, particularly when the pedigree on which the analyses were based was sparse 
(de Villemereuil et al., 2013). However, the decision to base our analyses on parent-
offspring trios was taken following consultation with Professor Chris Haley. The 
decision was driven by our data, which comprised a complex pedigree of multiple 
families of different sizes and structures, and number of cases too small to effectively 
explore the heritability using other methods despite such potential resultant 
inaccuracies. Although these analyses were limited by the available data, the results 
suggest that genetics are likely to be important in MS susceptibility in Orkney and 
Shetland as they are elsewhere, although we cannot say that the genetic risk in the 




However, to try to further assess the genetic contribution to today’s MS gene 
pool from the pedigree data by registration district, we explored the genetic 
contribution of the NIMS74 case and control ancestors. The distribution of the genetic 
proportions for cases, contiguous controls, and discontiguous controls across 
registration districts were all similar. This is clearly shown by the overlapping error 
bars, and therefore we cannot say that any district contributes an excess genetic 
proportion to the MS genepool. 
As mentioned, we were hindered by small sample sizes, both overall and by 
registration district. This was also problematic in the genetic clustering analyses where 
some registration districts appeared to contribute a large proportion of genetics to the 
NIMS74 gene pool (Figures 5.3-5.6). Fair Isle particularly appears to have a large 
genetic proportion for MS cases. Despite controlling for population size, this is an 
artefact of a very small population as in actuality, only one father and one mother of an 
MS case, giving a genetic score of 1 (0.5 + 0.5), came from Fair Isle. However this was 
enough within that very small population (n= 221 in 1891) to produce a comparatively 
large genetic proportion. Additionally, none of the selected contiguous or discontiguous 
controls had ancestors born in Fair Isle, attributable to the even smaller population size 
of this, the remotest of Shetland’s Isles, in the 20th century.  
The analyses were carried out within the limits of the data that we had and the 
controls that had been chosen at the outset of the NIMS09 and NIMS74 studies. To 
explore the question of the genetic contribution to MS in Orkney and Shetland properly, 
it would be advantageous to conduct analyses at the genomic level. Other interesting 
questions to explore would be whether there is a deeper pedigree connection between 
cases than we were able to detect. As mentioned earlier, Hoppenbrouwer et al. (2007) 




extended for 14 generations enabling the pattern of common ancestry to be 
established. Despite having deep pedigrees for many of our cases we do not have the 
same depth for everyone. Additionally, the records dating prior to 1855, when the 
statutory registration of births, marriages, and deaths was introduced, are less-
meticulously recorded. This means that tracing families to these distant generations 
becomes increasingly complicated or impossible. It is interesting to speculate, however, 
whether with more complete pedigrees we may see a similar pattern in the genetic 
isolates of Orkney and Shetland. 
Despite these shortcomings, these analyses show that there is a genetic 
contribution to MS in Orkney and Shetland which reflects the situation seen elsewhere. 
However, the low heritability estimates indicate that there needs to be a trigger for 
disease in susceptible individuals. The next three chapter explore such potential 
triggers, or risks, which are pertinent to these high-latitude islands, including a lack of 









CHAPTER 6: A SCOPING REVIEW TO MAP THE LITERATURE 
CONCERNING VITAMIN D, UV EXPOSURE, AND MS, TO IDENTIFY 
EVIDENCE FOR AN ASSOCIATION BETWEEN MS ONSET, 
PATHOLOGY, AND PROGRESSION 
6.1 Introduction 
Chapters 7 and 8 present two primary studies of environmental risk factors for 
MS. These two studies explore vitamin D levels in Orkney, and UV exposure in Shetland. 
However, to place these chapters into context, I present in this chapter a scoping 
review of the literature concerning vitamin D, UV exposure, and MS. I begin with an 
introduction defining vitamin D and a description of the vitamin D lifecycle. I then 
explore the best methods and limitations of vitamin D measurement in epidemiological 
studies. Next, I present a brief history of how the associations between UV exposure, 
vitamin D deficiency, and MS were initially made and highlight possible mechanisms by 
which such deficiencies interact with the immune system. Finally, I introduce key study 
designs in epidemiology and genetics. I discuss in more detail study types that have 
shown a consistent association between vitamin D deficiency, UV exposure, and MS, 
and discuss the challenges and complexities involved in inferring causation. I then 
present the methods, results, and discussion. 
6.1.1 Vitamin D 
Vitamin D is a fat-soluble secosteroid largely formed of two prohormones: 
ergocalciferol and cholecalciferol (Hewer et al., 2013). Ergocalciferol, or vitamin D2, is of 
plant origin. Within the diet, mushrooms are a particularly rich source of vitamin D2. 
Fungi synthesise ergosterols, which, on exposure to ultraviolet B (UVB) radiation from 
sunlight, are converted into ergocalciferol. Cholecalciferol, or vitamin D3, derives from 
animal sources including oily fish, eggs, and liver, and is also synthesised from 7-




UVB is a mid-wavelength light, making up 5-10% of all solar UV. Whilst 
overexposure causes sunburn, and chronic overexposure can lead to photoaging and 
increased risk of melanoma and non-melanoma skin cancers (Orteu et al., 2001; 
Biesalski and Obermueller-Jevic, 2001), UVB also has immunosuppressive properties 
(Tsunoda et al., 2005) and is responsible for initiating vitamin D synthesis via its action 
on cutaneous cholesterol. Vitamin D3 from sunlight exposure is the main source of 
vitamin D in humans (Holick, 2004a).  
6.1.2 The vitamin D lifecycle 
Several different mechanisms enable vitamin D to be produced, activated, 
utilised, and degraded. Firstly, cutaneous production of cholecalciferol requires 7-DHC, 
which is produced by the enzyme 7-dehydrocholesterol reductase (DHCR7). 7-DHC 
reacts with UVB to produce vitamin D. Once acquired, vitamin D undergoes an 
enzymatic conversion, or hydroxylation, by 25-hydroxylase (encoded by gene CYP2R1) 
in the liver to form 25-hydroxyvitamin D (25(OH)D. This 25(OH)D then undergoes a 
further hydroxylation by the enzyme 25-hydroxyvitamin D-1 alpha hydroxylase 
(encoded by CYP27B1) to become the active form of vitamin D, 1,25-dihydroxyvitamin 
D (1,25(OH)2D). This second hydroxylation occurs in the kidney, and also in other 
tissues of the body where CYP27B1 is present. The degradation of vitamin D begins 
with a further hydroxylation initiated by the enzyme 24-hydroxylase (encoded by 
CYP24A1), which leads to 24,25(OH)2D. 
The active form of vitamin D, 1,25(OH)2D, binds to the ligand-binding domain 
of the VDR, which, alongside another macromolecule, forms a complex at the vitamin D 
response element (VDRE). This complex results in vitamin D-regulated gene expression 
(Pike, 2011). The VDR regulates the expression of several hundred genes in over 30 
tissues and organs; it is furthermore present in cell membranes where it mediates a 




For transportation around the body, active or inactive vitamin D binds to 
vitamin D binding protein (DBP). The main function of DBP is to retain vitamin D and 
make it available to target tissues. Vitamin D can enter the target cell still bound to the 
DBP, or it may be delivered and cross the membrane without the DBP. Inactive 
25(OH)D can be hydroxylated to 1,25(OH)2D by CYP27B1 when it enters the cell. 
Vitamin D that has been produced following UV exposure is most quickly bound by DBP 
(Chun, 2012). Vitamin D3 has also been found to be more potent at raising serum 
25(OH)D than vitamin D2 (Trang et al., 1998; Tripkovic et al., 2017), and is considered 
to be more biologically active (Heaney et al., 2010). 
Each part of this chain is vital to the healthy production, activity, usage, and 
maintenance of vitamin D. A breakdown in any one part can result in deficiency. The 
different structures of the vitamin D, including inactive, active, and degraded, are all 
measurable, however some forms are better for assessing vitamin D status than others.  
6.1.3 Vitamin D measurement 
The current best estimate for determining individual circulating vitamin D 
measures is through analysis of blood for serum 25(OH)D. This inactive form of vitamin 
D is a robust and reliable marker with a long half-life (Seamans and Cashman, 2009; 
Mawer et al., 1969), and is not under as tight regulation as the active form (Norman, 
2008). Laboratory measurements are however limited in large population studies by 
logistical considerations which can prevent single, or follow-up, measures being taken. 
Because vitamin D varies seasonally, single, baseline measurements of vitamin D are 
not necessarily representative of long-term vitamin D status (Millen and Bodnar, 2008).  
Where individual serum measures or longitudinal data are unavailable, dietary 
data can be used to estimate both recent and lifetime vitamin D (Millen and Bodnar, 




capture rarely-eaten foods which may be vitamin D-rich. Moreover, it is vital to identify 
the dose, frequency and duration of vitamin D supplementation which is likely to 
contribute more to oral intake of vitamin D than diet alone (Millen and Bodnar, 2008).  
However, estimates of UV exposure as a determinant of circulating 25(OH)D 
may be more important in estimating vitamin D status than dietary data (Brot et al., 
2001). Methods for calculating UV exposure for a healthy vitamin D status have been 
developed (Webb and Engelsen, 2006). Latitudes further from the equator have been 
used as a proxy to indicate reduced UV exposure, which in turn has been used as a 
proxy for lower vitamin D levels (Holick, 2004a). However, ecological studies such as 
these do not allow for differences in UV exposure at the individual level.  
Satellite data can also be used to estimate UV exposure, and can give a measure 
of ambient UV for the geographical location and period under study. This method can 
enable calculation of lifetime UV exposure using information regarding participants’ 
places of residence throughout life (Lucas et al., 2011). However, this calculation still 
relies on estimates of time spent outside and therefore results in estimates, rather than 
direct measures, of individual UV exposure.  
Other studies quantitatively measure individual UV exposure using 
polysulphone badges (Webb et al., 1988), other types of dosimeters (Thieden et al., 
2004), actinic damage (Lucas et al., 2011), and sun exposure questionnaires to recall 
recent or lifetime sun exposure (van der Mei et al., 2003). Each of these methods can be 
applied in combination or used in isolation. Studies that have measured both UV 
exposure and vitamin D status have explored the direct impact of UV exposure on 
vitamin D, and also the impact of UV exposure on MS onset independent of vitamin D 
(Lucas et al., 2011). Several methods of quantifying or estimating vitamin D and UV 




6.1.4 Key study designs 
Several different types of epidemiological study design have been used to 
explore vitamin D, UV exposure, and MS. Each study design has different strengths and 
weaknesses, and are ranked in a hierarchy of evidence according to how much weight 
can be placed on the evidence they can produce. The higher up the hierarchy, the more 
robust the study (and therefore the evidence) is assumed to be. However, although the 
weight of evidence that can be placed on studies varies by the study design used, it also 
depends of the methodological rigour of the individual studies. The hierarchy of 
evidence contains the following: 
1) Systematic reviews of RCTs and meta-analyses 
2) Randomised controlled trials 
3) Cohort studies 
4) Case-control studies 
5) Cross-sectional surveys 
I present here an overview of the methodologies, strengths, and weaknesses of 
these study designs. I begin with number 5 on the hierarchy and work through to 
number 1. I finish with a discussion of the pros and cons of genetic study designs, which 
are not included in the general epidemiology hierarchy of evidence. 
6.1.4.1 Observational studies 
Observational studies are analytic and non-randomised, and involve the 
observation of study participants with no intervention by the investigators (Sedgwick, 
2014). There are three main types of observational study design: cross-sectional, case-
control, and cohort (Jepsen et al., 2004). Associations in observational studies result 
from four main factors. These are bias, confounding, chance, and cause. It is not 




epidemiological study, however strong study designs should aim to minimise bias, 
confounding, and chance, and to carefully assess their effects (Jepsen et al., 2004). 
Cross-sectional studies are useful for identifying associations between 
outcomes and potential exposures or risk factors. However, because cross-sectional 
studies assemble prevalent rather than incident cases of disease, outcomes and risk 
factors are identified simultaneously. As such, there is no temporal element in a cross-
sectional study and any identified associations may therefore represent consequences, 
rather than risk, of disease (Jepsen et al., 2004). This also means that the terms 
‘outcome’ and ‘exposure’ may be misleading, as cross-sectional studies provide no 
understanding of which presented first.  
Cross sectional studies are prone to some biases. Two types of selection bias are 
non-response bias and volunteer bias. Non-response bias is particularly problematic 
for studies based on surveys, and occurs when individuals who do not consent to 
participate in the study differ from those who do participate. This difference can lead to 
a sample that is not representative of the population (Sedgwick, 2014). Volunteer bias 
arises from a systematic difference between those who volunteer for a study and the 
source population. A further bias, ascertainment bias, occurs when the information 
recorded about participants is systematically different from the truth, and can result 
from response bias (where participants have systematically supplied information that 
deviates from the truth), or observer or assessment bias (where investigators 
systematically record information that deviates from the truth) (Sedgwick, 2015). 
Confounding, where a third variable obscures an association, can also occur in cross-
sectional studies. 
Case-control designs select a group with the outcome of interest and a group 




design is particularly useful for rare diseases, however where the frequency of an 
exposure is either very common or very uncommon in the population, case-control 
studies may be limited in detecting associations with precision (Koepsell and Weiss, 
2014). Typically, the power of case-control studies to observe an association increases 
with a higher ratio of controls to cases, up to 4:1 (Wacholder et al., 1992; Hennessy et 
al., 1999).  
Biases particularly relevant to case-control studies include selection bias and 
recall bias. Selection bias occurs when any apparent association between the exposure 
and the outcome is combined with the association of being selected as a case or control 
and the exposure, and can bias either towards or away from the null (Rothman et al., 
2008). Recall bias can occur when current health status affects recall of past exposures; 
those in the case group may recall past exposures which appear more salient than 
those in the control group (Jepsen et al., 2004). Nested case-control studies are set 
within a cohort study, where cases have an outcome of interest, and controls are 
selected from individuals who were at risk at the time that the cases occurred (Szklo 
and Nieto, 2012). Nested case-control studies reduce selection bias as both cases and 
controls are drawn from the same population, and recall bias is also reduced compared 
to a case-control study. There are also methods to reduce confounding. One possibility 
is to restrict the sample so that people with, for example, a comorbidity that could 
affect the outcome, are excluded. Statistical adjustment can also reduce confounding 
where differences between cases and controls have been identified. Finally, risk of 
confounding can also be reduced by matching cases to controls on a potentially 
confounding factor (Koepsell and Weiss, 2014).  
Cohort studies follow up a group, or cohort, to determine the occurrence of an 




outcome. Where follow-up of participants has occurred prior to the start of the study, 
the study design is retrospective; where follow-up occurs into the future, the design is 
prospective. For rare diseases particularly, cohort studies require a large study 
population and a follow-up long enough to observe sufficient outcomes associated with 
exposures to reduce the risk of chance findings (Jepsen et al., 2004). In cases where a 
latency period between exposure and outcome is lengthy, cohort studies are 
impractical to detect associations. Although cohort studies have a temporal element 
and therefore enable the identification of an exposure that precedes onset of disease – 
one of the principles of inferring a causal relationship – the association is not 
necessarily causal. Like the other studies discussed, cohort studies can be influenced by 
non-response bias and selection bias (Sedgwick, 2011). Furthermore, loss to follow-up 
can be particularly problematic, and can occur if individuals die, move away, or 
withdraw consent to continue in the study. These losses can be related to the exposure, 
the outcome, or both, and can lead to significant biases in the measurement of both 
exposure and outcome. Furthermore, cohort studies are prone to confounding, as 
confounding variables may be unavailable or difficult to collect across the whole study 
period (Hennekens et al., 1987).  
6.1.4.2 Intervention studies  
Intervention studies, unlike observational studies, involve the intervention of 
the researcher. There are several types of intervention study, including non-blinded 
trials, where both participants and researchers know what treatment is being 
administered, non-randomised trials, where participants are allocated to an 
intervention in a way that is not random, and randomised controlled trials (RCTs), 
which are considered the gold-standard of intervention studies (Bothwell et al., 2016) 




In a successful RCT, the randomisation process means that the groups under 
study are the same for measured and unmeasured factors, which reduces biases and 
confounding. At its most basic, the investigator compares a treated group with an 
untreated group, and observes the differences in, for example, disease progression. The 
controlled setting of the RCT, where ideally the only difference between groups is the 
administered treatment, enables evaluation of an intervention without the same noise 
found in observational trials (Thiese, 2014; Nardini, 2014).   
Nonetheless, RCTs are subject to complications, including selection bias, where 
the groups under study differ from each other at baseline in salient ways which can 
introduce confounding and bias results; performance and detection bias, which refer to 
systematic differences in the ways in which the groups are treated and in how the 
outcomes are treated respectively, and attrition bias where there is a systematic 
difference in withdrawals between the study groups leading to incomplete and biased 
outcomes (Kovesdy and Kalantar-Zadeh, 2012). There are ways to deal with such 
issues, including methods for randomisation, masking study participants and 
investigators to the treatment status of each group, known as double-blinding, and 
performing analyses that take into account participants lost to follow-up (Kovesdy and 
Kalantar-Zadeh, 2012).  
RCTs of potential new therapies usually include a placebo group – that is, a 
group that is the same in all ways as the group receiving treatment, but instead of the 
treatment are given an inert substance. This enables researchers to detect whether the 
treatment has an effect. However, where an effective therapy is in existence, it is 
usually considered unethical to deprive a group of treatment. In these cases, it is more 
usual to compare one group taking an existing treatment with another taking a new 




vitamin D therapy as a routine MS treatment, and therefore placebo groups are 
valuable in vitamin D therapy trials.  
 
6.1.4.3 Systematic reviews and meta-analyses 
There are multiple types of review study, however systematic reviews of RCTs 
alongside meta-analyses are placed at the top of the hierarchy of evidence. A meta-
analysis is a statistical technique that combines results from multiple quantitative 
studies, identified by systematic and exhaustive searches, with the aim of giving a more 
precise estimate of the effect than single studies in isolation (Grant and Booth, 2009). A 
systematic review, which can include a meta-analysis, is likewise the result of a 
systematic search for literature to identify all evidence on a subject. Systematic review 
research questions are usually very well-defined and narrow (Arksey and O'Malley, 
2005). Evidence sought on a subject is appraised and synthesised to obtain a full and 
impartial view of existing literature to answer the question. Findings may be used to 
understand what research has been undertaken, what uncertainties remain about 
findings, what is still unknown, and areas for future research. Systematic reviews 
should adhere to strict guidelines, and both meta-analyses and systematic reviews 
involve quality assessment of identified studies to determine inclusion or exclusion 
(Grant and Booth, 2009). The comparison of multiple – quality – studies in a systematic 
review lends this design its strength.  
Systematic reviews have historically focussed on RCTs, and collate evidence for 
healthcare intervention effectiveness in areas such as prevention, treatment, and 
rehabilitation. Such a rigorous review of the literature can guide policy-makers and 
hasten implementation of effective therapies into routine treatment. Such systematic 
reviews of RCTs are ultimately at the top of the hierarchy of evidence. However, clinical 




outcomes, or they do not use real-world settings which can impact their external 
validity (the extent to which findings can be generalised to populations and situations 
outside the study) (O’Neil et al., 2014). Therefore, systematic reviews of healthcare 
interventions using observational studies are becoming more prominent (O’Neil et al., 
2014). Although identifying causal associations from observational studies is not 
possible, and therefore a systematic review of observational studies cannot draw causal 
conclusions, the collation of several observational studies from different populations in 
which chance, bias, and confounding have been minimised has led to some 
observational systematic reviews with strong evidence for further exploration. This is 
particularly true when findings across multiple studies have shown similarly strong 
associations and dose-response relationships. Systematic reviews of observational 
studies, whilst still retaining the same risk of bias and confounding as observational 
studies, can in certain circumstances therefore be valuable in filling gaps left by 
systematic reviews of RCTs (O’Neil et al., 2014). Furthermore, such observational 
systematic reviews can highlight the prevalence of disease and increased risk of 
comorbidities, both of which can guide future research (Etminan et al., 2005; Jeon and 
Murray, 2008). 
6.1.4.4 Genetic studies 
Genetic epidemiology aims to establish the presence of genetic components for 
disease, and the genetic effect size or penetrance, which contributes to disease in 
comparison with environmental causes. In so doing, such genetic risks can be used for 
several purposes: to predict who is at risk for disease with the possibility of offering 
targeted interventions; to better understand the biological basis for the genetic effects 
which may lead to pharmacological developments, and to help identify causal pathways 
between exposures and outcomes (Bush and Moore, 2012; Smith and Hemani, 2014). 




examined to understand how the genes segregate in particular diseases, was initially 
successful in identifying variants that contribute to rare, single gene disorders, such as 
cystic fibrosis which have a highly penetrant, Mendelian pattern of inheritance (Bush 
and Moore, 2012; Marian, 2016). However, this approach has been less successful in 
identifying the genetic basis of common disorders, suggesting that the genetic 
architecture of rare and common diseases is different. The common disease/common 
variant hypothesis states that common disorders are likely to be influenced by genetic 
variation that is common in the population; which do not have Mendelian patterns of 
inheritance but may aggregate in families, and each of which may have very low 
penetrance (Bush and Moore, 2012; Marian, 2016). As such, each variant may 
contribute a small amount of increased disease risk, but there is no guarantee that 
carrying risk alleles will lead to disease manifestation. Such diseases, like MS, therefore 
likely manifest as a result of multiple genetic (and environmental) risks, each with a 
very small effect, but that together create an increasing genetic risk for disease. 
Finding evidence of such genes and their role in disease comes largely from 
genetic epidemiology studies (Marian, 2016). Various study designs have developed in 
this area of research. Two of the most common designs which I discuss here are 
genome-wide association studies (GWAS), and candidate gene studies. I also discuss 
Mendelian randomisation (MR) studies, which use genetic markers as a proxy for 
environmental exposures.  
The GWAS technique was first validated in a landmark 2007 paper (The 
Wellcome Trust Case Control Consortium, 2007). They are non-hypothesis driven, 
exploratory studies which can be performed for both binary and continuous traits, and 
are used to identify common variants in the genome with small or moderate effects 
(Bush and Moore, 2012). GWAS have been performed using cohort designs, where a 




conditions, which also enables interaction effects between genes and environment to 
be investigated in detail (Manolio, 2009). However, typically, GWAS use case-control 
designs, where common genetic variants are evaluated for an association with disease 
using affected and unaffected individuals. Some GWAS use family designs involving 
affected and unaffected family members, which controls for potential confounding by 
shared environmental exposures. Such a design additionally removes the possibility for 
population stratification bias, which arises from differences in genetic ancestry 
between cases and controls, although it also reduces power to detect main effects due 
to the increased genetic similarities between family members (Witte, 2010).  
As with all case-control designs, control selection should be representative of 
the source population (Witte, 2010). Convenience controls, where genotype 
information from controls who were involved in previous studies is used for control 
populations in current studies, are also used (Luca et al., 2008). The definition of the 
phenotype according to standardised criteria is also important, particularly when a 
study is based across multiple centres (Bush and Moore, 2012). However, recall bias, 
which can hamper traditional epidemiology studies, is not relevant to genetic studies, 
and large sample sizes also add strength to the design (Witte, 2010).  
GWAS conduct millions of tests across the genome in an effort to identify 
potential genetic risks. Each test has its own false positive rate and adjustment for 
multiple testing is therefore crucial (Bush and Moore, 2012). Various methods have 
been applied to correct for multiple testing, including the False Discovery Rate, 
permutation testing and genome-wide significance (Bush and Moore, 2012). However, 
the gold standard in confirming an identified effect is to replicate it in an independent 
sample (Bush and Moore, 2012) and this is where candidate gene studies are 




 Candidate gene studies are association studies where the aim is to identify the 
presence of a statistically significant association between specific genomic variation 
and disease. Genes are chosen based upon a biologically plausible hypothesis which 
may result from animal models, or from prior knowledge of the effect of genes on other 
traits (Hattersley and McCarthy, 2005). Today, candidate genes are often identified 
from significant results in GWAS and undertaken to replicate the observed effects 
(Bush and Moore, 2012). Like GWAS, such studies can be case-control, family-based or 
within-cohort; again family-based designs reduces some possible environmental 
confounding factors and are particularly useful in identifying rare variants (Zondervan 
and Cardon, 2007). As in traditional epidemiology, cohort studies are considered to be 
a very strong design (Manolio, 2009), although when a disease is rare the numbers of 
cases are likely to be low, and any resulting nested case-control studies are therefore 
likely to be small. Case-control designs are again the most widely used (Zondervan and 
Cardon, 2007). 
 When candidate gene association studies are undertaken to replicate an 
association observed from GWAS, the first aim is to reproduce the effect in an 
independent dataset from the same population as the GWAS. If the effect is replicated 
and confirmed, then a different population is targeted to identify whether it is 
population-specific or whether it is relevant to multiple human populations (Bush and 
Moore, 2012). Where the analysis is hypothesis-driven, the number of tests should be 
small and adjustment for multiple testing is not required to the same level as GWAS 
(Bush and Moore, 2012).  
 Replication has however been a frustratingly slow process, which may be 
attributed to several potential problems that limit ability of such studies to replicate 




general population, a candidate gene study sample size needs to be large enough to 
have the power to detect an effect which is likely to be smaller than anticipated, or to 
detect whether the initial result was spurious (Bush and Moore, 2012). The phenotype 
must also precisely adhere to an accepted standard; slight differences have the 
potential to prevent replication (Bush and Moore, 2012). Additionally, sample and 
variant selection, genotyping error, analytical techniques, and interpretation may 
reduce the ability to replicate observed associations (Hattersley and McCarthy, 2005). 
As well as potential biases within studies, publication bias may also be present, where 
only a small amount of the most ‘publishable’ (or significant) findings are to be found 
within the published literature. Findings which had not been replicated are thereby 
omitted from the evidence base, which could mean that the significant results reported 
are no more than chance findings (Ioannidis, 2003).  
Replication is important in confirming an association, and also in defining 
whether there is a potential causal pathway between an identified gene and the 
phenotype of interest. However, well-conducted Mendelian randomisation studies offer 
possibly the best evidence to evaluate a potential causal association. 
Mendelian randomisation studies seek to answer different questions to 
genetic association studies. As described above, genetic association studies aim to 
identify genes associated with complex traits. However, Mendelian randomisation 
studies use genetic variants as a proxy for modifiable environmental exposures. The 
basic idea underpinning Mendelian randomisation is that if a modifiable environmental 
exposure is related to an outcome, then a genetic variant that either alters the level of, 
or mirrors, the same exposure should be related to disease risk (Smith and Hemani, 
2014). The random allotment of alleles in meiosis (the process of cell division where 




RCT. Mendelian randomisation studies may therefore be viewed as ‘natural’ RCTs 
(Thanassoulis and O’Donnell, 2009), and it is this randomisation which protects 
Mendelian randomisation studies from many sources of bias and confounding. By using 
functional genetic variants as proxies for environmental exposures, Mendelian 
randomisation has several advantages over traditional epidemiology designs as genetic 
variants are not affected by behavioural, cultural or physiological factors that can 
confound associations; they are fixed from birth and so reverse causation and 
measurement error are excluded, and reporting of variants cannot be modified 
according to knowledge of disease status (Smith and Hemani, 2014). Additionally, 
genetic variants may act as long-term environmental exposures (Smith and Hemani, 
2014), for example a variant that lowers production of vitamin D can be considered 
equivalent to long-term, or lifetime, vitamin D insufficiency.  
As with genetic association studies, problems with Mendelian randomisation 
can occur when the biological association between genotype and phenotype is not 
accurate and reliable. Furthermore, confounding can occur as a result of population 
stratification (differences in allele frequencies in cases and controls resulting from 
systematic differences in ancestry (Springer, 2006b)) or linkage disequilibrium (the 
non-random association of alleles at different loci within a population (Springer, 
2006a)) of one functional variant with another, and pleiotropy, where the gene in 
question has multiple functions and phenotypic consequences and may therefore be 
acting on a different pathway to increase disease risk (Smith and Hemani, 2014). 
However, if it is concluded that there is no alternative way in which the variant could 
be affecting the outcome, then the Mendelian randomisation design provides strong 
evidence for causality which may have implications for the manner in which disease is 




There are therefore multiple study designs, which are increasingly 
sophisticated, aiming to establish the association and direction of causation between 
vitamin D deficiency and MS. However, the link between UV radiation, vitamin D 
deficiency and MS, was first spotted from ecological studies, where associations 
between a population (rather than individuals) and the outcome of interest, are 
identified. 
6.1.5 The association between vitamin D, UV exposure, and MS 
 The association between MS and UV exposure was first documented in 1960 
(Acheson et al., 1960). This observation followed the recognition of a pattern where MS 
prevalence increased as sunlight decreased resulting from distance from the equator. 
Additionally sunnier local climates were observed to be protective against MS (Acheson 
et al., 1960).  
Soon after this observation, sunlight’s role in initiating cutaneous synthesis of 
vitamin D was established (Rauschkolb et al., 1969), and a hypothesis was formulated 
for the aetiological involvement of vitamin D in MS (Goldberg, 1974). The role of 
vitamin D in the immune system was first identified in the 1980s (Bhalla et al., 1984), 
and in the late 1990s 1,25(OH)D3, the active form of vitamin D3, was found to prevent 
the onset of experimental autoimmune encephalomyelitis (EAE), a mouse-model of MS 
(Hayes et al., 1997). The role of vitamin D in VDR gene expression is also now 
hypothesised to have a significant role in large gene-gene interaction systems. These 
interactions may regulate immune processes that modulate MS activity, shown through 
greater MRI activity in vitamin D-deficient individuals (Munger et al., 2014). 
Also in the late 1990s, a hypothesis was proposed suggesting that the pattern of 
MS prevalence may reflect differential UV-induced autoimmune activity suppression 




shown to reduce inflammation and demyelination in EAE (Becklund et al., 2010; Wang 
et al., 2013; Wang et al., 2015).  
Both vitamin D and UVR similarly affect the activities of autoimmune-active 
dendritic and treg cells (Hart et al., 2011). Furthermore, sun exposure and vitamin D 
were found to be independent risk factors for CNS demyelination in a multicentre 
Australian case-control study (Lucas et al., 2011).  
Since the early recognition of a geographical pattern, many studies have 
continued to find increased MS prevalence with distance from the equator in both 
northern and southern hemispheres (Behrend, 1969; McCall et al., 1968; Acheson and 
Bachrach, 1960; Simpson S. Jr. et al., 2011; Hornabrook, 1971). The most influential 
studies are perhaps those of Kurtzke, who proposed the existence of a latitudinal 
gradient with geographical low, medium and high MS risk zones corresponding with 
distance from the equator (Kurtzke, 1975; Kurtzke, 1977; Kurtzke, 2000). High risk 
areas included most of Europe, the northern states of America, Canada, New Zealand, 
south-east Australia and east Russia; medium risk areas comprised the southern states 
of America, South Africa, the southern Mediterranean basin, the rest of Australia, parts 
of Latin America, the Ukraine and Russia into Siberia, and low risk areas consisted of 
Asian, African and northern South American countries (Kurtzke, 2000).  
This geographical pattern has been consistently observed in the literature. 
Notable exceptions, however, are Sicily and Malta. Situated at the same latitude, the two 
islands have a 10-fold difference in MS prevalence with Sicily being a high-risk area and 
Malta very low-risk (Dean et al., 1979; Vassallo et al., 1979). Follow-up studies found 
this difference to be enduring (Nicoletti et al., 2011; Dean et al., 2002). Plausible 
reasons for the disparity could be genetic and environmental differences which either 
lead to an increased risk in Sicily, or are protective in Malta. However, studies on these 




Migration studies also support the latitudinal gradient of MS risk. This effect 
was first noted in a 1967 study of European immigrants to South Africa, where the 
prevalence of MS in immigrants was markedly higher than in the South African 
population. MS was also observed much more frequently in those who had been older 
than 15 when they migrated (Dean, 1967). The authors concluded that particular 
susceptibility to an environmental risk is set in childhood; the risk in those who 
migrated in childhood was offset by a protective exposure in South Africa.  
Further studies have observed that people who migrate from countries with a 
high risk of MS to low-risk countries, or between high- and low-risk areas within the 
same country, have an MS risk intermediate between that of their place of origin and 
their new location (Gale and Martyn, 1995). MS prevalence in migrants who moved 
from the high-risk UK and Ireland to low-risk Australia was found to be significantly 
less than in their countries of origin. However, no difference was observed between the 
risk of MS in those migrating before or after 15 years of age, suggesting here that 
environmental risk of MS may accumulate over many years and is not specific to 
childhood and adolescence (Hammond et al., 2000). 
Increased risk of MS in migrants moving from low- to high-risk countries is 
evidenced by the increasing prevalence of MS in individuals of Asian, African and 
Caribbean origin in the UK (Elian et al., 1990), and in a large proportion of MS patients 
of Middle-Eastern origin in Oslo (Smestad et al., 2008). The lack of age sensitivity and 
MS risk is reinforced in this latter study, many of whom had migrated to Norway 
beyond the age of 15. This finding suggests that environmental risk within the country 
of immigration extends into adulthood (Smestad et al., 2008). In a study of immigrants 




and higher than their parents, which adds further weight to the evidence of an 
environmental factor or factors implicated in MS aetiology (Elian et al., 1990). 
Potential problems with migrant studies stem from the fact that people who 
migrate are not necessarily representative of the population of the country of origin. In 
ordinary circumstances migrants tend to be younger, healthier, and of a higher 
socioeconomic status than non-migrants from the same country (Gale and Martyn, 
1995). Moreover, there may be differences in healthcare provisions between the 
country of origin and new country which can alter the probability of diagnosis. 
However, a study of return migration in the French West Indies found that individuals 
who had migrated to and lived in France for several years before returning to 
Martinique or Guadeloupe had more cases of MS than would be expected against the 
non-migrating population. Furthermore, the incidence was higher for those who had 
been living in France at the age of 15 or younger (Cabre et al., 2005). The authors 
suggest that as the background genetics of both migrating population and those who 
remained resident in the French West Indies were not dissimilar, an unfavourable 
environmental exposure may have been present to which those who were younger 
than 15 years were particularly susceptible. Therefore, there is little consensus on 
when and how the risk of MS changes, or age-sensitivity at time of migration. However, 
the literature remains consistent in terms of migration altering the risk of MS.  
Further ecological evidence for an association between reduced sun exposure 
and MS risk has been accumulating. A month-of-birth effect was observed in studies of 
MS from the UK (Disanto et al., 2012; Willer et al., 2005), Scotland (Bayes et al., 2010), 
USA, Italy (Menni et al., 2012), Sicily (Salemi et al., 2000), Canada (Willer et al., 2005; 
Ramagopalan et al., 2009a; Sadovnick et al., 2007), Israel (Givon et al., 2012), Finland 




2009a; Salzer et al., 2010). A systematic review and meta-analysis of these studies 
confirmed the effect; pregnancies that occur mainly over the spring and summer 
months deliver children with lower risk of MS (Dobson et al., 2012). The mechanism for 
this effect is hypothesised to be maternal vitamin D, supported through the interaction 
between magnitude of month of birth effect, and latitude as a proxy for ambient UV 
radiation levels. Maternal vitamin D should be at its peak during months of greater 
sunshine, and declining over winter months. Therefore, children in the Northern 
Hemisphere who are born in November are at less risk of MS than those born in May.  
Animal models have also found UV exposure to selectively inhibit spinal cord 
demyelination (Wang et al., 2015), suppress EAE independent of vitamin D (Becklund 
et al., 2010), and reduce invariant natural killer T (iNKT) cell numbers (Yu and 
Cantorna, 2011). Additionally, a month-of-birth effect has been reproduced: 
overexpression of iNKT is protective against EAE, however low in-utero or neonatal 
vitamin D results in suboptimal numbers of iNKT. Moreover, early vitamin D deficiency 
appears to result in epigenetic changes to iNKT that cannot be reversed by subsequent 
vitamin D exposure (Yu and Cantorna, 2011), suggesting that in humans, prenatal 
vitamin D may be important in reducing future risk of autoimmunity. 
 
6.1.5 Are these associations causal? 
These ecological studies present evidence of an association between UV 
exposure, vitamin D, and MS risk, some of which has been reinforced in animal models 
of MS. However, establishing causation is a complex process for which Sir Austin 
Bradford Hill proposed a checklist for guidance (Hill, 1965). This checklist included 
criteria such as, among others, strength and consistency of associations, temporality – 




which a causal mechanism could result in the observed effect. However, Hill considered 
experimental evidence to provide the strongest support for causal inference (Hill, 1965).  
As described above (section 6.1.4.1), observational studies cannot provide 
evidence that establishes causation. As well as chance, bias, and confounding which, 
while they can be reduced, cannot be entirely excluded, there is the issue of reverse 
causation. Reverse causation is particularly problematic for studies of vitamin D and UV 
exposure in illnesses with long latency periods such as MS. It is thus not clear from 
observational studies if low vitamin D levels result from poorer health and reduced 
exposure to UV because of increasingly lower levels of mobility, or if instead low 
vitamin D causes poorer health and reduced mobility.  
There have been several systematic reviews of observational studies looking for 
associations between vitamin D and MS. A systematic review and meta-analysis of 
observational studies of vitamin D levels in people with MS found significantly lower 
vitamin D in cases compared to controls, and concluded that low vitamin D levels are 
associated with an increased risk of MS (Duan et al., 2014). However, two further 
systematic reviews used both observational and interventional study data. One of these 
studies explored vitamin D and autoimmune diseases, and found, like Duan et al. 
(2014), low vitamin D levels in people with MS compared to controls. They found no 
interventional studies of vitamin D supplementation and MS, however the 
observational studies that they included suggested that taking vitamin D supplements 
reduced risk of MS. They conclude that there is insufficient evidence to establish a 
causal link between circulating vitamin D levels and autoimmune disease risk, and 
highlight the need for more RCTs (Antico et al., 2012).  The second systematic review 
found cross-sectional (but not longitudinal) observational evidence of an association 
between vitamin D and autoimmune disease, and within the included interventional 




reduced MS disease exacerbation when vitamin D supplements were supplied. They 
also conclude that existing evidence is weak, and call for longer term RCTs with higher 
vitamin D doses (Kriegel et al., 2011). 
An umbrella review of observational systematic reviews and meta-analyses 
looked at environmental factors and MS. They found no association between vitamin D 
and MS, however there were consistent associations between MS and Epstein-Barr 
virus, smoking, and infectious mononucleosis (Belbasis et al., 2015). A further umbrella 
review that comprised observational systematic reviews and meta-analyses, and 
interventional meta-analyses, looked at the association between vitamin D and multiple 
health outcomes. They found no evidence of associations for autoimmune diseases. 
However, the review also highlighted a lack of meta-analyses for autoimmune 
outcomes, and again the need for more RCTs (Theodoratou et al., 2014).  
 
6.1.6 Summary 
A large body of work regarding vitamin D and MS has been produced, and has 
been summarised by multiple researchers. As described above, several systematic 
reviews of intervention and observational studies in the area of vitamin D and MS have 
been undertaken, and have been included in umbrella reviews. However, to date, whilst 
there is ample evidence to show an association between vitamin D and multiple 
sclerosis, there is a lack of evidence to indicate a causal relationship with the paucity of 
RCTs highlighted by multiple reviews.  
The literature regarding MS, vitamin D, and UV exposure encompasses a large 
volume of observational, intervention, and genetic studies, with various methods used 
in different study designs. The disparate research that exists in this area lends itself to a 





Systematic reviews, as discussed in section 6.1.4.3, require a focussed question 
to enable a rigorous evaluation of the literature, usually from a narrow range of quality-
assessed studies. Scoping reviews, however, do not ask such narrow questions and 
neither do they assess the literature for quality. As such, the scoping review 
methodology only enables general observations of the literature regarding study 
designs and findings; the lack of quality assessment means that causal inference cannot 
be construed from a scoping review regardless of the methodologies of included 
studies. Instead, scoping reviews usually tackle broader research questions than 
systematic reviews, and aim to identify all literature relevant to the area of study. In so 
doing, the scoping review provides a method to “examine the extent, range, and 
research activity” (Arksey and O'Malley, 2005) within an area of interest. All relevant 
literature can then be mapped, findings aggregated, and results presented in a broad, 
narrative account. As well as the extent of research in key areas, gaps in the literature 
may be identified which could help to guide future research. Furthermore, when a 
series of apparently complementary findings are observed, the possibility for a future 
systematic review to assess the findings more closely may be highlighted.  
However, despite their differences, both systematic reviews and scoping 
reviews should have methodologies that are rigorous and transparent (Arksey and 
O'Malley, 2005). The protocol (Appendix B) for the scoping review was designed 
according to the five-point framework of Arksey and O’Malley (Arksey and O'Malley, 
2005), with reference to more recent research expanding on the scoping review 
methodology (Levac et al., 2010). 
6.2 Methods 
We searched Medline, Embase, Biosis, Web of Science, and the World Health 
Organisation (WHO) International Clinical Trials Registry Platform (ICTRP) for papers 




through the Proquest Dissertations and Theses Global database (PQDT), and Google 
Scholar. Searches were carried out on 21 March 2016.  
Included articles defined MS according to the Poser (Poser et al., 1983) or 
McDonald (McDonald et al., 2001) criteria, or focussed on EAE as an animal model of 
MS. We included studies involving individual vitamin D and UV exposure measures, and 
MS patients of all ages. We included observational, experimental, and genetic studies. 
Ecological studies, and publications with no original data including meta-analyses and 
systematic reviews, were excluded. For reasons of time, papers in non-English 
languages were also excluded. 
Search terms included, but were not limited to, vitamin D, cholecalciferol, 
ergocalciferol, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, ultra-violet radiation, 
sun exposure, multiple sclerosis, relapsing remitting multiple sclerosis, primary 
progressive multiple sclerosis and experimental autoimmune encephalomyelitis. We 
used boolean operators OR and AND to link search terms. The full search strategy is 
listed in the protocol (Appendix B). 
Searches initially identified 5200 papers, of which 2219 were duplicates and 57 
were foreign language papers. Because of the quantity of papers identified, we decided 
at this stage to exclude EAE and focus on vitamin D and UV in MS exclusively. We also 
decided to include all studies that involved MS patients regardless of diagnostic criteria, 
to understand how MS was being defined across studies. A total of 2924 potentially 
relevant papers were put through for eligibility screening. One person (EW) screened 
all titles and abstracts against eligibility criteria, whilst a second person (RM) screened 
a random sample of 10% for agreement. Both reviewers were in complete agreement 
about studies to be excluded. There was 75% agreement regarding papers to be 




publication under question, and were resolved through discussion. Two further papers 
were identified from a meta-analysis of genetic variants and MS risk. 
 In total, we extracted data from 129 papers which have been used in the main 
summary and report (Figure 6.1). Where possible, we also extracted and tabulated data 
from the meeting abstracts, although information from these was clearly less detailed 
and was not included in the main synthesis. Tables of abstract data are presented in 
Appendix C. 





Exclusions from the title and abstract screening comprised studies which did 
not involve vitamin D or UV (651 excluded), or did not include MS patients (844 
excluded). The other excluded papers were reviews, commentaries, chapters 
containing no new data, and case reports. Exclusions from the full-text screening were 
for similar reasons, usually where the title and abstract alone had included insufficient 
information to make a decision.  
Papers fell largely into three categories of Observational, Intervention, and 
Genetic studies. Of the 127 identified papers, 72 were observational studies, 14 were 
intervention studies, and 43 were based on genetic analyses including the one 
Mendelian randomisation study.  
The large number of papers meant that presenting the results in a meaningful 
way was challenging. We therefore present the results in three sections according to 
study type, ending each section with a summary of the main findings. The first section 
focusses on observational studies; the second on intervention studies, and the third on 
genetic studies. The Mendelian randomisation study is included at the end of the 
Genetic section, however it is discussed separately from the other genetic studies 
owing to the different type of question that this study asks.  
As per Arksey and O’Malley’s recommendations, we begin each results section 
with summary tables providing overviews of the study designs, the geographical 
distribution of studies, vitamin D and UV radiation measures, and MS criteria. This 
process identified themes within the literature which we go on to present in greater 
detail. A final discussion and conclusion brings together all the separate elements 




6.2.1 Power and sample size 
To provide context regarding the power of studies included in this review, I 
calculated the sample sizes required to detect several hypothetical effect sizes. To 
begin, I calculated the Cohen’s d, or the standardised mean difference, in several studies 
included herein which had also been reported in Duan et al.’s systematic review (2011). 
The formula for Cohen’s d is  




where m1 is the mean of group 1, m2 is the mean of group 2, and 𝛿𝛿 is the pooled 
standard deviation (Cohen, 1988). 
 The standardised effect sizes were -0.12 (Shahbeigi et al., 2013), -0.10 (van der 
Mei et al., 2007), and 0.11 (Lonergan et al., 2011). A Cohen’s d of 0.2 reflects a small 
effect size, 0.5 is a medium effect size, and 0.8 is large (Cohen, 1988). As the 
standardised effect sizes obtained here suggest that the included studies identified 
small effects, I calculated the sample sizes required to detect small to medium effects, 
with power set at 0.80 and alpha at 0.05. The analyses showed that to detect an effect 
size of 1) d = 0.05 requires a sample size of 6280 in each group; 2) d = 0.1 requires 
1570 in each group; 3) d = 0.2 requires 393 in each group, and 4) d = 0.5 requires a 
sample size of 64 participants in each group.   
6.3 Results: Observational Studies 
These results comprise studies where vitamin D or UV exposure had not been 
externally manipulated. Table 6.1 shows that most studies in this category were 
concerned solely with vitamin D levels in people with MS. The remainder focussed on 
UV exposure, or both UV exposure and vitamin D, in MS. Vitamin D measurement varied 
across studies. The most widely used was 25(OH)D. Nine studies estimated vitamin D 




to overall vitamin D including UV exposure estimates (Table 6.1). For UV, most studies 
relied on self-report measures of sun exposure which were usually retrospectively 
collected. Most of these studies used validated questionnaires, which were sometimes 
combined with a quantitative measure of long-term UV exposure such as actinic skin 
damage, or short term exposure such as polysulphone dosimeters (Table 6.1). 
 By a large margin the most frequent study design was case-control, followed by 
cross-sectional (Table 6.2). Prospective longitudinal and cohort studies, which are 
higher up the hierarchy of evidence, are more lengthy and expensive to conduct, and 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Definitions of MS also varied across studies. However, most studies referred to 
the McDonald criteria (any version thereof), which provides some consistency across 
studies. The older studies, before the introduction of the McDonald criteria, often used 
the Poser criteria. Only one study applied the Schumacher criteria, whilst others 
identified MS cases as those confirmed by MRI or neurologists without specifying the 
criteria against which diagnoses were made. The studies which contained no 
information about the identification, diagnosis, or confirmation of MS cases for 
inclusion, were more troubling (Table 6.3). 
Geographically, studies were heavily weighted towards Europe and The 
Americas. The Eastern Mediterranean region was next best represented, with the 
contribution to this category largely from studies originating in Iran. South-East Asia 
was represented by two studies from India, and no identified studies originated in 
Africa. Five studies came from the Western Pacific region, including one from Japan and 
four from Australia (Table 6.4).  
   
 As anticipated, summarising the identified studies highlighted some gaps in 
research, particularly in terms of study design and geography. However, the process 
also enabled us to identify recurring themes which are discussed under separate 
headings below. Where study findings fall into multiple categories, repeated entries are 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3.1 General associations between Vitamin D/UV exposure and MS (Table 6.5) 
Blood vitamin D in MS 
 Twelve studies explored blood vitamin D levels in people with MS, with no 
specific focus on MS risk, onset, progression or subtype. All of these studies were case-
control designs, and their findings were divided into two opposing groups. Eight found 
that people with MS had significantly lower blood vitamin D than controls (Karampoor 
et al., 2016; Shaygannejad et al., 2010; Fahmi et al., 2014; Gelfand et al., 2011; Kubicka 
and Pierzchała, 2013; Niino et al., 2015; Suresh Kumar et al., 2013; Pandit et al., 2013). 
The remaining four found that people with MS did not have significantly different blood 
vitamin D levels to controls (Lonergan et al., 2011; Moghtaderi et al., 2013; Eskandari et 
al., 2015; Barnes et al., 2007). Those results that showed significantly lower vitamin D 
came from studies from five of the six geographical regions, with sample sizes ranging 
from 700 cases and 1000 controls (Karampoor et al., 2016) to 25 cases and 25 controls 
(Fahmi et al., 2014), and 30 cases and 15 controls (Kubicka and Pierzchała, 2013). 
Sample sizes in the studies that found no significant differences were generally smaller, 
although the largest comprised 632 cases to 226 controls (Lonergan et al., 2011), and 
with geographical regions limited to Europe and the Eastern Mediterranean.  
 Blood vitamin D in CIS was explored in two longitudinal studies both from 
Europe. One was retrospective and the other prospective. Both studies found that 
patients with CIS had significantly lower vitamin D compared to controls, indicating 
that vitamin D deficiency is potentially implicated early in MS. However one study 
divided vitamin D into 25(OH)D2 and 25(OH)D3, and found that, although levels of 
25(OH)D3 were significantly lower in people with CIS, levels of 25(OH)D2 did not differ 
between people with and without CIS (Behrens et al., 2016). These findings suggest 
that deficiency of 25(OH)D3, and not 25(OH)D2, may be an MS risk factor. Additionally, 




with and without CIS, suggesting that the mechanism for vitamin D deficiency as an MS 
risk factor is not related to its bioavailability. Instead, the authors hypothesise, vitamin 
D may be a marker for a closely correlated and potentially causal mechanism (Behrens 
et al., 2016), such as UV exposure.  
UV exposure in people with MS 
 Two studies, with sample sizes of 1013 cases and 1194 controls (Bäärnhielm et 
al., 2012), and 195 cases and 146 controls (Al-Shammri et al., 2015), found that cases 
had significantly lower levels of UV exposure compared to controls. However, another 
study of 45 cases and 90 controls (Eskandari et al., 2015) found that there was no 
difference between groups regarding UV exposure. 
Bäärnhielm et al.’s (2012) study originated in Europe, and utilised recall data of 
sun exposure for five years prior to study entry. Recall data may be influenced by 
response bias, which could strengthen the association between lack of UV and MS. The 
studies of Eskandari et al. (2015) and Al-Shammri et al. (2015), with their opposing 
findings, both originate from the Eastern Mediterranean; however Eskandari et al. 
(2014) (Iran) utilised measures of 25(OH)D as well as daily sun exposure whereas Al-
Shammri et al. (2015) (Kuwait) relied solely on self-reported daily sun exposure. 
Additionally, although the two countries are within the same world region, they have 
different dress codes. The hijab is compulsory in Iran and not in Kuwait. The strict 
Iranian dress code may mean that UV exposure is dictated by clothing cover. 
Additionally, fully-shrouded dressing in Kuwait was more frequently observed in 
newly-diagnosed MS patients compared with established cases or controls (Al-
Shammri et al., 2015).  
UV exposure and MS mortality 
 Two studies explored occupational UV exposure in relation to MS mortality. 




occupational UV exposure depending upon the geographical area of occupation and the 
occupation itself. These studies were based in the USA (Freedman et al., 2000) and 
Sweden (Westberg et al., 2009), and used all MS deaths within their study regions 
giving sample sizes of 5701 cases and 839 cases respectively. Both studies found strong 
negative associations between occupational UV exposure and risk of death from MS. 
These results suggest that reduced UV exposure, and vitamin D, may be implicated in 
MS. However, reverse causation cannot be excluded, for example people with MS or 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































     
    

























































































































































































































































































































































6.3.2 Associations between vitamin D/UV exposure and MS risk and onset (Table 
6.6) 
Blood vitamin D and risk of MS 
 Four studies fell into the category of blood vitamin D and MS risk, all of which 
originated in Europe. The results were fairly consistent. Although one large nested 
case-control study found that high vitamin D in the years preceding disease onset was 
associated with decreased MS risk (Salzer et al., 2012), the other three studies, and a 
further result from the dissenting study, all found no association between vitamin D 
levels and MS risk. One continuous cross-sectional study included 164 optic neuritis 
(ON) patients who were prospectively followed to see if vitamin D levels in acute ON 
can predict later development of MS. While vitamin D levels were low in both groups, 
there was no significant difference in vitamin D between those who developed MS and 
those who did not (Pihl-Jensen and Frederiksen, 2015). This finding suggests that in 
cases of ON, vitamin D levels are not useful for predicting future MS development. A 
further prospective study of 525 incident MS cases and over 12,000 controls found that 
although vitamin D was inversely associated with the onset of any autoimmune disease, 
the association specifically with MS was not significant (Skaaby et al., 2015). Two 
studies, one nested case-control and one large prospective population-based case-
control, were designed to investigate gestational (Salzer et al., 2012) and neonatal 
(Ueda et al., 2014) vitamin D respectively. Neither found evidence of an association 
between deficiency in these periods and later MS development.  
Blood vitamin D at MS onset 
 Two case-control studies aimed to ascertain how blood vitamin D levels at MS 
diagnosis compared to controls without MS. One study, from the Eastern 
Mediterranean, comprised 75 cases and 100 controls who were relatives of cases 
(Mazdeh et al., 2013). The other study was from Europe and included 40 cases and 40 




vitamin D levels were significantly lower in people with MS in the summer, but in no 
other seasons. Heat intolerance, which often affects people with MS (Emre, 1986), may 
account for this finding, as individuals with preclinical MS may instinctively avoid 
direct summer sunlight leading to reduced opportunity for vitamin D synthesis.  
UV exposure in early life and MS risk 
 Exposure to sunlight in early life and risk of MS was explored in six studies. One 
study of 1149 twin pairs specifically investigated childhood sun exposure (Islam et al., 
2007). The others, all case-control with sample sizes ranging from 136 case and 272 
controls to 1660 cases and 3050 controls, studied both childhood and adolescent sun 
exposure (Dalmay et al., 2010; Kampman et al., 2007; Bjornevik et al., 2014; van der 
Mei et al., 2003; Lucas et al., 2011). Studies originated from the Americas, Europe and 
Western Pacific regions, and all revealed significant associations between low sun 
exposure in early life and a greater risk of MS, revealing a similar pattern globally.  
A further case-control study of over 100 cases and controls found that a lack of 
childhood UV exposure was a risk factor for MS, and that this association was 
independent of current vitamin D status (Pandit et al., 2013). This finding may support 
Behrens et al.’s (2016) above-mentioned hypothesis that vitamin D could simply be a 
marker for a correlated causal mechanism (Behrens et al., 2016). However, it may also 
reflect lower past vitamin D levels, which may be harmful to future autoimmunity. 
UV exposure in early life and MS onset 
Two cross-sectional studies found that low sun exposure in both summer and 
winter during adolescence was significantly associated with a younger age of MS and 
RRMS onset (Laursen et al., 2016; McDowell et al., 2011a). These papers, with sample 
sizes of over 1000 and 500 cases respectively, suggest a mechanism whereby 
adolescent vitamin D deficiency, or a lack of UV, harms the development of the immune 




period in childhood and adolescence for reduced UV exposure and MS risk; 
alternatively it may reflect lower past vitamin D levels. Both studies use self-reported 
measures of sun exposure. However, one study also used self-reported place of 
residence in childhood and adolescence to estimate UV exposure, which was weighted 
by the length of time spent in that location between ages 6 and 15, and self-reported 
use of sunscreen. The authors found a significantly younger age at onset in those who 
had regularly used sunscreen in childhood and early adolescence (McDowell et al., 
2011a). 
UV exposure and MS risk 
 UV exposure and MS risk was explored more generally in four case-control 
studies. The sample sizes ranged from between 83 cases and 166 controls, to 1403 
cases and 395 controls. All but one study agreed that reduced sun exposure over a 
lifetime is significantly associated with greater MS risk (Alonso et al., 2011; Mansouri et 
al., 2014; Lucas et al., 2011). This latter study (Lucas et al., 2011), from Australia, also 
found that vitamin D and reduced UV exposure may be independently associated with 
greater risk of a first demyelinating event, and so were consistent with there being 
separate roles for these two risk factors (Lucas et al., 2011). The findings from the 
fourth paper which had the smallest sample size of the four showed no evidence of an 
association between sun exposure and MS risk in the tropical climate of Mexico 
(Espinosa-Ramírez et al., 2014).  
Vitamin D intake and MS risk 
Four studies were concerned with vitamin D intake and had similar findings. 
Two case-control studies found that low dietary vitamin D intake in childhood and 
adolescence (Kampman et al., 2007), or in adolescence only (Cortese et al., 2015), were 
associated with increased risk of MS. Cortese et al. (2015), in their sample of 935 cases 




protective effect although childhood intake did not. This finding suggests that 
deficiency or sufficiency in a specific period of life may present different risks for MS. 
Likewise, in a sample of 152 cases and 402 controls, cod liver oil consumption had a 
protective effect against MS in adolescents who reported low levels of outdoor activity 
during summer in Norway. This finding suggests that dietary supplementation can 
offset a lack of endogenous vitamin D and reduce MS risk (Kampman et al., 2007).  
However, a prospective study of 379 incident and 67 prevalent cases in the USA 
found no association between adolescent vitamin D intake and MS risk (Munger et al., 
2011). A further population-based case-control study of 1879 MS cases and 4135 
controls from Sweden found that fatty fish consumption was associated with a 
decreased occurrence of MS. Dividing groups based on their reported consumption, the 
authors compared high (one to seven times per week) and low 
(monthly/seldom/never) intake, and found a significantly decreased occurrence of MS 
in the high intake group (Bäärnhielm et al., 2014). As no difference was observed 
between high and low intake of lean fish, the authors conclude that vitamin D, found in 
fatty fish, was a candidate for the protective effect.  
Vitamin D intake and MS onset 
 One cross-sectional study of 948 relapsing-remitting and secondary 
progressive MS cases was concerned with childhood and adolescent vitamin D intake, 
and MS onset. Cod liver oil intake between 6 and 15 years of age was associated with 
later onset age. This same study also found, as noted above, that low UV exposure and 
sunscreen use between 6 and 15 years was a risk for earlier MS onset (McDowell et al., 
2011a). Although this study relies on self-reports of MS diagnosis and recall of 
childhood UV exposure and diet, the findings are nonetheless consistent with other 




life in which to ensure adequate UV exposure or vitamin D sufficiency for future 




































































































































































































































































































































































































































































































































































































    
     
      
      
     
    








































































































































































































































































































































































































































































































        
       
       



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































      
       
       
       
      























































































































































































































































































































































































































































































































6.3.3 Associations between vitamin D/UV exposure and MS progression (Table 
6.7) 
Blood vitamin D and MS progression 
 The relationship between vitamin D levels and MS progression were explored 
in fourteen papers. Progression was variously measured by relapses, changes in 
disease activity on MRI, the Extended Disability Status Scale (EDSS), the Multiple 
Sclerosis Severity Score (MSSS), and Patient-Determined Disease Steps (PDDS). Two of 
these studies were prospective, with around 450 participants. Each study found that 
low blood vitamin D was significantly associated with increased risk of disease activity 
on MRI, relapses, and EDSS (Ascherio et al., 2014; Mowry et al., 2012a). A smaller 
prospective study also found that vitamin D levels were associated with disease activity 
in CIS (Mowry et al., 2016). Seven studies from Europe, The Americas, Eastern 
Mediterranean, and Western Pacific also found that low vitamin D was significantly 
associated with MS progression by MSSS or EDSS. Study designs were case-control and 
cross-sectional, with sample sizes ranging from 25 cases and 25 controls through to 
469 cases. These complementary findings indicate a similar pattern globally, where low 
vitamin D is associated with greater MS progression (van der Mei et al., 2007; Fahmi et 
al., 2014; Weinstock-Guttman et al., 2011; Smolders et al., 2008; Mandia et al., 2014; 
Ascherio et al., 2014; Mowry et al., 2012b). A further two case-control studies 
(Shahbeigi et al., 2013; Kragt et al., 2009), each with around 100 cases, and 17 and 100 
controls respectively, reported a similar association which was observed only in 
women. Although direction of causation could not be assessed, the findings 
complement those of the other studies, and suggest that low vitamin D may be more 
than a consequence of reduced activity. 
Conversely, four case-control studies found that low vitamin D was not 
associated with MS progression by EDSS or MSSS. One of these studies comprised 339 




(Gelfand et al., 2011). Another was from Japan, with a relatively small sample size and 
low ratio of controls to cases (70 cases and 40 controls) (Niino et al., 2015). The 
remaining two studies were Iranian, one of which involved 700 cases and 1000 
controls (Karampoor et al., 2016) and the other 168 cases and controls (Nikanfar et al., 
2014). Although Fahmi et al.’s (2014) above-mentioned study with its opposing 
findings was also from Iran, it comprised a smaller sample size of 25 cases and 25 
controls which may explain the differences in results.  
UV exposure and MS progression 
 UV exposure before MS onset and in MS progression was explored in six cross-
sectional studies (Ramachandran et al., 2013; McDowell et al., 2011b; D'Hooghe et al., 
2012; Mandia et al., 2014; Jelinek et al., 2015; Zivadinov et al., 2013). The findings were 
generally consistent. In three studies with sample sizes of 219 (McDowell et al., 2011b), 
1372 (D'Hooghe et al., 2012) and 131 (Mandia et al., 2014) from the USA and Europe, 
low sun exposure was significantly associated with greater MS progression by MSSS, 
EDSS or PDSS. Intentional sun exposure was associated with ‘mild’ disability but was 
not related to relapse (Jelinek et al., 2015). Sun exposure was also positively associated 
with grey matter volume and whole brain volume independent of vitamin D in a cross-
sectional analysis of 263 MS patients and 69 controls from the USA (Zivadinov et al., 
2013).  
Three cross-sectional studies explored sun-sensitive skin types and risk of MS 
severity measured by EDSS and MSSS, two of which were UK-based. One study found 
that fair skin and no history of childhood sun burning was associated with slow disease 
progression to EDSS stages 1-4 (Ramachandran et al., 2013); similarly the other found 
that sun-sensitive skin types had a reduced risk of MS severity by EDSS and MSSS in 
females only (Woolmore et al., 2007). Conversely, the third study from Belgium found 




stage 6 in PPMS (D'Hooghe et al., 2012). This latter study included 1372 respondents, 
and focussed exclusively on PPMS while the other two did not differentiate between MS 
subtypes, suggesting the possibility that progression of different subtypes is associated 
with different risks. 
Finally, deliberate sun exposure recorded as a binary yes/no variable was not 
associated with health-related quality of life (HRQOL) as measured by the Multiple 
Sclerosis Quality of Life-54 questionnaire. Further findings from this study are 
discussed below (Jelinek et al., 2015). 
Vitamin D intake and MS progression 
 A significant positive association between vitamin D supplementation and 
relapse was found in one study (Jelinek et al., 2015), however after adjustment for 
other variables only latitude remained significantly predictive of relapse. With a sample 
size of 2469 people across 57 countries in Europe, The Americas, and Western Pacific, 
the study sample comprised self-reported doctor diagnosis of MS, vitamin D 
supplementation, quality of life, and deliberate sun exposure. Although these findings 
reinforce those of many of the above-mentioned studies, it is also limited in several 
ways. Specifically, relying on non-confirmed self-reports of MS diagnosis may mean 
that the sample contains people who suspect they have MS but have not been through a 
formal diagnostic procedure. Additionally, the self-report measures would be subject to 
recall bias, which is particularly problematic if the people within the study have 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3.4 Associations between vitamin D/UV exposure and MS subtype (Table 6.8) 
Blood vitamin D and MS subtype 
Fourteen papers explored blood vitamin D and MS subtype, including 
progressive disease and RRMS. Two of these studies, one cross-sectional with 267 cases 
(Smolders et al., 2008), and the other a retrospective cohort study of 181 cases 
(Thouvenot et al., 2015), found that vitamin D levels were significantly lower in 
patients with progressive MS compared to RRMS. These studies were both European, 
however another cross-sectional study from The Americas explored vitamin D levels in 
adult-onset MS (59 cases), young-adult-onset MS (33 cases) and childhood-onset MS 
(24 cases). No differences in vitamin D levels were observed between these three 
groups, suggesting that vitamin D deficiency may be irrelevant to onset age. Instead, 
factors including race and obesity were significantly associated with low vitamin D 
across all groups (Brenton et al., 2014).  
Three case-control studies found that patients with RRMS had significantly 
lower vitamin D levels than controls. It is notable, however, that one of these studies 
had a small sample size of 29 cases and 29 controls (Polachini et al., 2016), and the 
other two had a different numbers of cases and controls, with 92 cases to 60 controls 
(Correale et al., 2011) and 98 cases to 17 controls (Shahbeigi et al., 2013). Two of these 
studies were European and the latter Eastern Mediterranean.  
However, results from two further case-control studies, both from the Eastern 
Mediterranean, found that, in contrast, vitamin D levels were not significantly different 
between people with RRMS and controls. Both these studies involved equal numbers of 
cases and controls, with 37 of each in one study (Hejazi et al., 2014) and 168 of each in 




Eight studies had findings relating to vitamin D levels and relapse in RRMS. Five 
of these were case-control studies (Soilu-Hänninen et al., 2005; Correale et al., 2011; 
Pandit et al., 2013; Mazdeh et al., 2013; Nikanfar et al., 2014), with sample sizes ranging 
from 40 cases and 40 controls, to 168 cases and 168 controls. Findings were consistent 
across all studies, showing that patients in periods of relapse had significantly lower 
vitamin D than those in remission. Similarly, the other three studies found that patients 
with higher vitamin D levels were less likely to experience relapse. One of these studies 
was cross-sectional (Smolders et al., 2008), and the other two were prospective 
(Simpson et al., 2010; Runia et al., 2012), with sample sizes of 267, 145 and 73 
respectively. Only one study, with 40 PPMS cases and 60 controls, had a finding relating 
to vitamin D in PPMS. Unlike the RRMS results, no difference in vitamin D levels was 
observed between people with PPMS and controls (Correale et al., 2011). 
UV exposure and MS subtype 
One study explored UV exposure and progression in RRMS and PPMS leading to 
two findings. We discussed this study above under the UV exposure and MS 
progression section in Table 6.7 but, because the results were subtype-specific, we also 
present them in Table 6.8 for the sake of clarity (D'Hooghe et al., 2012). 
Vitamin D in paediatric-onset MS 
 Two longitudinal studies explored vitamin D in paediatric-onset MS. One was a 
prospective study of 302 children with acute demyelinating syndrome, 63 of which 
were diagnosed with MS. The results showed that low vitamin D was significantly 
associated with MS onset in children (Banwell et al., 2011), a finding at odds with 
Brenton et al.’s (2014) above-mentioned study. The other study of 100 paediatric MS 
cases was retrospective, and found that low vitamin D was significantly associated with 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
    
   
    
   









































































































































































































































































































































































































































































6.3.5 Associations between vitamin D/UV exposure and sex in MS (Table 6.9) 
Blood vitamin D in MS and sex  
 Six of our studies had sex-specific findings relating to blood vitamin D in MS, 
two of which showed an association between low vitamin D and greater MS 
progression in women and were discussed above in Table 6.7 (Shahbeigi et al., 2013; 
Kragt et al., 2009). A cross-sectional study from a tertiary care hospital in the USA 
showed extensive vitamin D insufficiency in the 80 female patients (Nieves et al., 1994). 
One case-control study of 30 cases and 15 controls in Poland found that vitamin D 
levels were also lower in women compared with men at a similar stage of disease 
(Kubicka and Pierzchała, 2013). Another prospective case-control study in the 
Netherlands, with 101 cases and 107 controls, found that low vitamin D levels were 
associated with increased odds of MS in women (Kragt et al., 2009).  
 Two studies, however, found positive associations between MS and vitamin D in 
women. One case-control study from the UK found that women had significantly higher 
vitamin D compared to men (Barnes et al., 2007), in direct contrast to Kubicka and 
Pierzchala (2013). The other study from Romania found that higher vitamin D was 
associated with better clinical outcomes in women, however this finding was not 
significant (Kinga and Balasa, 2015). Both studies were relatively small, with 29 cases 
and 22 controls, and 36 cases respectively. 
UV exposure in MS and sex 
 Two cross-sectional studies had sex-specific findings regarding UV exposure, 
one of which showed an association between greater sun-sensitivity and reduced risk 
of severe disease in females, and was discussed above in Table 6.7 (Woolmore et al., 
2007). The second study found that almost half of the 80 women with MS comprising 




Vitamin D intake in MS and sex 
 Two studies with female-only samples explored vitamin D intake in MS. One 
cross-sectional study found that vitamin D intake was much lower than the 
recommended level (Nieves et al., 1994). The other prospective cohort study had two 
relevant findings. Firstly, vitamin D from food had no association with MS incidence; 
however vitamin D intake from supplements was significantly associated with a 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We identified a large number of observational studies regarding vitamin D and UV 
exposure in MS, including general associations of these risk factors in people with MS, 
associations with MS risk, onset and progression, associations with different MS 
subtypes and associations with sex. The literature was large and heterogeneous, 
however overall, the following themes emerged: 
1. General associations: case-control studies from many different countries 
found lower vitamin D, and lower UV exposure, in cases compared to controls. 
Low vitamin D was also found longitudinally in patients with CIS. Where no 
difference was observed between cases and controls the studies tended to be 
smaller, suggesting a lack of power to detect an effect, or from world regions 
with specific customs which may create contrasting results. 
2. MS risk and onset: multiple case-control, prospective and cross-sectional 
studies across several regions globally investigated vitamin D levels and MS risk 
and onset. Those studies that specifically investigated vitamin D deficiency and 
risk of MS, and found no association between vitamin D levels and MS risk. 
However, in those studies that measured vitamin D at MS diagnosis, lower 
vitamin D levels were more often present in MS at the time of diagnosis 
compared to controls. Twin, case-control and cross-sectional studies from three 
world regions found that reduced sun exposure in early life was associated with 
a greater risk of MS or younger onset age. The case-control studies exploring 
early life vitamin D intake and MS risk had conflicting results, however a 
prospective cohort study concurred with one of the studies, finding no 
association with MS risk.  
3. MS progression: fourteen prospective, case-control and cross-sectional studies 




disease activity. The five papers that dissented from this finding involved world 
regions with specific customs, or certain populations such as African 
Americans, which may have a local effect on vitamin D levels. Associations 
between UV exposure and MS were mostly explored in cross-sectional studies 
which generally agreed that greater sun exposure was associated with slower 
disease progression, and was positively associated with brain volume 
independent of vitamin D status. Inconsistencies were observed regarding skin 
sensitivity and MS. 
4. MS subtype: studies from five world regions found that vitamin D was 
significantly lower in people with RRMS than controls, and in patients in 
relapse compared to remission. Additionally, people with higher levels of 
vitamin D were less likely to experience relapse. However, no association was 
observed with PPMS although only one study explored this. Two cohort studies, 
one prospective and one retrospective, found that low vitamin D was associated 
with paediatric onset MS or paediatric relapse rate. 
5. Sex: five of the eight studies in this section found significant associations 
between low vitamin D and MS, including risk and progression, in women. A 
lack of sun exposure and vitamin D intake in women with MS was also 
observed, although a prospective cohort study found that supplement use was 
protective. These studies largely originated from Europe and The Americas. 
Observational studies therefore show associations between MS, low vitamin D 
levels, and UV exposure. However, these observational associations require exploration 





6.4 Results: Intervention Studies 
These results comprise studies involving an externally manipulated 
intervention. The intervention studies comprise double-blind RCTs and double-blind, 
placebo-controlled RCTs (Table 6.10). A few other study designs were used including 
two open-label trials and three others which were less conventional, and did not fit a 
defined category. 
All intervention papers focussed on vitamin D supplementation as the exposure 
(Table 6.11). Various types of vitamin D were used, although most widely investigated 
was 25(OH)D3. However, 25(OH)D2, 25(OH)D, 1,25(OH)2D and alfacalcidol, a vitamin D 
analogue, were also explored under controlled conditions.  
 The McDonald criteria was often used to identify cases (Table 6.12), although 
one older study had used the Schumacher criteria. There was only one paper which 
failed to identify how their sample of MS patients had been diagnosed. One study, 
which concentrated on conversion from CIS to MS identified their sample as those who 
had not yet converted to MS by the McDonald criteria. 
Geographically, studies arose most often from The Americas and Europe (Table 
6.13). No studies originated from Africa or South-East Asia. The Eastern Mediterranean 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.4.1 Safety and tolerability of vitamin D therapy in MS (Table 6.14) 
Establishing the safety and tolerability of a potential new treatment is vital in 
drug development to ensure that any resulting therapy is safe with minimal side-
effects. Two papers from North America, one double-blind RCT (Wingerchuk et al., 
2005) and one open-label pilot study (Sotirchos et al., 2016), explored the safety and 
tolerability of vitamin D therapy in people with MS. Both found that vitamin D is safe 
and well-tolerated (Wingerchuk et al., 2005; Sotirchos et al., 2016). These two trials 
had sample sizes of 15 RRMS patients (Wingerchuk et al., 2005), and 40 RRMS patients 
in two groups of 20 (Sotirchos et al., 2016). The amount of vitamin D administered 
varied substantially between the two trials from 100 IU/day to 10,400 IU/day, and 
furthermore the intervention duration varied from 48 weeks to 26 weeks respectively. 
The effect of higher doses over longer periods is therefore not well understood from 
these studies. 
6.4.2 Blood vitamin D levels following vitamin D therapy in MS (Table 6.14) 
Four studies evaluated vitamin D levels in people with MS following vitamin D 
therapy, either as the primary research question or as part of a wider study. One 
double-blind RCT from Australia with 23 participants (Stein et al., 2011), and one 
retrospective evaluation of 49 US patients who had been taking high-dose versus low-
dose vitamin D for at least three months (Hiremath et al., 2009), both found that those 
taking a high dose had significantly higher vitamin D. Additionally, a double-blind 
placebo-controlled RCT from Norway involving 36 treatment and 32 placebo 
participants, found that those in the treatment group had significantly higher vitamin D 
levels (Røsjø et al., 2015). A further study involving the same dataset as Røsjø et al. 
(2015) found that people in the treatment group had sufficient year-round vitamin D, 
however those in the placebo group had generally low vitamin D levels which increased 




25(OH)D2, and the rest used 25(OH)D3. Intervention times ranged from ‘at least’ 13 
weeks, to 96 weeks. However, these studies are all in agreement that supplementing 
with vitamin D, and with higher doses of vitamin D, is effective at raising blood vitamin 
D levels in people with MS.  
6.4.3 Vitamin D therapy and disease progression (Table 6.14) 
Having determined if a treatment is safe and has a biological effect, it is then 
important to assess its effectiveness on disease outcomes. The remaining studies in this 
section focus on whether trials of vitamin D supplementation showed any effect on MS 
onset or MS progression. 
6.4.3.1 Vitamin D therapy and conversion to clinically definite MS 
  One study explored whether vitamin D therapy could prevent or delay 
conversion from ON to clinically definite MS (CDMS) (Derakhshandi et al., 2013). This 
double-blind, randomised, parallel-group trial was conducted in Iran. Patients with 
confirmed ON who did not fulfil McDonald’s MS criteria were randomly assigned to 
receive vitamin D or a placebo. During the twelve-month follow-up period, five of the 
eleven participants in the placebo group experienced a second demyelinating attack, 
compared to none of the thirteen treatment group participants. Although promising, 
small numbers, and a short follow-up period mean these results should be interpreted 
cautiously, however they may warrant a larger clinical trial. 
6.4.3.2 Vitamin D therapy and disease progression by EDSS 
 Three studies explored the impact of vitamin D therapy on the progression of 
MS assessed by the EDSS. Two RCTs that administered vitamin D3 in the treatment 
group versus a placebo group found no differences in disease progression when scored 
by EDSS (Kampman et al., 2012; Mosayebi et al., 2011). These studies were conducted 
in Norway and Iran respectively, ran for 96 and 26 weeks, and varied between daily 




vitamin D2 administered in a high dosage to one treatment group and low dosage to 
another, found that those who were given the high dosage had better EDSS scores 
(Stein et al., 2011). This study had a smaller sample size compared to the other two 
studies, did not include a placebo group, ran for 26 weeks, and involved daily 
supplementation. The methodological differences of this study compared with the 
others may account for some of the differences observed, however possibly of most 
interest is the difference in findings between the study exploring 25(OH)D2 and those 
looking at 25(OH)D3. 
6.4.4.3 Vitamin D therapy and disease progression by relapse 
 Six studies investigated the effect of vitamin D therapy on the progression of MS 
measured by relapses. Three of these studies used 25(OH)D3 as the intervention, and 
found that patients in the treatment groups had significantly fewer relapses (Burton et 
al., 2010; Goldberg et al., 1986; Pierrot-Deseilligny et al., 2012). These trials were 
conducted in North America and France. Another study, with the same finding, was 
conducted in Israel and used alfacalcidol (Achiron et al., 2015). The other two trials 
found no differences in relapse rate between the treatment and control groups 
(Kampman et al., 2012; Soilu-Hänninen et al., 2012). Both of these trials also used 
25(OH)D3, and came from Norway and Finland respectively. 
 Of the trials that found a negative association between supplementation and 
relapse, one was a randomised, double-blind, placebo controlled trial of 158 
participants with an intervention duration of 26 weeks (Achiron et al., 2015). The 
designs of the other studies were less methodologically rigorous. Goldberg et al.’s 
(1986) experimental study comprised 16 MS patients who also served as their own 
controls with data drawn from their case histories. One further observational, 
uncontrolled study of 156 RRMS patients over 26 weeks, included in this section 




relapses decreased as 25(OH)D3 increased. However, this effect plateaued above 
110nmol/L (Pierrot-Deseilligny et al., 2012). A final randomised, open-label trial of 49 
participants supplemented both groups with either 40,000 or 4000 IU per day, and ran 
for 52 weeks. 
The two trials that found no effect of vitamin D supplementation on relapse rate 
comprised sample sizes of between 32 and 35 in each group, and both administered 
20,000 IU of vitamin D3 per week. Both studies were randomised, double-blind, placebo 
controlled trials, and ran over a period of 96 weeks (Kampman et al., 2012) and 52 
weeks (Soilu-Hänninen et al., 2012). Perhaps crucially, those trials that observed a 
protective effect of vitamin D tended to use larger or more regular doses of vitamin D.  
6.4.4.4 Vitamin D therapy and disease progression by MRI 
 Four studies explored whether vitamin D therapy has an effect on disease 
progression by MRI activity. Two studies involved treatment versus placebo groups, 
and both were year-long trials of 25(OH)D3 administered weekly (Soilu-Hänninen et al., 
2012; Derakhshandi et al., 2013). Both studies, from Finland and Iran, found that there 
were significantly fewer lesions detected by MRI in the treatment group.  
Two further studies, both conducted over 26 weeks, found no differences in 
new MRI-detected lesions between groups. One of these studies involved a high-dose 
versus low-dose group, with 25(OH)D2 administered daily (Stein et al., 2011). This 
same study found that a high dose was associated with better EDSS scores. The other 
study involved 25(OH)D3 supplied to the treatment group each month, and a placebo 
group (Mosayebi et al., 2011). The duration of the intervention possibly accounts for 
the difference in findings; additionally, frequency of supplementation and a difference 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     
    
     
     























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 We identified fourteen intervention studies that directly explored the effect of 
vitamin D supplementation on people with MS. From these studies, four themes 
emerged: 
1. Safety and tolerability of vitamin D therapy: both studies found that vitamin 
D is indeed safe and well-tolerated, however these studies do not seek to 
understand whether vitamin D may be causally involved in the pathogenesis of 
MS or therapeutic as a treatment 
2. Vitamin D levels following vitamin D therapy: studies were all in agreement 
that supplementation, and with higher doses, were effective at raising blood 
vitamin D in MS. Again, these studies did not question a biologically causative or 
therapeutic role of vitamin D in MS 
3. Conversion or delay from ON to CDMS: one study sought to identify whether 
treatment with vitamin D may delay or prevent the conversion of ON to CDMS, 
finding a positive effect. Replication of this study with a greater sample size and 
in other study populations would lend support to a possible causal role of 
vitamin D in MS onset 
4. Effect of vitamin D on disease progression: progression was variously 
categorised by EDSS, relapse and MRI activity, and findings were inconsistent. 
Reasons for the heterogeneity of results include the multiple types and amounts 
of vitamin D administered, varying sample sizes, lengths of intervention, and 
different study designs 
Whilst interventional studies are useful for reducing the environmental noise 
present in observational studies, one further method of detecting associations between 




6.5 Results: Genetic Studies 
The genetic studies comprised genetic association and genome-wide 
association (GWA) studies. The most frequently used design was genetic association, 
and these were conducted using case control and family designs (Table 6.15). We found 
only three GWA studies. The ‘other’ column in Table 6.15 included twin studies, and 
whole exome sequencing of MS cases from multicase families. 
Most studies defined MS according to the McDonald or Poser criteria. Others 
state that MS has been neurologist- or MRI-confirmed, although specific criteria are not 
named. Only one study failed to state how MS had been identified and confirmed (Table 
6.16). 
Most studies were conducted in Europe, The Americas and the Western Pacific 
regions (Table 6.17). Once again, the only region which is not represented is Africa. 
 Tables 6.18 and onwards are presented according to findings by genotype. 
Where possible, SNPs that have been explored in multiple studies are presented 












































































































































































































































































































































































































































































































































































































































































































































































































































































































6.5.1 Identifying susceptibility loci in MS (Table 6.18) 
 One study aimed to find new susceptibility loci in MS (Australia and New 
Zealand Multiple Sclerosis Genetics Consortium (ANZgene), 2009). Using 1618 MS 
cases of European ancestry from Australia and New Zealand, and 3413 controls from 
the UK and people with European ancestry from the USA, two new susceptibility loci in 
chromosomes 12 and 20 were identified and subsequently replicated in an 
independent dataset. On chromosome 20q13 two of the identified SNPs were in 
complete linkage disequilibrium with two other SNPs (i.e. the alleles have not been 
separated by recombination) which are associated with susceptibility to other 
autoimmune diseases. However, on chromosome 12q13-14, the authors hypothesise 
the CYP27B1 may be the causal gene. This gene encodes the enzyme which converts 
25(OH)D into the bioactive 1,25(OH)2D, which has important immune functions (Prietl 






























































































































































































































































































6.5.2 The role of genes in vitamin D and MS (Table 6.19) 
The role of VDR variants in MS 
 Eighteen studies investigated general associations between MS and VDR 
variants. VDR SNPs comprised rs731236 (TaqI), rs7975232 (ApaI), rs1544410 (BsmI) 
and rs10735810, now merged into rs2228570 (FokI). The VDR is required for cellular 
response to 1,25(OH)2D3, and all tissues that directly respond to 1,25(OH)2D3 contain 
the VDR. Mutations in the VDR gene may prevent the expression of VDR, or may reduce 
its efficacy, leading to partial or total resistance to 1,25(OH)2D3 (Pike et al., 2011). 
 Two of the six studies that explored rs731236 (TaqI) found no evidence of 
linkage between rs731236 and MS (Steckley et al., 2000), or no differences between 
cases and controls in allele or genotype frequency (Garcia-Martin et al., 2013). 
However, the other four studies found evidence of allelic and genotypic differences 
between cases and controls.  
Two of these studies, from the Western Pacific and Europe, and Eastern 
Mediterranean, found that cases had a higher frequency of C alleles (Cox et al., 2012b; 
Narooie-Nejad et al., 2015a). The former had a considerably larger sample size. 
However, a third study found that cases had a lower frequency of C alleles compared to 
controls (Ben-Selma et al., 2015). This study, from South East Asia, again had a 
relatively small sample size.  
The fourth study that found a significant difference between genotype and 
allele frequency was from the Western Pacific, and found a higher frequency of t alleles 
in cases (Tajouri et al., 2005). Ben-Selma et al. (2015) did not find any differences in 
genotype frequencies, however they did find that T alleles were positively associated 
with MS. Conversely, Narooie-Nejad et al. (2015a) found that T alleles were negatively 




replicated in different populations. Small sample sizes which may be underpowered 
may contribute to the lack of agreement. 
 Five papers looked at rs7975232 (ApaI). Findings ranged from no evidence of 
linkage between VDR variant rs7975232 and MS (Steckley et al., 2000) and no 
differences in genotype or allelic frequencies in cases and controls (Ben-Selma et al., 
2015), to significant associations and differences in genotype and allele frequencies 
(Tajouri et al., 2005; Niino et al., 2000; Narooie-Nejad et al., 2015a). Once again, there 
was no consistency in findings among studies that reported differences between cases 
and controls; moreover each of these three studies defined MS according to different 
criteria.  
Rs2228570 (FokI) was explored in five studies. Four of these studies came from 
three world regions, and found no associations between rs2228570 and MS (Smolders 
et al., 2009b; Narooie-Nejad et al., 2015b; Cox et al., 2012b; Garcia-Martin et al., 2013). 
One of these studies had a comparatively large sample size (Cox et al., 2012b). There 
was however a statistically insignificant suggestion of increasing MS risk in people who 
were homozygous for the HLA-DRB1*1501 allele and rs2228570 (Cox et al., 2012a). 
Only one study found a genotype difference in cases compared to controls (Cierny et al., 
2015). 
 The two studies that looked at rs1544410 (BsmI) had contrasting results. One 
study found that cases had a significantly lower frequency of bb genotypes and b alleles 
compared to controls (Narooie-Nejad et al., 2015b); the other found that cases had 
significantly higher frequency of bb genotypes and b alleles compared to controls 
(Fukazawa et al., 1999). These studies also defined MS according to different criteria, 
comprised small sample sizes which may contribute to the contradictory findings, and 




The role of DBP genes in MS 
 Two papers examined the role of DBP genes (Steckley et al., 2000; Niino et al., 
2002). Among its other functions, DBP is involved in binding circulating vitamin D for 
transport to the liver, kidney, bone, and other target tissues (Uitterlinden, 2011). DBP is 
encoded by the gene Gc, and the two most common DBP SNPs are rs7041 and rs4588. 
Combinations of these two SNPs result in six DBP isotypes where differences in protein 
configuration lead to differences in vitamin D binding affinity. Aspartic acid and 
threonine, and glutamic acid and threonine, both correspond to Gc1 which has the 
strongest binding affinity; aspartic acid and lysine corresponds to Gc2 and has the 
lowest binding affinity (Braithwaite et al., 2015; Uitterlinden, 2011). Two restriction 
enzymes, where amino acid substitutions had been identified, were explored: HaeIII, 
located at codon 416 (rs7041) and StyI, located at codon 420 (rs4588). Neither paper 
found any evidence of an association between DBP and MS, however the sample sizes 
were again very small for association studies (Steckley et al., 2000; Niino et al., 2002).  
The role of vitamin D metabolism genes in MS 
Six papers explored vitamin D metabolism genes and MS, all of which looked at 
CYP genes. CYP27B1 encodes the enzyme 25-hydroxyvitamin D3 1-alpha hydroxylase 
which catalyses the conversion of calcidiol to calcitriol; CYP27A1 is also involved in 
vitamin D metabolism although its role is more controversial (Jones and Prosser, 
2011). One paper looked at one CYP27A1 and several CYP27B1 SNPs. They found no 
association between the CYP27A1 SNP and MS in their Chinese study population 
(Zhuang et al., 2015). The majority of papers however studied CYP27B1 with diverse 
results. Three studies found significant associations between MS and some or all of the 
SNPs under study (Sundqvist et al., 2010; Ramagopalan et al., 2011; Zhuang et al., 
2015), while others failed to find any significant associations (Ban et al., 2013; 




SNP rs118204009, one of which used whole genome sequencing. They found that the 
SNP was present in all affected family members; furthermore, it showed an association 
with MS in a large MS cohort in their North American population (Ramagopalan et al., 
2011). However, the studies that attempted to replicate this finding, all of which were 
case-control designs from Europe and the Western Pacific, failed to find evidence of an 
association (Zhuang et al., 2015; Ban et al., 2013; Barizzone et al., 2013). There is 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    
    
     
     
     
     











































































































































































































































































































































































































































































































































































     
     
      
      
     
     


























































































































































































































































































































































6.5.3 The role of genes in vitamin D and MS risk, onset, and clinical course (Table 
6.20) 
The role of VDR variants in 25(OH)D and MS risk, onset, and clinical course 
 Sixteen papers explored VDR variants and MS, eight of which were concerned 
with rs731236 (TaqI). Two of these six studies found that different rs731236 alleles 
were associated with an increased risk of MS (Al-Temaimi et al., 2015) or progressive 
MS (Tajouri et al., 2005).Another study found that rs731236 is associated with a 
reduced risk of MS when it co-segregates with HLA-DRB1*1501 (Agliardi et al., 2011). 
This same paper also found that rs731236 modulates VDR expression in HLA-
DRB1*1501-positive individuals (Agliardi et al., 2011). A further paper found that 
although there was no association between rs731236 and MS risk, the presence of 
rs731236 slightly modulates the risk of MS conferred by the presence of HLA-
DRB1*1501 (Irizar et al., 2012). Four additional studies found no association between 
rs731236 and MS risk (Partridge et al., 2004; Simon et al., 2010b; Garcia-Martin et al., 
2013; Sioka et al., 2011). Furthermore, no associations were found between rs731236 
and disease progression (Al-Temaimi et al., 2015), or onset age or clinical course of MS 
(Garcia-Martin et al., 2013). Sample sizes, study designs, and diagnostic criteria varied 
across these studies. 
 Three papers looked at rs7975232 (ApaI). Three findings showed that there 
was no association between rs7975232 and MS risk (Al-Temaimi et al., 2015; Simon et 
al., 2010b; Irizar et al., 2012). One study found that the presence of rs7975232 
modulates the risk of MS conferred by the presence of HLA-DRB1*1501 (Irizar et al., 
2012). Additionally, the AA genotype was associated with low disease progression, 
characterised by a low EDSS score (Al-Temaimi et al., 2015).  
 Six papers looked at rs2228570 (FokI). One study explored the interaction 




of increasing risk between rs2228570 and individuals who were homozygous for HLA-
DRB1*1501 (Cox et al., 2012b). A further study found a protective effect against MS in ff 
genotypes (Partridge et al., 2004), and another found that the ff genotype frequency 
was lower in people with more advance disease (Mamutse et al., 2008). None of the 
remaining studies found any associations between rs2228570 and MS risk (Garcia-
Martin et al., 2013; Simon et al., 2010b; Al-Temaimi et al., 2015), rs2228570 and 
disease progression (Al-Temaimi et al., 2015), or rs2228570 and onset age or clinical 
course (Garcia-Martin et al., 2013). These studies all explored slightly different 
hypotheses and used different terms to define MS, and therefore replication is not 
really achieved. However, there is some consistency in a lack of effect between 
rs2228570 and MS across several different populations. 
 Three papers explored rs1544410 (BsmI) and MS. Although one study found 
that there was an increased risk of MS in carriers of the C allele (Al-Temaimi et al., 
2015), three other findings showed no association with risk (Simon et al., 2010b; Sioka 
et al., 2011) and no association with disease progression (Al-Temaimi et al., 2015). Two 
further VDR SNPS, rs2254210 and rs98784, were explored in one twin study (Orton et 
al., 2008). There was no association with MS. 
The role of DBP genes in 25(OH)D and MS risk, onset, and clinical course 
 Two papers were concerned with the role of DBP genes in vitamin D and MS. 
Additionally, a GWA study found that although vitamin D may have beneficial effects on 
the risk of MS, these effects may be reduced in the presence of the HLA-DRB1*1501 
allele (Simon et al., 2011). Two further studies found no association between two DBP 
SNPs and MS risk in the US (Simon et al., 2010b), or DBP and age of onset in a Japanese 




The role of vitamin D metabolising genes in 25(OH)D and MS risk, onset, and 
clinical course 
 Three papers were concerned with vitamin D metabolism genes and MS. Simon 
et al. (2011) found that the presence of HLA-DRB1*1501 alongside certain vitamin D 
metabolising genes, reduces any potential beneficial effect of vitamin D on MS risk. SNP 
rs2248359 in gene CYP24A1, which has a role in the decline of circulating vitamin D, 
was found to modify the relationship between 25(OH)D and the hazard of relapse in a 
prospective cohort study, however the finding was not statistically significant after 
adjustment for multiple testing (Lin et al., 2014a). The final paper found no association 
between vitamin D metabolising SNPs and MS risk (Simon et al., 2010b). This literature 
presents an ambiguous picture with multiple genes and SNPs tested across multiple 
populations, with different diagnostic criteria. 
The role of other genes in 25(OH)D and MS risk, onset, and clinical course 
 Other genes which did not fit into the above categories include 7-
dehydrocholesterol reductase which is on the vitamin D pathway, the protein kinase 
family of genes which are involved in vitamin D gene signalling, and the human 
leukocyte antigen complex, the DRB1*1501 allele of which increases MS risk. 
Further SNPs studied by Lin et al. (2014a) modified the relationship between 
25(OH)D and hazard of relapse. This association was however not significant after 
adjustment for multiple testing.  
 The final two studies in this category looked at various HLA-DRB1 alleles. One 
study found that alleles that expressed non-responsive VDRE motifs were significantly 
associated with reduced MS risk, suggesting that vitamin D regulation of HLA-DR 
expression is important (Nolan et al., 2012). The other study, however, found that VDRE 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     
     
     
     
      
      




































































































































































































































































































































































































































































































































































   
   
    
    
   
    

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.5.4 Associations between vitamin D genes and vitamin D levels in MS (Table 
6.21) 
The association between VDR variants and 25(OH)D levels in people with MS 
 The association between serum 25(OH)D and VDR variants was explored in 
seven papers which focussed on rs731236 (TaqI), rs7975232 (ApaI), rs2228570 (FokI), 
and rs1544410 (BsmI). The findings for rs731236, rs7975232, and rs1544410 came 
from four papers. These studies, from European and Eastern Mediterranean countries, 
were all of a case-control design. They all agreed that rs731236, rs7975232, and 
rs1544410, are not associated with vitamin D levels in patients with MS (Al-Temaimi et 
al., 2015; Agnello et al., 2016; Yamout et al., 2016; Smolders et al., 2009a).  
 Agreement was not unanimous in the papers regarding rs2228570 and vitamin 
D levels in people with MS. One of the five studies that explored rs2228570, was a twin 
study, originating from The Americas. This study found no association between 
rs2228570 and vitamin D levels in MS (Orton et al., 2008). However, two of the 
remaining four studies, both case-control designs and from Europe, found that 
rs2228570 was significantly associated with higher vitamin D levels (Al-Temaimi et al., 
2015), and higher summer vitamin D levels (Smolders et al., 2009b). The two 
remaining papers found associations between rs2228570 ff genotypes and vitamin D in 
MS. One study found that rs2228570 ff genotype was associated with significantly 
higher vitamin D than FF and Ff genotypes (Agnello et al., 2016). The other found an 
interaction between the ff genotype and dietary vitamin D intake which was associated 
with higher levels of vitamin D and with a reduced risk of MS (Simon et al., 2010b). 
Although the hypotheses tested are also slightly different, findings that rs2228570 may 
have an effect on vitamin D levels in people with MS are relatively consistent. 
The association between DBP genes and serum 25(OH)D levels in people with MS 
Only one paper explored DBP genes and vitamin D levels in people with MS. 




were associated with 25(OH)D in a GWAS of healthy European cohorts. The effects 
were replicated: significant associations were observed between SNPs rs7041 and 
rs2282679 and blood vitamin D levels in people with MS. Furthermore, the C allele of 
rs7041 and the T allele of rs2282679 produced an additive effect of a 4.4 nmol/L (95% 
CI 0.9-7.9) and 4.5 nmol/L (95% CI 0.6-8.4) increase in blood vitamin D respectively 
(Laursen et al., 2015). However, no correction for multiple testing was applied to the 
analyses, leading to an inflated possibility of type 1 errors. Further results from this 
study are discussed below.  
The association between vitamin D metabolising genes and serum 25(OH)D levels 
in people with MS 
 Four papers studied the effect of several metabolising genes on blood vitamin D 
levels in people with MS. Heterozygosity in CYP27B1 was significantly associated with 
low calcitriol levels (Ramagopalan et al., 2011), and two other SNPs in the same gene 
were also significantly associated with vitamin D levels in MS and controls (Orton et al., 
2008). CYP2R1 genes were also associated with blood vitamin D in MS. CYP2R1 encodes 
the enzyme vitamin D 25-hydroxylase, and is thought to be an important part of the 
process which converts cholecalciferol to calcidiol. In both CYP2R1 rs2060793 and 
rs10741657 the effect of the A allele was found to be dominant. Additionally, the 
presence of the A allele in rs10741657 resulted in a 6.9 nmol/L (95% CI 3.3-10.4) 
increase in blood vitamin D in people with MS (Laursen et al., 2015).  
However, another study found that a different SNP in CYP2R1 was associated 
with lower blood vitamin D levels. Individuals who were heterozygous for the minor 
allele had significantly lower vitamin D levels (7.1 nmol/L (95% CI 2.12-12.08)) than 
those who were homozygous. Additionally, those who were homozygous for the major 
allele had vitamin D levels 12.4 nmol/L (95% CI 3.94-20.89) lower (Lin et al., 2014a). 




conclusions regarding their involvement in blood vitamin D and MS, however there 
does appear to be a suggestion that vitamin D metabolising genes are involved with 
blood vitamin D levels in people with MS. 
 One study also looked at NADSYN1, which encodes an enzyme involved in the 
synthesis of cholesterol from 7-dehydrocholesterol. Although the two SNPs explored 
were significantly associated with vitamin D in a GWAS of a healthy cohort, the finding 
was not replicated in this MS study (Laursen et al., 2015).  
The association between other genes and serum 25(OH)D levels in people with MS 
Other genes that were explored in relation to 25(OH)D levels in people with MS 
included two that are involved in cell adhesion (VCAM1 and CD6), one involved in 
protein binding (PLEK), another in cell proliferation, growth and cell cycle progression 
(RPS6KB1), one with a role in mitochondrial ribosome assembly and stability 
(MPV17L2), and one protein kinase gene with multiple cellular functions including 
insulin signalling and endothelial cell regulation (PRKCB). Of these, the VCAM, PLEK and 
RPS6KB1 SNPs were associated with significantly higher vitamin D levels in people with 
MS. A dose-response relationship was observed. People who were homozygous for the 
minor allele had significantly higher vitamin D levels compared to those homozygous 
for the common allele (Lin et al., 2014a). The other two SNPs, for CD6 and MPV17L2, 
were associated with lower vitamin D levels, again exhibiting a dose-response 
relationship (Lin et al., 2014a). Additionally, a further paper by the same authors found 
that a SNP in PRKCB was associated with lower vitamin D levels, and showed a 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
    
   
    
    
    




























































































































































































































































































































































































































































































































































































































6.5.5 Associations between genes and UV exposure in MS (Table 6.22) 
The association between VDR variants and UV exposure in people with MS 
 The association between VDR variants, UV exposure, and MS was assessed in 
two studies. Genotype ff30875 was significantly protective against disability in cases 
stratified by sun exposure (median years’ exposure/year of life) and sunbathing habits 
(never, versus rarely/occasional/frequent) (Mamutse et al., 2008). One further study 
from Tasmania found a significantly increased risk of MS among people who reported 
low childhood winter sun exposure and were GG compared to AA homozygous in the 
Cdx-2 VDR variant. A dose-response relationship was also observed, with heterozygous 
people having an intermediate risk. There was however no significant association with 
MS risk in the same gene in people who reported higher childhood sun exposure 
(Dickinson et al., 2009). These two papers present diverse findings, however both 
identified protective interactions between VDR variants and UV exposure on MS 
disability and risk, for which more research is needed for clarity. 
The association between other genes and UV exposure in people with MS 
 Other genes that were explored in relation to UV exposure and MS were all 
variants of the melanocortin 1 receptor (MC1R) gene, which, among other things, can 
lead to an increased sensitivity to UV exposure. Three studies reported a significant 
increased risk of MS or worse disease outcome in those with MC1R variants (Partridge 
et al., 2004; Strange et al., 2010), one of which reported that the effect was most strong 
in women (Dwyer et al., 2008). The other study, a cross-sectional design, found that of 
the six variants studied, four variants were not associated with disability. However, the 
remaining two variants were significantly associated with greater disability. People 
with a history of childhood sunburn and Asp294His CG/GG genotypes had lower MSSS 
scores than those with childhood sunburn and CC genotypes, and there was no 
significant association between these variants, MSSS scores, and childhood weekend 




summer sun exposure was protective against MS only in people who do not have red 
hair colour (RHC) variants of MC1R (Dwyer et al., 2008). Some of the MC1R variants are 
therefore associated with MS, and interact with UV exposure apparently mitigating MS 
risk in European and Tasmanian populations. However, as different hypotheses were 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































      
       
       
       
       
       






















































































































6.5.6 Mendelian randomisation studies 
 Only one Mendelian Randomisation study was identified in the searches for this 
review (Mokry et al., 2015). This study sought to investigate whether genetically-
lowered levels of blood vitamin D were associated with MS. Four SNPs associated with 
25(OH)D were initially identified in a GWAS of the SUNLIGHT consortium. These SNPs 
comprised rs2282679 (DBP), rs6013897 (CYP24A1) and rs10741657 (CYP27R1) 
(vitamin D metabolism), and rs12785878 (DHCR7). Further testing using the Canadian 
Multicentre Osteoporosis Study demonstrated that 25(OH)D-decreasing alleles were 
significantly associated with lower levels of circulating 25(OH)D. The Mendelian 
randomisation study was then carried out using these SNPs and the Multiple Sclerosis 
Genetic Consortium Study.  
 Results showed that people who carry genes which lead to lower circulating 
vitamin D levels have a significantly increased risk of MS. Such findings provide 
promising evidence for a causal relationship between long-term vitamin D deficiency 
and MS. 
6.5.7 Summary 
 We identified a large number of studies which researched genes involved in 
vitamin D, UV, and MS. Although we categorised the studies under various headings, 
very few themes emerged from the literature with regards to patterns of findings or 
replication of findings. To summarise, the following areas were explored in the 
literature: 
1. Identifying susceptibility loci in MS: we found only one GWAS as a result of 
our searches, which identified gene CYP27B1 as being a possible causal gene 
2. The role of genes in vitamin D and MS: VDR variants rs731236 (TaqI), 
rs731236 (ApaI), rs2228570 (FokI), and rs7975232 (BsmI) were all explored in 




observed, firstly a positive association between rs731236 C alleles and MS in 
two world regions, and secondly no association between rs2228570 and MS in 
three world regions. There was no agreement for rs731236 or rs7975232 
studies. Likewise, no associations were observed in two studies investigating 
DBP genes, and three replication attempts from two world regions failed to find 
associations between vitamin D metabolism genes and MS previously identified 
by GWAS  
3. The role of genes in vitamin D and MS risk, onset, and clinical course: 
rs731236 (TaqI) showed possible associations with MS risk and progression 
when it interacts with HLA-DRB1*1501; however there was no other association 
with MS risk, onset, or clinical course. The other VDR variants likewise 
presented an ambiguous picture. Further possible interactions between HLA-
DRB1*1501 alleles with vitamin D metabolising genes may increase or reduce 
MS risk.  
4. Associations between vitamin D genes and serum vitamin D levels in 
people with MS: four papers which were consistent in diagnostic criteria and 
from two world regions were in agreement that there was no association 
between blood vitamin D levels in people with MS and VDR variants rs731236 
(TaqI), rs7975232 (ApaI), or rs1544410 (BsmI). Overall there was some 
evidence that rs2228570 (FokI) may have an effect on blood vitamin D levels in 
MS, but there was a general lack of consistency in the hypotheses tested. The 
role of DBP on blood vitamin D levels in MS was replicated in one paper from an 
original GWAS. Of the vitamin D metabolising gene, CYP27B1 appears to have an 
effect on blood vitamin D in MS, while the roles of CYP21R and NADSYN1 are not 




5. Associations between genes and UV exposure in people with MS: there was 
some evidence to suggest that UV exposure may protect against MS risk and 
disability level in some individuals with particular genotypes. There was 
however no replication of these effects. 
6. Mendelian randomisation: The Mendelian randomisation study used DBP 
SNPs, vitamin D metabolising genes, and genes involved in vitamin D synthesis 
as proxies for the environmental exposure of vitamin D deficiency. They found 
evidence between long-term, or lifetime, vitamin D deficiency, and MS risk. This 
design provides perhaps the best evidence for a causal association between 
vitamin D deficiency and MS risk which requires replication.  
The literature regarding genes, vitamin D, UV, and MS, therefore adds up to a 
large, heterogeneous evidence base. Many of the studies identified through this scoping 
study comprise sample sizes that are too small to have the power to detect such small 
effect sizes, and as replication is considered to be the gold standard in confirming an 
effect, the literature is still largely lacking.  
6.6 Discussion and Conclusion 
6.6.1 Discussion 
 This scoping review was based upon a methodical and comprehensive search of 
the literature regarding MS, vitamin D, and UV exposure, from which we identified over 
one hundred relevant studies. To aggregate and present the findings in a meaningful 
way, we divided the studies into three broad categories and tabulated relevant data as 
both an overview of literature and to group findings for comparison. We then discussed 
the results in a narrative synthesis. This Discussion aims to integrate the main findings 
from the observational, intervention, and genetic study results to discuss the evidence 





6.7.1.1 The association between vitamin D, UV exposure, and MS  
Each category of observational, intervention, and genetic studies contained a 
large and heterogeneous body of work comprising multiple study designs, diagnosis 
methods, types of vitamin D, and from multiple world regions. No study was conducted 
in any African country; additionally, no intervention study, and only two each of genetic 
and observational studies, came from South-East Asia. This means that large areas 
globally are under-represented in the literature and therefore little understood. The 
vast majority of research came from Europe and the Americas (mainly North America), 
with the remainder from the Eastern Mediterranean, particularly Iran, and the Western 
Pacific, usually Australia.  
The role of UV exposure in MS was considerably less-well researched in each 
category than vitamin D. The independent actions of vitamin D and UV exposure that 
have been noted in observational and animal studies, as well as the established 
importance of UV exposure on vitamin D synthesis (Lucas et al., 2011; Becklund et al., 
2010; Wang et al., 2013; Wang et al., 2015), would suggest that UV exposure is a 
potentially valuable line of research. Additionally, large observational studies with 
quantitatively-measured UV exposure may help to ascertain how UV exposure may 
affect MS risk in addition to, and independent of, vitamin D. Furthermore, greater 
understanding about the actions of genes on exposure to UV radiation would be 
beneficial.  
However, despite the literature lacking in these areas, a number of themes 
emerged with complementary and opposing findings. We summarised these findings at 
the end of each section, and review and collate the results here:  
1) Blood vitamin D: observational studies have fairly consistently found lower 




levels are often lower in people at the time of MS diagnosis compared to 
controls. However, as discussed, difficulties in obtaining accurate estimates of 
vitamin D that are representative of an individual’s long-term vitamin D status, 
may impact the results of these observational studies and lead to some 
contradictory findings. From the genetic studies, blood vitamin D levels do not 
appear to be associated with VDR variants rs731236 (TaqI), rs7975232 (ApaI), 
or rs1544410 (BsmI), however rs2228570 (FokI) may be associated with 
significantly higher vitamin D levels in people with MS. DBP SNPs rs7041 and 
rs2282679 were also associated with higher vitamin D levels, although the 
vitamin D metabolising genes produced more heterogeneous results. The 
experimental literature unanimously found that vitamin D supplements were 
safe, well-tolerated, and effective at raising blood vitamin D levels in people 
with MS.  
2) MS risk and onset: observational studies found that low vitamin D levels were 
not generally associated with MS risk or onset. However, a possible delay in 
conversion from ON to clinically definite MS was observed in one vitamin D 
therapy trial. Genetic studies identified possible interactions between a VDR 
SNP and HLA-DRB1*1501 that may increase MS risk. The Mendelian 
randomisation study provides possibly the strongest support for an increased 
risk of MS with long-term vitamin D deficiency, which requires replication. 
Evidence from a genetic study found that UV exposure interacting with 
particular genotypes may be protective against MS. However, as these findings 
have not yet been replicated they need to be interpreted with extreme caution. 
3) MS disease activity: A number of observational studies found that low vitamin 
D levels were associated with greater disease activity, were lower in people 




relapse compared to those in remission. UV exposure may also have positive 
effects on disease activity although this association has been identified only 
through cross-sectional studies. The experimental evidence showed some 
potentially positive effects of vitamin D therapy in reducing disease activity, 
however the different methods used for measuring disease activity and in 
vitamin D dosage quantities make the studies difficult to compare. 
Unreplicated evidence from a genetic study, again therefore requiring extreme 
caution in interpretation, found that UV exposure interacting with particular 
genotypes may be protective against worsening MS disability. 
4) MS subtype and gender-specific observations: Observational studies 
showed that increased sun exposure and vitamin D intake in childhood and 
adolescence may be protective against MS, however longitudinal evidence 
suggests that there is no effect of early vitamin D intake on later life MS risk. 
Nonetheless, two longitudinal studies found that low vitamin D levels were 
associated with paediatric-onset MS and the relapse rate in paediatric MS. 
Greater MS risk and MS progression were noted in women only, and women 
were found to have generally low vitamin D levels. Women were also found to 
have low levels of sun exposure and low vitamin D intake, however 
supplementation appeared to be protective against MS in women in a 
longitudinal study.  
 
 These themes show that there are patterns within the literature: many similar 
hypotheses have been tested and exploratory analyses conducted in different datasets. 
There is clear evidence of an association between MS and vitamin D, and MS and UV 





There are several limitations to this study. Firstly, a scoping study is an iterative 
process which is shaped according to the literature produced by the searches. After the 
first search, we refined the inclusion criteria to eliminate animal models, as the 
quantity of literature identified was unfeasible to adequately review given the amount 
of time and word count available.  
Our inclusion criteria also originally specified papers that defined MS according 
to the Poser or McDonald criteria only; however following searches we decided to 
accept all papers, regardless of MS diagnosis method, that also met the other inclusion 
criteria. This is because it seemed important to understand how MS was being defined 
across the literature, and to thereby identify possible difficulties with comparison. We 
also broadened our original vitamin D inclusion terms to all types of vitamin D that 
were identified by searches, including vitamin D analogues. In genetic studies we 
included all articles involving vitamin D-related genes that met other inclusion criteria. 
In so doing, we cast a wide net to try to identify as much of the relevant literature as we 
could.  
Secondly, the field of genetics has evolved very quickly. This means that the 
methods used in some of the genetic studies included herein are today considered 
outdated; the generally small sample sizes in older studies are also problematic as the 
power to detect associations – particularly for rare variants – will be too low. 
Furthermore, by only including studies that have been carried out in MS patients, and 
that explicitly mention vitamin D or UV exposure, it is likely that we have missed some 
relevant information from much larger, and more recent studies. Such studies include a 
recent International Multiple Sclerosis Genetics Consortium GWAS, which identified 48 
novel, and 49 known, susceptibility variants for MS (International Multiple Sclerosis 




publications included in this scoping review were significantly associated with MS, 
including VCAM1, PLEK, GALC, CD40, CYP24A1, and CD6, however the only SNP that was 
the same both in this scoping review and in the GWAS was rs2248359 in CYP24A1. This 
GWAS includes almost 15,000 MS cases and 25,000 controls, and therefore provides 
stronger evidence than any of the studies included herewith. That none of the other 
SNPs identified by publications included in this review appear in this GWAS means that 
the evidence against any real associations is fairly strong. Other GWAS of vitamin D in 
non-MS populations may also have yielded useful information regarding genes that 
affect vitamin D. The SUNLIGHT consortium GWAS, involving a sample size of upwards 
of 30,000 individuals, confirmed previous associations between circulating vitamin D 
levels and rs2282679 (GC), rs10741657 (CYP2R1), and rs6013897 (CYP24A1). They 
also identified a novel association with rs12785878 (DHCR7) (Wang et al., 2010). All 
these susceptibility variants have since been confirmed in a further study in a UK 
population which found an association with type 1 diabetes (Cooper et al., 2011), and 
furthermore, have all been found to be associated with low circulating vitamin D and an 
increased risk of MS in the Mendelian randomisation study discussed earlier (Mokry et 
al., 2015). 
Thirdly, our searches resulted in the identification of a wide-ranging and large 
literature which concentrated exclusively on individually-measured vitamin D, vitamin 
D genes, and UV exposure or related genes in people with MS. Searching the literature 
for specific comorbidities, such as bone mineral conditions, could have yielded further 
studies with individual vitamin D measures and possibly also UV exposure data. There 
were similarly other lines of research that we could have explored, including cellular 
effects of vitamin D deficiency in MS, and also possible interactions between vitamin D 
deficiency and medication. There is some evidence to suggest that interferon β, used in 




interferon β when vitamin D levels are low appears to increase risk of relapse (Stewart 
et al., 2012). This may explain some of the findings regarding low vitamin D and risk of 
relapse and may have contributed further understanding to our scoping review. 
Additionally, focussing further on the known genetic risk of HLA-DRB1*1501 and how it 
may interact with vitamin D deficiency could have broadened the review to more 
deeply understand further mechanisms in the way that a genetic risk factor and 
widespread environmental risk factors interact. However, we were unable to follow all 
the literature trails, but there is scope for further studies to explore in detail these 
other areas.  
Finally, vitamin D and UV exposure in MS are fast-moving areas of research, and 
this study is therefore limited by the time at which the searches were conducted. This 
review is thus an overview of the literature on the search day, but it should be noted 
that several papers have since been published which would have contributed to this 
scoping study. Of note, a second Mendelian randomisation study was published which 
explored three SNPS, one of which had been explored in the previous Mendelian 
randomisation study and two of which were different. The findings were however 
complementary to the effects observed in the first study, thereby lending further 
support to a possible causal link between vitamin D deficiency and MS risk (Rhead et 
al., 2016). Additionally, a third Mendelian randomisation study was published which 
looked into evidence for a causal relationship between low vitamin D and high BMI in 
paediatric-onset MS (Gianfrancesco et al., 2017). It found that children with a genetic 
risk score that indicates higher circulating vitamin D levels had a reduced risk of 
paediatric-onset MS (Gianfrancesco et al., 2017). Vitamin D deficiency was variously 
found to be associated with, and not associated with, paediatric-onset MS in the 
observational literature, and therefore this study adds considerable evidence to the 




sectional study found an effect of season and relapse, whereby the strong seasonal 
variation of circulating vitamin D was negatively correlated with the rate of relapse 
(Hartl et al., 2017).  
6.6.3 Conclusion 
This scoping study aimed to provide an overview of the existing literature 
examining vitamin D and UV radiation in the context of MS onset, pathology, and 
progression. To be transparent about our methods, we followed Arksey and O’Malley’s 
recommendations alongside those of Levac. 
It is clear that a large amount of work has been undertaken and is ongoing, and 
has resulted in a very heterogeneous literature. The observational literature was wide-
ranging, incorporating multiple world regions and study designs, and clearly showed 
that low vitamin D levels are associated with MS. However, without excluding reverse 
causation, the role of vitamin D deficiency in MS risk and progression is still unclear. 
The literature is also still ambiguous regarding the roles of UV exposure, and dietary 
vitamin D intake and supplementation, particularly at certain times of life, and their 
potential impact on MS risk, onset, and progression.  
As highlighted by the systematic reviews discussed in the introduction, the 
intervention literature has scope for further investigations into the role of vitamin D in 
MS. New RCTs exploring both the possible therapeutic role of vitamin D, and also its 
possible protective effect in preventing or delaying onset, would be beneficial. Such 
RCTs should however include large enough doses of vitamin D, and be of a long enough 
duration, to produce and observe any beneficial effects.  
Finally, the field of genetics is producing a vast amount of literature in this area of 
research, however there appear to have been few concerted attempts at replication. 




provided much clarity regarding the roles of different genes and variants involved with 
vitamin D, UV exposure, and MS. There are, therefore, still multiple questions that need 
answering, and scope for meta-analyses of GWAS which would provide clarity.  
However, there is clearly an association between MS, vitamin D, and UV exposure. 
To further understand the roles of vitamin D and UV exposure as potential MS risk 
factors in the Northern Isles, the following two chapters present the primary studies 
undertaken for this thesis. Chapter 7 concentrates on vitamin D in Orkney, while 








CHAPTER 7. FARMING, FOREIGN HOLIDAYS AND VITAMIN D IN 
ORKNEY  
7.1 Introduction 
 In earlier chapters I introduced Orkney, detailing its high-latitude geographical 
location, climate, and high prevalence of MS. The heritability analysis suggested that, as 
elsewhere, a genetic predisposition is necessary but other risk factors must also be 
present for disease to manifest. In Chapter 6 I reviewed the literature regarding 
vitamin D, UV, and MS, and showed that vitamin D deficiency is an important risk factor 
for MS with an increasing evidence base. Vitamin D deficiency is therefore a pertinent 
risk factor for investigation in Orkney.  
 The body of this chapter, from section 7.2 to 7.2.5, consists of my paper, 
Farming, foreign holidays, and vitamin D in Orkney, which was published in May 2016 
(Weiss et al., 2016). The published version can be found at 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155633, and is 
presented in Appendix D. As outlined in the paper, James F Wilson, Ruth McQuillan, and 
I, conceived and designed the study. Stephanie Read gave me statistical advice 
regarding how to carry out the multiple imputation for missing data, and Lina Zgaga 
supplied the R script to convert crude vitamin D into May-adjusted vitamin D thus 
removing seasonal effects, and which had been previously used in a paper involving 
vitamin D measurements (Zgaga et al., 2011). I ran all analyses. Data were contributed 
by Harry Campbell and Malcolm G Dunlop (Scottish Colorectal Cancer Study (SOCCS)) 
and James F Wilson (ORCADES). Blood from ORCADES was analysed for vitamin D 
levels by a Glasgow laboratory in 2011, which had previously analysed samples for 
SOCCS using the same methods. I wrote the majority of the paper, into which I 




remained anonymous and the other of whom chose to sign his review and was William 
Grant of the Sunlight, Nutrition, and Health Centre (SUNARC).  
The paper begins with an introduction setting the research into context, before 
moving into the methods, results, a discussion, and conclusion. However, this chapter 
will be rounded with a brief conclusion (section 7.3) to place the paper into the overall 
context of this thesis.  
7.2 Farming, foreign holidays and vitamin D in Orkney 
7.2.1 Introduction 
Multiple sclerosis is a chronic, complex disease with genetic, environmental and 
behavioural factors implicated in its aetiology (Dyment et al., 2004). Greater distance 
from the equator is associated with increasing MS prevalence (Simpson S. Jr. et al., 
2011); increasing latitude is also noted for weaker ultraviolet B (UVB) radiation which 
inhibits cutaneous production of vitamin D (Webb et al., 1988). As such, one 
environmental risk factor is thought to be vitamin D deficiency, however, vitamin D is 
also a marker for exposure to UV radiation, the benefits of which may be independent 
of vitamin D production (Becklund et al., 2010; Wang et al., 2013; Lucas et al., 2011). A 
variety of factors hinder or prevent UVB from reaching the earth's surface, including 
latitude and weather (Holick, 2008), or from initiating cutaneous vitamin D synthesis, 
such as sun protection creams and clothing cover. 
Although a recent systematic review of vitamin D status worldwide found that 
vitamin D concentrations do not appear to be dependent upon latitude (Hilger et al., 
2014), exposure to ultraviolet B (UVB) radiation from sunshine is the most potent 
source of vitamin D for humans (Holick, 2004a). In the United States, a latitudinal 
relationship exists between wintertime vitamin D and wintertime UV doses (Grant and 




such latitudes (Webb et al., 1988; Grant and Holick, 2005). This latitudinal relationship 
further reflects the latitudinal MS prevalence distribution in the US (Grant and Holick, 
2005). Additionally, a significant relationship between regional UVB radiation and MS 
prevalence has been noted in France in the French farming population and their 
families (Orton et al., 2011). Increasing MS prevalence was associated with decreasing 
ambient UVB; the trend was additionally found to be stronger in both wintertime and 
in women (Orton et al., 2011). A similar relationship between decreasing UV and 
increasing prevalence has been identified in Newfoundland (Sloka et al., 2008) and 
Australia (van der Mei et al., 2001). 
Controversy remains regarding the role of vitamin D in chronic conditions; 
whilst deficiency may have a causal role in the aetiology of some diseases it may also 
simply be a biomarker for ill health. A body of evidence is however accumulating, 
suggesting a causal role for vitamin D in MS risk, pathology and progression (Ascherio 
et al., 2014; Munger et al., 2006; Mokry et al., 2015). A recent Mendelian randomisation 
study found genetically lowered 25-hydroxyvitamin D (25(OH)D) level by one standard 
deviation in log-transformed 25(OH)D was associated with a two-fold increased risk of 
MS (Mokry et al., 2015). Interactions between vitamin D and the major genetic risk 
factor, HLA-DRB1*1501, have been identified (Ramagopalan et al., 2009b), and several 
rare variants conferring MS risk have been found in the CYP27B1 gene, which encodes 
an enzyme which catalyses the conversion of 25(OH)D to the bioactive form 
(Ramagopalan et al., 2011). Further, early exposure to vitamin D in-utero and in 
neonatal mice led to optimal numbers of invariant natural killer T cells (Yu and 
Cantorna, 2011), deficiency of which are observed in MS patients (van der Vliet et al., 
2001; Yu and Cantorna, 2011). Alongside the month-of-birth effect, where children 




adequate in-utero vitamin D increasingly appears to be critical for future 
autoimmunity.  
The beneficial role of UV exposure independent of vitamin D production has 
been supported in animal studies, using experimental autoimmune encephalomyelitis 
(EAE) as the model for MS. Continuous treatment with UVB was found to suppress 
clinical signs of EAE which, although leading to slight elevations in serum 25(OH)D3, 
were insufficient to cause disease suppression by vitamin D (Becklund et al., 2010). 
Furthermore, suppression of EAE was found to occur upon irradiation of mice to 
narrow-band UV light, with a wavelength of between 300 and 315 nm and a peak of 
effectiveness at 311 nm. As vitamin D requires a wavelength between 270 and 300 nm, 
optimally between 295 and 300 nm to initiate cutaneous synthesis, the narrow band 
UV supressing EAE had no effect on 25(OH)D levels (Wang et al., 2013), strongly 
suggesting a role of UV exposure independent of vitamin D. In MS, an Australian multi-
centre case-control study found higher sun exposure and higher vitamin D levels to be 
independently associated with lower risk for first demyelinating events (Lucas et al., 
2011). 
Scotland, between latitudes 54o and 60o north, has inadequate strength of 
sunshine between October and March for vitamin D synthesis (Webb and Engelsen, 
2006); a cloudy climate year-round further leads to widespread vitamin D deficiency 
(Rhodes et al., 2010) strongly indicating limited UV exposure in the population. The 
protective effect of supplementation and sunny holidays on 25(OH)D in Aberdeen, a 
Scottish city at 57o north, has previously been noted in a study of postmenopausal 
women (Mavroeidi et al., 2013). Orkney, an isolated archipelago ten to sixty miles from 
the north coast of Scotland, is an area of exceptionally high MS prevalence (Visser et al., 




totalling 21,349 at the 2011 census. The 2011 census also revealed an ongoing 
agricultural tradition with 10% of the workforce employed in agriculture or fishing. 
As an independent risk factor, or as a marker of UV exposure, it is important to 
understand the determinants of plasma vitamin D in the context of MS and other 
diseases of public health importance. In this study we aimed to describe vitamin D 
levels in Orkney (Figure 7.1). This involved identifying the prevalence of vitamin D 
deficiency in Orkney compared to the Scottish mainland, and establishing the 
determinants of circulating plasma 25-hydroxyvitamin D (25(OH)D) in Orkney. 
Figure 7.1 Map of Orkney in relation to the Scottish mainland and north-west 
periphery of Europe, with 57th and 59th degrees of latitude 
 
7.2.2 Materials and Methods 
7.2.2.1 Study populations 
The study population comprised Orkney Complex Disease Study (ORCADES) 
participants, recruited from 2005 to 2011, and Scottish Colorectal Cancer Study 
(SOCCS) controls, which ran from 1999 to 2006. Both these studies have been 




ORCADES, a cross-sectional genetic epidemiology study concerned with identifying 
genetic factors that influence complex disease, comprised 2078 participants with at 
least one Orcadian grandparent. SOCCS, a case-control study of colorectal cancer in 
Scotland, included 2235 adult controls without colorectal cancer, identified from the 
Community Health Index in Scotland as being aged within 5 years their matched case, 
of the same sex and living in the same area. All participants provided written, informed 
consent prior to participation. Both studies have ethical approval from NHS Orkney, 
NHS Grampian or NHS Lothian. 
7.2.2.2 25-hydroxyvitamin D measurement  
 Fasting blood samples were drawn from ORCADES participants using the 
Sarstedt Monovette system. Samples were processed and transferred for storage at -
400 C, and later -800 C, until analysis. Blood was drawn from all SOCCS participants, 
processed and transferred for storage at -800 C. Both studies ran over multiple years, 
and therefore measures per month comprise blood drawn in multiple Januarys, 
multiple Februarys and so on. 
Vitamin D status is determined by measuring circulating 25(OH)D  which is 
generally considered the best indicator of vitamin D status (Seamans and Cashman, 
2009). Both 25(OH)D2 and 25(OH)D3 were measured using the liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method. The total of the two measures was 
taken for total circulating 25(OH)D, however most samples from both studies 
contained no 25(OH)D2. The lower limit of detection using LC-MS/MS was 10 nmol/L. 
All samples were measured in the same laboratory following standard protocols; 
quality control procedures were performed according to current best evidence for 




A range of cut-offs to define sufficiency and deficiency have been proposed, 
however in line with other recent studies we considered circulating 25(OH)D of 50 
nmol/L or over to be sufficient (Ross et al., 2011), 25 to 50 nmol/L to be at risk of 
deficiency or insufficient, and deficiency to be less than 25 nmol/L (Pearce and 
Cheetham, 2010). We additionally explored those at the lower end of deficiency, where 
we considered circulating 25(OH)D below 12.5 nmol/L to be severely deficient (Zgaga 
et al., 2011). 
7.2.2.3 Lifestyle factors 
ORCADES participants attended clinics where several biometric measures were 
recorded. Each participant also completed a medical and lifestyle questionnaire from 
which vitamin D intake, physical activity (PA) and socioeconomic status (SES) were 
derived.   
BMI was calculated as kg/m2 and treated as a continuous variable. Height was 
taken without shoes and weight wearing only light clothing. Based on questionnaire 
data we derived a variable encompassing work and leisure time PA throughout the 
year. Participants classified leisure activity as either 1) light (mostly sitting, light 
housework) or 2) moderate exercise; and likewise work activity as 1) mostly sitting, 2) 
mostly standing, 3) manual work or 4) heavy manual work. Dietary vitamin D intake 
was estimated from two self-administered food frequency questionnaires, the 
cardiovascular disease questionnaire (CVDQ) and bone density questionnaire (BDQ). 
The CVDQ was treated as the primary source due to the higher response rate, however 
information contained in the BDQ that was not present in the CVDQ was merged to 
create the most comprehensive variable possible. Further, a research nurse-
administered drug questionnaire sought information about medications and dietary 
supplements. Participants also described their frequency of taking holidays within or 




Although the Scottish Index for Multiple Deprivation (SIMD) is available for Orkney, the 
scattered and heterogeneous population means that concentrations of poverty or 
affluence are difficult to identify; moreover neighbouring islands are grouped together 
in units thus there is little discrimination (Scottish Index of Mulitple Deprivation, 
2012). Principal Components Analysis (PCA) is a statistical technique to reduce a 
number of variables into a few independent dimensions reflecting the underlying 
patterns in the data, and was used here to construct SES indices (Vyas and 
Kumaranayake, 2006). To establish a variable that differentiates between individuals, 
three SES variables were thereby derived from 10 questionnaire items with significant 
loadings in PCA (S1 Table).  Additionally, we applied an occupational prestige score to 
questionnaire occupation information which was then included in the PCA (Nakao and 
Treas, 1990). Holidays, car age and council tax band loaded significantly onto the first 
component; housing tenure, length of car ownership and highest qualification loaded 
significantly onto the second component, and job prestige score, years in education and 
supervisory role at work loaded significantly onto the third. This third component 
captures “non-traditional” lifestyles reflecting managerial, administrative and 
professional positions in contrast to traditional agricultural work. Time outside in 
summer was summed from participants’ estimates of average time spent without a roof 
covering on summer work and leisure days. Data from SOCCS included age, sex, month 
of blood sample and 25(OH)D measurement. 
7.2.2.4 Statistical analyses 
 We matched the ORCADES and SOCCS datasets on age to within two years 
(Table 7.1) to remove any differences arising from age structures. Matching was carried 
out blind excepting dataset of origin and age. Because of the large effect of season on 
vitamin D levels, we standardised 25(OH)D measurements to the month of May; values 




in May (Zgaga et al., 2011). The mean of monthly means in the mainland Scottish data is 
34.4 nmol/L; in the Orcadian data the mean of monthly means is 37.7 nmol/L. The May 
means are 33.8 nmol/L and 35.5 nmol/L, respectively. We used May-standardised 
measurements for all analyses concerned with determinants of vitamin D, and also to 
compare Orkney and mainland Scotland in deficiency levels. For analyses concerned 
with vitamin D and time of year we used crude 25(OH)D measures. Data are presented 
as mean (standard deviation). 
Table 7.1 Distribution of age and crude vitamin D in age-matched Orkney and 
mainland Scotland datasets. The mainland dataset excludes people from above 
the 57th degree of latitude 








Participants 1453 36.2 1453 35.4 
< 40 46 (3.17) 26.8 46 (3.17) 36.5 
40 – 49 263 (18.1) 33.4 263 (18.1) 39.5 
50 – 59 399 (27.5) 35.7 400 (27.5) 38.7 
60 – 69 466 (32.1) 37.9 464 (31.9) 33.3 
70 + 279 (19.2) 39.5 280 (19.3) 30.4 
Sex (male) 590 (40.6)  37.2 794 (54.6) 35.4 
Sex (female) 863 (59.4) 35.6 659 (45.4) 35.4 
 
We plotted crude 25(OH)D by location as a density plot and by month, and 
compared using a t-test. We compared vitamin D by age group using t-tests. To 
compare levels of deficiency in Orkney and mainland Scotland, we divided participants 
into groups of deficiency and plotted May-adjusted vitamin D for each deficiency group 
and location and tested for differences using chi-square tests. 
For determinants of May-adjusted 25(OH)D in Orkney, we ran a series of 
bivariable models of May-adjusted 25(OH)D against environmental and demographic 




These significant variables comprised BMI, age at venepuncture, foreign holidays, PA, 
SES, dietary vitamin D and working status. Sex was also a covariate. A large percentage 
of missing data (S2 Table) was imputed using Multiple Imputation of Chained 
Equations (MICE)(van Buuren and Goothuis-Oudshoorn, 2011) after excluding 28 
individuals with missing outcome data. We ran 68 cycles of 100 imputations and 
pooled the results in a linear regression model. We ran the same model using complete 
cases only. Statistical tests were two-sided with p<0.05 taken as significant. Finally, we 
applied a one-way ANOVA to compare mean May-adjusted 25(OH)D across the three 
groups of participants that we identified as a result of our analyses.  
We assessed homoscedasticity by inspection of a QQ plot, and distribution of 
residuals using a histogram with superimposed normal curve. Independence was 
checked using the Durbin Watson statistic, multicollinearity and outliers using the VIF 
statistic and Cook’s distance, respectively. All analyses were conducted using R 
software version 3.2.0 (R Core Team, 2015). 
7.2.3 Results  
For this study, 64 individuals were excluded from ORCADES who were not 
resident in Orkney, 10 who had MS, as well as 8 duplicate measures. Characteristics of 
ORCADES participants are presented in Table 7.2. Twenty-three people were excluded 
from the Scottish Colorectal Cancer Study who lived above the 57th degree of latitude. 
For comparison analyses, data were age-matched giving a final count of 1453 people in 






Table 7.2 Characteristics of ORCADES Study participants (n=1972) 
Characteristic No or mean SD % or range 
Age at venepuncture (years) 53.4 15.3 16.5 – 100.2 
Sex    
Female 1191 - 60.4 
Male 781 - 39.6 
Body Mass Index (kg/m2) 27.7 4.9 16.9 – 53.9 
Vitamin D intake (μg) 4.4 3.1 0.00 – 34.1 
Physical activity* 5.1 1.2 3.0 – 8.0 
Summer minutes outdoors 223 142 4.8 – 900 
Working  1367 - 69.3 
Retired 547 - 27.7 
Holidays outside the UK    
< once a year 1472 - 74.6 
Once a year 329 - 16.7 
> once a year 105 - 5.3 
Years in education 16 1.2 1.0 – 23 
Qualification level    
O & standard grades, CSE 275 - 13.9 
Highers, A levels 787 - 39.9 
Certificates/diplomas 739 - 37.5 
Bachelor/Master degree 88 - 4.5 
Doctorate 13 - 0.7 
* Physical activity scored from 1 (mostly sitting; inactive) to 4 (heavy manual labour; 
active) across different domains within work and leisure. Each score is the sum of 
answers creating an individual value for each participant. 
 
Using age-matched data we compared mean 25(OH)D in Orkney to mainland 
Scotland (Figure 7.2). Orkney had significantly higher crude 25(OH)D than mainland 
Scotland (Orkney 35.3 (18.01), Mainland 31.7 (21.18), t(2800)=-4. 93, p=8.5 x 10-7). 
Mean 25(OH)D was higher in Orkney for every month except August when the 
mainland peaks at ~50 nmol/L. The distribution of vitamin D levels is shifted to the 




by age group (Table 7.3). Results for each age group are significantly different, however 
in the under 40s, 40 to 49 and 50 to 59 age groups, mainland Scotland has higher 
vitamin D, whilst in the 60 to 69 and over 70s age groups, Orkney has significantly 
higher vitamin D. Comparing Orkney with the mainland by deficiency group, we found 
that more people in Orkney had insufficient vitamin D, χ2 (1, N=2863)=30.3, p=3.8 x 10-
8; however, Orkney had significantly fewer people with circulating 25(OH)D of 
<12.5nmol/L (severely deficient) compared with the mainland, χ2 (1, N=2863)=64.3, 
p=1.1 x 10-15 (Figure 7.4). 
Table 7.3 Comparison of vitamin D in Orkney and mainland Scotland by age group 






t-test  p-value 
< 40 46; 46 26.8 36.5 -2.67 0.009 
40 – 49 263; 263 33.4 39.5 -3.13 0.002 
50 – 59 399; 400 35.7 38.7 -1.97 0.049 
60 – 69 466; 464 37.95 33.28 3.59 0.0004 






Figure 7. 2 Mean crude vitamin D concentration (nmol/L) per month by location, 
using age-matched data. Orkney’s mean vitamin D is higher than the mainland for 
every month except August and November. Each study ran over consecutive 







Figure 7. 3 Comparison of May-adjusted vitamin D distribution in Orkney and 
mainland Scotland using age-matched data. The distribution for Orkney is to the 
right of the distribution for the mainland, reflecting the lower prevalence of 







Figure 7.4 Comparison of percentage of people in May-adjusted vitamin D 
deficiency groups by location. The main differences occur in the severely 
deficient group (<12.5 nmol/L) which has significantly fewer people from the 
Orkney sample (χ2(1)=64.2, p=1.10 x 10-15), and the ‘at risk’ category (25-<50 
nmol/L) which has significantly fewer people from the mainland Scottish sample 
(χ2(1)=30.3, p=3.78 x 10-8). 
 
 
To explore correlates of vitamin D in Orkney we ran two multivariable regression 
analyses, using both imputed data and complete cases. Each model yielded similar 




lower BMI, more foreign holidays, older age and increased PA. Associated with lower 















































































































































































































































































































































































































































































































































































































































































































































































































































The association between older age and higher vitamin D required further 
exploration; we began by comparing foreign holiday-takers and their non-holidaying 
counterparts. We found that people over 50 were significantly more likely to take 
foreign holidays at least once a year compared to people under 50 (Table 7.5, Figure 
7.5) (χ2(1)=6.4, p=0.0083). We termed this the ‘Saga’ effect. Additionally, we found that 
foreign holidays had a stronger effect on people over 50 who had their blood drawn in 
the low vitamin D (weaker UVB) season (October to March) compared with people who 
had their blood drawn in the high vitamin D (stronger UVB) season (April to 





Table 7. 5 Comparison of people over 50 who holiday outside the UK at least 
once a year (n=281) and people over 50 who holiday outside the UK less than 
once a year or never (n=851). Unpaired t-tests applied to continuous data; chi-
square tests applied to categorical data 
 Over-50s, 
holiday 









Socio-economic status 1 1.01 (0.775) -0.299 (0.919) -22.6 <2.2x10-16 
Job prestige score 0.320 (1.08) -0.192 (0.955) -7.09 5.14x10-12 
Socio-economic status 3 
(“non-traditional”) 
0.182 (1.05) -0.285 (0.915) -6.50 2.13x10-10 
Supervisory role at work     
Yes 186 (66.4) 377 (45.1)   
No 94 (33.6) 459 (54.9) 38.2 6.43x10-10 
Years in education 15.9 (1.26) 15.5 (1.14) -5.39 1.13x10-6 
Body mass index (kg/m2) 27.6 (3.91) 28.9 (5.03) 4.41 1.19x10-5 
Highest qualification     
O & standard grades, CSE 33 (11.8) 102 (12.1)   
Highers, A levels 114 (40.7) 246 (29.3)   
Certificates/diplomas 113 (40.4) 461 (54.8)   
Bachelor/Master/PhD 20 (7.14) 32 (3.81) 22.2 5.82x10-5 
Summer minutes 252 (146) 214 (136) -3.38 0.000777 
Age 62.9 (7.62) 64.4 (8.63) 2.55 0.0109 
Bodyfat % 33.71 (7.51) 34.9 (8.07) 2.34 0.0197 
Socio-economic status 2 0.430 (0.758) 0.316 (0.758) -2.06 0.0400 
Vitamin D intake (μg) 5.09 (3.60) 4.78 (3.13) -1.12 0.261 
Physical activity 5.21 (1.20) 5.16 (1.26) -0.37 0.710 
 
Table 7. 6 Mean May-adjusted vitamin D (nmol/L) according to season of 
venepuncture (high season (April-September, n=96) vs low season (October-
March, n=185)) in people over 50 who take a holiday outside the UK at least once 
a year. Linear regression with May-adjusted vitamin D as the outcome 
 Std Beta Beta (95% CI) Std error p-value 
High season over-50s 0.17 7.86 (3.57-12.15) 2.18 0.000349 





Figure 7.5 Percentage of people per age group in ORCADES who holiday outside 
the UK at least once a year. People over 50 take significantly more holidays than 
those under 50 
 
To explore under-40s further, we ran the same analyses comparing those who 
do and do not holiday outside the UK that were used for over-50s (S3 Table). The same 
results were significant, excepting body fat percentage, socio-economic status 2, age, 
and summer minutes spent outside. 
We also identified a ‘farmer effect’ (Table 7.7). Participants employed in 




mean vitamin D levels than participants in non-traditional professions that kept them 
indoors (farmers 36.9 (18.0), non-farmers 33.8 (11.8), t(383)=2.46, p=0.014). Further, 
farmers tended to be older. 
 
Table 7.7 Comparison of farmers (n=265) and non-farmers (n=1649) on variables 
of interest in Orkney. Farmers are anyone who identified their primary profession 
as farmer. Unpaired t-tests applied to continuous data; chi-square tests applied 
to categorical data 
 Farmers 
No (%) or 
Mean (SD) 
Non-farmers 
No (%) or Mean 
(SD) 
t-test or χ2 p-value 
Age 60.7 (11.4) 52.4 (11.5) -8.86 <2.2x10-16 
Socio-economic status 3 
(“non-traditional”) 
-0.30 (0.58) 0.10 (1.02) 8.77 <2.2x10-16 
Years in education 15.4 (1.01) 16.1 (1.24) 10.16 <2.2x10-16 
Socio-economic status 1 -0.439 (1.00) 0.0990 (0.973) 7.86 5.39x10-14 
Physical activity 5.87 (1.23) 5.10 (1.21) -7.60 8.89x10-13 
Highest qualification     
O & standard grades, CSE 24 (9.16) 251 (15.3)   
Highers, A levels 84 (32.1) 702 (42.8)   
Certificates/diplomas 153 (58.4) 586 (35.8)   
Bachelor/Master/PhD 1 (0.382) 100 (6.10) 55.9 4.29x10-12 
Bodyfat % 30.4 (8.65) 33.1 (8.63) 4.51 9.05x10-6 
Supervisory role at work     
Yes 109 (41.3) 866 (53.2)   
No 155 (58.7) 763 (46.8) 12.8 0.000342 
Socio-economic status 2 0.281 (0.917) 0.0672 (0.921) -3.39 0.000771 
Body mass index (kg/m2) 28.4 (4.80) 27.7 (4.96) -2.12 0.035 
Vitamin D intake (μg) 4.71 (2.93) 4.40 (3.20) -1.29 0.19 
Summer minutes 236 (151) 221 (141) -1.21 0.225 
* School examinations taken in the UK at ~16 years of age 
** School examinations taken in the UK at ~18 years of age 
To test for differences in mean vitamin D across the ‘Saga’ group, farmers, and 
non-farmers who are under 50 and do not take foreign holidays, we did a one-way 




we therefore concluded that vitamin D varies significantly across these groups with 
people over 50 who take foreign holidays having higher vitamin D than farmers, who 
had higher vitamin D than non-farmers and people under 50 who remain in the UK 
(Figure 7.6). 
Figure 7.6 Mean May-adjusted vitamin D (nmol/L) in different groups in 
ORCADES. 95% confidence interval bars are given. “Saga” refers to people 
over 50 who take a holiday outside the UK at least once a year; “Farmer” 
to people who identified their primary profession as farming; “Other” is 
people under 50 who take a holiday outside the UK less than once a year, 






We aimed to compare vitamin D levels in Orkney and mainland Scotland, and to 
identify the determinants of Orkney vitamin D. Definitions of vitamin D deficiency are 
much discussed, however it has been proposed that circulating 25(OH)D above 50 
nmol/L are sufficient (Ross et al., 2011; Holick et al., 2011). Vitamin D status in 
Scotland has been previously explored (Zgaga et al., 2011). Deficient and high risk 
individuals comprised 63.4% in the previous study; in our Orkney dataset deficient and 
high risk individuals comprised 65.3%. However, people with severe deficiency (<12.5 
nmol/L) comprised 11.8% of the former study and only 5.0% of the latter. Therefore 
although perhaps initially surprising that mean vitamin D was higher in Orkney despite 
the higher latitude, the smaller percentage of people with severe deficiency in Orkney 
led to this elevation. In both datasets the majority are either deficient or at risk of 
deficiency which could have significant health implications (Holick, 2004a). 
Ability to synthesise vitamin D decreases with age (MacLaughlin and Holick, 
1985); it is well established that older age is associated with lower vitamin D and 
increased deficiency risk (Zgaga et al., 2011; Mithal et al., 2009). However, we found 
that lifestyle factors particular to Orkney contributed to better vitamin D in older 
compared to younger people. 
Participants who took foreign holidays had higher vitamin D than those who 
did not take foreign holidays; furthermore, taking foreign holidays increased by age 
group. Less than 20% of under-40s in our Orkney sample took foreign holidays, 
whereas over 30% in the 70 and over group reported leaving the UK at least once a 
year. Weak sunshine within the UK leads to fewer opportunities for UV exposure and 
UVB-mediated vitamin D synthesis, and the effect of foreign holiday sun exposure has 
been previously associated with improved vitamin D in Scotland (Mavroeidi et al., 




the year with the exception of two months: August and November. Although we were 
unable to explore this further, mainland Scotland’s August elevation of vitamin D could 
be attributed to the effect of holidays, following one month after school holidays. In 
November, however, mainland Scotland’s mean vitamin D levels were only minimally 
higher than Orkney. We found that mean vitamin D in people 50 and over taking 
foreign holidays was significantly higher than vitamin D levels in the rest of the sample. 
Foreign holidays contributed more to vitamin D levels on blood drawn in months of 
weaker UVB. We were unable to explore at what time of year people take holidays, 
however this finding suggests that foreign holidays become more important as a source 
of UV exposure and therefore vitamin D for Orkney residents in winter. As older people 
tend to have more freedom to travel outside peak season, they are able to derive most 
benefit by seeking sun in seasons of scarce sunshine in Orkney. People over 50 who 
take foreign holidays were found to differ from those who do not take holidays mainly 
in variables denoting financial security. They were also more likely to have lower BMI 
and body fat percentage suggesting possible healthier lifestyles than their non-
holidaying counterparts.  
We also examined under 40s, the age group in which MS is most likely to be 
diagnosed and pregnancies are most likely to occur, thereby potentially conferring risk 
to the unborn child. In this group, we found that the main differences in those who do 
or do not take holidays out of the UK are related to financial security. Only 75 of the 400 
people who are under 40 reported leaving the UK for a holiday at least once a year, 
therefore, in the most at-risk group, inadequate UV exposure in Orkney is compounded 
by a low prevalence of foreign holidays.   
The ‘non-traditional’ SES group derived from PCA, comprising job prestige 




These variables, reflecting “non-traditional” lifestyles of managerial, administrative, 
and professional occupations in contrast to traditional agricultural work, related to 
farmers and non-farmers. Farmers were found to be slightly less educated, possibly as 
a result of leaving school at the minimum leaving age about half a year to a year before 
the first set of examinations. Farmers were also less likely to describe themselves as 
having a supervisory role at work than non-farmers, and also had a slightly lower-than-
average job prestige score. The inverse association between vitamin D and a higher 
score in this variable means that farmers, who scored lower, had better vitamin D. 
Farmers in our cohort were also more likely to be older than non-farmers, further 
contributing to our finding of vitamin D increasing with age. 
Physical inactivity and obesity have previously been related to low vitamin D in 
a large American cohort (Brock et al., 2010); the association between lower BMI and 
higher 25(OH)D is also well established (Jorde et al., 2010). The mechanism for lower 
vitamin D in the presence of higher BMI is thought to be a result of increased deposition 
of vitamin D in body fat (Wortsman et al., 2000), making BMI a proxy for adiposity. 
However, BMI does not distinguish between body fat and fat free mass, and is not 
always a reliable indicator of adiposity in people with lower body fat but greater 
muscle mass (Wellens et al., 1996). The farmers in our cohort reflected this difficulty: 
they had lower body fat percentage but higher BMI than non-farmers. We found 
farmers were more active and leaner than non-farmers and it is perhaps therefore fair 
to assume they have higher than average muscle mass. Nevertheless, in the 
multivariable models BMI followed what is expected. 
Farmers had mean vitamin D significantly higher than non-farmers, but 
significantly lower than people over 50 who take foreign holidays. Summer minutes 




test for farmers versus non farmers and time spent outside. Farmers, perhaps 
unsurprisingly, were found to spend significantly more time outside than non-farmers 
which enables maximisation of even the smallest window of vitamin-D strength 
sunshine. Although Zgaga et al. found higher vitamin D consumption led to slight 
improvements in plasma vitamin D (Zgaga et al., 2011), we found that diet was not 
associated with vitamin D in Orkney. However, difficulties involved in building a 
variable with the available data likely contributed to this finding.  
Both studies were recruited on an ‘opt in’ basis which may result in the samples 
representing a healthier than average population; however a strength of this study was 
the large number of participants in each cohort. Particularly novel was the number of 
farmers in our Orkney cohort, enabling us to explore vitamin D in a select group within 
a rural population which is not often studied. All vitamin D samples from both cohorts 
were analysed in the same laboratory using the same procedures, helping maintain 
consistency and reliability of results. We had access to a variety of detailed measures to 
explore vitamin D in Orkney; however data on time spent outside and vitamin D intake 
were somewhat limited and these may thus be more strongly implicated in vitamin D 
than we were able to detect. Nevertheless, we found significant effects and reliable 
relationships for vitamin D with foreign holidays, BMI, physical activity, and age.  
7.2.5 Conclusion 
 Mean vitamin D in Orkney was higher than mainland Scotland, driven largely by 
a lower percentage of individuals with severe deficiency in Orkney. Overall 
concentrations in both cohorts were low with most people either deficient or at risk of 
deficiency, suggesting that UV exposure for much of the year is low. Older Orkney 
residents were more likely to have better vitamin D than younger residents, largely 
resulting from the ‘Saga’ and ‘Farmer’ effects. Those most at risk of deficiency in Orkney 




increased risk of MS diagnosis. Within these main child-bearing years, a lack of UV 
exposure and vitamin D deficiency may result in significant autoimmune implications 
for offspring. The significant contribution of foreign holidays to Orkney vitamin D is 
consistent with the findings of previous UK studies; the importance of foreign holidays 
in providing adequate UV exposure to UK residents is underappreciated. We have 
found that younger ages are more at risk from inadequate UV exposure and vitamin D 
deficiency in Orkney, a county with a very high prevalence of MS. Further research 
exploring the relationship between vitamin D and quantitatively-measured exposure to 
UV radiation from sunshine and physical activity, as well as more detailed dietary 
information in Shetland, the most northerly UK county with an MS prevalence lower 
than Orkney, would help further elucidate the roles of UV exposure and vitamin D as 
MS risk factors in these islands. 
7.3 Conclusion 
 As discussed, mean vitamin D in Orkney was higher than in mainland Scotland. 
It is possible, however, that this difference resulted from differences in the handling of 
the samples following blood draw and before analysis, and also in the laboratory 
procedures for analysis. The SOCCS study ran between 1999 and 2006. Blood in the 
SOCCS study was analysed for vitamin D in one batch in late 2008 or early 2009 
(personal communication, Vaughan-Shaw, 20 November 2017), and the oldest samples 
would have therefore been stored for up to ten years. ORCADES ran between 2005 and 
2011. Blood was analysed for vitamin D in one batch in 2011, and therefore the oldest 
samples would have been stored for up to six years (personal communication, Wilson, 
15 November 2017). Both sets of samples were processed and frozen. The SOCCS 
samples were frozen at -800; the ORCADES samples were frozen at -400 and then -800 
until analysis. Although there was a difference in both the length of time and 




resilient metabolite for long-term storage and is not adversely affected by differences 
in temperature, even when not frozen or refrigerated, over the short-term (Colak et al., 
2013; Lissner et al., 1981; Hollis, 2008), 
One further potential complication in comparing these samples from different 
studies is that they were analysed at different times. This could introduce some intra-
laboratory variation, which could potentially lead to better detection of vitamin D levels 
in Orkney, therefore making it appear that mean Orkney vitamin D was higher. 
However, as shown in Table 7.3, there was a strong age effect whereby higher vitamin 
D levels were found in the younger population in the mainland, and in the older 
population in Orkney. This finding could be explained by the effect of holidays and 
outdoor working. Furthermore, when examining vitamin D by month, the mainland is 
higher than Orkney in August, which may also be explained by the effect of holidays 
following on one month after the end of school holidays (although data to test this were 
unavailable). It therefore seems unlikely that there was a systematic difference in 
measurement between the samples from the two studies as different age groups and 
different months show different patterns.  
Finally, although the samples were analysed at different times, the ORCADES 
team specifically chose the same laboratory, the Scottish Trace Element and 
Micronutrient Diagnostic and Research Laboratory (STEMDRL), as the SOCCS study for 
analyses of blood vitamin D (personal communications, Vaughan-Shaw, 20 November 
2017; Wilson, 15 November 2017). As well as using the same liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method, the same laboratory would also be 
subject to the same quality control procedures, instrument maintenance and 
equipment calibration, which are important in ensuring as much consistency and 




 Methods for blood vitamin D measurement in STEMDRL changed in 2014, 
which was subsequent to all analyses for these studies (personal communication, 
Vaughan-Shaw, 20 November 2017). Therefore, whilst it should be noted that there are 
some differences in the handling of samples and different times of analysis that could 
lead to some differences observed between SOCCS and ORCADES datasets, care has 
been taken minimise such variation. Again, as noted above, vitamin D is a stable 
metabolite (Lissner et al., 1981; Hollis, 2008), and so it seems unlikely that these 
differences would have led to the observed results.  
It is important to note that this study of vitamin D levels in Orkney has shown 
that vitamin D deficiency is particularly prominent in younger people in a population 
which has a high prevalence of MS. From the literature, and from our study of the 
heritability of MS in Orkney, there is clearly a requirement for a risk factor which 
increases the risk of MS in genetically susceptible individuals. Vitamin D deficiency in 
Orkney is a strong candidate for one such environmental risk factor.  
 Additionally, UV exposure itself may be important in mitigating MS risk. To 
further understand how UV exposure may be affecting the populations in such high-
latitude islands Chapter 8 explores individually-measured UV exposure in Shetland, 









CHAPTER 8: THE VIKING UV STUDY 
8.1 Introduction 
Following the Orkney vitamin D study, we explored how individual and lifestyle 
factors contribute to UVB exposure in Shetland. In this chapter I describe the methods 
and present the results of the Viking UV study. I discuss our findings in the context of 
the wider literature and their implications for the population of Shetland. However, I 
firstly describe UVB’s place in the spectrum of radiation from the sun, and discuss 
environmental and personal factors known to affect our exposure to UV. I then define 
how vitamin D-strength UV exposure is measured, and briefly summarise the 
importance of UV exposure to human health.  
8.1.1 Sunlight and UV radiation 
 Sunlight comprises a range of electromagnetic radiation of various 
wavelengths. The wavelengths are used to categorise sunlight into three groups: 
infrared radiation, visible light, and UV radiation. However, because these groups are 
all part of a larger continuum (the electromagnetic spectrum), the divisions between 
bands are not exclusive, and some overlapping of wavelength occurs. The UV spectrum 
spans wavelengths from 200-400nm, shorter than visible light (400-700nm), and 
infrared radiation (700nm to 1mm). UV itself is furthermore divided into three 
categories dependent on wavelength: UVA (320-400nm), UVB (280-320nm), and UVC 
(100-280nm) (Orteu et al., 2001).  
UVC is fully absorbed by ozone and does not reach the Earth’s surface (Figure 
8.1). UVB is filtered by ozone; however, UVB rays make up between 5 and 10% of all UV 
radiation at the Earth’s surface. In humans, UVB is absorbed by epidermal skin and 
penetrates through to the papillary dermis. It causes erythema and sunburn. Over the 




melanoma. However, UVB is also the principal source of vitamin D in humans (Orteu et 
al., 2001; Holick and Jenkins, 2009).  
UVA comprises 90-95% of all UV radiation at the Earth’s surface. It penetrates 
ozone and infiltrates the skin more deeply than UVB. Unlike UVB, UVA is also able to 
penetrate water and glass. Excessive UVA exposure increases risk of photoaging and 
melanoma (Narayanan et al., 2010). 
  
Figure 8.1 UV rays and the earth's surface 
 
(creativecommons.org/licenses/by-nc-sa/2.5/au/legalcode, Energizer Australia 
(2017)) 
 
8.1.2 What affects our exposure to UVB radiation? 
Two groups of factors, which I will term environmental and personal, affect our 
exposure to UV radiation. Environmental factors affect the amount of UVB available on 
the Earth’s surface. These include the solar zenith angle, ozone, weather conditions, 
surface reflectivity, latitude, season, and time of day. The definitions of high and low 
latitude are shown in Figure 8.2. Personal factors include sunscreen use, clothing cover, 
and sun-seeking or sun-avoidance behaviours. Vitamin D synthesis is also dependent 




Figure 8.2 Latitude regions. Polar regions are high latitude, temperate zones are 
mid-latitude, and the tropics stretching across the equator are low latitude 
 
(Bureau of Meteorology Training Centre, 2017) 
8.1.2.1 Environmental factors  
The solar zenith angle (SZA) is the angle between a hypothetical line that 
ascends vertically from any location on earth, and the position of the sun in the sky. The 
SZA is affected by the time of day, time of year, and latitude. Small SZA are associated 
with summer months, midday hours, and low latitude areas, whilst large SZA are 
characteristic of winter months, early morning and late evening hours, and high 
latitude regions (Webb, 2006). Small SZA are favourable for UVB infiltration and 
subsequent vitamin D production. This is because when the sun is high in the sky, there 
is less distance for the rays to travel through the atmosphere, and the resultant energy 
is concentrated on a relatively small area. Large SZA are less beneficial as the radiation 
has a longer path through the atmosphere; there is more chance that the radiation will 
be attenuated, and additionally, at the Earth’s surface, the energy is spread over a large 
area (Webb, 2006). At high latitudes, winter sunshine is insufficient to initiate vitamin 




The SZA therefore has an important role in the amount of potential UV that can 
reach the Earth. However, several other, less predictable, environmental factors can 
inhibit UVB infiltration. As mentioned previously, ozone absorbs UVB. Ozone is found 
principally in the stratosphere and follows a global pattern with the least ozone 
occurring around the tropics and the most at the edge of the polar regions. Between 
these two extremes, the amount of ozone increases with latitude. Ozone is also subject 
to seasonality. At mid-latitudes, ozone is at its minimum in the summer and winter 
months and at its maximum in spring and autumn (Webb, 2006). Lower levels of ozone 
result in greater potential for vitamin D synthesis by UVB (Kimlin, 2008).  
As well as ozone, UV radiation can be scattered by other atmospheric particles, 
including oxygen, nitrogen, aerosols, and water vapour. Low-level air pollution also 
reduces UV levels, particularly in urban environments (Kimlin, 2008). Areas of high 
altitude also usually have greater UV infiltration than low altitude areas because the 
distance for the rays to travel is smaller and there is less chance of attenuation by these 
atmospheric particles. 
Finally, cloud cover can have a significant impact on UV infiltration. The amount 
of UV that reaches the Earth’s surface is variable depending upon the density of cloud 
cover, and the size, shape, and composition of the clouds. Light clouds that do not cover 
the sun are unlikely to impact the UV reaching the earth. However, overcast skies 
significantly reduce UV (Kimlin, 2008; Webb, 2006). Conversely, in certain 
circumstances, clouds can briefly increase the amount of available UV (Kimlin, 2008). In 
areas of high surface albedo or reflectivity, for example newly-laid snow, some 
radiation is reflected from the surface. This reflected UV may then be back-scattered by 




returns the UV to the Earth’s surface thereby increasing ambient UV (Kimlin, 2008; 
Webb, 2006). 
Environmental factors clearly impact how much UV reaches the Earth’s surface. 
However, personal reasons affect the amount of UV to which we are exposed. 
8.1.2.2 Personal factors   
Personal factors comprise behaviours which affect the amount of UV that 
reaches our skin. Clothing cover and sunscreen both provide barriers which block UVB, 
and thereby prevent cutaneous vitamin D synthesis. Holick (2004b) estimated that 
when following guidelines for proper use, SPF15 reduces vitamin D synthesis by over 
98%, and SPF8 by up to 95%. Additionally, the amount of time spent outdoors, the 
period during the day spent outdoors, and the amount of skin exposed to the sun, all 
affect UVB exposure. As mentioned above, summer midday hours are most efficient for 
UV’s infiltration to Earth, and therefore exposing skin to sunlight during these times 
maximises the amount of UVB that it is possible to receive. However, it is important to 
note that prolonged exposure is not beneficial to vitamin D levels, and is likely to be 
harmful (Webb, 2006; Byrne, 2014). Instead, short, regular periods of exposure are 
sufficient to increase vitamin D levels. People who avoid the sun, or who cover their 
skin with sunscreen or clothing, are at more risk of vitamin D deficiency, and will not 
gain other health benefits from sunlight. 
Age and skin type are two other important factors which can result in low 
vitamin D levels regardless of UVB exposure. As mentioned in Chapter 7, the ability to 
synthesise vitamin D decreases with age, as the amount of 7-dehydrocholesterol (7-
DHC) in the skin is reduced (MacLaughlin and Holick, 1985). Age therefore comes with 




Skin type also affects the amount of UVB that can initiate vitamin D synthesis. 
Darker skins contain more melanin which absorbs UV radiation. This absorption 
protects skin from sunburn, however it also means that UV is effectively prevented 
from entering other skin cells, thereby reducing the amount of 7-DHC that can be 
converted into previtamin D3. People with dark skins who live in high-latitude regions 
are therefore at particular risk of vitamin D deficiency (Webb, 2006).   
8.1.3 Measurement of UVB 
 One sign that skin has been exposed to adequate sunlight for vitamin D 
synthesis is erythema, defined as a just-perceptible reddening (but not burning) of the 
skin (Webb, 2006). However, simply measuring UV exposure is not informative of the 
erythemal action of the exposure (CIE Standard, 1998). UV radiation that elicits 
erythema can be measured using the minimal erythema dose (MED). The MED reflects 
individuals’ sensitivity to UV, dependent on factors including skin pigmentation, 
previous UV exposure, and anatomical site. The MED is therefore different for each 
individual. Furthermore, there are observational difficulties including how to define the 
erythema (CIE Standard, 1998). However, Lo et al. (1986) found that when the MED 
had been met in people of different skin types – in this study Indian and Pakistani 
immigrants to the UK compared to UK residents of European heritage – the amount of 
vitamin D produced was equivalent. 
 Despite its uses, the subjective nature and lack of standardisation of the MED 
was problematic when trying to use it as a measure of UV radiation (Diffey, 2002b). The 
standard erythema dose (SED) was therefore proposed and is widely used as an 
erythemally-weighted UV radiation measurement. One SED is equivalent to an 
erythemal effective exposure of 100Jm-2 (CIE Standard, 1998). To give an indication of 
the practical meaning of this measure, Diffey (2002b) provides the following examples: 




around 30-40 SED; b) 4 SED would elicit moderate erythema on white, previously 
unexposed skin, but would not produce erythema on skin that had been previously 
exposed.   
8.1.4 UVB radiation and health 
The effectiveness of using sunlight to treat conditions such as tuberculosis 
(Gardiner, 1915; Holmboe, 1916), psoriasis (Alderson, 1923), and rickets (Chick et al., 
1922), were well-recognised before the biological actions of UV exposure were 
understood. Since then, our understanding of how the different wavelengths of UV 
confer different biological effects, and of the importance of adequate UVB exposure to 
human health, has grown.  
Underexposure to UVB has been cited as a risk factor for many diseases, 
including but not limited to, several types of cancers (Grant, 2002; Boscoe and 
Schymura, 2006), cardiovascular disease (Holick, 2004a; Holick, 2002), bone health 
including rickets and osteoporosis (Holick, 2004a), and autoimmune diseases including 
rheumatoid arthritis, type 1 diabetes mellitus, and MS (Ponsonby et al., 2002). 
Underexposure has also been associated with increased mortality from cancer (Grant, 
2002). 
The concomitant reduction in vitamin D levels with lower levels of UVB 
exposure is considered a risk factor for many of these conditions. A 2009 study 
estimated that maintaining sufficient vitamin D levels (40 ng/mL) would reduce the 
economic burden of disease by €187,000 per year in Western Europe (Grant et al., 
2009).  
However, as discussed in Chapters 6 and 7, UVB exposure also has 
immunosuppressive properties. UV induces the innate immune system, thereby 




immune system, thus reducing autoimmune and allergic responses (Schwarz, 2010). 
Several authors have linked this reduced autoimmune response to a reduced risk of MS 
(Wang et al., 2013; Lucas et al., 2011; Tsunoda et al., 2005). However, 
immunosuppression from UV, particularly in the UVB range, has been linked to adverse 
health outcomes such as risk of melanoma in individuals who show particular 
susceptibility to UV (Yoshikawa et al., 1990). To maintain optimal health, adequate but 
judicious UVB exposure seems to be vital, for both its immunosuppressive properties 
and for its role in vitamin D synthesis. 
Our study of vitamin D in Orkney found that foreign holidays are an important 
contributor to the population’s vitamin D levels. However, farming was also associated 
with higher vitamin D levels. Farming involves greater-than-average time spent 
outside, meaning that the strength of Orkney UV can be sufficient to initiate vitamin D 
synthesis. To understand how local lifestyles may affect individual exposure to UV and, 
potentially, vitamin D levels in the highest-latitude county of the UK, we ran the Viking 
UV Study in Shetland. 
8.1.5 Aims 
Our aim was to investigate UV exposure in Shetland. We had two objectives to 
achieve this aim.  
1) Identify correlations between UV exposure and a range of personal and 
lifestyle factors. 
2) Determine how these factors may each contribute to individual UV exposure in 
Shetland. 
8.2 Methods 
8.2.1 Study Population 
All UV study participants had previously consented to take part in the Viking 




epidemiology study involving around 2000 Shetlanders, and is concerned with 
identifying genetic factors that influence complex disease. Data were collected at a 
measurement clinic where biometric measurements were recorded and blood was 
drawn. Additional data included cognitive function tests and a comprehensive health 
survey. 
There were two phases of recruitment for the UV study. Firstly, we identified a 
subset of 200 VIKING participants who had not yet attended their clinic appointment, 
and approached them by mail. One hundred and twenty-six people registered interest. 
Available participants were booked into the VIKING clinic from 12th June 2014 to 2nd 
September 2014. Participants who were unable to attend a clinic during these times 
agreed to receive a study pack and instructions by post and to mail back the data. To 
increase our sample size, we identified in the same manner and approached an 
additional 95 VIKING participants by mail and asked them to participate in the postal 






Figure 8.3 Flow chart illustrating the recruitment of the Viking UV study 
 
Inclusion criteria for the UV study comprised VIKING participants aged 
between 18 and 70. Fourteen participants aged between 71 and 78 were also contacted 
and agreed to participate; ten returned completed study data before the oversight was 
noticed, and we therefore decided to include these data in the analyses. Individuals 
were also excluded if they had taken a holiday outside of Shetland, or had used a 
sunbed within two months prior to the data collection. This time limit was based on the 




8.2.2 Data collection 
 The UV study ran between weeks beginning 16th June 2014 and 3rd September 
2014. Each participant contributed data collected over a period of one week. The start 
date of the data collection week varied depending upon when participants visited the 
clinic or when they received their postal study pack. Data for the UV study consisted of 
measures of UV exposure and physical activity alongside personal characteristics such 
as skin type. The UV study data were then combined with VIKING data. Details of all 
data are below. 
8.2.2.1 UV measurement 
Each participant was either sent, or, if they attended a clinic, given, a 
polysulphone badge (Figure 8.4). Polysulphone badges consist of a square of cardboard 
with an aperture of polysulphone film. On exposure to UVB radiation, the UV 
absorbance of the film increases. The UV absorbance is measured before and after 
exposure at 330nm in a UV spectrophotometer to give a measure of the UV dose, which 
is calculated as a continuous variable in SEDs. We ordered the badges from Dr Richard 
Kift of Manchester University and returned them to him for measurement following 
exposure.  
We supplied one badge per participant. Participants were instructed to wear 
their badge on their right or left lapel every day for one week, ensuring that it was not 
covered by clothing. We chose the lapel site because it is an area where the badge can 
be easily attached and be unobstructed by clothing cover. Other studies have used the 
shoulder/chest site for polysulphone dosimetry (Kimlin et al., 1998a; Kimlin et al., 
1998b; Cahoon et al., 2013; Diffey et al., 1996). Additionally, as there is a strong 
correlation between radiation received at the right and left side of the upper chest, we 
considered that we need not specify exact badge placement (Waterston et al., 2004). 




inside a small brown envelope. This was to ensure that no UV light entered the badge 
before commencement of the study. Following the end of the study, participants were 
asked to return the badges to the black pocket, place and seal them inside the brown 
envelope, and either hand them into the clinic or send them back to us in a prepaid 
envelope that we supplied.  
Figure 8.4 Polysulphone badge 
 
We asked all participants to keep a sun exposure diary for the duration of their 
study week (Appendix E). We asked how much time each day had been spent outside 
and during which time periods, beginning with ‘before 8.30am’, and every hour 
thereafter until the final category of ‘after 5.30pm’. We also asked how much skin was 
exposed during these outdoor periods (face, hands, head, arms, legs, feet, and torso). 
We asked whether participants had been wearing sunscreen which we recorded as a 
dichotomous (yes/no) variable. Other questions included whether participants 
considered their activity levels to have been ‘normal’ for the day of week and time of 
year. This was to determine whether participants were changing their behaviour as a 




 We calculated a variable from the sun exposure diary for ‘time spent outside’, 
which we weighted by the time periods during the day in which participants were 
outside. We refer to this variable as ‘skin exposed (weighted)’. To calculate this 
variable, we used a score developed by Diffey (2002a), where we assigned a percentage 
of ambient daily UV per person per hour (Table 8.1). 
Table 8.1 Daily UV percentage by hour, from Diffey et al. (1990) 
Time Daily UV (%) 
Before 8.30 6 
8.30am – 9.30am 8 
9.30am – 10.30am 12 
10.30am – 11.30am 15 
11.30am – 12.30pm 17 
12.30pm – 1.30pm 15 
1.30pm – 2.30pm 12 
2.30pm – 3.30pm 8 
3.30pm – 4.30pm 4 
4.30pm – 5.30pm 2 
After 5.30pm 1 
 
For example, if someone was outside for five minutes between 10.30 and 11.00, 
and again for thirty minutes between 1.30 and 2.30, they scored ((5/60) × 15) + 
((30/60) × 12) = 7.25. We repeated this process for each day of the week and summed 
the daily totals to give a final score for each participant’s study week. 
Finally, we obtained satellite-measured ambient vitamin D-strength UV from 
the Tropospheric Emissions Monitoring Internet Service (TEMIS). These daily ambient 
vitamin D-strength UV measurements take into account cloud cover, and we obtained 
data for the complete study period from June to September 2014. We centred the 




N and 1.14 W. From these data, we calculated the maximum amount of vitamin D-
strength ambient UV that was available during each participant’s study week.  
8.2.2.2 Lifestyle factors 
VIKING participants attended measurement clinics where height and weight 
were recorded, and body fat percentage was measured from a DEXA scan. We 
calculated BMI from the height and weight measurements. Each VIKING participant 
also completed medical and lifestyle questionnaires. Four of the usual 10 questions 
from the Fitzpatrick skin type scale were asked in the VIKING questionnaire. To derive 
a reliable variable for skin type we asked the remaining six Fitzpatrick questions as 
part of the UV study Sun Exposure Questionnaire (Appendix E). We collated data 
concerning the Fitzpatrick skin type questions from the separate sources, and 
categorised individuals into six groups according to their score. Those scoring 0-6 have 
skin type 1 (always burns); 7-13 skin type 2 (burns easily); 14-20 skin type 3 (burns 
moderately); 21-34 skin type 5 (rarely burns) and over 35 skin type 6 (never burns). 
  Physical activity data were recorded in VIKING. Each VIKING participant 
completed the long version of the self-administered International Physical Activity 
Questionnaire (IPAQ). The IPAQ is an internationally-validated questionnaire 
developed for use with adults between the ages of 15 and 69 (Craig et al., 2003). It 
comprises questions about activity undertaken during the previous seven days. Activity 
is divided into four domains: work, active transportation, domestic and garden, and 
leisure time. It further separates these domains into walking, moderate activity, and 
vigorous activity. Domain-specific and activity-specific scores can be calculated. For 
domain-specific scores, the separate totals for walking, moderate activity, and vigorous 
activity within each domain are summed. For activity-specific scores, the specific type 
of activity across all domains is summed. Activity scores can also be calculated as MET-




used by a seated individual at rest. Different types of activity can be weighted by their 
energy requirements to give the MET. The MET can then be multiplied by the number 
of minutes that the activity was performed, giving MET-minutes (IPAQ, 2013). We 
calculated all IPAQ activity scores in accordance to the IPAQ scoring protocol (IPAQ, 
2013). We calculated activity as both a total of domain-specific activity, and activity in 
MET-minutes per week.  
We collected additional activity data in the UV study from a limited number of 
pedometers, which counted the total steps taken. Participants of the UV study who 
were attending the measurement clinic for VIKING were given pedometers on a first-
come, first-served basis. The pedometers were reset before distribution, and were 
sealed with masking tape. This was in an effort to reduce participants’ knowledge of 
their step-counts and thereby reduce the possibility of score inflation. Each participant 
was given an information sheet with pictures demonstrating how the pedometer 
should be worn: horizontally on a waistband, halfway between belly button and hip. On 
their return to the clinic, participants handed the pedometer to the receptionist who 
recorded the step count for the previous seven days. We used the total of the first six 
days as the activity total as the final day was incomplete and depended upon the time at 
which the participant returned for their clinic appointment. 
 We used information from the VIKING questionnaire to construct indices for 
socio-economic status in the same manner as for ORCADES. Using PCA, we derived two 
variables from 9 questionnaire items, and the occupation question to which we 
assigned an occupational prestige score (Nakao and Treas, 1990) (Table 8.2). Years in 
education, highest qualification, job prestige score, and supervisory role at work loaded 
significantly onto the first component; housing tenure, council tax band, number of 




component. The first component is therefore capturing education and professional 
roles while the second is concerned with financial security.  
Table 8.2 Principal components analysis 
 
PC1 PC2 
Years in education 0.79 -0.10 
Highest qualification 0.76 -0.01 
Job prestige score 0.65 0.08 
Housing tenure -0.20 0.54 
Council tax band 0.13 0.55 
Number of vehicles owned -0.07 0.34 
Holidays in the UK 0.21 0.56 
Holidays outside the UK 0.21 0.62 
Supervisory role at work 0.33 0.19 
Eigenvalue 1.98 1.40 
% Explained 20.9 16.3 
% Cumulative 20.9 37.2 
 
8.2.2.3 Sample size 
Sample size was limited by three factors. These were 1) how many people could 
be seen at the VIKING measurement clinic; 2) the amount of time that VIKING had left 
to run, and 3) how long there would be sufficient UVB in Shetland. With these fixed 
parameters, we needed to work out what an acceptable level of accuracy would be. We 
therefore aimed to recruit 180 participants into the UV study. We considered this to be 
an achievable and realistic target which would enable us to detect correlations of 0.2 
with a 95% confidence interval of 0.05 to 0.34.  
8.2.4 Statistical analyses 
8.2.4.1 Relationship between individual UV and other variables 
To explore the data and examine the relationship between individual UV 
exposure (SED) and other variables we conducted bivariate Pearson correlations for 
continuous variables, t-tests for binary variables, and an ANOVA for the categorical 




for multiple testing. This is because, in exploratory analyses, the number of tests have 
not been specified a priori and the precise number of familywise tests are 
undetermined. Furthermore, only a subset of tests are documented. This means that 
the nominal familywise error rate cannot be calculated with certainty. Attempting to 
adjust for multiple tests can then lead to the rejection of true associations (Rothman, 
1990a; Bender and Lange, 2001; Rubin, 2017).  
The variables that we tested comprised personal characteristics, including age, 
sex, skin type, skin exposed (weighted), indoor or outdoor occupation, working or 
retired, the two SES variables from PCA, and ambient UV. We also tested physical 
activity variables, including pedometer step count, and the totals for the IPAQ work, 
domestic, transportation, leisure, and walking domains, and the totals of moderate and 
vigorous MET minutes per week and the total IPAQ score. Finally, we tested weight and 
body fat variables including weight, waist and hip measurements, body fat percentage, 
and BMI.  
8.2.4.2 Bivariable and multivariable models 
Before conducting the bivariable and multivariable analyses we applied a 




Figure 8.5 Square root transformation of UV dose 
Untransformed SED Square root transformed SED 
  
 
For determinants of UV exposure, we ran a series of bivariable models of SED 
against environmental and demographic variables of interest. Significant variables 
were put into multivariable models. These significant variables comprised sex, body fat 
percentage, indoors or outdoors occupation, IPAQ total score, total steps, Fitzpatrick 
skin type, skin exposed (weighted), TEMIS ambient UV, and SES1. We also included age. 
We ran two multivariable models. The first comprised the full sample size and used the 
IPAQ total score variable for physical activity. The second model comprised the subset 
of participants who had been given a pedometer, and, as well as including the IPAQ 
total score for physical activity in the model, we included total steps taken. We 
transformed all continuous variables into z-scores so that their mean was 0 and 
standard deviation equal to 1. This was to simplify interpretation of the results and to 




We assessed homoscedasticity by inspection of a QQ plot, and distribution of 
residuals using a histogram. We checked independence using the Durbin Watson 
statistic, multicollinearity and outliers using the variance inflation factor (VIF) statistic 
and Cook’s distance, respectively. All analyses were conducted using R software version 
3.2.0 (R Core Team, 2015). 
8.2.3 Ethical approval 
Ethical approval was obtained for VIKING, and we applied for and were granted 
ethical approval for an amendment to the VIKING protocol from NHS Lothian. We 
completed a level 1 self-audit form in compliance with the Edinburgh University 
Research Ethics committee through which we identified no complex ethical issues 
requiring further scrutiny. All our participants gave their informed consent prior to the 
VIKING and UV study commencement.  
8.3 Results 
 A total of 246 people consented to participate in the UV study, and were sent or 
given study packs consisting of a questionnaire and polysulphone badge. Of the 246 
people who agreed to participate, 196 (80% of the total) returned data, and, of these 
people, 132 (54% of the total) completed the questionnaire and had worn their badge 
as instructed. Of these 132 participants, 64 (48%) had worn a pedometer. 






Table 8.3 Participant characteristics excluding late or unreturned study packs 
(n=196) 
Characteristic No or mean SD % or range 
Age at time of study 52.5 13.0 19.8 -78.7 
Under 30 13 - 6.6% 
30 to under 40 24 - 12.2% 
40 to under 50 38 - 19.4% 
50 to under 60 64 - 32.7% 
60 to under 70 40 - 20.4% 
70 and over 16 - 8.2% 
Sex    
Female 122 - 62.2% 
Male 74 - 37.8% 
Erythemal dose (SED) 4.7 3.7 0.2 – 22.0 
Body fat 31.8 8.3 10.5 – 50.5 
BMI 27.4 4.6 18.7 – 46.3 
Occupation    
Indoor 174 - 88.8% 
Outdoor 22 - 11.2% 
Working/retired    
Working 161 - 82.1% 
Retired 35 - 17.9% 
Physical activity 7665.0 6115.5 297 – 29178 
Skin type    
Skin type 1 0 - 0% 
Skin type 2 11 - 5.6% 
Skin type 3 47 - 24.0% 
Skin type 4 101 - 51.5% 
Skin type 5 30 - 15.3% 
Skin type 6 0 - 0% 
Skin exposed (weighted) 34.0 29.5 1.3 – 185.1 




Table 8.4 compares people who did and did not return study data. For most 
variables, there is no significant difference between returners and non-returners. 




for the first PCA socioeconomic status variable. This corresponded to people with a 
higher socioeconomic status. 
 
Table 8.4 Comparison of people who returned their study data (n=196) and 
people who did not return their study data (n=50). Unpaired t-tests applied to 
continuous data; chi-square tests applied to categorical data 
 Returners 
No (%) or Mean (SD) 
Non-returners 
No (%) or Mean (SD) 
t-test or χ2 
 
p-value 
Age 52.5 (12.9) 46.9 (21.7) -0.6 0.5 
Sex      
Female 122 (62) 27 (54) 1.1 0.3 
Male 74 (38) 23 (46)   
% Body fat 31.8 (8.3) 33.2 (9.1) 1.0 0.3 
Occupation     
Indoor 174 (89) 46 (92) 0.4 0.5 
Outdoor 22 (11) 4 (8)   
Skin type group     
2 11 (5.8) 0 (0) 1.5 0.7 
3 47 (24.9) 5 (27.8)   
4 101 (53.4) 11 (61.1)   
5 30 (15.9) 2 (11.1)   
IPAQ total score 7664.9 (6115.5) 7714.6 (6316.5) 0.05 0.9 
Socioeconomic 
status 1 
0.06 (0.9) 0.5 (0.9) 2.2 0.03 
Socioeconomic 
status 2 
0.21 (0.9) 0.26 (0.9) 0.3 0.8 
 
 In the bivariate analyses, correlations between SED and variables of interest 






Table 8.5 Correlation coefficients for the relationship between variables with SED 
Variable r (95% CI) df P 
TEMIS ambient UV 0.30 (0.16, 0.42) 194 1.7 × 10-5 
Skin exposed (weighted) 0.70 (0.62, 0.77) 193 2.2 × 10-16 
SES principal component 1 -0.11 (-0.27, 0.06) 136 0.21 
SES principal component 2 0.19 (0.03, 0.35) 136 0.02 
IPAQ:    
Work 0.29 (0.16 0.41) 193 3.7 × 10-5 
Transportation 0.14 (-0.00004,  0.27) 193 0.05 
Domestic 0.04 (-0.09  0.18) 193 0.53 
Leisure 0.07 (-0.07, 0.20) 193 0.35 
Walking 0.20 (0.06, 0.33) 193 0.005 
Moderate MET-mins per week 0.16 (0.02, 0.30) 193 0.02 
Vigorous MET-mins per week 0.28 (0.14, 0.40) 193 8.7 × 10-5 
Total score 0.28 (0.14, 0.40) 193 6.9 × 10-5 
Total steps 0.38 (0.19, 0.54) 94 0.0002 
Weight 0.10 (-0.04, 0.24) 193 0.16 
Waist 0.02 (-0.12, 0.16) 193 0.76 
Hip -0.09 (-0.23,  0.05) 193 0.20 
% body fat -0.16 (-0.30, -0.02) 193 0.03 
BMI -0.04 (-0.18,  0.09) 193 0.54 
 
 Variables skin exposed (weighted), SES principal component 2, IPAQ work and 
walking domains, moderate and vigorous MET-mins per week, the IPAQ total score, and 
pedometer total steps, were significantly and positively correlated with SED. Body fat 
percentage was significantly and negatively correlated with SED. No other correlations 
were significant. 
 The t-tests revealed that males had higher SED than females (male 6.0 (4.3), 
female 3.4 (2.9), t(114)=-3.6, p=0.0005). Working outdoors was also associated with 
higher SED (working indoors 4.4 (3.4), working outdoors 7.5 (4.5), t(24)=3.1, p=0.005). 




4.5 (3.4), retired 5.7 (5.0), t(43)=-1.5, p=0.1). Finally we ran an ANOVA to examine the 
relationship between skin type and SED. This association was not significant (F3,185 = 
1.22, p = 0.30). 
To explore determinants of SED in Shetland we ran two multivariable 
regression analyses. The first (Model 1) used questionnaire-derived physical activity 
data from the sample who had returned full data (132 participants). The second (Model 
2) used a subset of these 132 participants, who were the 64 participants who had worn 
a pedometer. Model 2 therefore included pedometer-derived step-count data and 
responses to the physical activity questionnaire. The models produced slightly different 
results.  
Model 1 results are presented in Table 8.6. TEMIS ambient UV was significantly 
associated with a larger SED (Figure 8.6). There was a significant association with age, 
such that older individuals had a higher SED (Figure 8.7). Working outdoors was also 





Table 8.6 Results of linear regression including questionnaire-derived physical 
activity data, with square root transformed SED as the outcome and z-scored 
predictor variables 
 Multivariable model (n=132) 
Predictors Est (95% CI) p-value 
Intercept 2.03 (1.41, 2.67) 2.8  × 10-9 
TEMIS ambient UV 0.21 (0.10, 0.34) 0.0004 
Age 0.19 (0.07, 0.31) 0.002 
Indoor occupation -0.44 (-0.96, -0.02) 0.04 
IPAQ total score 0.11 (-0.02, 0.22) 0.09 
Fitzpatrick skin phenotype   
Skin type 3 0.28 (-0.21, 0.77) 0.27 
Skin type 4 0.36 (-0.09, 0.82) 0.12 
Skin type 5 0.50 (-0.22, 1.01) 0.06 
Skin exposed (weighted) 0.08 (-0.02, 0.20) 0.13 
Sex (male) 0.15 (-0.16, 0.47) 0.34 
Socioeconomic status 2 0.03 (-0.08, 0.15) 0.57 
Body fat % 0.04 (-0.10, 0.18) 0.59 
R2 = 0.34; adjusted R2 = 0.28 






Figure 8.7 Mean SED by decade of age, Model 1 
 





Model 2 results are presented in Table 8.7. Again, ambient UV and older age are 
both associated with higher SED (Figures 8.9 and 8.10). Total steps taken was also 
associated with a higher SED (Figure 8.11). 
Table 8.7 Results of linear regression including pedometer-derived physical 
activity data, with square root transformed SED as the outcome and z-scored 
predictor variables 
 Multivariable model (n=64) 
Predictors Est (95% CI) p-value 
Intercept 1.90 (1.12, 2.69) 1.1 × 10-5 
Total steps (pedometer) 0.37 (0.21, 0.52) 1.3 × 10-5 
Age 0.21 (0.05, 0.38) 0.01 
TEMIS ambient UV 0.18 (0.003, 0.32) 0.02 
Body fat % 0.14 (-0.05, 0.34) 0.14 
Sex (male) 0.31 (-0.16, 0.78) 0.19 
Fitzpatrick skin phenotype   
Skin type 3 0.14 (-0.57, 0.86) 0.68 
Skin type 4 0.26 (-0.47, 0.99) 0.47 
Skin type 5 0.39 (-0.45, 1.22) 0.35 
Socio-economic status 2 0.05 (-0.10, 0.2) 0.48 
Indoor occupation -0.19 (-0.74, 0.35) 0.48 
IPAQ total score 0.02 (-0.12, 0.18) 0.77 
Skin exposed (weighted) 0.004 (-0.14, 0.15) 0.95 





Figure 8.9 Scatterplot of the association between TEMIS ambient UVB and SED, 
Model 2 
 






Figure 8.11 Scatterplot of the association between step count and SED, Model 2 
 
 
We examined why working outdoors was associated with higher SED in Model 
1, but not in Model 2. Of the 132 people in Model 1, 16 people were classified as mainly 
working outdoors. Of these 16 people, 11 had pedometers and were therefore counted 
within the 64 people in Model 2. It seems that, in Model 2, a higher step-count might 
have been a proxy for working outdoors. 
 Finally, we examined several traits, including the sex, occupation, and physical 
activity of individuals who had very high UV readings, as these individuals may be 
informative about what contributes to greater UV exposure. The 10 highest UV badge 
readings ranged from 13.2 to 22.0 SED. These participants were aged 50 or over, were 
predominantly male, and several worked outdoors (Table 8.8). A chi-square test 




occupation (χ2(3, N = 132) = 1.04, p =0.79); however, within our dataset, significantly 
more men than women work in outdoor occupations (χ2(1, N = 132) = 18.14, p <0.01). 
The two individuals in Table 8.8 who work mainly indoors (teachers) were on school 
holidays, and their data collection week coincided with favourable weather.  
 Following this, we graphed the rainfall, sunshine, and TEMIS ambient UV for 
each week throughout the study period (Figure 8.12). As expected, ambient UV 
decreased throughout August; however, participants with high UV scores tended to 
have their data collected over weeks during which there was more sunshine and less 
rainfall. An exception to this is one participant whose data collection week commenced 
on 6 August 2014. According to weather data (Figure 8.12), this was a week of good 
sunshine but also very high rainfall. Closer inspection of daily data (not shown) found 
that the majority of the rain fell over the final four days; the first three days of the week 

































































































































































































































































































































































































































































We aimed to understand how different variables are related to UV exposure, 
and to identify determinants of UV exposure, in Shetland. To do so, we ran a series of 
bivariate analyses with individual UV exposure as the outcome. We then ran two 
multivariable models, including all participants with complete data in Model 1, and the 
subset of participants who had been supplied with a pedometer in Model 2. All analyses 
conducted for this chapter were exploratory; that is, they were not seeking to test any 
hypotheses that had been specified a priori. As such, we did not adjust for multiple 
testing. However, any confirmatory studies that use multiple tests would require a 
more stringent p-value. 
In Shetland, we found that individual UV exposure is generally low, as may be 
expected in a county situated at such a high latitude. The highest weekly exposure was 
22 SED. Diffey (2002b) suggested that an SED of 4 on previously unexposed skin should 
cause moderate erythema. The mean exposure for each day would therefore have been 
insufficient to produce moderate erythema. However, it is unlikely that UV exposure 
was evenly spread across the study days – the weather does not follow such a 
consistent pattern. On some days the exposure could have resulted in erythema whilst 
on other days it would not. Such fluctuation in exposure could have health implications 
for the population of Shetland.  
We found that older participants had greater UV exposure than younger 
participants in both multivariable models. Furthermore, in Model 1, we observed that 
working indoors was associated with reduced UV exposure. Indoor working was not 
associated with reduced UV exposure in Model 2; however, the total pedometer steps 
was associated with higher UV exposure. Further examination of these data suggested 
that, because many pedometer-wearers in Model 2 were also outdoor workers, total 




Similar patterns involving age and outdoor workers have been observed 
elsewhere. A prospective observational study found that, in Denmark, individuals aged 
younger than 20 years had significantly more sun exposure per year. However, 
gardeners received the most UV exposure on work days (Thieden et al., 2004). Another 
study found that, in Thailand and South Korea, where sunshine is abundant, older 
adults have higher vitamin D levels. Older adults, who are more likely to be retired, also 
have increased amounts of leisure time to spend outdoors (Nimitphong and Holick, 
2013). Additionally, the changing economy has meant that whilst older people tend to 
work in traditional occupations which are often outdoors, younger adults are pursuing 
office-based careers which reduces their sun exposure and therefore vitamin D levels 
(Choi et al., 2011; Chailurkit et al., 2011). We observed a similar pattern in Orkney 
where outdoor workers had significantly better vitamin D than indoor workers. Like in 
Thailand and South Korea, Orcadians with better vitamin D tended to be older and had 
increased leisure time for sun-seeking (Weiss et al., 2016) (Chapter 7). One study from 
the United States found no association with age and UV exposure, however this study 
was limited to adults aged 40 and over (Cahoon et al., 2013). The positive effect of age 
with UV exposure in Shetland therefore complements findings from elsewhere; 
however, as older people are no more likely to have an outdoor occupation than 
younger people in our cohort, this effect is probably not related to outdoor occupations 
in Shetland.  
Total steps taken was the only physical activity variable that was associated 
with greater UV exposure. It is interesting that no other physical activity variable 
significantly contributed to UV exposure, particularly as physical activity has been 
linked to an increased risk of sunburn (Jardine et al., 2012) and non-melanoma 




reasonable to assume that physical activity is often associated with greater sun 
exposure.  
In bivariate analyses, the physical activity variable most strongly correlated 
with UV exposure was total steps taken. Several IPAQ domains were also significantly 
correlated with UV exposure, but the correlations were weaker. The IPAQ data that 
were most strongly correlated with UV exposure were the work domain, vigorous MET 
minutes per week, and the total IPAQ score. However, the IPAQ data comprise many 
forms of physical activity and do not differentiate between indoor or outdoor activity. 
Greater indoor activity, or activity outwith daylight hours, would lead to these smaller 
correlations between activity and UV exposure. IPAQ data also relies on recall data for 
the seven days preceding questionnaire completion, which may not be as accurate in 
describing exercise taken. There is also no scope for defining the period during the day 
or week during which exercise was taken. The pedometer data are instead collected at 
the time of activity and do not rely on recall. It could be argued that, within daily life, 
people are more likely to have a higher step count when they are outside and are more 
likely to be outside in better weather – making the most of pleasant weather in a county 
characterised by overcast skies. It is therefore possible that total steps taken is the best 
indicator of physical activity in favourable weather when UV is plentiful.  
The strongest of all the correlations with UV exposure was the skin exposed 
(weighted) variable. However, this variable was not significant in either multivariable 
model. The way in which skin exposed (weighted) was constructed may mean that it 
acts as a proxy for UV exposure. A high score for skin exposed (weighted) indicates that 
fewer clothes were worn and more time (or periods in the middle of the day) was spent 
outside, and it is therefore likely to reflect warmer and sunnier weather when UV 




ambient UVB was only moderately correlated with individual UV exposure, but was 
significantly associated with greater UV exposure in both models. Ambient UV was 
previously identified as a strong predictor of individual UV exposure in a US cohort 
(Cahoon et al., 2013). 
We found no difference in UV exposure between men and women in either 
multivariable model. Other studies also did not find a difference between men and 
women. One study found that there was no significant difference in UV exposure 
between boys and girls in England on weekdays, although boys received significantly 
more UV at weekends (Diffey et al., 1996). A study from Denmark found that there was 
no difference in UV exposure between men and women, although girls received a 
significantly higher UV dose than boys (Thieden et al., 2004). However, a US study 
found that men received a significantly higher UV dose than women (Cahoon et al., 
2013). Although we found no significant sex differences in either model, the t-test 
showed that males were higher in UV exposure. However, in our data we also found 
that men were significantly more likely to work outdoors. 
It is important to note that directly comparing our results with other studies is 
complicated by several factors, including the anatomical placement of the dosimeter. 
Other studies have asked participants to wear UV badges on their wrist (Thieden et al., 
2004; Thieden et al., 2005b; Thieden et al., 2005a), shoulder (Kimlin et al., 1998a; 
Chodick et al., 2008; Cahoon et al., 2013), chest (pinned to clothing or on a necklace) 
(Diffey et al., 1996), and multiple anatomical sites (Herlihy et al., 1994). These 
differences in the anatomical placement of the dosimeter can lead to differences in UV 
exposure measurement (Diffey et al., 1977). Furthermore, different types of dosimeter 
have been used to collect UV exposure data, including, among others, polysulphone film 




electronic dosimeters (Thieden et al., 2004; Thieden et al., 2005b; Thieden et al., 2005a; 
Thieden et al., 2006). Therefore, although patterns can be observed within the 
literature, it is difficult to directly compare studies with substantially different 
methodologies.  
Additionally, there is little literature assessing the repeatability of polysulphone 
to measure individual UV exposure. Repeatability requires that, for a sample, two 
measurements are made under identical conditions on each subject (National Institute 
for Standards and Technology, 1994). Reliability can then be assessed by relating the 
extent of within-subject measurement error to between-subject measurement error. 
Where reliability is high, within-subject variability is small compared to between-
subject variability (Bartlett and Frost, 2008). To achieve identical conditions for the 
measurement of UV using polysulphone, the simultaneous wearing of two or more 
badges at the same body site would be necessary. Although studies have been 
undertaken to understand how different anatomical placement of badges can result in 
different levels of UV measurement, the actual repeatability of the UV exposure 
measure has not been assessed (Waterston et al., 2004). The reliability of how different 
dosimeters perform when measuring individual UV exposure has also not been 
explored. Such a study would be a type of reproducibility study. Reproducibility refers 
to variation in measurement made on the same subject, however one condition 
changes. In this case, it may be wearing two different types of UV dosimeter. It may be 
that each type of dosimeter yields different results. Such a study could be valuable in 
understanding the limitations and comparability of different methods used in different 
studies. 
However, most studies that explore individual UV exposure attempt to 




ambient UV (Cahoon et al., 2013), or sun exposure diaries (Chodick et al., 2008; Køster 
et al., 2017). Although the present study showed a weak correlation with ambient UV, 
there was a strong correlation with skin exposed (weighted) which, as described 
earlier, took into account length of time and periods of the day spent outside. We did 
not, however, explore the repeatability of polysulphone film. 
 There were further limitations to our study. One limitation of polysulphone 
film is that it provides a cumulative measure of UV exposure which cannot be broken 
down into smaller units of time, whilst electronic dosimeters have enabled UV 
exposure to be time-stamped. The cumulative measure therefore depends on the length 
of time for which the polysulphone was worn. Polysulphone studies have been carried 
out over two days (Kimlin et al., 1998a; Herlihy et al., 1994), seven days (Cahoon et al., 
2013), and others have been over longer periods with different badges for weeks and 
weekends (Diffey et al., 1996). We provided participants with one badge for one week, 
which meant that we were also unable to ascertain differences in UV exposure 
behaviours between weekdays and weekends. However, by providing one badge only, 
we hoped to make the study easier for participants and to increase compliance.  
We were also limited by the amount of time that we had in which to conduct the 
study and by the amount of funding available. Physical activity data can be gathered 
with much greater accuracy. However, at the time of the study, these methods were 
beyond our budget. We therefore used the combination of pedometers and IPAQ. It is 
important to note that, since the study was carried out, there have been advances in 
physical activity data collection. Wearable physical activity trackers which can 
synchronise to a smartphone app have substantially reduced in price and are likely to 




 Finally, we would have liked to measure vitamin D levels for all participants of 
the UV study, to understand how UV exposure in Shetland translates to blood vitamin 
D. However, again for reasons of time and funding, we were unable to do so. 
8.5 Conclusion 
Individual UV exposure was generally low in the summer months in Shetland. 
This could have consequences for vitamin D levels in the islanders and for their general 
health. We found that greater UV exposure was associated with ambient UV as well as 
total steps taken. Total steps could reflect working outdoors or taking advantage of 
favourable weather when it arrives. Indoor workers receive less UV exposure than 
outdoor workers; however as Shetland is a largely indoor-working archipelago, few 
people are able to take full advantage of periods of sunshine. We found that younger 
people get less UV exposure than older people in Shetland, a county with a high 
prevalence of MS. This finding is consistent with other literature of both countries with 
abundant sunshine and other high-latitude countries. Like the findings of our Orkney 
vitamin D study, the reduced exposure to UVB in younger people who are within their 
child-bearing years could have consequences for the autoimmune health of offspring, as 
well for the individuals who are within the peak years for MS diagnosis. Further 
research to understand how UV exposure translates into vitamin D levels in this 
population would help to understand the health implications of both UV exposure and 




CHAPTER 9. CONCLUSIONS 
A history of transient neurological disease, characterised by intermittent 
paralysis that customarily results in a final decline is well-recorded in diaries, personal 
correspondence, medical notes, and literature dating from medieval times. However, 
this collection of symptoms that can indicate MS were only recognised as a disease 
towards the end of the nineteenth century. Since that time, diagnostic criteria have 
become increasingly sophisticated as our understanding of the biological and molecular 
processes that are characteristic of MS has grown. However, different presentations 
and symptoms of MS, as well as differential diagnoses that require exclusion, can result 
in a difficult and sometimes lengthy diagnostic procedure.  
Alongside these advances, several factors have been identified that are 
associated with increased risk of MS. A higher frequency of MS noted in families of 
affected individuals led to the suggestion of genetic involvement. GWAS have since 
identified genetic variants, each with a modest effect. Variants at the HLA locus confer 
the strongest genetic effects. Environmental risk factors, which have fairly consistently 
been associated with increased MS risk, include EBV infection and smoking. Many 
ecological studies have also identified an association between higher latitudes and 
greater MS prevalence. This finding led to the formulation of a theory whereby reduced 
UV exposure at higher latitudes leads to vitamin D deficiency, and results in an 
increased risk of MS.  
The high prevalence of MS in Orkney and Shetland was first observed in the 
1950s (Sutherland, 1956). Subsequent studies continued to find a high prevalence of 
MS in the Northern Isles, with Orkney most affected. However, despite several 
researchers conducting studies into MS in these archipelagos, mainly in the 1970s and 
early 1980s, the search for possible reasons for the high prevalence has not proved 




Orkney and Shetland has historically meant that travel to and from the islands has been 
limited, resulting in genetic isolation. Such isolation may have consequences for health. 
Previous work in Orkney and Shetland explored genetic effects and MS (Roberts et al., 
1979; Roberts et al., 1983; Roberts, 1991), and the possible involvement of 
environmental exposures (Poskanzer et al., 1981). However, these studies did not set 
out to investigate two pertinent risk factors resulting from the high-latitude 
geographical location and often overcast weather of Orkney and Shetland: reduced UV 
exposure and vitamin D deficiency.  
This thesis aimed to explore risk factors for MS in Orkney and Shetland that 
may help to explain the high prevalence. I followed two avenues of research. The first 
comprised potential adverse health consequences resulting from genetic isolation, 
which may lead to a greater risk of MS. These explorations used datasets of MS cases 
collected in the 1970s and in recent prevalence and genetic epidemiological studies 
(Poskanzer et al., 1980a; Visser et al., 2012; McQuillan et al., 2008). The second 
involved potential health consequences from the high-latitude geographical location of 
Orkney and Shetland. These analyses comprised data from recent genetic 
epidemiological studies and from data collected for this thesis in cohorts of people 
without MS.  
9.1 Findings and limitations 
I began by conducting analyses using MS cases in Orkney and Shetland 
alongside data from both recent and historic datasets. My three aims were to: 1) to 
understand whether MS cases cluster more frequently in particular parishes or isles 
than expected by chance; 2) to calculate heritability estimates of MS in Orkney and in 
Shetland, and 3) to explore whether particular parishes or isles contribute more to the 




Clustering studies have been used to identify possible causes for disease by 
detecting an excess of cases against a background rate. These types of studies are often 
used to identify an environmental aetiology, such as polluted water sources, exposure 
to heavy metals, or risks associated with certain occupations. However, in such 
investigations, studies of diseases with a short period of latency between exposure and 
disease onset are less complicated to conduct than diseases such as MS, where any 
environmental cause may precede disease onset or diagnosis by many years. Many 
studies in multiple geographical areas have attempted to elucidate potential causes for 
apparent clusters of MS, but none have been fruitful. Clustering studies can 
furthermore be hindered by problems, including how to define disease and how to 
define the population at risk. These two factors were of the greatest concern in our 
analyses (Chapter 4). With incomplete case ascertainment, an inaccurate population-at-
risk, and no information regarding possible exposures between birth and disease onset, 
the results of our study must be interpreted very cautiously. There is a strong 
possibility that, because of these problems, the aggregations of disease that I observed 
are artefacts rather than disease clusters; additionally, there are multiple plausible 
reasons for any apparent clusters that could not be excluded by these data. 
 Several studies have estimated the heritability of MS. Using twin studies, these 
heritability estimates have ranged from modest (0.15 (95% CI 0.0, 0.77)) to substantial 
(0.64 (95% CI 0.36-0.76)) (Table 5.1). I estimated the heritability of liability to disease 
using parent-offspring trios, and obtained estimates of heritability that were consistent 
with the literature (Chapter 5). However, despite the high prevalence of MS in Orkney 
and Shetland, and the inclusion of all cases about which I had a good degree of 
certainty, the sample sizes were small with few parent-offspring cases. This meant that 
the confidence intervals were wide and crossed zero, leading to a high degree of 




there is a genetic component to MS in Orkney and Shetland, although probably no more 
than is found elsewhere. 
My further investigations into the possibility that some parishes or isles may 
have contributed more to the MS gene pool than others were also hindered by the small 
sample sizes, which led to overlapping error bars in each district and therefore 
ambiguity in interpreting results. This limitation meant that it was not possible to 
conclude that genes arising from any district in the archipelagos were more responsible 
for the high prevalence of MS than those from other districts; however, neither was it 
possible to rule this out.  
In the second half of the thesis I explored environmental risk factors using 
cohorts based in Orkney, Shetland, and mainland Scotland, comprising people who do 
not have MS. These two cross-sectional studies explored vitamin D in Orkney and UV 
exposure in Shetland, respectively.  
Contrary to what was expected, I found that people in Orkney had higher mean 
vitamin D than people in mainland Scotland (Chapter 7). On closer investigation, I 
found that, although levels of vitamin D were low in both cohorts, Orkney had a smaller 
proportion of people who were severely deficient. It was this difference that led to the 
higher mean vitamin D in Orkney.  
I also found that, contrary to previous findings, older people in Orkney had 
higher vitamin D levels than younger people. There is considerable evidence that 
supports a decline in vitamin D levels with increasing age. Furthermore, there is a 
biological reason for this effect, as our ability to synthesise vitamin D decreases as we 
get older. However, certain behaviours can result in the opposite effect. In Orkney, this 




and to take foreign holidays. Furthermore, although I did not have data to support this 
theory, I suspect that older people are less likely to have work and schooling 
restrictions to prevent them from taking foreign holidays at times of year when there is 
no possibility of sunshine-induced vitamin D synthesis in Orkney. However, what this 
means is that the younger generation, who are more likely to work indoors and miss 
any benefits of Orkney sunshine, and are less likely to holiday abroad, are at increased 
risk of vitamin D deficiency. This deficiency comes during a period of life in which MS is 
most likely to be diagnosed, and when pregnancies are most likely to occur, potentially 
conferring risk to the unborn child. 
My investigations into individual UV exposure in Shetland found a similar 
pattern to that observed in Orkney. Individual UV exposure was generally low, even in 
the summer months (Chapter 8). Complementing previous literature, I found that 
greater ambient UV, and also the total number of steps taken measured by pedometers, 
were associated with greater UV exposure. The total steps variable likely acts in two 
ways: firstly, it appears to be a proxy for working outdoors where, like the farming 
cohort in Orkney, the occasional vitamin D-strength sunshine is maximised. Secondly, 
total steps probably reflects better weather. This is because people are more likely to 
walk further (leading to a greater step-count) when they are outside, and are more 
likely to be outside when the weather is favourable. Also, like the Orkney vitamin D 
study, I found that older people were more likely to receive more UV exposure than 
younger people in Shetland. Quite how that translates to vitamin D levels is unknown; 
however, it is concerning that the younger population are, again, more vulnerable to 
low levels of a modifiable risk factor during a possibly critical period of their lives, in 




 9.2 Future Steps 
 There are several ways that this work can be carried forward. To begin, I will 
discuss in broad terms the direction that future research could take which has been 
noted throughout this thesis. I will then focus on the direction that studies conducted in 
Orkney and Shetland could follow.  
Firstly, the scoping review highlighted how few intervention studies have been 
undertaken, particularly over periods of time long enough, and with doses of vitamin D 
high enough, to achieve a biological – and potentially beneficial – effect. As such, the 
literature does not currently provide evidence of a causal link between vitamin D and 
MS onset and/or progression. However, the scoping review did reveal some promising 
intervention studies with results regarding vitamin D supplementation and slower 
progression of MS, measured by both disability score and by MRI-identified lesions. 
Furthermore, one study found that vitamin D may suppress conversion from clinically 
isolated syndrome to MS, which deserves further exploration and attempts at 
replication.  
More intervention studies into the effects of vitamin D on MS risk and 
progression are warranted. This need is all the more keenly felt when placed alongside 
evidence from Mendelian randomisation studies, which show an increased risk of MS 
with lifetime vitamin D deficiency. Further trials comprising adequate vitamin D 
supplementation over a long enough period to observe a reliable effect could produce 
fruitful results in understanding whether vitamin D has the ability to prevent or delay 
MS onset, and whether it has a therapeutic effect in established MS. Such findings could 
be incredibly valuable and beneficial in both protecting susceptible populations and in 




Secondly, the scoping review highlighted that the literature exploring the role of 
UV exposure in MS is scarce; compared to the vitamin D literature, UV exposure is 
under-researched. The literature that does exist is heterogeneous with diverse findings. 
There is undoubtedly scope to further explore the role of UV exposure in MS risk and 
disease progression, both as a determinant, and independent, of vitamin D. 
Additionally, it would be beneficial to examine whether gestational or childhood 
exposure is crucial, particularly as this may lead to the ability to target interventions 
towards pregnant women or children, or whether lifetime UV exposure is as important 
in any mitigation of MS risk. 
Thirdly, the Viking UV study highlighted that the repeatability and 
reproducibility of UV dosimeter measures have been little explored. This gap could 
provide an opportunity to explore how reliable the measures obtained by using such 
dosimeters are, and also how studies that use different methods can be reconciled.  
  Looking specifically at the Viking UV study in Shetland, it is important to 
understand how UV exposure translates into vitamin D levels at such high latitudes, 
and how these compare to Orkney. Ensuring comparability of the blood samples with 
ORCADES may however be difficult, particularly as the laboratory used for both SOCCS 
and ORCADES has changed their methods of blood vitamin D analysis in the interim. 
This limitation should be noted in future studies that attempt to compare Shetland 
vitamin D measures with Orkney. Similarly, there is ongoing development of more 
accurate ways in which to measure physical activity and UV exposure. Should a more 
detailed follow-up study be commenced, it would be advantageous to use these more 
detailed methods, such as electronic time-stamped dosimeters, which provide a more 
accurate account of sun exposure over different periods of time, including weekdays 




help to understand if the lower MS prevalence in Shetland compared to Orkney could 
be attributed to intake of oily fish, as it has elsewhere at similar latitudes (Bäärnhielm 
et al., 2014). More detailed dietary data, as well as measurement of individual UV 
exposure in Orkney could also help to further understand the pattern of vitamin D 
noted in the Orkney Vitamin D Study. Incorporating such data into analyses would help 
to form a clearer picture of the determinants of UV exposure and vitamin D in both 
archipelagos. 
Finally, although the limitations inherently associated with clustering analyses, 
alongside the available data, mean that there is no positive way to move forward that 
could increase clarity, there are ways in which the heritability of MS could be further 
explored. It was clear that my studies of the genetic contribution to MS in Orkney and 
Shetland using genealogical data did not produce reliable results; however, today there 
are methods for measuring heritability genomically. Pedigree analyses are limited by 
the size and accuracy of the pedigrees on which they are based; however, marker-based 
approaches in which relatedness is estimated can result in less biased and more precise 
estimates. Similarly, explorations of genomic data may provide clarity regarding the 
genetic contribution to disease in these archipelagos, including the presence and 
frequency of rare and deleterious mutations, which may act to increase MS risk in these 
genetic isolates. 
9.3 Policy and Public Health Implications 
It is of concern that both studies found that vitamin D deficiency and reduced 
UV radiation are more frequently observed in the younger generations in these islands. 
With changing lifestyles in which people are increasingly working indoors, for example 
in office environments, over traditional, outdoor occupations, such as farming, the 
prevalence of these risk factors is only likely to increase. It should be remembered that 




factors for MS, are important for protection against other diseases including bone 
conditions and some cancers. 
That said, offering advice regarding vitamin D supplementation is a thorny 
issue. As described in the scoping review, it remains unclear how much vitamin D 
should be taken, and for how long, to have a clinically beneficial effect. However, 
vitamin D is a relatively safe and well-tolerated supplement, which appears to have 
multiple favourable effects for health. I myself have not hesitated to take a daily 
supplement and will continue to do so, particularly while residing in a northerly 
latitude. As D3 appears to be more biologically active and better at raising blood 
vitamin D levels than D2, it would seem that D3 or a combination of D2 and D3 would be 
advisable, and, depending upon age and circumstances, from 400IU per day (Holick et 
al., 2011). Such an amount is unlikely to be harmful and the correct level of 
supplementation may be helpful. However, a vitamin D-rich diet, including oily fish, 
eggs, red meat, and fortified foods such as breakfast cereals and some milk and juices 
may also have a beneficial and healthful impact. 
 Vitamin D from sunlight enters the circulatory system more quickly than that 
from dietary sources and, moreover, carries no risk of toxicity. However, attempting to 
provide advice about obtaining vitamin D from sunshine is fraught with difficulties 
resulting from the myriad personal and environmental factors that can affect UV-
induced vitamin D synthesis. There is no one-size solution for every individual and 
therefore any such exposure should be undertaken judiciously, taking care not to burn. 
Moderation is key; however because strong sunshine is in short supply in these high-
latitude islands it could be difficult to achieve moderate levels of exposure on a normal 
day, and a danger of over-exposure on occasional bright, strongly-lit days, which could 




 There is an argument that a modifiable risk factor, such as vitamin D deficiency, 
should be addressed generally by fortification of dairy products (as it is in the US), and 
particularly in at-risk communities by routine and regular supplementation. However, 
there is currently not the weight of evidence to support such a programme. If further 
research were able to establish a causal connection between vitamin D deficiency and 
MS, there could be little argument for a swift translation into policy to attempt to 
modify these risk factors in at-risk communities. It must be hoped that communities 
such as Orkney and Shetland could benefit from such research and subsequent policy 
implementation, in an effort to reduce MS and its effects, and to protect a vulnerable 
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Appendix A: Additional information for Table 4.2 
Six cases were identified within 500 yards of each other in Berkshire, England. 
Following an earlier hypothesis (Cone et al., 1934), this cluster was attributed to the 
high lead content of the soil and water. Later research, however, failed to identify any 
increased risk in people who worked with lead or in high-lead areas (Campbell et al., 
1950).  
Fourteen cases were identified in the 10,000-strong population of Mansfield, 
Massachusetts. The town water supply had been polluted some years prior to this 
cluster, and was identified as a possible aetiological factor (Eastman et al., 1973). 
However, as only eight of these fourteen cases had lived near the polluted water supply, 
and one had not been born during the period of pollution, chance, or other 
unrecognised agents, may have caused this cluster. 
 Possible occupational clusters of MS have also been investigated. In the 1940s 
an apparent cluster of four MS cases among people working with lamb swayback, a 
demyelinating disease in sheep resulting from copper deficiency, was observed. 
However, MS was also present in regions where there was no swayback, and there was 
no demonstrable effect of copper deficiency on MS (Campbell et al., 1947; Dean et al., 
1985).  
Further, research on a cluster of MS in Key West, Florida noted that seven of the 
nineteen definite cases were nurses who worked at the same hospital. However, a later 
study revealed there was no increased risk to medical personnel of working with MS 
patients (Dean and Gray, 1990). A potential hazard close to the hospital was noted: a 
landfill site that oozed red vermillion and regularly caught fire (Ingalls, 1986a). 




ooze was from ships’ paint and contained mercury, and that burning sent hazardous 
material into the air.  
Six cases in two families were observed in the 450-strong population of 
Mossyrock, Washington. Koch et al. (1974) postulated that this cluster was associated 
with a possible but unconfirmed smallpox epidemic fifty years prior. However in later 
years a further unconfirmed theory attributed the cluster to smelting cinnabar to 





Appendix B: Scoping Review Protocol 
Methods 
Framework stage 1: Identify a Research Question 
A starting research question is - “A scoping review to map the literature 
concerning vitamin D, UV exposure and multiple sclerosis, to identify evidence for an 
association between MS onset, pathology and progression”. This question is broad to be 
inclusive and reduce the risks of missing relevant articles, however it is anticipated that 
the development of the research question will be an iterative process, with increasingly 
refined questions emerging once the volume and extent of literature has been assessed 
(Arksey and O'Malley, 2005).  
Framework stage 2: Identifying Relevant Studies 
 To be as inclusive as possible, we will undertake several different searches 
involving electronic databases, hand-searching reference lists of key papers and 
searching any key journals identified as a result of earlier searches. We will further 
endeavour to identify grey literature. 
For the reason of time and resources, searches will be limited to English-
language publications.   
Eligibility criteria 
 We will include observational study designs (cohort, case-control, cross-
sectional) studies, experimental (randomised control trials (RCTs)) and genetic studies 
(Mendelian randomisation, genome-wide association studies (GWAS) and candidate 
gene studies) that examine the association between vitamin D, either 25(OH)D or 
1,25(OH)D, or UV exposure, and MS defined according to the Poser (Poser et al., 1983) 
or McDonald (McDonald et al., 2001) criteria. Studies involving MS patients of all age 




Ecological studies that do not use individual measures of either vitamin D or UV 
exposure will be excluded.  
More detailed inclusion and exclusion criteria may be developed ‘post-hoc’ as 
familiarity with the type and focus of identified literature increases (Arksey and 
O'Malley, 2005). To be transparent, if feasible, excluded studies will be tabulated and 
presented in the final review with the reason for exclusion. 
Databases  
We will search Medline, Embase, Biosis, Web of Science and the World Health 
Organisation (WHO) International Clinical Trials Registry Platform (ICTRP). We will 
search for grey literature through the Proquest Dissertations and Theses Global 
database (PQDT), and from a search of Google Scholar. 
Search Strategy 
The following terms will be used to search for relevant papers. Boolean operators 
AND and OR will be used to link search terms. Where options exist, search terms will be 
exploded to include all variations of the term. 
Vitamin D OR 
Cholecalciferol OR 
Ergocalciferol OR 
25-hydroxyvitamin D OR 










Sun exposure OR 
UV OR 
UVB OR  
UVR OR 




Multiple sclerosis OR 
Relapsing Remitting Multiple Sclerosis OR 
Primary Progressive Multiple Sclerosis OR 
Neuromyelitis optica OR 
Devic disease OR 
Tranverse myelitis OR 
Optic neuritis OR 
Experimental autoimmune encephalomyelitis OR 
EAE 
Framework stage 3: Study Selection 
Study selection will be an iterative process with refinement of the search 
strategies following assessment of the volume of identified literature. Eligibility criteria 
will be pilot-tested on a random sample of articles and refined accordingly. One 
investigator will assess all titles and abstracts against these refined eligibility criteria. A 
second investigator will assess 20% of title and abstracts against these eligibility 
criteria; levels of agreement will be evaluated and disagreement resolved by consensus. 
Study abstracts that do not meet eligibility criteria will be excluded. Where there is 




full text will be sourced. The full text will also be sourced for all studies that meet the 
inclusion criteria.  
Framework stage 4: Charting the Data 
To form the evidence base of the scoping study and summarise work that has 
been undertaken to date, extracted data will be entered into a spreadsheet based on 
Arksey and O’Malley’s recommendations (Arksey and O'Malley, 2005), including the 
following headings.  
Author, year of publication, study location 
Intervention type and comparator (if any); duration of the intervention 
Study populations 




Standardised measures (if any) 
This form will be tried on a small selection of papers and refined further so that 
data extracted will reflect the aims of this scoping study (Levac et al., 2010). One 
investigator will read each article and extract relevant data; a subset of papers will be 
checked by a second investigator. Study quality is not generally assessed in a scoping 
review as the aims are to map the literature and identify gaps in the evidence base, and 
to pinpoint areas for future systematic review (Arksey and O'Malley, 2005; Levac et al., 
2010). 
Framework stage 5: Collating, Summarising and Reporting Results 
Collating, summarising and reporting results will be tackled in three distinct 
steps as laid out by Levac et al. (Levac et al., 2010). Firstly, basic descriptive numerical 




The distribution of studies geographically 
Range of interventions/study designs 
Measures used 
Research methods used 
Secondly, we anticipate that this process will identify themes in the literature 
around which the following review can be built under section headings to report the 
results. To ensure that a consistent approach in reporting findings is maintained, 
Arksey and O’Malley suggest the use of a template, firstly summarising the 
characteristics of papers included in each section, and then a series of headings to 
structure the commentary around. These headings may include, depending on the 
section, interventions, sample sizes, participants, methods, outcomes, studies from 
world regions, and gaps remaining in the research (Arksey and O'Malley, 2005). 
This consistent approach should give a comprehensive overview of the existing 
literature, allow comparisons across different studies and identify gaps in the evidence 
base (Arksey and O'Malley, 2005). It should also enable Levac’s third point to be 
addressed: to relate the meaning of the findings to the study purpose and discuss the 
implications for future research (Levac et al., 2010). Finally, this approach will allow 
complete transparency at every stage of the process, so that any potential biases in the 
reporting are clear. 
Conclusion 
This protocol outlines a method for systematically conducting a scoping review of peer-
reviewed material, concerning the roles of vitamin D and UV exposure in MS onset, 
pathology and progression. The scoping review method enables disparate research to 
be collated and synthesised to provide insight into the different avenues of research 
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Abstract
Orkney, north of mainland Scotland, has the world’s highest prevalence of multiple sclerosis
(MS); vitamin D deficiency, a marker of low UV exposure, is also common in Scotland.
Strong associations have been identified between vitamin D deficiency and MS, and
between UV exposure and MS independent of vitamin D, although causal relationships
remain to be confirmed. We aimed to compare plasma 25-hydroxyvitamin D levels in Ork-
ney and mainland Scotland, and establish the determinants of vitamin D status in Orkney.
We compared mean vitamin D and prevalence of deficiency in cross-sectional study data
from participants in the Orkney Complex Disease Study (ORCADES) and controls in the
Scottish Colorectal Cancer Study (SOCCS). We used multivariable regression to identify
factors associated with vitamin D levels in Orkney. Mean (standard deviation) vitamin D
was significantly higher among ORCADES than SOCCS participants (35.3 (18.0) and 31.7
(21.2), respectively). Prevalence of severe vitamin D deficiency was lower in ORCADES
than SOCCS participants (6.6% to 16.2% p = 1.1 x 10−15). Older age, farming occupations
and foreign holidays were significantly associated with higher vitamin D in Orkney. Although
mean vitamin D levels are higher in Orkney than mainland Scotland, this masks variation
within the Orkney population which may influence MS risk.
Introduction
Multiple sclerosis is a chronic, complex disease with genetic, environmental and behavioural
factors implicated in its aetiology [1]. Greater distance from the equator is associated with
increasing MS prevalence [2]; increasing latitude is also noted for weaker ultraviolet B (UVB)
radiation which inhibits cutaneous production of vitamin D [3]. As such, one environmental
risk factor is thought to be vitamin D deficiency, however, vitamin D is also a marker for expo-
sure to UV radiation, the benefits of which may be independent of vitamin D production [4–
6]. A variety of factors hinder or prevent UVB from reaching the earth's surface, including lati-
tude and weather [7], or from initiating cutaneous vitamin D synthesis, such as sun protection
creams and clothing cover.
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Although a recent systematic review of vitamin D status worldwide found that vitamin D
concentrations do not appear to be dependent upon latitude [8], exposure to ultraviolet B
(UVB) radiation from sunshine is the most potent source of vitamin D for humans [9]. In the
United States, a latitudinal relationship exists between wintertime vitamin D and wintertime
UV doses [10], likely resulting from the few days in which vitamin D can be produced at such
latitudes [3, 10]. This latitudinal relationship further reflects the latitudinal MS prevalence dis-
tribution in the US [10]. Additionally, a significant relationship between regional UVB radia-
tion and MS prevalence has been noted in France in the French farming population and their
families [11]. Increasing MS prevalence was associated with decreasing ambient UVB; the
trend was additionally found to be stronger in both wintertime and in women [11]. A similar
relationship between decreasing UV and increasing prevalence has been identified in New-
foundland [12] and Australia [13].
Controversy remains regarding the role of vitamin D in chronic conditions; whilst defi-
ciency may have a causal role in the aetiology of some diseases it may also simply be a bio-
marker for ill health. A body of evidence is however accumulating, suggesting a causal role for
vitamin D in MS risk, pathology and progression [14–16]. A recent Mendelian randomisation
study found genetically lowered 25-hydroxyvitamin D (25(OH)D) level by one standard devia-
tion in log-transformed 25(OH)D was associated with a two-fold increased risk of MS [16].
Interactions between vitamin D and the major genetic risk factor, HLA-DRB11501, have been
identified [17], and several rare variants conferring MS risk have been found in the CYP27B1
gene, which encodes an enzyme which catalyses the conversion of 25(OH)D to the bioactive
form [18]. Further, early exposure to vitamin D in-utero and in neonatal mice led to optimal
numbers of invariant natural killer T cells [19], deficiency of which are observed in MS patients
[19, 20]. Alongside the month-of-birth effect, where children born after a winter gestation are
at higher risk of MS [21], the role of adequate in-utero vitamin D increasingly appears to be
critical for future autoimmunity.
The beneficial role of UV exposure independent of vitamin D production has been sup-
ported in animal studies, using experimental autoimmune encephalomyelitis (EAE) as the
model for MS. Continuous treatment with UVB was found to suppress clinical signs of EAE
which, although leading to slight elevations in serum 25(OH)D3, were insufficient to cause dis-
ease suppression by vitamin D [4]. Furthermore, suppression of EAE was found to occur upon
irradiation of mice to narrow-band UV light, with a wavelength of between 300 and 315 nm
and a peak of effectiveness at 311 nm. As vitamin D requires a wavelength between 270 and
300 nm, optimally between 295 and 300 nm to initiate cutaneous synthesis, the narrow band
UV supressing EAE had no effect on 25(OH)D levels [5], strongly suggesting a role of UV
exposure independent of vitamin D. In MS, an Australian multi-centre case-control study
found higher sun exposure and higher vitamin D levels to be independently associated with
lower risk for first demyelinating events [6].
Scotland, between latitudes 54° and 60° north, has inadequate strength of sunshine between
October and March for vitamin D synthesis [22]; a cloudy climate year-round further leads to
widespread vitamin D deficiency [23] strongly indicating limited UV exposure in the popula-
tion. The protective effect of supplementation and sunny holidays on 25(OH)D in Aberdeen, a
Scottish city at 57° north, has previously been noted in a study of postmenopausal women [24].
Orkney, an isolated archipelago ten to sixty miles from the north coast of Scotland, is an area
of exceptionally high MS prevalence [25]. Seventeen of the 70 islands are inhabited with a pre-
dominantly rural population totalling 21,349 at the 2011 census. The 2011 census also revealed
an ongoing agricultural tradition with 10% of the workforce employed in agriculture or fishing.
As an independent risk factor, or as a marker of UV exposure, it is important to understand
the determinants of plasma vitamin D in the context of MS and other diseases of public health
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importance. In this study we aimed to describe vitamin D levels in Orkney (Fig 1). This
involved identifying the prevalence of vitamin D deficiency in Orkney compared to the Scottish




The study population comprised Orkney Complex Disease Study (ORCADES) participants,
recruited from 2005 to 2011, and Scottish Colorectal Cancer Study (SOCCS) controls, which
ran from 1999 to 2006. Both these studies have been described in detail elsewhere [26, 27].
Briefly, ORCADES, a cross-sectional genetic epidemiology study concerned with identifying
genetic factors that influence complex disease, comprised 2078 participants with at least one
Orcadian grandparent. SOCCS, a case-control study of colorectal cancer in Scotland, included
2235 adult controls without colorectal cancer, identified from the Community Health Index in
Scotland as being aged within 5 years their matched case, of the same sex and living in the
same area. All participants provided written, informed consent prior to participation. Both
studies have ethical approval from NHS Orkney, NHS Grampian or NHS Lothian.
25-hydroxyvitamin D measurement
Fasting blood samples were drawn from ORCADES participants using the Sarstedt Monovette
system. Samples were processed and transferred for storage at -400 C, and later -800 C, until
analysis. Blood was drawn from all SOCCS participants, processed and transferred for storage
at -800 C. Both studies ran over multiple years, and therefore measures per month comprise
blood drawn in multiple Januarys, multiple Februarys and so on.
Vitamin D status is determined by measuring circulating 25(OH)D which is generally con-
sidered the best indicator of vitamin D status [28]. Both 25(OH)D2 and 25(OH)D3 were mea-
sured using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The
total of the two measures was taken for total circulating 25(OH)D, however most samples from
Fig 1. Map of Orkney in relation to the Scottish mainland and north-west periphery of Europe, with
57th and 59th degrees of latitude.
doi:10.1371/journal.pone.0155633.g001
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both studies contained no 25(OH)D2. The lower limit of detection using LC-MS/MS was 10
nmol/L. All samples were measured in the same laboratory following standard protocols; qual-
ity control procedures were performed according to current best evidence for 25(OH)D mea-
surement in population studies [29].
A range of cut-offs to define sufficiency and deficiency have been proposed, however in line
with other recent studies we considered circulating 25(OH)D of 50 nmol/L or over to be suffi-
cient [30], 25 to 50 nmol/L to be at risk of deficiency or insufficient, and deficiency to be less
than 25 nmol/L [31]. We additionally explored those at the lower end of deficiency, where we
considered circulating 25(OH)D below 12.5 nmol/L to be severely deficient [32].
Lifestyle factors
ORCADES participants attended clinics where several biometric measures were recorded. Each
participant also completed a medical and lifestyle questionnaire from which vitamin D intake,
physical activity (PA) and socioeconomic status (SES) were derived.
BMI was calculated as kg/m2 and treated as a continuous variable. Height was taken without
shoes and weight wearing only light clothing. Based on questionnaire data we derived a variable
encompassing work and leisure time PA throughout the year. Participants classified leisure
activity as either 1) light (mostly sitting, light housework) or 2) moderate exercise; and likewise
work activity as 1) mostly sitting, 2) mostly standing, 3) manual work or 4) heavy manual
work. Dietary vitamin D intake was estimated from two self-administered food frequency ques-
tionnaires, the cardiovascular disease questionnaire (CVDQ) and bone density questionnaire
(BDQ). The CVDQ was treated as the primary source due to the higher response rate, however
information contained in the BDQ that was not present in the CVDQ was merged to create the
most comprehensive variable possible. Further, a research nurse-administered drug question-
naire sought information about medications and dietary supplements. Participants also
described their frequency of taking holidays within or outside the UK (never, less than once a
year, once a year, more than once a year). Although the Scottish Index for Multiple Deprivation
(SIMD) is available for Orkney, the scattered and heterogeneous population means that con-
centrations of poverty or affluence are difficult to identify; moreover neighbouring islands are
grouped together in units thus there is little discrimination [33]. Principal Components Analy-
sis (PCA) is a statistical technique to reduce a number of variables into a few independent
dimensions reflecting the underlying patterns in the data, and was used here to construct SES
indices [34]. To establish a variable that differentiates between individuals, three SES variables
were thereby derived from 10 questionnaire items with significant loadings in PCA (S1 Table).
Additionally, we applied an occupational prestige score to questionnaire occupation informa-
tion which was then included in the PCA [35]. Holidays, car age and council tax band loaded
significantly onto the first component; housing tenure, length of car ownership and highest
qualification loaded significantly onto the second component, and job prestige score, years in
education and supervisory role at work loaded significantly onto the third. This third compo-
nent captures “non-traditional” lifestyles reflecting managerial, administrative and professional
positions in contrast to traditional agricultural work. Time outside in summer was summed
from participants’ estimates of average time spent without a roof covering on summer work
and leisure days. Data from SOCCS included age, sex, month of blood sample and 25(OH)D
measurement.
Statistical analysis
Wematched the ORCADES and SOCCS datasets on age to within two years (Table 1) to
remove any differences arising from age structures. Matching was carried out blind excepting
Vitamin D in Orkney
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dataset of origin and age. Because of the large effect of season on vitamin D levels, we standard-
ised 25(OH)D measurements to the month of May; values obtained thereby represent those
that would be expected if every sample were drawn in May [32]. The mean of monthly means
in the mainland Scottish data is 34.4 nmol/L; in the Orcadian data the mean of monthly means
is 37.7 nmol/L. The May means are 33.8 nmol/L and 35.5 nmol/L, respectively. We used May-
standardised measurements for all analyses concerned with determinants of vitamin D, and
also to compare Orkney and mainland Scotland in deficiency levels. For analyses concerned
with vitamin D and time of year we used crude 25(OH)D measures. Data are presented as
mean (standard deviation).
We plotted crude 25(OH)D by location as a density plot and by month, and compared
using a t-test. We compared vitamin D by age group using t-tests. To compare levels of defi-
ciency in Orkney and mainland Scotland, we divided participants into groups of deficiency and
plotted May-adjusted vitamin D for each deficiency group and location and tested for differ-
ences using chi-square tests.
For determinants of May-adjusted 25(OH)D in Orkney, we ran a series of bivariable models
of May-adjusted 25(OH)D against environmental and demographic variables of interest.
Those that were significant were put into a multivariable model. These significant variables
comprised BMI, age at venepuncture, foreign holidays, PA, SES, dietary vitamin D and working
status. Sex was also a covariate. A large percentage of missing data (S2 Table) was imputed
using Multiple Imputation of Chained Equations (MICE)[36] after excluding 28 individuals
with missing outcome data. We ran 68 cycles of 100 imputations and pooled the results in a lin-
ear regression model. We ran the same model using complete cases only. Statistical tests were
two-sided with p<0.05 taken as significant. Finally, we applied a one-way ANOVA to compare
mean May-adjusted 25(OH)D across the three groups of participants that we identified as a
result of our analyses.
We assessed homoscedasticity by inspection of a QQ plot, and distribution of residuals
using a histogram with superimposed normal curve. Independence was checked using the Dur-
bin Watson statistic, multicollinearity and outliers using the vif statistic and Cook’s distance,
respectively. All analyses were conducted using R software version 3.2.0 [37].
Results
For this study, 64 individuals were excluded from ORCADES who were not resident in Orkney,
10 who had MS, as well as 8 duplicate measures. Characteristics of ORCADES participants are
presented in Table 2. Twenty-three people were excluded from the Scottish Colorectal Cancer
Table 1. Distribution of age and crude vitamin D in age-matched Orkney andmainland Scotland datasets. The mainland dataset excludes people
from above the 57th degree of latitude.
Orkney Mean 25OHD Mainland Mean 25OHD
No (%) (nmol/L) No (%) (nmol/L)
Participants 1453 36.2 1453 35.4
< 40 46 (3.17) 26.8 46 (3.17) 36.5
40–49 263 (18.1) 33.4 263 (18.1) 39.5
50–59 399 (27.5) 35.7 400 (27.5) 38.7
60–69 466 (32.1) 37.9 464 (31.9) 33.3
70 + 279 (19.2) 39.5 280 (19.3) 30.4
Sex (male) 590 (40.6) 37.2 794 (54.6) 35.4
Sex (female) 863 (59.4) 35.6 659 (45.4) 35.4
doi:10.1371/journal.pone.0155633.t001
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Study who lived above the 57th degree of latitude. For comparison analyses, data were age-
matched giving a final count of 1453 people in each dataset.
Using age-matched data we compared mean 25(OH)D in Orkney to mainland Scotland
(Fig 2). Orkney had significantly higher crude 25(OH)D than mainland Scotland (Orkney
35.3 (18.01), Mainland 31.7 (21.18), t(2800) = -4. 93, p = 8.5 x 10−7). Mean 25(OH)D was
higher in Orkney for every month except August when the mainland peaks at ~50 nmol/L.
The distribution of vitamin D levels is shifted to the right in Orkney (Fig 3). We compared
vitamin D in Orkney and mainland Scotland by age group (Table 3). Results for each age
group are significantly different, however in the under 40s, 40 to 49 and 50 to 59 age groups,
mainland Scotland has higher vitamin D, whilst in the 60 to 69 and over 70s age groups, Ork-
ney has significantly higher vitamin D. Comparing Orkney with the mainland by deficiency
group, we found that more people in Orkney had insufficient vitamin D, χ2 (1, N = 2863) =
30.3, p = 3.8 x 10−8; however, Orkney had significantly fewer people with circulating 25(OH)
D of<12.5nmol/L (severely deficient) compared with the mainland, χ2 (1, N = 2863) = 64.3,
p = 1.1 x 10−15 (Fig 4).
To explore correlates of vitamin D in Orkney we ran two multivariable regression analyses,
using both imputed data and complete cases. Each model yielded similar results (Table 4). Var-
iables significantly associated with higher 25(OH)D included lower BMI, more foreign holi-
days, older age and increased PA. Associated with lower 25(OH)D was the “non-traditional”
SES grouping.
Table 2. Characteristics of ORCADES Study participants (n = 1972).
Characteristic No or mean SD % or range
Age at venepuncture (years) 53.4 15.3 16.5–100.2
Sex
Female 1191 - 60.4
Male 781 - 39.6
Body Mass Index (kg/m2) 27.7 4.9 16.9–53.9
Vitamin D intake (μg) 4.4 3.1 0.00–34.1
Physical activity* 5.1 1.2 3.0–8.0
Summer minutes outdoors 223 142 4.8–900
Working 1367 - 69.3
Retired 547 - 27.7
Holidays outside the UK
< once a year 1472 - 74.6
Once a year 329 - 16.7
> once a year 105 - 5.3
Years in education 16 1.2 1.0–23
Qualification level
O & standard grades, CSE 275 - 13.9
Highers, A levels 787 - 39.9
Certificates/diplomas 739 - 37.5
Bachelor/Master degree 88 - 4.5
Doctorate 13 - 0.7
* Physical activity scored from 1 (mostly sitting; inactive) to 4 (heavy manual labour; active) across different
domains within work and leisure. Each score is the sum of answers creating an individual value for each
participant.
doi:10.1371/journal.pone.0155633.t002
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The association between older age and higher vitamin D required further exploration; we
began by comparing foreign holiday-takers and their non-holidaying counterparts. We found
that people over 50 were significantly more likely to take foreign holidays at least once a year
compared to people under 50 (Table 5, Fig 5) (χ2(1) = 6.4, p = 0.0083). We termed this the
‘Saga’ effect. Additionally, we found that foreign holidays had a stronger effect on people over
50 who had their blood drawn in the low vitamin D (weaker UVB) season (October to March)
Fig 2. Mean crude vitamin D concentration (nmol/L) per month by location, using age-matched data.Orkney’s mean vitamin D
is higher than the mainland for every month except August and November. Each study ran over consecutive years and measurements
taken in the samemonth each year were pooled.
doi:10.1371/journal.pone.0155633.g002
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compared with people who had their blood drawn in the high vitamin D (stronger UVB) sea-
son (April to September) (Table 6).
To explore under-40s further, we ran the same analyses comparing those who do and do
not holiday outside the UK that were used for over-50s (S3 Table). The same results were sig-
nificant, excepting body fat percentage, socio-economic status 2, age, and summer minutes
spent outside.
Fig 3. Comparison of May-adjusted vitamin D distribution in Orkney andmainland Scotland using
age-matched data. The distribution for Orkney is to the right of the distribution for the mainland, reflecting the
lower prevalence of severe deficiency, and peaks higher.
doi:10.1371/journal.pone.0155633.g003
Table 3. Comparison of vitamin D in Orkney andmainland Scotland by age group.
N = Orkney; Scotland Orkney mean crude 25(OH)D Mainland mean crude 25(OH)D t-test p-value
< 40 46; 46 26.8 36.5 -2.67 0.009
40–49 263; 263 33.4 39.5 -3.13 0.002
50–59 399; 400 35.7 38.7 -1.97 0.049
60–69 466; 464 37.95 33.28 3.59 0.0004
70+ 279; 280 38.51 30.39 4.84 1.6x10-6
doi:10.1371/journal.pone.0155633.t003
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We also identified a ‘farmer effect’ (Table 7). Participants employed in “traditional” agricul-
tural occupations that kept them outdoors had significantly higher mean vitamin D levels than
participants in non-traditional professions that kept them indoors (farmers 36.9 (18.0), non-
farmers 33.8 (11.8), t(383) = 2.46, p = 0.014). Further, farmers tended to be older.
To test for differences in mean vitamin D across the ‘Saga’ group, farmers, and non-farmers
who are under 50 and do not take foreign holidays, we did a one-way ANOVA. This ANOVA
Fig 4. Comparison of percentage of people in May-adjusted vitamin D deficiency groups by location. The main differences
occur in the severely deficient group (<12.5 nmol/L) which has significantly fewer people from the Orkney sample (χ2(1) = 64.2,
p = 1.10 x 10−15), and the ‘at risk’ category (25-<50 nmol/L) which has significantly fewer people from the mainland Scottish sample
(χ2(1) = 30.3, p = 3.78 x 10−8).
doi:10.1371/journal.pone.0155633.g004
Vitamin D in Orkney
PLOS ONE | DOI:10.1371/journal.pone.0155633 May 17, 2016 9 / 18
was significant: Welch's F(2, 481.99) = 54.49, p = 2.2 x 10−16, and we therefore concluded that
vitamin D varies significantly across these groups with people over 50 who take foreign holi-
days having higher vitamin D than farmers, who had higher vitamin D than non-farmers and
people under 50 who remain in the UK (Fig 6).
Discussion
We aimed to compare vitamin D levels in Orkney and mainland Scotland, and to identify the
determinants of Orkney vitamin D. Definitions of vitamin D deficiency are much discussed,
however it has been proposed that circulating 25(OH)D above 50 nmol/L are sufficient [30,
38]. Vitamin D status in Scotland has been previously explored [32]. Deficient and high risk
individuals comprised 63.4% in the previous study; in our Orkney dataset deficient and high
risk individuals comprised 65.3%. However, people with severe deficiency (<12.5 nmol/L)
comprised 11.8% of the former study and only 5.0% of the latter. Therefore although perhaps
initially surprising that mean vitamin D was higher in Orkney despite the higher latitude, the
smaller percentage of people with severe deficiency in Orkney led to this elevation. In both
datasets the majority are either deficient or at risk of deficiency which could have significant
health implications [9].
Ability to synthesise vitamin D decreases with age [39]; it is well established that older age is
associated with lower vitamin D and increased deficiency risk [32, 40]. However, we found that
lifestyle factors particular to Orkney contributed to better vitamin D in older compared to
younger people.
Table 4. Results of linear regression for complete cases and imputed data using May-adjusted vitamin D as the outcome.
Multivariable models
Model 1a (n = 628) Model 2b (n = 1949)
Predictors Est (95% CI) p-value Est (95% CI) p-value
Intercept 32.4 (18.5, 46.2) 5.25x10-6 30.3 (22.2, 38.3) 2.2x10-13
Body mass index (kg/m2) -0.75 (-1.02, -0.47) 1.95x10-7 -0.54 (-0.70, -0.38) 7.5x10-11
Holidays outside the UK
< once a year -0.93 (-4.38, 2.52) 0.59 0.75 (-1.34, 2.85) 0.48
Once year 5.03 (0.20, 9.86) 0.041 6.47 (3.47, 9.47) 0.000024
> once a year 18.7 (11.3, 26.2) 1.04x10-6 13.5 (9.07, 18.0) 3.4x10-9
Age at venepuncture 0.24 (0.11, 0.36) 0.0003 0.14 (0.07, 0.22) 0.00030
Physical activity 1.66 (0.58, 2.75) 0.003 1.42 (0.65, 2.19) 0.00032
Socio-economic status 3 (“non-traditional”) -2.10 (-3.57, -0.64) 0.005 -1.74 (-2.71, -0.78) 0.00043
Summer minutes outside 0.0046 (-0.00398, 0.013) 0.29 0.006 (-0.00028, 0.012) 0.062
Socio-economic status 2 0.32 (-1.30, 1.94) 0.70 0.69 (-0.34, 1.72) 0.19
Vitamin D intake (μg) 0.201 (-0.18, 0.60) 0.30 0.14 (-0.17, 0.46) 0.37
Working (not retired) -2.07 (-6.61, 2.47) 0.37 -0.18 (-2.45, 2.09) 0.88
Sex (male) 1.06 (-1.55, 3.67) 0.43 -0.12 (-1.77, 1.52) 0.88
Socio-economic status 1 -0.013 (-1.85, 1.82) 0.99 -0.075 (-1.17, 1.02) 0.89
a Model 1 constructed using complete cases in the original dataset, R2 = 0.204.
b Model 2 constructed using 68 datasets with missing data completed by imputation (100 cycles), R2 = 0.111 (People missing outcome data were
excluded from the imputation model).
Socio-economic status was derived from principal components analysis.
doi:10.1371/journal.pone.0155633.t004
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Participants who took foreign holidays had higher vitamin D than those who did not take
foreign holidays; furthermore, taking foreign holidays increased by age group. Less than 20%
of under-40s in our Orkney sample took foreign holidays, whereas over 30% in the 70 and over
group reported leaving the UK at least once a year. Weak sunshine within the UK leads to
fewer opportunities for UV exposure and UVB-mediated vitamin D synthesis, and the effect of
foreign holiday sun exposure has been previously associated with improved vitamin D in Scot-
land [24]. Orkney mean vitamin D remained higher than mainland Scotland throughout the
year with the exception of two months: August and November. Although we were unable to
explore this further, mainland Scotland’s August elevation of vitamin D could be attributed to
the effect of holidays, following one month after school holidays. In November, however, main-
land Scotland’s mean vitamin D levels were only minimally higher than Orkney. We found
that mean vitamin D in people 50 and over taking foreign holidays was significantly higher
than vitamin D levels in the rest of the sample. Foreign holidays contributed more to vitamin
D levels on blood drawn in months of weaker UVB. We were unable to explore at what time of
year people take holidays, however this finding suggests that foreign holidays become more
important as a source of UV exposure and therefore vitamin D for Orkney residents in winter.
As older people tend to have more freedom to travel outside peak season, they are able to derive
most benefit by seeking sun in seasons of scarce sunshine in Orkney. People over 50 who take
foreign holidays were found to differ from those who do not take holidays mainly in variables
denoting financial security. They were also more likely to have lower BMI and body fat per-
centage suggesting possible healthier lifestyles than their non-holidaying counterparts.
Table 5. Comparison of people over 50 who holiday outside the UK at least once a year (n = 281) and people over 50 who holiday outside the UK
less than once a year or never (n = 851). Unpaired t-tests applied to continuous data; chi-square tests applied to categorical data.
Over-50s, holiday Over-50s, no holiday t-test or p-value
No (%) or Mean (SD) No (%) or Mean (SD) Chi-square
Socio-economic status 1 1.01 (0.76) -0.30 (0.92) -22.6 <2.2x10-16
Job prestige score 0.32 (1.08) -0.19 (0.96) -7.09 5.1x10-12
Socio-economic status 3 (“non-traditional”) 0.18 (1.05) -0.29 (0.92) -6.50 2.1x10-10
Supervisory role at work
Yes 186 (66.4) 377 (45.1)
No 94 (33.6) 459 (54.9) 38.2 6.4x10-10
Years in education 15.9 (1.26) 15.5 (1.14) -5.39 1.1x10-6
Body mass index (kg/m2) 27.6 (3.91) 28.9 (5.03) 4.41 1.2x10-5
Highest qualification
O & standard grades, CSE* 33 (11.8) 102 (12.1)
Highers, A levels** 114 (40.7) 246 (29.3)
Certificates/diplomas 113 (40.4) 461 (54.8)
Bachelor/Master/PhD 20 (7.14) 32 (3.81) 22.2 5.8x10-5
Summer minutes 252 (146) 214 (136) -3.38 0.001
Age 62.9 (7.62) 64.4 (8.63) 2.55 0.01
Bodyfat % 33.7 (7.51) 34.9 (8.07) 2.34 0.02
Socio-economic status 2 0.43 (0.76) 0.32 (0.76) -2.06 0.04
Vitamin D intake (μg) 5.09 (3.60) 4.78 (3.13) -1.12 0.26
Physical activity 5.21 (1.20) 5.16 (1.26) -0.37 0.71
* School examinations taken in the UK ~16 years of age
** School examinations taken in the UK ~18 years of age
doi:10.1371/journal.pone.0155633.t005
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Fig 5. Percentage of people per age group in ORCADES who holiday outside the UK at least once a year. People over 50 take
significantly more holidays than those under 50.
doi:10.1371/journal.pone.0155633.g005
Table 6. Mean May-adjusted vitamin D (nmol/L) according to season of venepuncture (high season
(April-September, n = 96) vs low season (October-March, n = 185)) in people over 50 who take a holi-
day outside the UK at least once a year. Linear regression with May-adjusted vitamin D as the outcome.
Std Beta Beta (95% CI) Std error p-value
High season over-50s 0.17 7.86 (3.57–12.2) 2.18 0.00035
Low season over-50s 0.19 8.33 (5.23–11.4) 1.57 1.75x10-7
doi:10.1371/journal.pone.0155633.t006
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We also examined under 40s, the age group in which MS is most likely to be diagnosed and
pregnancies are most likely to occur, thereby potentially conferring risk to the unborn child. In
this group, we found that the main differences in those who do or do not take holidays out of
the UK are related to financial security. Only 75 of the 400 people who are under 40 reported
leaving the UK for a holiday at least once a year, therefore, in the most at-risk group, inade-
quate UV exposure in Orkney is compounded by a low prevalence of foreign holidays.
The ‘non-traditional’ SES group derived from PCA, comprising job prestige score, educa-
tion years and supervisory role at work, was associated with vitamin D. These variables, reflect-
ing “non-traditional” lifestyles of managerial, administrative and professional occupations in
contrast to traditional agricultural work, related to farmers and non-farmers. Farmers were
found to be slightly less educated, possibly as a result of leaving school at the minimum leaving
age about half a year to a year before the first set of examinations. Farmers were also less likely
to describe themselves as having a supervisory role at work than non-farmers, and also had a
slightly lower-than-average job prestige score. The inverse association between vitamin D and
a higher score in this variable means that farmers, who scored lower, had better vitamin D.
Farmers in our cohort were also more likely to be older than non-farmers, further contributing
to our finding of vitamin D increasing with age.
Physical inactivity and obesity have previously been related to low vitamin D in a large
American cohort [41]; the association between lower BMI and higher 25(OH)D is also well
established [42]. The mechanism for lower vitamin D in the presence of higher BMI is thought
to be a result of increased deposition of vitamin D in body fat [43], making BMI a proxy for
adiposity. However, BMI does not distinguish between body fat and fat free mass, and is not
Table 7. Comparison of farmers (n = 265) and non-farmers (n = 1649) on variables of interest in Orkney. Farmers are anyone who identified their pri-
mary profession as farmer. Unpaired t-tests applied to continuous data; chi-square tests applied to categorical data.
Farmers Non-farmers t-test or p-value
No (%) or Mean (SD) No (%) or Mean (SD) Chi-square
Age 60.7 (11.4) 52.4 (11.5) -8.86 <2.2x10-16
Socio-economic status 3 (“non-traditional”) -0.30 (0.58) 0.10 (1.02) 8.77 <2.2x10-16
Years in education 15.4 (1.01) 16.1 (1.24) 10.16 <2.2x10-16
Socio-economic status 1 -0.44 (1.00) 0.09 (0.97) 7.86 5.4x10-14
Physical activity 5.87 (1.23) 5.10 (1.21) -7.60 8.9x10-13
Highest qualification
O & standard grades, CSE* 24 (9.2) 251 (15.3)
Highers, A levels** 84 (32.1) 702 (42.8)
Certificates/diplomas 153 (58.4) 586 (35.8)
Bachelor/Master/PhD 1 (0.4) 100 (6.1) 55.9 4.3x10-12
Bodyfat % 30.4 (8.7) 33.1 (8.6) 4.51 9.1x10-6
Supervisory role at work
Yes 109 (41.3) 866 (53.2)
No 155 (58.7) 763 (46.8) 12.8 0.0003
Socio-economic status 2 0.28 (0.92) 0.07 (0.92) -3.39 0.0008
Body mass index (kg/m2) 28.4 (4.80) 27.7 (4.96) -2.12 0.04
Vitamin D intake (μg) 4.71 (2.93) 4.40 (3.20) -1.29 0.19
Summer minutes 236 (151) 221 (141) -1.21 0.23
* School examinations taken in the UK at ~16 years of age
** School examinations taken in the UK at ~18 years of age
doi:10.1371/journal.pone.0155633.t007
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always a reliable indicator of adiposity in people with lower body fat but greater muscle mass
[44]. The farmers in our cohort reflected this difficulty: they had lower body fat percentage but
higher BMI than non-farmers. We found farmers were more active and leaner than non-farm-
ers and it is perhaps therefore fair to assume they have higher than average muscle mass. Nev-
ertheless, in the multivariable models BMI followed what is expected.
Farmers had mean vitamin D significantly higher than non-farmers, but significantly lower
than people over 50 who take foreign holidays. Summer minutes outside was not significant in
the multivariable analyses, however we performed a t-test for farmers versus non farmers and
time spent outside. Farmers, perhaps unsurprisingly, were found to spend significantly more
time outside than non-farmers which enables maximisation of even the smallest window of
vitamin-D strength sunshine. Although Zgaga et al. found higher vitamin D consumption led
to slight improvements in plasma vitamin D [32], we found that diet was not associated with
vitamin D in Orkney. However, difficulties involved in building a variable with the available
data likely contributed to this finding.
Both studies were recruited on an ‘opt in’ basis which may result in the samples representing
a healthier than average population; however a strength of this study was the large number of
Fig 6. Mean May-adjusted vitamin D (nmol/L) in different groups in ORCADES. 95% confidence interval
bars are given. “Saga” refers to people over 50 who take a holiday outside the UK at least once a year;
“Farmer” to people who identified their primary profession as farming; “Other” is people under 50 who take a
holiday outside the UK less than once a year, and are not farmers.
doi:10.1371/journal.pone.0155633.g006
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participants in each cohort. Particularly novel was the number of farmers in our Orkney
cohort, enabling us to explore vitamin D in a select group within a rural population which is
not often studied. All vitamin D samples from both cohorts were analysed in the same labora-
tory using the same procedures, helping maintain consistency and reliability of results. We had
access to a variety of detailed measures to explore vitamin D in Orkney; however data on time
spent outside and vitamin D intake were somewhat limited and these may thus be more
strongly implicated in vitamin D than we were able to detect. Nevertheless, we found signifi-
cant effects and reliable relationships for vitamin D with foreign holidays, BMI, physical activ-
ity and age.
Conclusion
Mean vitamin D in Orkney was higher than mainland Scotland, driven largely by a lower per-
centage of individuals with severe deficiency in Orkney. Overall concentrations in both cohorts
were low with most people either deficient or at risk of deficiency, suggesting that UV exposure
for much of the year is low. Older Orkney residents were more likely to have better vitamin D
than younger residents, largely resulting from the ‘Saga’ and ‘Farmer’ effects. Those most at
risk of deficiency in Orkney were under 40, an age group traditionally considered at lower risk
of deficiency, but at increased risk of MS diagnosis. Within these main child-bearing years, a
lack of UV exposure and vitamin D deficiency may result in significant autoimmune implica-
tions for offspring. The significant contribution of foreign holidays to Orkney vitamin D is
consistent with the findings of previous UK studies; the importance of foreign holidays in pro-
viding adequate UV exposure to UK residents is underappreciated. We have found that youn-
ger ages are more at risk from inadequate UV exposure and vitamin D deficiency in Orkney, a
county with a very high prevalence of MS. Further research exploring the relationship between
vitamin D and quantitatively-measured exposure to UV radiation from sunshine and physical
activity, as well as more detailed dietary information in Shetland, the most northerly UK
county with an MS prevalence lower than Orkney, would help further elucidate the roles of UV
exposure and vitamin D as MS risk factors in these islands.
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Supplementary table 1. Principal components for socio-economic status 
variables. The most significant loadings are in bold.  
  
PC1 PC3 PC2 
Holidays in the UK 0.70 0.17 0.01 
Holidays outside the UK 0.65 0.28 0.16 
Car age -0.55 0.14 -0.45 
Council tax band 0.45 0.24 -0.25 
Boat ownership 0.33 0.05 -0.02 
Job prestige score 0.16 0.76 0.21 
Years in education 0.16 0.72 -0.19 
Supervisory role at work 0.16 0.52 0.16 
Housing tenure 0.08 0.07 0.67 
Length of car ownership 0.01 0.03 0.59 
Highest qualification -0.28 0.27 0.41 
Eigenvalue 2.34 1.27 1.06 
% Explained 15.3 14.7 12.4 
% Cumulative 15.3 30.0 42.6 
 
 
Supplementary table 2. Missing data in the Orkney dataset in variables of 
interest  
 
Variable N missing 
May-adjusted vitamin D* 23 
Age at venepuncture 0 
Sex 0 
Body mass index (kg/m2) 72 
Physical activity 669 
Vitamin D intake 703 
Summer minutes outside 531 
Work/retired 58 
Holidays outside the UK 66 
SES1 268 
SES2 268 
SES3 (“non-traditional”) 268 





Supplementary table 3. Comparison of people under 40 who holiday outside 
the UK at least once a year (n=75) and people under 40 who holiday outside the 
UK less than once a year or never (n=325). Unpaired t-tests applied to 






No (%) or Mean 
(SD) 
Under 40s, no 
holiday 





Socio-economic status 1 0.70 (0.75) -0.258 (0.80) -9.15 <6.4x10-15 
Highest qualification     
O & standard grades, CSE 7 (9.33) 62 (19.2)   
Highers, A levels 31 (41.3) 183 (56.7)   
Certificates/diplomas 26 (34.7) 65 (20.1)   
Bachelor/Master/PhD 11 (14.7) 13 (4.03) 23.1 3.7x10-05 
Socio-economic status 3 
(“non-traditional”) 
0.94 (1.04) 0.31 (0.9) -4.44 2.6x10-05 
Supervisory role at work     
Yes 51 (69.9) 149 (46.6)   
No 22 (30.1) 171 (53.4) 12.91 0.0003 
Years in education 17.2 (1.2) 16.6 (1.3) -3.56 0.0005 
Job prestige score 0.48 (1.1) -0.002 (0.9) -2.98 0.004 
Body mass index (kg/m2) 24.8 (3.8) 26.0 (4.9) 2.37 0.019 
Bodyfat % 27.1 (7.5) 28.5 (9.1) 1.36 0.18 
Physical activity 5.01 (1.2) 5.18 (1.27) 1.03 0.31 
Socio-economic status 2 -0.38 (1.06) -0.51 (1.04) -0.902 0.37 
Vitamin D intake (μg) 3.60 (2.6) 3.45 (3.2) -0.32 0.75 
Age 31.9 (6.3) 32.04 (6.3) 0.168 0.87 








Appendix E: VIKING UV Study 
 
1) NHS Lothian ethical approval 
2) Internal ethics self-audit form 
3) Participant Information Sheet 


































































    





   
   










































      
   















   
21-03-2014 version 1 
VIKING HEALTH STUDY – SHETLAND            
Participant Information Sheet – Viking UV extension 
 
Lead investigator: Dr. James Flett Wilson, Centre for Population Health Sciences, 
University of Edinburgh 
 
Summary 
This information sheet gives details about the Viking Health Study – Viking UV 
extension, a sub-study of the Viking Health Study – Shetland. This extension has been 
designed to investigate risk factors for multiple sclerosis. In addition to taking part in 
the Viking Health Study, participants for the Viking UV extension will also be asked to 
wear an ultraviolet measurement badge for one week, and to complete a short 
questionnaire every day for that same week. You will also be asked to wear a 
pedometer from your first clinic visit to your return visit, which will count the number 
of steps you take each day. Before deciding if you want to participate in this extension, 
it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. 
 
Background to the Study 
Multiple sclerosis (MS) is found more commonly in regions of the world that are further 
north and south, and is more common in Orkney and Shetland than anywhere else in the 
world. Whilst it is known that genes play a part in MS, this is not enough on its own to 
cause the disease; that is, it is believed that one or more environmental risk factors must 
also be present. One such possible risk factor is vitamin D deficiency. Sunlight is our best 
source of vitamin D, but is weaker and in shorter supply the further north or south you 
go. The Viking UV extension seeks to understand how the vitamin D levels of people in 
Shetland are affected by their individual exposure to UV, as well as other lifestyle factors. 
 
What will you be asked to do? 
To measure the amount of sunlight that you are getting, you will be asked to wear a 
polysulphone badge all day and every day for one week. This badge looks like a 35mm 







to the clothing of the upper left arm or lapel. If you would prefer not to pierce your 
clothing, there will be an option to wear the badge on a black Velcro armband, again on 
the upper left arm. To further understand how much skin is exposed to UV, we will also 
be asking you to complete a short sun exposure questionnaire every evening. There are 
only five questions and it should take no longer than ten minutes to complete. There will 
also be a few extra questions on the first day to find out your natural skin type, and these 
questions will add to those asked in the Viking Health Study questionnaire. These extra 
questions should take no longer than five minutes to complete. 
 
We will also be measuring physical activity, and you will be asked to wear a pedometer 
which will count the number of steps you take every day between your first Viking Health 
study clinic visit and your following clinic visit. The pedometer will clip onto your belt or 
waistband at the left or right hip.  
 
All papers and equipment will be handed to you and returned at your scheduled Viking 
Health Study clinics. If you decide not to take part, this will not affect your normal health 
care in any way, or your participation in the rest of the study. 
 
What will you gain from completing the questionnaire?  
You will be contributing to improving the health of the community in Shetland and 
increasing our understanding of a possible risk factor for MS. 
 
What will be done with the information collected? 
All information will be held on computer in an anonymous fashion so that no names are 
kept together with personal or health information. This information will only be 
identifiable by a code number. All information will be held securely at the Centre for 
Population Health Sciences at the University of Edinburgh under the restrictions 
described in the Data Protection Act and kept in strictest confidence.  
 
Dr Dylan Murphy, General Practitioner, Lerwick Health Centre, South Road, Lerwick, 
Shetland, ZE1 0RB, has agreed to be our independent advisor; and if you would like to 
speak to him for information about the study he can be reached on 01595-693201.  
If you wish to make a complaint about the study please contact NHS Shetland, 
Complaints Officer, Brevik House, Lerwick, ZE1 0TG. 
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  21-03-2014 version 1 
Participant ID: VIKI                                                                   
CONSENT FORM FOR PARTICIPANTS 
 
Title of project: Viking Health Study – Shetland: Viking UV extension 
 
Principal researcher: Dr. James Flett Wilson, University of Edinburgh 
 
Please initial box if you agree with the statement 
 
I confirm that I have read and understood the Participant Information 
Sheet for the above study and have had the opportunity to ask 
questions.  
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, and without my 
medical or legal rights being affected. I agree to take part in the Viking 
UV extension 
 
__________________________ ________________ _______________________ 
Name of participant   Date    Signature 
 
___________________________ ________________ ________________________ 
Name of person taking consent Date    Signature 
VIKI 
Viking Health Study-Shetland 
Version 1, 13-03-2014 







VIKI no. _______________ 
UV badge no. _______________ 
Viking UV Study 
Skin Type Questionnaire 
Please circle those that apply to you (one per question) 
1) What is the natural colour of your 
skin that is not exposed to 
sunlight (covered with clothing)? 
0. Reddish 
1. Pale 
2. Beige or olive 
3. Brown 




2) How many freckles do you have 
on your skin that is not exposed 





3) Do you turn brown after sun 
exposure? (Including both 








4) How sensitive is your face to the 
sun? 
0. Very sensitive 
1. Sensitive 
2. Sometimes sensitive 
3. Rarely sensitive 
4. Never have a problem 
 
5) How often do you tan? (Either 








6) When did you last expose your 
body to the sun? 
0. +3 months ago 
1. 2-3 months ago 
2. 1-2 months ago 
3. Weeks ago 






















Sun Exposure Diary - Day 1 
Date _________________________________________________ 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso 
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 
3.30pm – 4.30pm  face hands  head arms legs feet torso 
4.30pm – 5.30pm  face hands  head arms legs feet torso 





3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
 
Yes  No 
 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 





Sun Exposure Diary - Day 2 
Date _________________________________________________ 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso 
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 
3.30pm – 4.30pm  face hands  head arms legs feet torso 
4.30pm – 5.30pm  face hands  head arms legs feet torso 






3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
Yes  No 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 





Sun Exposure Diary - Day 3 
Date _________________________________________________ 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso  
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 
3.30pm – 4.30pm  face hands  head arms legs feet torso 
4.30pm – 5.30pm  face hands  head arms legs feet torso 





3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
Yes  No 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 





Sun Exposure Diary - Day 4 
Date _________________________________________________ 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso 
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 
3.30pm – 4.30pm  face hands  head arms legs feet torso 
4.30pm – 5.30pm  face hands  head arms legs feet torso 





3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
Yes  No 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 





Sun Exposure Diary - Day 5 
Date _________________________________________________ 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso 
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 
3.30pm – 4.30pm  face hands  head arms legs feet torso 
4.30pm – 5.30pm  face hands  head arms legs feet torso 





3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
Yes  No 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 





Sun Exposure Diary - Day 6 
Date _________________________________________________ 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso 
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 
3.30pm – 4.30pm  face hands  head arms legs feet torso 
4.30pm – 5.30pm  face hands  head arms legs feet torso 





3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
Yes  No 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 








Sun Exposure Diary - Day 7 
Date _________________________________________________ 
 
1) How much time did you spend out of doors without a roof covering 
between the hours of: 
Before 8.30am  H________ M________ 
8.30am – 9.30am  H________ M________ 
9.30am – 10.30am  H________ M________ 
10.30am – 11.30am  H________ M________ 
11.30am – 12.30pm  H________ M________ 
12.30pm – 1.30pm  H________ M________ 
1.30pm – 2.30pm  H________ M________ 
2.30pm – 3.30pm  H________ M________ 
3.30pm – 4.30pm  H________ M________ 
4.30pm – 5.30pm  H________ M________ 
After 5.30pm   H________ M________ 
 
2) How much skin was exposed (no clothing covering) when you were 
outside? (Circle all that apply) 
Before 8.30am  face hands  head arms legs feet torso 
8.30am – 9.30am  face hands  head arms legs feet torso 
9.30am – 10.30am  face hands  head arms legs feet torso 
10.30am – 11.30am  face hands  head arms legs feet torso 
11.30am – 12.30pm  face hands  head arms legs feet torso 
12.30pm – 1.30pm  face hands  head arms legs feet torso 
1.30pm – 2.30pm  face hands  head arms legs feet torso 
2.30pm – 3.30pm  face hands  head arms legs feet torso 




4.30pm – 5.30pm  face hands  head arms legs feet torso 
After 5.30pm   face hands  head arms legs feet torso 
 
3) Did you apply sunscreen at any time during the day (including 
moisturisers with sun protection factor (SPF))?  
Yes  No 
 
4) Has today been normal (for the time of year and day of week) in terms of 
time spent outdoors?  
 
Yes  No 
 
 
5) If No, do you normally spend more or less time outdoors (at this time of 
year and this day of week)?  
 






Thank you for taking part in the Viking UV Study 
This completes the questionnaire 
 
Please place your UV badge in the black pouch and brown envelope, and 
return to Edinburgh in the envelope provided 
